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ABSTRACT	
Tissue	ischaemia	has	a	varied	aetiology	and	presentation,	with	the	potential	to	affect	multiple	organ	systems	
and	 lead	 to	 significant	 morbidity	 and	 mortality.	 The	 detection	 of	 clinical	 ischaemia	 with	 microdialysis	
sampling	 forms	 the	primary	 focus	of	 this	work.	Microdialysis	 (MD)	allows	 the	extracellular	 composition	of	
tissue	 to	be	characterised	 in	vivo	and	 is	 incorporated	 into	a	new	class	of	analyser.	Rapid	 sampling	on-line	
microdialysis	(rsMD),	analyses	the	dialysis	liquid	stream	from	a	patient	on-line,	at	high	time	resolution.	The	
device	 has	 been	 validated	 in	 ex-vivo	 bench	 work	 and	 animal	 studies,	 however	 I	 aimed	 to	 utilise	 this	
technology	to	create	a	tool	that	reliably	detects	tissue	ischaemia	in	the	following	clinical	settings:1		
1. Detection	of	colonic	ischaemia	following	abdominal	aortic	aneurysm	(AAA)	repair	
2. Detection	of	an	anastomotic	leak	following	formation	of	a	gastrointestinal	(GI)	anastomosis	
3. Renal	transplant	allograft	viability	assessment	in	the	preservation	period	
In	a	prospective	observational	study	of	10	patients	undergoing	AAA	repair,	a	MD	catheter	was	tunnelled	into	
the	mesentery	 of	 the	 sigmoid	 colon.	 Each	 patient	 underwent	monitoring	 for	 incremental	 changes	 in	 the	
concentration	of	the	metabolic	markers	of	ischaemia.	I	identified	transient	subclinical	ischaemic	events	that	
have	 not	 been	 previously	 described	 and	 demonstrated	 that	MD	may	 act	 as	 an	 effective	 tool	 in	 the	 early	
diagnosis	of	colonic	ischaemia.	
In	my	 second	 study,	 I	 aimed	 to	 assess	 the	 feasibility	 of	 using	 rsMD	 in	 the	 early	 detection	 of	 anastomotic	
leaks	following	formation	of	a	GI	anastomosis.	I	developed	an	ex-vivo	MD	protocol	for	intraperitoneal	lactate	
measurement	 and	 sampled	 drain	 fluid	 from	 20	 patients	 having	 undergone	 GI	 surgery.	 In	 a	 confirmed	
anastomotic	leak,	I	identified	a	rise	in	intraperitoneal	lactate	concentrations	3	days	prior	to	the	development	
of	symptoms	and	7	days	prior	to	the	confirmation	of	the	diagnosis.		
In	my	final	study,	 I	aimed	to	assess	the	feasibility	of	utilising	rsMD	for	organ	viability	assessment	 in	a	DCD	
porcine	model.	7	un-perfused	and	8	perfused	kidneys	were	monitored	at	room	temperature	in	the	control	
group	with	 5	 kidneys	monitored	 in	 the	 preservation	 group.	 These	 kidneys	 underwent	 SCS	 after	 retrieval,	
followed	 by	 tissue	 monitoring.	 This	 preliminary	 study	 provided	 a	 baseline	 ischaemic	 profile	 for	 porcine	
kidneys	 whilst	 validating	 the	 technique,	 allowing	 appropriate	 comparison	 when	 examining	 the	 effect	 of	
organ	preservation	via	SCS	or	HMP.	14	porcine	kidneys	were	subjected	to	15	minutes	warm	ischaemia,	then	
placed	upon	models	of	SCS	or	HMP.	I	demonstrated	that	HMP	appears	superior	to	SCS	at	attenuating	injury	
accumulated	during	warm	ischaemia	and	that	rsMD	is	feasible	for	the	assessment	of	 lactate	concentration	
during	organ	preservation.	
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LIST	OF	ABBREVIATIONS		
AAA	 Abdominal	aortic	aneurysm	
ABGs	 Arterial	blood	gases	
AMP	 Adenosine	monophosphate	
ARDS	 Acute	respiratory	distress	syndrome	
ATP	 Adenosine	Triphosphate	
CIT	 Cold	ischaemic	time	
CO2	 Carbon	dioxide	
CRP	 C-reactive	protein	
CT	scan	 Computer	tomography	scan	
DCD	 Donation	after	circulatory	death	
DIC	 Disseminated	intravascular	coagulation	
ECD	 Extended	criteria	donors	
Fc	 Ferrocene		
FEP	 Fluorinated	ethylene	propylene	
FIA		 Flow	injection	analysis		
FL	 Fluorescein	
G	 Glucose	
GIA		 Gastro-intestinal	anastomosis	
Gly	 Glycerol	
GOx	 Glucose	oxidase	
H+	 Hydrogen	ion	
H2O2	 Hydrogen	peroxide	
HIF-1	 Hypoxia-inducible	factor	1	
HMP	 Hypothermic	machine	perfusion	
HOCl	 Hypochlorous	acid	
HPLC	 High-pressure	liquid	chromatography	
HRP	 Horseradish	peroxidase	
HTK	 Histidine-tryptophan-ketoglutarate	
IC	 Ischaemic	colitis	
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IIA	 Internal	iliac	artery	
IMA	 Inferior	mesenteric	artery	
IMV	 Inferior	mesenteric	vein	
IRI	 Ischaemia-reperfusion	injury	
ITU	 Intensive	treatment	unit	
IVC	 Inferior	vena	cava	
L	 Lactate	
L/G	 Lactate/Glucose	
L/P	 Lactate/Pyruvate	
LOx	 Lactate	oxidase	
MD	 Microdialysis	
MODS	 Multiple	organ	dysfunction	syndrome	
NADH	 Nicotinamide	adenine	dinucleotide	
NO3-	 Nitrate	ion	
P	 Pyruvate	
PEEK	 Polyetherethylketone	
pHi	 Intramucosal	pH	
R	 Recovery	
RR	 Relative	recovery	
rsMD	 Rapid	sampling	on-line	microdialysis	
S	 Sulphur	ion	
SCS	 Static	cold	storage	
SIRS	 Systemic	inflammatory	response	syndrome	
SMA	 Superior	mesenteric	artery	
SO42-	 Sulphate	ion	
SOx	 Substrate	oxidase	enzyme	
WCC	 White	cell	count	
WIT	 Warm	ischaemia	time		
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OUTLINE	OF	THESIS	
Chapter	1	defines	ischaemia	and	describe	the	biochemical	pathways	that	result	in	tissue	ischaemia.	I	detail	
the	cellular	effects	of	ischaemia	and	the	biochemical	markers	within	the	tissue	that	allow	for	the	detection	
and	monitoring	of	ischaemia,	introducing	the	concept	of	microdialysis.	I	describe	the	underlying	principles	of	
the	technique,	describing	the	construction	of	a	typical	microdialysis	catheter	and	examining	 its	 limitations,	
leading	 to	 the	 concept	 of	 online	 analysis	 with	 the	 rapid	 sampling	 microdialysis	 analyser	 (rsMD).	 I	
subsequently	 outline	 previously	 performed	 research	 utilising	 offline	microdialysis	 and	 the	 rsMD	 analyser,	
whilst	describing	the	next	planned	research	steps	to	further	build	on	the	previous	work.	It	is	this	work	that	
forms	 the	 core	 content	 of	 this	 thesis	 and	 is	 illustrated	 in	 subsequent	 chapters.	 In	 the	 remaining	pages	of	
Chapter	1,	I	introduce	the	subsequent	studies	carried	out.		
In	 my	 first	 study,	 I	 monitored	 in-vivo	 for	 ischaemia	 in	 the	 colon	 following	 AAA	 repair.	 The	 introduction	
pertaining	 to	 Study	 1	 outlines	 bowel	 ischaemia	 as	 a	 clinical	 entity,	 its	 pathophysiology	 and	 various	
aetiologies,	 clinical	 presentation	 and	management.	 The	 link	 between	 AAA	 repair	 and	 bowel	 ischaemia	 is	
further	 elucidated	 and	 a	 hypothesis	 is	 drawn	 for	 further	 examination.	 In	 my	 second	 study,	 I	 assess	 the	
feasibility	of	utilising	rsMD	to	detect	and	monitor	for	 leaks	 in	gastrointestinal	anastomoses.	 In	Chapter	1,	 I	
provide	 the	 background	 to	 this	work,	 detailing	 the	 concept	 of	 anastomotic	 leaks,	 their	 incidence	 and	 risk	
factors.	 I	 describe	 the	 diagnosis,	 management	 and	 the	 previous	 research	 carried	 using	 microdialysis	 to	
reduce	 the	 rates	 of	 anastomotic	 leaks	 and	 improve	 outcomes.	 In	 my	 third	 and	 final	 study,	 I	 assess	 the	
feasibility	of	employing	the	rsMD	analyser	as	a	 tool	 for	 tissue	viability	assessment	during	the	preservation	
period	 in	 a	 renal	 transplant	 model.	 The	 introduction	 to	 this	 study	 is	 detailed	 in	 the	 remaining	 pages	 of	
Chapter	1.	Here	 I	 describe	 the	process	of	 kidney	 transplantation,	 its	 importance	and	 the	 relevance	of	 the	
ischaemic	 injury	 that	 is	 accrued	during	 the	preservation	period	 and	 current	 techniques	 to	 ameliorate	 this	
injury.	
In	Chapter	2	we	describe	the	various	technical	components	that	are	 integrated	into	the	rsMD.	I	also	detail	
the	methodology	used	to	set	up	the	analyser,	obtaining	the	data	and	the	subsequent	analysis	of	the	data.	
Chapter	3	focuses	on	my	first	study,	the	in-vivo	detection	of	colonic	 ischaemia	in	the	postoperative	period	
following	AAA	repair.	 I	provide	 the	specific	methodology	 for	 this	 study,	detailing	 the	study	design,	patient	
recruitment,	analyser	set	up	and	catheter	modification,	in-vivo	and	ITU	protocols.	In	Chapter	3	I	document	
the	results	and	interpretation	of	these	results	for	each	patient	recruited,	and	discussed	the	challenges	faced	
during	this	study.	
	 18	
In	 Chapter	 4	 I	 outline	 the	 methodology	 and	 results	 from	 my	 second	 study,	 assessing	 the	 feasibility	 of	
employing	 the	 rsMD	 analyser	 to	 monitor	 for	 ischaemia	 in	 a	 GI	 anastomosis	 and	 potentially	 detect	
anastomotic	leaks.	
Chapter	5	details	my	final	study,	evaluating	the	feasibility	of	utilising	rsMD	in	organ	viability	assessment	 in	
the	preservation	period.	I	provide	an	experimental	overview	of	the	sub-studies	undertaken,	a	description	of	
the	 experimental	 protocols	 and	 methodology	 that	 I	 carried	 out.	 I	 present	 my	 findings	 along	 with	 my	
interpretation	of	the	data.		
In	my	final	chapter,	Chapter	6,	I	present	my	overall	conclusions	and	critical	analysis	of	the	experimental	work	
carried	out,	alongside	the	challenges	and	limitations	encountered.	I	conclude	by	discussing	potential	future	
work	and	further	clinical	studies.		 	
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1 CHAPTER	1	–	INTRODUCTION	
1.1 ISCHAEMIA	
1.1.1 Metabolic	changes	in	ischemia	
Ischaemia	 is	 a	 pathological	 condition	with	 a	 varied	 aetiology.	 From	 the	Greek,	 ischaimía;	 isch-	 restriction,	
hema	 or	 haema	 blood,	 it	 describes	 an	 inadequate	 blood	 supply	 to	 an	 organ	 or	 tissue.	 	 This	 results	 in	 a	
relative	deficit	of	oxygen	 (hypoxia),	whereby	 the	metabolic	 requirements	of	 the	 tissue	exceed	 the	 supply.	
With	a	deficit	 in	oxygen	delivery,	anaerobic	metabolism	within	the	tissue	ensues.	In	a	normal	physiological	
setting	 with	 adequate	 oxygen	 supply,	 glucose	 enters	 the	 glycolytic	 pathway	 in	 the	 cytoplasm	 of	 the	 cell	
(Figure	1).	
	
Figure	1	–		Glycolysis	overview	
Illustration	by	author	–	SD	
This	 process	 converts	 one	molecule	 of	 glucose	 into	 two	molecules	 of	 pyruvate,	 and	makes	 energy	 in	 the	
form	of	adenosine	triphosphate	(ATP).	The	pyruvate	enters	the	mitochondria	of	the	cells	and	is	oxidised	into	
acetyl-CoA	and	CO2	by	the	pyruvate	dehydrogenase	complex.	During	this	process,	3	molecules	of	ATP	and	1	
molecule	 of	 NADH	 are	 formed	 for	 each	molecule	 of	 pyruvate.	 In	 the	 presence	 of	 oxygen,	 the	 acetyl-CoA	
enters	the	citric	acid	cycle	inside	the	mitochondrial	matrix	and	is	oxidised	to	CO2,	whilst	also	reducing	NAD	to	
NADH	(Figure	2).	The	net	energy	gain	from	one	cycle	is	3	NADH	and	1	ATP.	Thus,	the	total	energy	yield	from	
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one	 glucose	 molecule	 (2	 pyruvate	 molecules)	 is	 6	 NADH	 and	 2	 ATP.	 NADH	 undergoes	 oxidative	
phosphorylation	by	the	electron	transport	chain	to	create	more	ATP.		
Figure	2	–	Overview	of	the	citric	acid	cycle		
Illustration	by	author	–	SD	
There	is	a	theoretical	yield	of	38	ATP	molecules	from	the	complete	oxidation	of	one	glucose	molecule	during	
aerobic	metabolism,	however	there	are	losses	due	to	active	transport	of	molecules	using	carriers.	The	likely	
yield	 is	 closer	 to	 30	 ATP	 molecules	 per	 glucose	 molecule	 metabolised.2	 The	 process	 of	 oxidative	
phosphorylation	 in	 the	 electron	 transport	 chain	 is	 dependent	 on	 oxygen	 as	 the	 final	 electron	 acceptor,	
allowing	 electrons	 to	 pass	 through	 the	 system.	 In	 the	 absence	 of	 oxygen,	 other	 less	 oxidising	 substances	
such	 as	 sulphate	 (SO42-),	 nitrate	 (NO3-)	 or	 sulphur	 (S)	 are	 used.	 These	 terminal	 electron	 acceptors	 have	
smaller	 reduction	 potentials	 than	 oxygen,	 meaning	 that	 less	 energy	 is	 released	 per	 oxidised	 glucose	
molecule.	Anaerobic	respiration	 is	therefore	much	 less	efficient	than	aerobic	respiration	 in	producing	ATP,	
yielding	 only	 2	 ATP	 molecules	 per	 glucose	 molecule	 that	 is	 oxidised.	 Anaerobic	 and	 aerobic	 metabolism	
share	 the	 initial	 pathway	 of	 glycolysis,	 which	 does	 not	 require	 oxygen,	 however	 aerobic	 metabolism	
continues	with	the	Krebs	cycle	and	oxidative	phosphorylation.	
Cells	 that	are	exposed	to	prolonged	 ischaemic	stress	undergo	anaerobic	metabolism,	 this	utilises	different	
metabolic	 pathways	 to	 produce	 energy.	 The	 pyruvate	 is	 not	 transported	 into	 the	 mitochondrion,	 but	
remains	in	the	cytoplasm,	where	it	is	converted	to	waste	products	that	may	be	removed	from	the	cell.	The	
two	pyruvate	molecules	produced	from	a	glucose	molecule	during	glycolysis,	are	metabolised	to	lactate	by	
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the	 enzyme	 lactate	 dehydrogenase.	 The	 intracellular	 rise	 in	 lactate	 and	 the	 accumulation	 of	 H+	 from	
anaerobic	 hydrolysis	 of	 ATP	 leads	 to	 lactic	 acidosis,	 which	 results	 in	 significant	 cellular	 dysfunction.	
Intracellular	accumulation	of	lactate	creates	a	concentration	gradient	favouring	its	release	from	the	cell.		
The	extracellular	 lactate	can	be	converted	back	to	pyruvate,	which	can	then	be	aerobically	metabolised	to	
carbon	 dioxide	 and	 ATP.	 The	 heart,	 liver,	 and	 kidneys	 use	 lactate	 to	 produce	 energy	 in	 this	 manner.	
Alternatively,	hepatic	and	 renal	 tissues	can	use	 lactate	 to	produce	glucose	via	another	metabolic	pathway	
referred	to	as	gluconeogenesis.	Lactate	is	transported	back	to	the	liver	where	it	 is	converted	into	pyruvate	
by	 the	 Cori	 cycle	 using	 the	 enzyme	 lactate	 dehydrogenase.	 Pyruvate	 is	 the	 first	 substrate	 of	 the	
gluconeogenic	pathway	and	can	then	be	used	to	generate	glucose.3	Lactate	is	cleared	from	blood,	primarily	
by	the	liver	(75-85%),	with	the	kidneys	(10-20%)	and	skeletal	muscles	(5%)	doing	so	to	a	lesser	degree.	The	
ability	of	the	liver	to	metabolise	lactate	is	concentration-dependent	and	progressively	decreases	as	the	level	
of	 blood	 lactate	 increases.	 Lactate	 uptake	 by	 the	 liver	 is	 also	 impaired	 by	 several	 other	 factors,	 including	
acidosis,	 hypoperfusion	 and	 hypoxia.	 In	 the	 presence	 of	 hypoxia,	 the	 extracellular	 H+	 produced	 from	 the	
hydrolysis	of	ATP	combines	with	lactate,	forming	lactic	acid.	The	accumulation	of	serum	lactate	overwhelms	
the	cellular	buffering	capacity	and	results	in	systemic	acidosis.4,5	
1.1.2 Cellular	effects	of	ischaemia	
The	result	of	a	reduction	in	the	blood	supply	to	a	specific	organ	is	well	recognised	as	a	critical	factor	in	the	
clinical	outcome	of	organ	transplantation	or	aortic	aneurysm	surgery.		Whilst	restoration	of	the	blood	flow	
to	ischemic	tissue	is	essential	to	prevent	irreversible	organ	injury,	reperfusion	may	augment	the	tissue	injury	
even	 further.	Varadarajan	et	 al	whilst	 examining	 the	effect	 of	 reperfusion	on	human	 liver	 transplantation	
and	 Parks	 et	 al	 by	 surgically	 inducing	 intestinal	 ischaemia	 in	 an	 animal	 model,	 demonstrated	 that	 the	
histological	changes	of	 ischaemic	 injury	after	3	hours	of	 liver	or	 intestinal	 ischaemia	followed	by	1	hour	of	
reperfusion	were	worse	than	the	changes	observed	after	4	hours	of	 ischaemia.6,7	The	cellular	damage	that	
takes	place	after	reperfusion	of	a	previously	viable	ischaemic	tissue	is	known	as	ischaemia-reperfusion	injury	
(IRI).8	
IRI	 may	 ensue	 in	 various	 clinical	 environments,	 including	 during	 organ	 transplantation,	 cardiopulmonary	
bypass,	following	aortic	cross-clamping	or	thrombolytic	therapy.	The	reperfusion	of	ischaemic	tissue	in	these	
settings,	 results	 in	 a	 local	 and	 systemic	 inflammatory	 response	 with	 subsequent	 global	 microvascular	
dysfunction	and	deranged	tissue	barrier	function.	The	inflammatory	response,	if	severe	enough,	can	lead	to	
the	 development	 of	 the	 systemic	 inflammatory	 response	 syndrome	 (SIRS)	 or	 multiple	 organ	 dysfunction	
syndrome	 (MODS).	 These	 two	 clinical	 entities	 account	 for	 up	 to	 40%	 of	 intensive	 care	mortality.8	Whilst	
oxygen	 is	 fundamental	 to	 our	 physiology	 and	 functioning,	 the	 crucial	 requirement	 for	 ATP	 via	 oxidative	
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phosphorylation	 is	 equally	 balanced	 by	 the	 potential	 risk	 of	 oxidative	 damage	 to	 lipids,	 nucleic	 acids	 and	
proteins.	 Therefore	 both	 the	 intra-cellular	 and	 systemic	 oxygen	 concentrations	 are	 closely	 controlled	 by	
various	response	pathways,	which	affect	protein	expression	and	cellular	activity.9	
Sustained	 ischaemia	results	 in	a	combination	of	metabolic,	cellular	and	ultra-structural	changes	within	 the	
tissue.	 These	 include	 cellular	 acidosis,	 altered	membrane	potential	 and	 ionic	 distribution,	 cellular	 swelling	
with	cytoskeletal	derangement	and	a	reduction	in	available	ATP.	Hypoxic	tolerance	varies	between	different	
cell	types	and	depends	on	metabolic	rate	and	intrinsic	adaptive	mechanism.	However,	when	the	threshold	is	
reached,	 cellular	 necrosis	will	 inevitably	 follow	extended	periods	of	 hypoxia	or	 anoxia.	 In	 the	presence	of	
hypoxia,	the	rate	of	oxygen	dependent	oxidative	phosphorylation	decreases	which	results	in	a	reduction	in	
the	 synthesis	 of	 energy-rich	 phosphates	 such	 as	 ATP	 or	 phosphocreatine.	 Subsequently,	 ATP-dependent	
membrane	ion	pump	function	is	deranged,	allowing	for	the	passive	diffusion	of	calcium,	sodium	and	water	
into	the	cell.	The	rise	in	intracellular	calcium	and	cellular	oedema	leads	to	cellular	structural	derangement.	
The	 breakdown	 of	 adenine	 nucleotide	 causes	 an	 intracellular	 accumulation	 of	 hypoxanthine,	 which	 is	
subsequently	 converted	 to	 a	 toxic	 reactive	 oxygen	 species.10	 Ischaemia	 triggers	 expression	 of	 pro-
inflammatory	gene	products	such	as	 leucocyte	adhesion	molecules,	cytokines	and	bioactive	agents	such	as	
endothelin	 and	 thromboxane	 A2.	 Ischaemia	 also	 represses	 certain	 protective	 agents	 such	 as	
thrombomodulin,	 prostacyclin,	 nitric	 oxide	 and	 nitric	 oxide	 synthase.8,11	 The	 resultant	 pro-inflammatory	
state	 acts	 to	 further	 increase	 the	 tissues	 vulnerability	 to	 injury	 following	 reperfusion.	 The	 regulation	 of	
vascular	endothelial	growth	factor	(VEGF)	expression	is	an	example	of	how	hypoxia	can	trigger	physiological	
responses	 via	 an	 array	 of	 molecular	 mechanisms.	 VEGF	 is	 key	 in	 angiogenesis,	 and	 its	 expression,	 when	
induced	 by	 hypoxia,	 can	 act	 to	 optimise	 tissue	 perfusion.	 In	 the	 presence	 of	 hypoxia,	 transcriptional	
activation	 increases	 VEGF	 production	 and	 mRNA	 stabilisation	 acts	 to	 reduce	 the	 breakdown	 of	 VEGF	
mRNA.12	 Transcriptional	 activation	 is	 mediated	 by	 the	 binding	 of	 hypoxia-inducible	 factor	 1	 (HIF-1)	 to	 a	
hypoxia-response	 element	 localised	 on	 the	VEGF	 gene.13	 In	 hypoxic	 conditions,	 the	HIF-1a level	 increases	
significantly	which	then	dimerises	 to	HIF-1b,	 leading	to	 the	rapid	accumulation	of	HIF-1	which	triggers	 the	
transcriptional	activation	of	VEGF	and	other	target	genes.14	
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1.1.3 System	based	response	to	ischaemia	reperfusion	injury	
A	 broad	 range	 of	 clinical	 sequelae	 secondary	 to	 IRI	 have	 been	 described.	 They	 range	 from	 reperfusion	
arrhythmias	 and	 delayed	 graft	 function	 to	 potentially	 fatal	 multi-organ	 dysfunction	 syndrome	 (MODS).	
Typically	 the	 clinical	 response	 varies	 according	 to	 the	 individual,	 however	 the	 presence	 of	 hypertension,	
diabetes	and	hypercholesterolaemia	increases	the	susceptibility	of	potential	injury.8	
1.1.3.1 Gastrointestinal	ischaemia	reperfusion	injury	
IRI	 to	 the	 gastrointestinal	 tract	 is	 characterised	 by	 reduced	 barrier	 function.	 Pathological	 conditions	 or	
iatrogenic	 injury	 such	 as	 may	 occur	 after	 aortic	 surgery	 or	 with	 strangulated	 bowel,	 may	 result	 in	
gastrointestinal	 IRI.	 The	 intestinal	 barrier	 safeguards	 against	 potentially	 dangerous	microorganisms	within	
the	 bowel	 lumen,	 however	 ischaemic	 injury	 can	 disrupt	 this	 defensive	 function.	 An	 ischaemic	 injury	 can	
result	 in	 increased	 intestinal	permeability	 and	potential	 bacterial	 translocation	 into	 the	 systemic	or	portal	
circulations.15	 Intestinal	 IRI	 is	 also	 associated	 with	 reduced	 absorption,	 impaired	 gut	 motility	 and	 the	
activation	 of	 the	 complement	 cascade	 with	 promotion	 of	 circulating	 leucocytes	 by	 translocated	 bacteria	
resulting	 in	 the	 development	 of	 the	 systemic	 inflammatory	 response	 syndrome	 (SIRS).	 Numerous	 innate	
pathways	have	been	demonstrated	 to	 safeguard	gastrointestinal	barrier	 function	when	 in	 the	presence	of	
hypoxia.	Physiological	activation	of	adenosine	 receptors	within	 the	 intestinal	epithelium	activates	 chloride	
secretion	and	thereby	acts	to	promote	barrier	function.16	CD73	mediated	conversion	of	AMP	to	adenosine	
has	been	demonstrated	to	play	a	vital	role	in	the	maintenance	of	barrier	function	during	ischaemic	events.17	
These	mechanisms	may	 allow	 the	 further	 identification	 of	 novel	 therapeutic	 tools	 that	 can	 attenuate	 the	
severity	of	the	SIRS	that	results	in	intestinal	IRI.	
1.1.3.2 Renal	ischaemia	reperfusion	injury	
The	mechanisms	involved	in	the	development	of	IRI	within	the	kidney	depend	on	the	metabolic	properties	
within	the	different	regions	of	the	kidney.9	Oxygenation	levels	within	the	renal	parenchyma	vary	significantly	
depending	on	the	region.	The	highest	oxygen	levels	are	seen	within	the	renal	cortex,	with	decreasing	oxygen	
tensions	in	the	outer	medulla	and	the	lowest	oxygen	levels	in	the	papillae.	This	oxygen	gradient	is	a	result	of	
counter	 current	orientation	of	arteriovenous	vasa	 recta	within	 the	 renal	medulla.	Cells	within	each	 region	
display	specialised	adaptation	to	allow	functioning	at	a	specific	oxygen	level	in	their	microenvironment.9	The	
epithelium	within	the	renal	cortex	utilises	predominantly	O2	dependent	metabolism	of	fatty	acids,	ketones,	
lactate	and	amino	acids.	The	cells	within	the	outer	medulla	metabolise	succinate,	however	they	are	adapted	
to	 shift	 to	 O2	independent	 glucose	 and	 lactate	metabolism	when	O2	 levels	 decrease.	 The	 cells	 within	 the	
inner	medulla	largely	metabolises	glucose	to	generate	ATP	via	anaerobic	glycolysis.		It	is	largely	evident	that	
certain	areas	of	the	kidney	are	more	prone	to	ischaemic	injury.	The	renal	cortex	has	a	relatively	high	oxygen	
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reserve	 and	 therefore	moderate	 amounts	 of	 hypoxia	 are	 well	 tolerated.	 In	 contrast	 the	 outer	medullary	
epithelium	is	more	vulnerable	to	hypoxia	due	to	the	heavy	reliance	on	oxidative	metabolism	and	the	limited	
O2	reserve.	The	epithelium	within	the	renal	papillae	 functions	 in	a	relatively	hypoxic	environment	with	the	
lowest	oxygen	tensions	and	are	therefore	adapted	to	be	able	to	maintain	viability	and	function	during	short	
periods	of	ischaemia.	However,	with	prolonged	ischaemia	the	epithelium	is	susceptible	to	ischaemic	injury.	
Cessation	of	arterial	blood	flow	in	the	kidney,	the	associated	hypoxia	and	subsequent	reperfusion	initiates	a	
complex	cascade	of	events	that	results	in	severe	cellular	injury	and	tissue	death.	Four	distinct	phases	of	the	
response	 to	 renal	 IRI	 have	 been	 identified.	 The	 initial	 adaptation	 phase,	 is	 characterised	 by	 depletion	 of	
mitochondrial	ATP,	movement	of	electrolytes	across	the	cell	membrane,	associated	cellular	oedema	and	the	
initiation	of	cellular	stress	responses.10	The	subsequent	extension	phase	typically	takes	place	when	the	renal	
blood	 flow	 has	 been	 restored,	 triggering	 a	 cascade	 of	 inflammatory	 processes.	 Parenchymal	 endothelium	
and	epithelium	cells	secrete	chemokines	and	cytokines,	expressing	adhesion	molecules,	which	results	in	the	
promotion	of	lymphocyte	activation.	These	lymphocytes	can	produce	reactive	oxygen	species,	which	results	
in	 stromal	 and	epithelial	 injury.	 This	 is	 followed	by	 the	maintenance	phase,	which	 is	 characterised	by	 cell	
death	induced	by	severe	inflammation	despite	the	restoration	of	blood	flow	and	resolution	of	hypoxia.	Often	
mild	 to	 moderate	 injury	 occurs	 in	 the	 adaptation	 phase,	 with	 the	 continued	 injury	 in	 the	 extension	 and	
maintenance	 phase	 leading	 to	 progression	 to	 severe	 injury	 and	 cell	 death.	 The	 final	 phase	 is	 termed	 the	
repair	 phase	 and	 is	marked	by	normalisation	of	 the	oxygen	 gradients	 and	 recession	of	 inflammation.	 It	 is	
characterised	by	 cellular	proliferation,	 tissue	 regeneration	and	 restoration	of	 function.	Kidney	dysfunction	
secondary	 to	 IRI	 is	 a	 result	 of	 vascular	 and	 renal	 tubular	 injury.10	 The	 subsequent	 endothelial	 damage	
produces	 vasoconstriction,	 arterial	 smooth	 muscle	 dysfunction,	 leukocyte	 congestion	 and	 inflammation,	
further	 tissue	 hypoxia	 and	 injury.	 The	 epithelial	 cells	 slough	 into	 the	 collecting	 ducts,	 causing	 urinary	
obstruction	with	retrograde	leaking	of	filtered	fluid.	Afferent	arteriolar	vasoconstriction	further	compounds	
the	 injury	with	microvascular	thrombosis,	plugging,	reducing	glomerular	filtration	rate	(GFR),	derangement	
of	the	counter	current	mechanism	and	reduction	or	absolute	cessation	of	urine	production	in	the	kidney.		
1.1.3.3 Multi-organ	dysfunction	syndrome	
A	 severe	 and	 potentially	 devastating	 clinical	 syndrome	 that	 results	 from	 the	 development	 of	 IRI	 is	multi-
organ	dysfunction	 syndrome	 (MODS).	MODS	 is	 characterised	by	 remote	 injury	 to	organs	 and	 system	with	
resulting	physiological	derangement,	and	 is	a	 leading	cause	of	death	 in	 critically	 ill	patients.	The	mortality	
rate	is	closely	correlated	to	the	number	and	extent	of	the	failed	organ	systems.	Risk	factors	that	have	been	
identified	for	the	development	of	MODS	include,	severe	sepsis,	major	surgery,	aortic	cross	clamping	during	
aortic	 surgery,	 haemorrhagic	 shock,	 pancreatitis	 and	 extensive	 skins	 burns.8	 The	 respiratory	 system	 is	
frequently	 injured	 in	 MODS,	 and	 is	 marked	 by	 the	 development	 of	 acute	 respiratory	 distress	 and	
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insufficiency	 within	 24	 hours	 of	 the	 initial	 ischaemic	 event.	 The	 development	 of	 the	 acute	 respiratory	
distress	 syndrome	 (ARDS)	 and	 respiratory	 failure	 may	 proceed	 this.18	 This	 will	 typically	 be	 followed	 by	
dysfunction	of	other	organ	systems	such	as	renal,	myocardial,	gastrointestinal,	hepatic	and	central	nervous	
system	 as	well	 as	 the	 immune	 and	 coagulation	 system,	 resulting	 in	 immunocompromise,	 thrombosis	 and	
disseminated	intravascular	coagulation	(DIC).	
1.1.4 Measuring	the	metabolic	markers	of	tissue	ischaemia	
Measuring	 the	concentration	of	 serum	 lactate	 is	an	appropriate	 index	of	 tissue	perfusion.	However,	 there	
are	several	limitations.	For	a	significant	increase	in	blood	lactate	to	occur,	lactate	must	be	released	into	the	
systemic	circulation	and	 the	 rate	of	production	must	exceed	hepatic,	 renal,	and	skeletal	muscle	uptake.	A	
systemic	 rise	 in	 serum	 lactate	 concentration	 may	 develop	 many	 hours	 after	 the	 critical	 oxygen	 delivery	
threshold	in	the	tissue	has	been	reached.	 	 It	has	been	demonstrated	that	venous	saturation	can	fall	below	
50%,	before	a	rise	 in	serum	lactate	concentration	 is	evident.19	Therefore	regional	hypoperfusion	of	 tissues	
may	 be	 present	 despite	 normal	 serum	 lactate	 concentrations.	 Sampling	 and	 analysing	 the	 lactate	
concentrations	 in	 the	 tissue	directly	 can	achieve	greater	 sensitivity	and	 specificity.	Quantifying	 the	 lactate	
and	 glucose	 concentrations	 in	 the	 tissue,	 in	 order	 to	 calculate	 the	 lactate/	 glucose	 (L/G)	 ratio	 is	 a	 good	
marker	 of	 anaerobic	 metabolism,	 and	 hence	 tissue	 ischaemia.	 During	 anaerobic	 metabolism	 glucose	 is	
converted	 to	 lactate	 which	 is	 catalysed	 by	 lactate	 dehydrogenase.	 In	 the	 presence	 of	 tissue	 ischaemia,	
without	 the	 delivery	 of	 new	 glucose	 molecules	 the	 glucose	 is	 consumed	 to	 provide	 energy	 and	 the	
concentrations	 will	 decrease.	 Subsequently	 the	 lactate	 concentration	 and	 the	 L/G	 ratio	 will	 increase.	
Similarly,	 the	 lactate/pyruvate	 (L/P)	 ratio	 is	 also	 an	 effective	 tool	 to	 gauge	 tissue	 ischaemia.	 These	 two	
techniques	 allow	 us	 to	 differentiate	 between	 the	 causes	 of	 a	 tissue	 lactate	 rise.	 Aerobic	 hypermetabolic	
conditions	such	as	sepsis	and	trauma	result	in	an	increase	in	lactate	concentration,	however	there	will	be	a	
concomitant	 rise	 in	 both	 pyruvate	 and	 glucose	 concentrations	 due	 to	 increased	 perfusion	 and	 a	
catecholamine	 surge	which	 stimulates	 both	 glycogenolysis	 and	 gluconeogenesis.	 In	 this	 environment,	 the	
L/G	and	L/P	 ratios	 stay	 largely	 constant.	Monitoring	glycerol	 concentration	changes	 in	 the	 interstitial	 fluid	
can	 also	 be	 used	 as	 a	 marker	 of	 ischaemic	 cellular	 injury.20	 The	 fall	 in	 pH	 in	 the	 extracellular	 fluid	 as	
anaerobic	metabolism	ensues	causes	enzyme	dysfunction	and	the	 ionic	pumps	they	control,	which	 in	 turn	
effects	the	ionic	gradient	across	the	cellular	membranes.	An	influx	of	calcium	ions	caused	by	impairment	to	
the	calcium	channel	pumps,	activates	phospholipases	that	 in	turn	degrades	the	phospholipid	chains	within	
the	cellular	membrane.	This	results	in	the	accumulation	of	glycerol	within	the	tissue	and	the	interstitial	fluid,	
allowing	sampling	and	analysis.	Measuring	specific	metabolites	and	their	precursors,	such	as	glucose,	lactate,	
pyruvate	and	glycerol	allows	direct	quantification	of	cellular	metabolism,	oxygen	delivery	and	hence	blood	
flow.		
1.2 MICRODIALYSIS	
1.2.1 Principle	of	microdialysis	
Microdialysis	is	a	minimally	invasive	technique	that	allows	the	interstitial	composition	of	organic	tissue	to	be	
characterised	 in	 vivo.	 A	 fine	 tubular	 dialysis	 catheter	 is	 introduced	 into	 the	 target	 tissue.	 A	 physiological	
saline	based	solution	is	then	slowly	pumped	across	a	semipermeable	membrane,	which	equilibrates	with	the	
surrounding	extracellular	tissue	fluid	(Figure	3).	Low	molecular	weight	compounds	can	diffuse	into	or	out	of	
the	 lumen	of	the	catheter	along	concentration	gradients.	Large	molecules,	such	as	proteins	and	molecules	
bound	to	proteins,	are	excluded	by	the	semipermeable	membrane.	The	small	pore	size	of	the	microdialysis	
membrane	acts	as	an	effective	enzyme	inhibitor	by	excluding	enzymes	that	may	degrade	specific	analytes.	
Once	 the	 molecules	 enter	 the	 lumen	 of	 the	 catheter,	 the	 dialysate	 can	 then	 be	 sampled,	 stored	 and	
analysed.	During	 this	 process,	 fluid	 is	 not	 removed	 from	 the	 tissue	 being	 studied,	 allowing	 sampling	with	
minimal	 physiological	 disruption.	 Continuous	 tissue	monitoring	 is	 achieved	 by	 the	 insertion	 of	 these	 fine	
microdialysis	catheters.	
	
Figure	3	–	The	Microdialysis	Catheter	mimics	a	‘blood	capillary’		
Illustration	by	author	–	SD.	There	is	an	exchange	of	substances	from	the	extracellular	fluid.	Molecules	from	the	extracellular	fluid	diffuse	across	the	
semi-permeable	membrane	and	into	the	perfusion	fluid.	They	are	then	carried	out	of	the	catheter	for	sampling	and	further	analysis.	
1.2.2 Limitations	
With	 technological	 advances,	 microdialysis	 probes	 and	 catheters	 are	 increasingly	 becoming	 smaller	 and	
more	effective,	however	 the	 invasive	nature	of	 this	 technique	poses	ethical	questions	and	 infers	practical	
limitations.	Morgan	et	al,	 in	a	quantitative	assessment	of	 the	damage	endured	by	 the	blood	brain	barrier	
when	 utilising	 microdialysis	 as	 a	 sampling	 technique,	 identified	 fluctuations	 in	 the	 microcirculation	 and	
alterations	 in	 the	 tissue	morphology.21	Rates	of	cellular	metabolism	and	 the	 integrity	of	 the	barrier	where	
also	 disrupted.	 Acute	 reactions	 from	 the	 trauma	 of	 implantation,	 such	 as	 localised	 necrosis	 and	
Blood	capillary
cell
Microdialysis	probe
Extracellular	
fluid
	 28	
inflammatory	responses	must	be	considered	when	undertaking	long-term	sampling,	as	they	may	affect	the	
experimental	outcome.	Numerous	studies	have	shown	the	optimal	 time	period	to	perform	microdialysis	 is	
within	the	first	48	hours	after	implantation.22,23	
Offline	microdialysis	has	a	relatively	low	temporal	and	spatial	resolution	compared	to	other	biosensors.	The	
temporal	resolution	can	be	determined	by	the	length	of	the	sampling	intervals	and	the	spatial	resolution	is	
determined	by	 the	dimensions	of	 the	probe.	 The	probe	 size	 requirement	 varies	depending	on	 the	 clinical	
application	and	the	target	tissue.	 Intracerebral	application	requires	probes	of	1-2	mm	whilst	subcutaneous	
monitoring	may	require	probe	lengths	of	a	few	centimetres	and	diameters	of	a	few	hundred	micrometres.		
In-vivo	studies	utilising	microdialysis	 sampling	are	often	 limited	by	 the	probe’s	 recovery.	Determination	of	
recovery	can	be	time	consuming	and	often	requires	pilot	experiments.	Recovery	is	largely	dependent	on	the	
perfusion	flow	rate,	with	a	 lower	flow	rate	allowing	a	higher	recovery.	However,	 if	 the	flow	rate	 is	set	too	
low,	 very	 small	 volumes	 of	 dialysate	 are	 produced	 for	 sampling.	 Small	 volumes	 of	 dialysate	 may	 be	
insufficient	 for	 adequate	 analysis	 and	 can	 introduce	 large	 inaccuracies	 if	 subjected	 to	 evaporation.	 A	 low	
flow	 rate	 also	 has	 the	 effect	 of	 reducing	 the	 temporal	 resolution	 of	 the	 study.	 Careful	 consideration	 is	
needed	to	optimise	the	 flow	rate,	maximise	the	recovery	and	hence	the	sensitivity	of	 the	analytical	assay.	
Further	 complexity	 may	 arise	 when	 lipophilic	 compounds	 are	 present	 in	 the	 analyte.	 These	 compounds	
adhere	to	the	tubing,	probe	and	analyser	components	resulting	in	significant	inaccuracies.	
1.2.3 Set	up	of	the	online	rapid	sampling	microdialysis	analyser	
Many	studies	employing	microdialysis	as	a	sampling	technique	utilise	an	‘offline’	method.	The	low	flow	rate	
used	in	such	studies	results	in	extremely	small	volumes	of	dialysate,	to	the	order	of	2μl	per	minute.	This	fluid	
is	 collected	 in	 airtight	 vials,	 frozen	 and	 stored	 for	 later	 batch	 analysis.	 Most	 investigators	 use	 the	
commercially	 available	 CMA	 600	 analyser	 (CMA/Microdialysis,	 Stockholm,	 Sweden),	which	 utilises	 a	 high-
pressure	 liquid	 chromatography	 (HPLC)	 system	 for	 separation	 of	 components	 and	 a	 range	 of	 detection	
methods	 including	 absorbance	 and	 fluorescence.	 The	 time	 burden	 for	 clinical	 and	 research	 staff,	 risk	 of	
evaporation	 altering	 concentrations,	 pooling	 of	 samples	 which	 affects	 the	 concentration	 of	 analytes,	 and	
practical	 issues	with	 having	many	 of	 samples	make	 ‘offline’	microdialysis	 challenging.24	 The	 characteristic	
feature	 of	 the	 research	 projects	 presented	within	 this	 thesis	 is	 the	 use	 of	 a	 novel	 ‘online’	 rapid	 sampling	
microdialysis	 analyser.	 In	 this	 system,	 the	dialysate	 is	 directed	 from	 the	outlet	 tubing	of	 the	microdialysis	
probe	 to	 the	 system	 for	 immediate	 analysis.	 Analysis	 takes	 place	 every	 30	 seconds	 and	 is	 capable	 of	
operating	independently	for	up	to	5	days	with	minimal	input.	The	system	has	previously	been	validated	in	an	
animal	experimental	model,	 in	clinical	studies	examining	bowel	 ischaemia	and	whilst	employed	to	monitor	
cerebral	metabolism	in	the	intensive	care	unit	following	traumatic	brain	injury.25,26	The	aim	of	the	assay	is	to	
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sample	at	30-second	intervals	and	determine	the	glucose	and	lactate	concentrations	within	the	dialysate	and	
therefore	the	target	tissue.	The	rsMD	system	is	composed	of	four	major	elements:	
1. Microdialysis	sampling	of	analytes	from	the	target	tissue	
2. Flow	injection	analysis	(FIA)	system	which	creates	a	liquid	stream	of	dialysate	combined	with	an	external	
mediator	buffer	
3. Bio	recognition	element,	where	the	biological	molecules	within	the	dialysate	are	recognised	
4. Transduction	component,	where	the	biological	recognition	of	the	analyte	is	converted	into	a	measured	
electrical	signal		
1.2.3.1 Microdialysis	
Microdialysis	 was	 originally	 conceptualised	 in	 the	 early	 1970's	 by	 Professor	 Urban	 Ungerstedt	 of	 the	
Karolinska	 Institute	 in	Stockholm.	 	Whilst	examining	the	cross-section	of	a	blood	vessel	among	fluorescent	
nerve	endings,	Ungerstedt	conceptualised	the	use	of	a	semipermeable	membrane	within	a	dialysis	tube	as	
"an	artificial	blood	capillary"	in	order	to	monitor	chemical	processes.27	Microdialysis	is	based	on	the	passive	
diffusion	 of	 molecules	 through	 a	 semipermeable	 membrane.28	 The	 cylindrical	 membrane	 utilised	 has	 a	
diameter	 of	 250	 μM,	 with	 a	 pore	 size	 that	 confers	 a	 20000	 Daltons	 cut	 off.	 This	 limits	 the	 size	 of	 the	
molecules	 passing	 into	 the	 dialysate,	 preventing	 large	molecules	 such	 as	 proteins	 and	 enzymes	 diffusing	
across	and	therefore	 increasing	 the	selectivity	of	 the	 technique.	 In	a	clinical	 setting	 the	membrane	cut	off	
also	prevents	the	potentially	harmful	passage	of	tissue	born	viruses	and	prions	in	to	the	dialysate.	A	solution	
that	matches	the	physiological	ionic	composition	of	the	extracellular	fluid	is	pumped	through	the	catheter	at	
a	 predetermined	 rate,	 any	 molecules	 present	 in	 the	 extracellular	 fluid	 then	 diffuse	 down	 concentration	
gradients	 across	 the	membrane	 into	 the	dialysate.	 The	 clinical	microdialysis	 catheter	 is	 a	 concentric	 tube,	
with	its	wall	acting	as	the	semi-permeable	membrane.	The	physiological	solution	is	perfused	into	the	probe	
via	an	inner	tube	and	an	outer	tube	carries	out	the	dialysate	fluid	for	analysis.	
1.2.3.2 Flow	Injection	Analysis	System	
FIA	 is	 an	 analytical	 method	 where	 the	 dialysate	 is	 automatically	 injected	 into	 a	 moving	 liquid	 stream,	
through	 low	 volume	 tubing	 and	 directly	 into	 the	 valve	 system.	 The	 valve	 then	 samples	 the	 dialysate	 and	
200nls	of	dialysate	is	then	injected	into	one	of	two	analysis	streams.	Each	stream	is	then	accelerated	through	
the	enzyme	reactors.	
1.2.3.3 Bio	recognition	
The	 biosensor,	which	 provides	 the	 system	with	 bio	 recognition,	 comprises	 a	 protein	with	 specific	 surface	
recognition	sites	for	the	desired	analyte.	Enzymes	are	chosen	for	their	high	substrate	specificity.	
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1.2.3.4 Transduction	
Transduction	 is	 the	 conversion	 of	 the	 products	 of	 the	 enzymatic	 reaction	 into	 a	 measurable	 response.	
Enzyme	 based	 biosensors	 can	 be	 divided	 in	 three	 broad	 categories:	 First	 generation	 biosensors	 are	 the	
product	 of	 the	 enzymatic	 reaction	 triggers	 an	 electrical	 response	 as	 it	 directly	 diffuses	 to	 the	 electrode	
within	the	biosensor.	Glucose	oxidase	catalyses	the	oxidation	of	the	substrate	molecule	 in	the	presence	of	
O2,	resulting	in	the	reduction	of	O2	to	H202.	This	 is	a	cyclic	process	and	requires	a	continuous	supply	of	O2.	
Such	biosensors	are	used	in	cardiovascular	surgery	to	detect	O2	 levels.29	A	 limitation	of	these	biosensors	 is	
the	erroneous	detection	of	other	oxidisable	molecules,	 such	as	ascorbic	acid,	which	 is	naturally	occurring.	
Second	generation	biosensors	carry	electrons	from	the	enzyme	reaction	to	the	electrode	surface	by	utilising	
a	 synthetic	 mediator.30	 Ferrocene	 monocarboxylate	 (Fc)	 is	 commonly	 used	 to	 carry	 electrons	 from	 the	
substrate	oxidase	enzyme	to	the	electrode,	thereby	avoiding	oxygen	interference.	This	biosensor	is	utilised	
in	 blood	 glucose	monitoring	 kits	 commonly	 used	 in	 a	 clinical	 ward.	 These	 biosensors	measure	 the	 signal	
response	by	direct	oxidation	or	reduction	of	the	substrate	enzyme,	thereby	minimising	the	 interference	of	
other	 oxidisable	 or	 reducible	molecules.	 Such	biosensors	 require	 the	use	of	 small	 redox	proteins	 or	 small	
enzymes	 such	 as	 horseradish	 peroxidase	 (HRP).31	 A	 two-layered	 biosensor	 is	 typically	 used	 allowing	
adequate	 flow	 of	 substrate	 and	 avoiding	 interference	 from	 ascorbic	 acid	 (Figure	 4).	 The	 first	 nanoporous	
membrane	 contains	 immobilised	 substrate	 (glucose	 or	 lactate)	 oxidase	 enzyme	 (SOx),	 an	 oxidoreductase	
enzyme	which	simultaneously	catalyses	the	oxidation	of	the	substrate	molecule	and	the	reduction	of	oxygen	
to	hydrogen	peroxide	(H2O2).	The	second	membrane	contains	another	oxidoreductase	enzyme,	horseradish	
peroxidase	 (HRP),	 which	 catalyses	 the	 reduction	 of	 H2O2	 produced	 in	 the	 previous	 step	 to	 H2O,	 and	 the	
oxidation	 of	 Ferrocenium	 (II)	 to	 Ferrocenium	 (III)	 ions.	 The	 Fc	 (III)	 ions	 are	 then	 detected	 by	 means	 of	
reduction	on	the	surface	of	the	electrode,	producing	a	current.	The	transduction	in	this	system	is	formed	by	
an	electrochemical	sensor,	measuring	at	constant	potential,	the	current	created	by	the	electrons	produced	
as	a	result	of	the	enzymatic	processes.	
Figure	4	–	Modified	second	generation	biosensor	using	horseradish	peroxidase	
Illustration	by	author	–	SD	
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1.2.4 Recovery	
The	 dialysing	 properties	 of	 a	 microdialysis	 catheter	 can	 be	 expressed	 as	 its	 recovery	 (R)	 for	 a	 particular	
substance.	Microdialysis	relies	on	diffusion	of	molecules	along	concentration	gradients	from	the	extracellular	
fluid	 across	 the	 semi-permeable	 membrane	 into	 the	 catheter.	 Due	 to	 the	 constant	 flow	 within	 the	
microdialysis	catheter,	there	is	often	insufficient	time	for	an	equilibrium	to	develop	between	dialysate	and	
extracellular	fluid.	Subsequently,	the	concentration	of	analytes	 in	the	dialysate	 is	often	 less	than	the	 ‘true’	
concentration	in	the	extracellular	fluid.	The	ratio	between	the	concentration	of	the	analyte	in	the	dialysate	
(outlet	 tubing)	and	the	concentration	of	 the	analyte	 in	 the	extracellular	 fluid	 in	 the	tissue	 is	known	as	 the	
relative	 recovery	 (RR).	The	RR	of	a	microdialysis	catheter	 is	 inversely	proportional	 to	 the	rate	of	perfusion	
within	the	catheter	and	can	never	reach	100%	in	the	presence	of	flow.		
Numerous	methods	have	been	identified	that	allow	the	determination	of	RR	in	vitro.	Jacobson	et	al	in	1985	
introduced	the	zero	flow	method	where	the	fact	that	passive	diffusion	across	the	membrane	in	states	of	zero	
flow	depends	on	the	concentration	gradient	of	the	metabolites	and	is	used	as	a	measurement	of	the	RR.32	
Another	technique	for	calculating	the	RR	is	the	no-net-flux	method	described	by	Lonnroth	et	al,	which	states	
that	when	there	is	no	concentration	gradient	between	two	fluid	compartments,	the	net	flux	of	metabolites	
will	 be	 zero.33	 This	 theory	 is	 further	 extrapolated	 with	 the	 retro	 dialysis	 method,	 whereby	 known	
concentrations	of	the	metabolites	are	added	to	the	perfusion	fluid.	The	concentration	of	the	metabolites	in	
the	dialysate	fluid	can	then	be	measured,	allowing	calculation	of	the	RR:	
!!"#	%"&'( = *"# − *(,&*"# 	 	
Cin	and	Cout	are	the	concentrations	of	the	metabolites	in	the	perfusion	fluid	and	in	the	dialysate,	respectively.	
Determination	of	 in	vivo	recovery	is	complicated,	with	multiple	varying	factors.	These	include	as	flow	rate,	
physiology	 of	 the	 tissue,	 molecular	 weight	 of	 analyte,	 enzymatic	 degradation	 of	 analyte,	 length	 of	 the	
membrane,	blood	flow	within	the	tissue,	shape	and	ionic	charge	of	the	substance	and	temperature.	These	
factors	can	be	standardised	in	an	experimental	model.	Therefore	with	a	pre-set	flow	rate,	in	a	specific	target	
tissue,	using	the	same	microdialysis	catheter,	 the	RR	for	a	known	substance	will	be	constant.34	Changes	 in	
tissue	 physiology	 can	 however	 not	 always	 be	 controlled.	 In	 an	 experimental	 model,	 Stallknecht	 et	 al	
demonstrated	a	significant	 increase	 in	the	RR	of	glycerol	 from	0.75	to	0.95	 in	human	skeletal	muscle	after	
strenuous	exercise.35	Using	a	retro-dialysis	method,	the	study	identified	a	relative	loss	of	the	radio	labelled	
Glycerol	(14C)	added	to	the	perfusate,	indicating	an	increase	in	recovery.	The	reason	for	this	increase	in	the	
RR	of	exercising	muscle	is	unknown,	although	the	passive	movement	of	muscle	has	been	shown	to	increase	
the	recovery	of	K+	in	a	similar	study.	36	In	a	clinical	prospective	study,	monitoring	the	myocardium	of	patients	
undergoing	aortic	valve	and	bypass	surgery,	the	authors	showed	the	RR	of	glucose	and	lactate	decreased	as	
	 32	
the	 temperature	 of	 the	 tissue	 fell.	 	 This	 phenomenon	 is	 a	 result	 of	 the	 reduced	 Brownian	 motion	 of	
molecules	 and	 subsequent	 decrease	 in	 diffusion	 of	 molecules	 across	 the	 membrane.37	 These	 findings	
emphasise	the	importance	of	considering	changes	in	recovery	when	interpreting	microdialysis	data.		When	
utilising	 microdialysis	 to	 monitor	 continuing	 metabolic	 processes,	 a	 balance	 between	 a	 flow	 rate	 that	
provides	an	acceptable	RR	and	a	flow	rate	that	supplies	sufficient	dialysate	volumes	for	accurate	analysis	is	
needed.	The	application	of	a	rapid	sampling	method	can	effectively	analyse	small	volumes	of	dialysate	fluid,	
to	the	order	of	nano	litres,	delivered	by	a	microdialysis	catheter.24,25	As	metabolic	processes	continue,	RR	will	
change	equally	for	all	substances	being	monitored.	Therefore,	the	use	of	ratio	changes	between	metabolites	
such	as	the	glucose/lactate	or	lactate/pyruvate	ratio	successfully	negates	the	artefact	effect	of	a	change	in	
RR.	
1.2.5 Microdialysis	in	research	
When	local	oxygen	delivery	fails	to	meet	the	metabolic	needs	of	the	tissue,	 Ischaemia	develops	within	the	
tissue	 resulting	 in	 the	 commencement	 of	 anaerobic	 metabolism.	 There	 are	 subsequent	 changes	 in	 the	
concentration	of	metabolites	 in	 the	glycolytic	pathway.	These	substrates	can	be	measured	and	monitored	
continuously	by	microdialysis.	The	first	studies	of	microdialysis	were	performed	in	brain	tissue,	where	it	was	
demonstrated	 that	 the	 technique	 could	 monitor	 local	 concentrations	 of	 neurotransmitters.38,39	 The	
technique	was	further	developed	in	animal	models	to	monitor	metabolism,	reflecting	local	blood	perfusion	
and	thereby	 ischaemia.40,41	Ungerstedt	et	al	were	the	 first	 to	outline	the	clinical	potential	of	microdialysis,	
demonstrating	that	microdialysis	catheters	could	be	implanted	into	cerebral	tissue	during	neurosurgery.34,42	
Currently	microdialysis	is	used	to	monitor	metabolic	changes	during	ischaemia	in	patients	with	subarachnoid	
haemorrhage,	neurovascular	surgery	and	in	patients	with	traumatic	brain	lesions,	where	it	may	be	a	guiding	
tool	in	therapy.43-47	In	reconstructive	surgery,	microdialysis	can	be	used	as	a	postoperative	monitoring	tool	to	
detect	 compromised	 perfusion	 in	 free	 flaps,	 allowing	 early	 surgery	 before	 irreversible	 ischaemia	 takes	
place.48,49	Microdialysis	has	been	used	to	monitor	cardiac	metabolism,	when	specific	observations	have	been	
made	 within	 the	 myocardial	 septum	 that	 are	 not	 recordable	 with	 conventional	 techniques.50-52	 During	
vascular	surgery,	acute	variations	in	limb	flow	can	be	detected	using	subcutaneous	microdialysis.53	To	date	
microdialysis	has	been	used	to	monitor	ischaemia	experimentally	in	a	range	of	tissues	including	brain,	liver,	
bowel,	kidney,	heart,	muscle	and	fat	however	also	been	used	in	a	wide	variety	of	other	experimental	models	
which	are	not	necessarily	associated	with	ischaemic	processes.50,54-59		
Microdialysis	has	also	been	utilised	to	monitor	gastrin	release	in	the	stomach,	determining	the	response	to	
ingestion	of	 food,	blockade	of	acid	production	and	vagal	excitation.60	Cibicek	et	al	utilised	microdialysis	 in	
rats,	 monitoring	 physiological	 measurements	 and	 gastric	 ischaemia	 after	 coeliac	 artery	 ligation.61	 They	
demonstrated	that	the	increase	in	the	ratios	of	lactate/pyruvate	and	lactate/glucose	was	more	pronounced	
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during	 gastric	 ischaemia,	 than	 the	 changes	 in	 glycerol	 and	 more	 effective	 in	 identifying	 ischaemia	 than	
monitoring	 the	 flow	 indicator	 of	 H2O	 efflux. Numerous	 investigators	 have	 sampled	 histamine	 from	 the	
entero-chromaffin	cells	in	the	gastric	mucosa	during	surgically	created	ischaemia.62	Sorensen	et	al	monitored	
the	postoperative	course	of	free	jejunal	flaps	when	used	in	the	reconstruction	of	the	oesophagus	in	patients	
undergoing	oesophagectomy.	They	monitored	 for	 signs	of	 ischaemia	and	correlated	 this	with	 the	onset	of	
complications	 such	 as	 leaks	 and	 dehiscence.	 They	 demonstrated	 that	 lactate/glucose	 ratios	were	 reliable	
markers	of	ischaemia	and	advocated	microdialysis	as	a	tool	for	monitoring	free	jejunal	flaps.63	 
The	 metabolism	 of	 the	 liver	 with	 microdialysis	 sampling	 has	 also	 been	 examined	 by	 numerous	 groups.	
Takahashi	 et	 al,	 using	 in	 vivo	 microdialysis	 in	 rats,	 showed	 that	 stimulation	 of	 hepatic	 nerves	 leads	 to	
glycogenesis	 via	 activation	 of	 α-adrenergic	 receptors	 and	 eicosanoids	mediators.64	 Nowak	et	 al	measured	
lactate,	glucose,	pyruvate	and	glycerol	 following	 liver	 transplantation	 in	a	porcine	model.	The	metabolites	
were	 sampled	every	 20	minutes,	 during	 the	donor	 retrieval,	 cold	 preservation	 and	post	 transplantation.65	
They	subsequently	 translated	 their	methodology	 into	a	clinical	 study,	monitoring	 for	metabolic	changes	 in	
liver	graft	in	10	patients.66	This	study	validated	the	technique	for	the	in	vivo	monitoring	of	the	liver	following	
transplantation.	Björnsson	et	al	and	Lsaksson	et	al	were	able	to	independently	utilise	in	vivo	microdialysis	in	
the	monitoring	of	metabolites	in	a	rodent	ischaemia	reperfusion	model.67,68	
When	 employed	 in	 pharmacokinetic	 studies,	 microdialysis	 has	 the	 advantage	 that	 it	 samples	 only	 the	
unbound	fraction,	which	 is	the	pharmacologically	active	component	of	the	drug.	 It	eliminates	the	effect	of	
enzyme	 degradation	 and	 further	 sample	 preparations.	 For	 example,	 Beier	 et	 al examined	 the	 role	 of	
microdialysis	 in	 the	 intraperitoneal	 monitoring	 of	 rodents.69 Microdialysis	 is	 widely	 used	 in	 the	 clinical	
monitoring	of	ischaemia	following	traumatic	brain	injury	or	intracranial	haemorrhages	in	the	neurointensive	
care	unit.70	Microdialysis	 sampling	of	metabolites	 in	 this	 setting,	demonstrates	 characteristic	 changes	 that	
allows	 the	 surgeons	 to	 identify	 secondary	 ischaemia	more	 accurately	 and	 earlier	 than	 typical	monitoring.	
Investigators	 have	 demonstrated	 that	 increasing	 levels	 of	 glycerol	 within	 the	 interstitium	 correlates	 with	
damage	 of	 neuronal	 membranes	 and	 an	 increasing	 lactate/pyruvate	 ratio	 is	 an	 early	 marker	 of	 cerebral	
ischaemia.71	 Microdialysis	 is	 now	 routinely	 used	 in	 Sweden	 to	 monitor	 patients	 after	 brain	 trauma	 and	
dramatically	helps	to	reduce	mortality	in	patients	with	severe	head	injuries.72 
In	 vivo	microdialysis	 has	 been	 used	 to	 sample	 cardiac	 troponin	 T	 and	 aspartate	 transaminase	 in	 patients	
undergoing	 coronary	 artery	 bypass	 surgery.73	 Kennergen	 et	 al	 demonstrated	 that	 increasing	 myocardial	
concentrations	 of	 troponin	 T	 and	 aspartate	 transaminase	 correlated	 closely	 with	 changes	 seen	 on	
electrocardiography	and	directly	preceded	serum	concentration	rise.73	
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1.3 PREVIOUS	RESEARCH	UTILISING	THE	NOVEL	CUSTOM	RSMD	
ANALYSER	
The	online	rapid	sampling	microdialysis	analyser	 (rsMD)	that	was	utilised	 in	all	 the	studies	 included	 in	 this	
PhD,	was	 designed,	 assembled,	modified	 and	 optimised	 at	 Imperial	 College	 London,	 by	 Professor	Martyn	
Boutelle’s	group	 in	the	Department	of	Bioengineering.	The	 initial	clinical	application	for	the	novel	analyser	
was	 in	 the	monitoring	 of	metabolism	 in	 the	 cerebral	 cortex	 of	 the	 brain	 in	 patients	 requiring	 emergency	
craniotomy	 for	 traumatic	 or	 spontaneous	 intracerebral	 haematoma.	 Parkin	 et	 al	 placed	 a	 sterile	
microdialysis	catheter	within	the	cerebral	cortex	in	patients	following	surgery.	Their	aim	was	to	investigate,	
at	high	temporal	resolution,	the	dynamic	changes	in	glucose	and	lactate	concentrations	during	the	evolution	
of	an	acute	brain	injury	in	order	to	better	understand	the	pathophysiology.74	Subsequent	to	this,	Bhatia	et	al	
utilised	 the	 analyser	 to	 detect	 adverse	 metabolic	 changes	 in	 the	 brain	 during	 intracranial	 aneurysm	
surgery.26	Sterile	microdialysis	catheters	were	inserted	into	the	cortex	at	the	start	of	surgery	and	monitoring	
took	place	whilst	patients	underwent	clipping	of	their	aneurysms.	The	rsMD	was	successfully	able	to	detect	
metabolic	 changes	 intraoperatively,	 reflecting	 disturbances	 in	 blood	 flow	 in	 vulnerable	 arterial	 territories	
and	localised	ischaemia	secondary	to	cortical	retraction	by	the	surgeon.	
Following	 these	 clinical	 studies,	 the	 Department	 of	 Bioengineering	 collaborated	 with	 the	 Department	 of	
Surgery,	 led	by	 Professor	Ara	Darzi,	with	 the	 aim	of	 adapting	 the	 rsMD	 system	 for	 use	 in	 gastrointestinal	
surgery.	The	researchers,	Mr	Samer	Deeba	and	Ms	Emma	Corcoles,	had	the	primary	aim	of	in-vivo	detection	
and	monitoring	of	 ischaemia	 in	human	bowel.	 In	their	 first	study,	Deeba	et	al,	used	the	rsMD	to	evaluate,	
the	 metabolic	 changes	 that	 occur	 intraoperatively	 within	 the	 colon	 during	 surgical	 resection.75	 They	
recruited	 seven	 patients	 that	 were	 undergoing	 elective	 laparotomies	 and	 left	 hemicolectomies	 for	 both	
benign	 and	 malignant	 processes.	 Following	 intraoperative	 colonic	 mobilisation,	 prior	 to	 ligation	 of	 the	
arterial	supply,	sterile	microdialysis	catheters	were	tunnelled	into	the	anti-mesenteric	borders	of	each	colon.	
The	 catheter	was	 connected	 to	 the	 rsMD,	which	 in	 turn	 analysed	 for	 serial	 glucose	 and	 lactate	 dialysate	
concentrations.	 The	 arterial	 supply	was	 then	 ligated	 and	 the	 colon	 resected	whilst	monitoring	 continued.	
After	 transection	 of	 the	 arteries,	 the	 dialysate	 glucose	 concentration	 dropped	whilst	 the	 dialysate	 lactate	
concentration	 increased	 in	 all	 cases.	 The	 authors	 calculated	 the	mean	 changes	 in	 analyte	 concentrations	
away	 from	 the	 baseline	 and	 identified	 that	 glucose	 concentrations	 decreased	 at	 10	 minutes	 [-
0.261±0.085mM	(p=0.0175,	n=7)].	The	concentrations	rose	 following	this	and	recovered	 [0.062±	0.232mM	
(p=0.795,	 n=7)]	 at	 17	 minutes.	 Within	 a	 few	 minutes	 following	 this,	 there	 was	 a	 dramatic	 and	 steady	
decrease	in	glucose	concentration	in	all	patients.	When	comparing	the	lactate	concentrations	in	these	cases,	
the	authors	found	that	levels	were	steady	with	minimal	deviation	away	from	the	baseline	during	the	first	17	
minutes.	Following	this,	there	was	a	steady	increase	in	lactate	concentration,	which	inversely	mirrored	the	
fall	 in	 glucose	 concentration.	 The	 authors	 suggested	 that	 the	 initial	 increase	 in	 glucose	 concentration	
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following	 ligation	 of	 the	 arterial	 supply	 was	 secondary	 to	 compensatory	 autoregulatory	 responses	 that	
mobilised	 local	 glucose	 stores,	 until	 a	 threshold	was	 reached	 in	which	 this	mechanism	ceased	 to	 function	
adequately.	 Deeba	 et	 al’s	 second	 study	 centred	 on	 monitoring	 and	 detecting	 ischaemia	 within	
gastrointestinal	 anastomoses	 in	 animal	 models.	 The	 authors	 created	 five	 colo-colic	 stapled	 anastomoses	
with	the	sigmoid	colon	in	anaesthetised	pigs.	Each	anastomosis	was	subjected	to	ischaemia	by	clamping	the	
feeding	 arteries	 within	 the	mesentery.	 Each	 anastomosis	 was	monitored	 during	 this	 period	 by	 the	 rsMD	
analyser	for	the	metabolic	markers	of	ischaemia.	Results	were	pooled	and	mean	values	were	calculated.	The	
authors	 identified	 a	 drop	 in	 the	 glucose	 dialysate	 concentration	 at	 30	minutes	 following	 clamping	 of	 the	
vessels,	by	0.044	±	0.003mM	(n=5).	With	respects	to	the	lactate	dialysate	concentrations,	there	was	an	initial	
rise	by	0.39	±	0.14mM	at	17	minutes	and	then	a	subsequent	fall	 to	0.18	±	0.056mM	at	30	minutes.	These	
findings	 were	 in	 keeping	 to	 those	 first	 in	 the	 study,	 with	 the	 consumption	 of	 glucose	 by	 ongoing	 tissue	
metabolism	and	increasing	lactate	production	secondary	to	the	commencement	of	anaerobic	metabolism.			
1.4 NEXT	STEPS	FOR	THE	RSMD		
The	 previous	 pilot	 studies	 by	Deeba	 et	 al	 proved	 the	 suitability	 and	 efficacy	 of	 using	 the	 rsMD	 in	 animal	
models	 with	 experimentally	 established	 bowel	 ischaemia.	 However,	 the	 next	 challenge	 would	 be	 to	
demonstrate	the	device’s	sensitivity	and	specificity	in	identifying	bowel	ischaemia	in	a	human	clinical	model	
with	pathologically	derived	ischaemia.	It	 is	this	challenge	that	provides	the	context	and	one	of	the	primary	
aims	of	this	PhD.		
Bowel	ischaemia	was	first	described	as	a	complication	following	vascular	surgery,	in	particular	secondary	to	
the	 ligation	 of	 the	 inferior	 mesenteric	 artery	 (IMA)	 during	 abdominal	 aortic	 aneurysm	 (AAA)	 repair.76,77	
However,	we	recognize	that	there	are	now	many	different	pathological	mechanisms	that	can	result	in	bowel	
ischaemia,	which	alongside	its	vague	clinical	presentation	makes	the	diagnosis	challenging.	Bowel	ischaemia	
following	 AAA	 repair	 has	 a	 reported	 incidence	 of	 up	 to	 42%	 and	 is	 associated	 with	 a	 significantly	 high	
morbidity	and	mortality.78,79	Early	diagnosis	and	prompt	surgical	intervention	are	paramount	in	reducing	the	
mortality	from	this	serious	complication,	however	current	modalities	for	investigation	are	neither	sufficiently	
sensitive	nor	accurate	to	establish	an	early	diagnosis.	It	is	clear	that	a	safe,	accurate	and	effective	tool	which	
allows	 objective	 quantification	 of	 ischaemia,	 is	 required	 to	 detect	 and	 monitor	 this	 clinical	 entity	 at	 the	
bedside.	With	this	mandate	in	mind,	I	aimed	to	develop	a	clinical	experimental	protocol	that	would	allow	an	
assessment	of	the	feasibility	of	utilising	online	rsMD	to	detect	for	the	presence	of	colonic	ischaemia	at	the	
bedside	 in	patients	 that	had	undergone	elective	AAA	repair.	This	was	the	 first	study	that	 I	undertook,	 it	 is	
described	in	greater	detail	in	Chapter	3.	
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Dehiscence	and	leakage	from	a	gastrointestinal	anastomosis	is	a	major	complication	and	is	associated	with	
considerable	morbidity	and	a	high	mortality	rate.	Reported	rates	of	colonic	anastomotic	leaks	vary	between	
3-15%,	with	mortality	 rates	up	 to	40%.	 80-82	Typically,	 the	diagnosis	 is	 confirmed	with	contrast	 radiological	
studies.	The	trigger	for	investigation	is	a	clinical	or	biochemical	deterioration	in	these	patients,	such	as	signs	
of	sepsis,	worsening	abdominal	pain,	prolonged	ileus	or	acute	renal	failure.		A	subset	of	these	patients	will	
quickly	develop	systemic	inflammatory	response	syndrome	(SIRS)	and	septic	shock,	which	can	lead	to	multi-
organ	 failure	 (MOF).	 There	 is	 a	 genuine	 clinical	 need	 for	 a	quantitative,	 in-vivo	 tool	 that	monitors	 in	 ‘real	
time’,	a	GI	anastomosis	during	the	early	post-operative	period.	This	tool	should	be	able	to	identify	‘high	risk’	
anastomoses	and	detect	subclinical	 leaks	before	the	onset	of	signs	and	symptoms,	thereby	preventing	the	
patient	 from	 becoming	 clinically	 compromised.	 In	 my	 second	 study,	 I	 aimed	 to	 assess	 the	 feasibility	 of	
utilising	online	rsMD	as	an	adjunct	in	developing	a	sensitive	tool	for	the	in-vivo	detection	of	ischaemia	within	
a	 GI	 anastomoses.	 This	 is	 detailed	 in	 Chapter	 4	 of	 this	 thesis.	 This	 builds	 on	 previously	 described	 work	
performed	by	Deeba	et	al	using	the	rsMD	in	an	ex-vivo	porcine	experimental	model.	My	final	study	focuses	
on	 solid	 organ	 transplantation	 and	 is	 borne	 out	 of	 personal	 interest	 and	 also	 of	 great	 clinical	 need.	
Transplantation	 of	 kidneys,	 liver	 and	 pancreas	 remains	 the	 gold	 standard	 treatment	 for	 failure	 of	 these	
organs.	As	such,	the	growth	in	the	number	of	patients	waiting	for	a	transplant	has	outpaced	the	supply	of	
available	 organs.83,84	With	 waiting	 lists	 expanding	 and	 patients	 dying	 everyday	whilst	 waiting	 for	 suitable	
organs,	further	examination	into	improving	graft	survival,	expanding	the	donor	pool	and	reducing	the	risk	of	
complications	 is	 imperative.	 During	 all	 stages	 of	 transplantation	 the	 allograft	 sustains	 varying	 degrees	 of	
ischaemic	 injury,	 this	 is	 associated	 with	 delayed	 graft	 function,	 reduced	 graft	 survival	 and	 increased	
morbidity.85	A	sensitive	and	accurate	tool	that	is	capable	of	detecting	and	quantifying	tissue	ischaemia	would	
have	a	key	role	 in	assessing	the	viability	of	allografts	during	the	transplantation	process.	Such	 information	
might	allow	 the	 surgeon	 to	 stratify	 the	 risk	of	 transplanting	extended	criteria	organs,	potentially	 reducing	
the	 number	 of	 organs	 discarded	 and	 expanding	 the	 donor	 pool.	 Such	 stratification	may	 guide	 the	 use	 of	
preservation	 strategies	 and	 novel	 tissue	 modulators	 possibly	 improving	 graft	 survival.	 My	 aim	 was	 to	
examine	the	 feasibility	of	employing	 the	rsMD	analyser	as	a	 tool	 for	organ	viability	assessment	during	 the	
various	phases	of	transplantation	by	monitoring	for	the	metabolic	markers	of	 ischaemia.	The	details	of	the	
various	experiments	conducted	towards	this	aim	are	discussed	in	Chapter	5.	
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1.5 IN-VIVO	DETECTION	OF	COLONIC	ISCHAEMIA	FOLLOWING	
ABDOMINAL	AORTIC	ANEURYSM	REPAIR	
1.5.1 Colonic	ischaemia	
Colonic	ischaemia	is	caused	by	circulatory	insufficiency	to	the	colon	and	has	a	wide	variety	of	causes.	Clinical	
manifestations	 range	 from	 transient	 spontaneously	 resolving	 injury	 associated	 with	 a	 good	 prognosis,	 to	
fulminant	 ischaemia	 with	 transmural	 infarction,	 resulting	 in	 necrosis,	 perforation	 and	 death.	 Bowel	
ischaemia	was	 initially	 first	described	as	a	complication	 following	 ligation	of	 the	 IMA	during	AAA	repair	or	
colonic	resection.76,77	It	is	now	recognised	to	be	attributable	to	a	wide	variety	of	causes,	which	along	with	its	
variable	clinical	presentations	and	associated	morbidity	and	mortality,	makes	the	diagnosis	and	subsequent	
management	challenging.		
There	are	several	factors	that	influence	and	regulate	perfusion	of	the	colon,	including	local	auto-regulatory	
mechanism,	metabolic	demand	of	the	tissue,	extrinsic	factors,	and	systemic	and	local	humoral	mediators.	A	
mismatch	between	the	supply	and	demand	of	oxygen	within	the	tissue	leads	to	ischaemia.	The	finely	tuned	
balance	that	develops	between	the	supply	of	oxygen,	key	nutrients	and	the	consumption	of	these	elements	
allows	 for	maximal	 and	 efficient	metabolic	 activity	within	 the	 tissue.	 This	 equilibrium	 can	 be	 affected	 by	
changes	 in	 the	 systemic	 circulation,	 such	 as	 clinical	 states	 characterised	 by	 generalised	 hypotension	 and	
hypoperfusion	or	by	functional	or	anatomical	changes	in	the	local	blood	flow,	such	as	arterial	vasospasm	or	
occlusion.		
The	 incidence	of	bowel	 ischaemia	 is	higher	 in	elderly	patients	with	risk	 factors	 for	atherosclerotic	vascular	
disease,	however	angiographic	studies	rarely	identify	an	index	lesion.	Visible	abnormalities	include	tortuous	
long	colic	arteries	and	narrowing	of	the	small	vessels.86	It	is	likely	that	disease	of	the	low	calibre	segmental	
vessels	 renders	 the	 bowel	 vulnerable	 to	 ischaemic	 injury	 in	 some	 patients.	 Several	 physiological	 factors	
predispose	the	colon	to	ischaemic	injury.	The	colon	contains	less	blood	perfusing	its	tissues	by	weight	than	
the	 rest	 of	 the	 gastrointestinal	 tract,	 and	 hence,	 relatively	 low	 blood	 flow.87-89	 In	 the	 colonic	 wall,	 the	
muscularis	and	submucosal	layers	contain	networks	of	capillaries,	which,	during	periods	of	ischaemic	stress,	
facilitate	perfusion	of	the	tissue	by	collateral	flow.	This	layer	is	less	developed	in	the	colon	than	in	the	small	
bowel,	resulting	in	a	relatively	higher	risk	for	the	development	of	ischaemic	colitis.	The	watershed	areas	of	
the	colon,	the	splenic	flexure	and	the	recto-sigmoid	junction,	have	a	limited	collateral	blood	supply	and	are	
also	susceptible	during	periods	of	low	flow.89-91	
Bowel	ischaemia	was	first	described	as	a	complication	secondary	to	vascular	surgery,	and	is	still	a	significant	
complication	of	abdominal	aortic	surgery.	Aortic	surgery	is	associated	with	up	to	a	42%	incidence	of	clinically	
detectable	bowel	 ischaemia.	This	 is	either	as	a	 result	of	 ligation	of	 the	 IMA	or	 intraoperative	hypotension	
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resulting	 in	hypoperfusion	of	 the	 IMA	 in	patients	with	 chronic	 atherosclerotic	occlusion,	 therefore	usually	
affecting	the	distal	left	sided	colon.92-94	Colonic	ischaemia	following	endovascular	abdominal	aortic	aneurysm	
repair	 (EVAR)	 has	 also	 been	 reported.95	 There	 are	 many	 conditions	 that	 predispose	 patients	 to	 bowel	
ischaemia,	however	the	commonest	generalised	mechanism	to	lead	to	colonic	 ischaemia	is	hypotension	or	
hypovolaemia.96	 Hypotension	 may	 be	 a	 result	 of	 sepsis	 or	 impaired	 left	 ventricular	 function	 and	
hypovolaemia	from	haemorrhage	or	dehydration,	all	of	which	will	compromise	the	systemic	perfusion	and	
trigger	compensatory	reflex	mesenteric	vasoconstriction.	As	previously	discussed,	the	colon	is	more	prone	to	
ischaemic	 injury	 than	 other	 organs	 including	 the	 remainder	 of	 the	 gastrointestinal	 tract.	 These	 low	 flow	
clinical	states	can	precipitate	ischemia	when	mesenteric	microvascular	atherosclerosis	is	present	and	also	in	
isolation	when	mesenteric	vasoconstriction	is	significant.		
Bowel	 ischaemia	can	be	classified	 into	two	broad	types:	non-gangrenous	and	gangrenous	type,	accounting	
for	85%	and	15%	respectively	of	all	cases.	Within	the	non-gangrenous	type,	two	further	forms	of	ischaemia	
are	described.	The	first	 is	transient	 ischaemia	 involving	the	mucosa	and	submucosa,	which	 is	typically	self-
limiting	with	 little	 sequelae.	The	second	 is	 ischaemia	of	 the	underlying	muscularis	which	 results	 in	healing	
with	 fibrosis	 and	 subsequent	 stricture	 formation.78	 Gangrenous	 bowel	 ischaemia	 is	 a	 result	 of	 transmural	
ischaemia	 or	 infarction,	 involving	 all	 the	 layers	 of	 the	 bowel	 wall,	 which	 results	 in	 gangrene	 and	
perforation.79	 Approximately	 70%	 of	 patients	 with	 confirmed	 bowel	 ischaemia	 present	 with	 pathology	
involving	the	descending	colon	and	rectum.	Ischaemia	at	the	splenic	flexure	constitutes	approximately	20%,	
with	the	remaining	10%	confined	to	the	ascending	colon.	Surgical	ligation	or	pathological	obliteration	of	the	
IMA,	 such	as	after	AAA	 repair,	 usually	 results	 in	 ischaemic	 injury	 to	 the	 left	 sided	 colon	 including	 sigmoid	
colon	 and	 rectum.	 Low	 blood	 flow	 systemic	 states,	 such	 as	 after	 trauma,	 can	 present	 with	 symptoms	
suggestive	of	bowel	ischaemia	within	the	retroperitoneal	portions	of	the	ascending	colon.		
1.5.2 Anatomical	relevance	
The	pathogenesis	of	colonic	ischaemia	is	better	understood	through	an	appreciation	of	the	vascular	anatomy	
of	the	colon	and	rectum.	The	colon	acquires	its	blood	supply	from	the	branches	of	the	superior	mesenteric	
artery	(SMA)	and	the	inferior	mesenteric	artery	(IMA),	whilst	the	rectum	and	anal	canal	are	supplied	by	the	
branches	of	the	IMA	and	the	internal	iliac	arteries.97	The	mesenteric	circulation	has	an	extensive	network	of	
collateral	communications	via	anastomotic	vascular	arcades	created	by	these	major	abdominal	vessels.	This	
collateral	 vasculature	 provides	 a	 potential	 mechanism	 for	 maintaining	 adequate	 perfusion	 to	 abdominal	
organs,	 including	 the	 colon	 and	 rectum,	 when	 major	 mesenteric	 branches	 are	 surgically	 ligated	 or	
obliterated,	or	pathologically	occluded.98	 The	main	 collateral	 communication	exists	between	 the	SMA	and	
IMA	and	 is	of	 significant	 importance	 for	 this	discussion.	The	principal	conduits	 for	collateral	 flow	between	
the	SMA	and	the	IMA	are	the	marginal	artery	of	Drummond,	the	arc	of	Riolan	and	the	meandering	artery	of	
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Moskowitz.	 The	 marginal	 artery	 of	 Drummond	 is	 the	 primary	 collateral	 arcade	 between	 the	 two	 major	
mesenteric	arteries,	located	within	the	mesentery	of	the	colon,	approximately	2-3	cm	from	the	mesenteric	
border	of	 the	bowel.99	 It	 is	usually	a	continuous	artery	that	runs	parallel	 to	 the	bowel,	and	receives	direct	
blood	flow	from	the	ileocolic,	right	colic,	middle	colic,	left	colic	and	sigmoidal	arteries.100	The	marginal	artery	
is	better	developed	in	the	left	colon	and	is	often	inconsistent	and	poorly	developed	in	the	right	colon	in	25-
75%	of	patients.101	Within	this	collateral	arcade,	there	exists	two	watershed	points,	which	are	potential	sites	
for	segmental	ischaemia:	Griffiths’	point,	at	the	splenic	flexure	where	branches	of	the	middle	colic	and	left	
colic	 meet,	 and	 Sudecks’s	 point,	 where	 the	 last	 sigmoidal	 branch	 and	 the	 superior	 haemorrhoidal	 artery	
meet.	 	 In	the	presence	of	normal	physiological	mesenteric	arterial	 flow,	the	marginal	artery	of	Drummond	
remains	 relatively	 small	 in	 calibre,	 however	 it	 can	markedly	 dilate	 when	 the	 IMA	 or	 SMA	 is	 occluded	 in	
response	to	redirected	flow.	This	marginal	artery	can	provide	adequate	blood	supply	to	the	entire	left	colon	
in	the	case	of	occlusion	of	the	IMA.	During	the	open	repair	of	abdominal	aortic	aneurysms	repairs,	the	IMA	is	
either	surgically	ligated	or	occluded	during	the	pathogenesis	of	the	aneurysm,	however	the	colon	will	remain	
adequately	perfused	 in	 the	presence	of	a	patent	marginal	artery.	During	 the	course	of	 rectal	excision,	 the	
IMA	 is	 ligated	 flush	 to	 the	 abdominal	 aorta	 as	 matter	 of	 course,	 and	 with	 satisfactory	 flow	 through	 the	
middle	 colic	 and	 marginal	 artery	 the	 left	 sided	 colon	 remains	 sufficiently	 perfused.	 The	 arc	 of	 Riolan	
represents	a	series	of	collateral	arcades	located	centrally	within	the	mesentery	near	the	root,	formed	from	
the	 communication	 between	 the	 middle	 colic	 and	 left	 colic	 arteries	 and	 is	 present	 in	 about	 7-10%	 of	
population.	 The	 meandering	 artery	 of	 Moskowitz	 is	 formed	 by	 an	 anastomoses	 between	 the	 proximal	
segment	of	the	middle	colic	artery	and	the	ascending	branch	of	the	left	colic	artery,	and	it	travels	along	the	
base	of	the	mesentery.102	This	collateral	channel	is	capable	of	expanding	significantly	if	flow	is	re-directed	in	
the	presence	of	arterial	ligation	and	can	be	palpated	intraoperatively.	Its	presence	would	mitigate	against	a	
high	 mesenteric	 resection	 during	 a	 left	 sided	 colonic	 procedure,	 as	 potential	 ligation	 of	 this	 vital	 artery	
would	 result	 in	 ischaemia	 of	 the	 ascending	 colon	 or	 the	 small	 intestines	 (with	 retrograde	 flow	 in	 the	
meandering	artery	of	Moskowitz),	or	ischaemia	of	the	sigmoid	colon	and	upper	rectum	(with	antegrade	flow	
meandering	artery).	
Despite	the	extensive	collateral	anastomotic	channels	between	the	colon	and	rectum,	colonic	anastomoses	
are	 more	 at	 risk	 of	 dehiscence	 and	 leakage	 secondary	 to	 ischaemia,	 than	 compared	 to	 small	 bowel	
anastomoses.	By	weight,	the	colon	has	less	blood	flow	than	the	remaining	gastrointestinal	tract,	and	active	
colonic	 peristaltic	 movements,	 have	 shown	 to	 increase	 intraluminal	 pressure	 which	 results	 in	 further	
reduced	 blood	 flow.103	 The	 distribution	 of	 blood	 flow	 through	 these	 collateral	 channels	 explains	 the	
preferential	 development	of	 ischemic	 injury	 at	Griffith’s	 and	 Sudeck’s	 critical	 points.	 These	 regions	within	
the	 colon	 and	 rectum	 are	 anatomically	 vulnerable	 to	 ischemic	 injury	 following	 surgical	 ligation	 of	 arterial	
branches	supplying	the	colon	and	or	rectum.	
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Griffiths’	point	corresponds	to	the	collateral	anastomoses	between	the	SMA	and	the	IMA,	near	the	splenic	
flexure	 of	 the	 colon.	 At	 this	 critical	 point	 the	 continuity	 of	 the	 marginal	 artery	 of	 Drummond	 may	 be	
interrupted	in	as	many	as	5-7%	of	individuals.104	Deficiency	of	this	collateral	communication	in	this	territory	
may	compromise	the	blood	supply	to	the	splenic	flexure	or	left	colon	from	the	middle	colic	artery,	if	the	IMA	
is	 ligated.	 This	 is	 particularly	 relevant	 during	 abdominal	 aortic	 aneurysm	 repair	 and	 for	 colon	 cancer	
resections.	 A	 reduction	 in	 blood	 supply	 in	 this	 region	 can	 be	 observed	 in	 up	 to	 30%	 of	 individuals.104	
Consequently	surgeons	often	avoid	creating	anastomoses	in	the	region	of	the	splenic	flexure,	after	ligation	
of	 the	 left	 colic	 artery	 or	 the	 IMA.	 The	 concern	 is	 that	 insufficient	 blood	 supply	 would	 not	 allow	 tissue	
healing	within	 the	 anastomoses,	 which	may	 lead	 to	 anastomotic	 dehiscence,	 leak	 and	 sepsis.105	 Sudeck’s	
point	corresponds	to	the	anastomoses	between	the	systemic	and	visceral	circulation,	via	 the	small	vessels	
that	 join	 the	 superior	 rectal	 artery	 to	 the	 middle	 rectal	 arteries.106	 When	 the	 IMA	 is	 ligated	 surgically,	
perfusion	 of	 the	 distal	 sigmoid	 and	 upper	 rectum	 is	maintained	 by	 this	 collateral	 circuit.	 However,	 it	 has	
been	shown	clinically	that	this	point	in	the	marginal	circulation,	at	the	rectosigmoid	junction,	is	not	as	critical	
as	 originally	 thought.	 The	 creation	 of	 colonic	 anastomoses	 in	 this	 area	 is	 common	 practice	 and	 is	 rarely	
complicated	by	 ischaemia.103	A	greater	understanding	of	the	surgical	anatomy	and	presence	or	absence	of	
these	 collateral	 channels	 is	 important	 in	 appreciating	 the	 underlying	 mechanisms	 that	 cause	 bowel	
ischaemia	during	AAA	repair	and	increase	the	risk	of	anastomotic	leaks	following	bowel	resection.	This	will	
form	the	basis	of	our	second	experimental	study	and	is	described	in	Chapter	4.	
1.5.3 Clinical	presentation,	diagnosis	and	management	
There	are	no	specific	pathological	signs	that	accompany	the	onset	of	bowel	ischaemia,	however	the	clinical	
presentation	 consists	 of	 a	 range	 of	 nonspecific	 symptoms.	 Signs	 and	 symptoms	 vary	 from	 generalised	
abdominal	pain	in	non-gangrenous	mucosal	ischaemia	to	generalised	peritonitis	with	fulminant	sepsis	due	to	
gangrenous	 transmural	 infarction	 with	 colonic	 perforation.	 The	 magnitude	 of	 the	 presentation	 will	 vary	
according	to	the	extent	and	severity	of	 the	 ischaemic	 injury,	 the	speed	at	which	the	 insult	progresses,	 the	
colon’s	 ability	 to	 facilitate	 perfusion	 and	 its	 capacity	 to	 protect	 against	 bacterial	 dissemination.	 Ischaemic	
injuries	 secondary	 to	 emboli	 presents	 acutely	with	 extreme	 symptoms,	 this	 is	 in	 contrast	 to	 the	 insidious	
presentation	of	chronic	atherosclerotic	vascular	insufficiency.	The	severity	of	the	ischaemic	injury	is	reduced	
in	 the	 latter	 group,	 as	 the	 chronic	 nature	 of	 the	 disease	 process	 allows	 for	 the	 formation	 of	 a	 vascular	
collateral	 supply.107,108	 Park	 et	 al,	 in	 a	 single	 centre	 prospective	 analysis	 of	 147	 consecutive	 patients	with	
confirmed	 bowel	 ischaemia	 on	 endoscopic	 examination	 with	 histological	 findings,	 examined	 the	 positive	
predictive	 risk	 factors.	 They	 identified	 old	 age	 (greater	 than	 60	 years	 old),	 haemodialysis,	 hypertension,	
diabetes	mellitus,	hypoalbuminaemia	and	the	use	of	constipation	inducing	agents	as	significant	factors	in	the	
development	of	bowel	ischaemia.109	
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The	 commonest	 signs	 and	 symptoms	 include	 abdominal	 pain,	 diarrhoea,	 change	 in	 bowel	 function	 and	
haematochezia.	 	 The	 abdominal	 pain	 associated	with	 bowel	 ischaemia	 is	 characterised	 by	 its	 generalised,	
intermittent	 and	 colicky	 nature.	 It	may	 be	 associated	with	 nausea,	 vomiting	 and	 loss	 of	 appetite.	 Clinical	
examination	of	 the	patient	will	 reveal	 normal	 and	 stable	 cardiovascular	 parameters,	 occasional	 low-grade	
fever,	 mild	 abdominal	 distension	 and	 abdominal	 tenderness	 over	 the	 ischaemic	 segment	 of	 colon.	
Laboratory	 examinations	may	 reveal	 a	 moderate	 leucocytosis	 accompanied	 by	 a	 left	 shift	 in	 the	 ratio	 of	
immature	 to	mature	neutrophils.110	These	symptoms	can	be	difficult	 to	differentiate	 in	 the	post-operative	
period	from	typical	post-surgical	symptoms.	 	Therefore,	making	an	early	diagnosis	of	bowel	 ischaemia	as	a	
complication	following	AAA	repair,	is	particularly	challenging.	The	subtlety	of	these	symptoms	is	frequently	
missed	and	the	diagnosis	made	when	gross	systemic	features	develop,	resulting	in	increased	morbidity	and	
mortality.	 These	 patients	 progress	 to	 develop	 full	 thickness	 transmural	 gangrenous	 ischaemic	 colitis,	
presenting	 with	 fulminant	 septic	 shock,	 acute	 onset	 severe	 abdominal	 pain,	 high	 fevers	 and	 precipitous	
cardiovascular	 instability,	 marked	 by	 hypotension	 and	 tachycardia.	 Abdominal	 examination	 may	 reveal	
localised	peritonitis,	which	may	progress	to	four	quadrant	generalised	peritonitis	and	rigidity.	However,	in	an	
unconscious	and	intubated	patient,	following	complex	aortic	surgery	with	blood	loss,	myocardial	depression	
and	 a	 prolonged	 warm	 ischaemia	 time	 from	 aortic	 cross	 clamping,	 these	 severe	 symptoms	 of	 bowel	
infarction	 can	 be	 difficult	 to	 elucidate.	 This	 results	 in	 a	 delayed	diagnosis	 of	 this	 dangerous	 complication,	
which	further	increases	morbidity	and	mortality.		
A	 diagnosis	 of	 bowel	 ischaemia	 can	 be	 made	 in	 the	 presence	 of	 characteristic	 clinical	 findings	 in	 an	
appropriate	setting.	Serum	concentrations	of	lactate,	lactate	dehydrogenase	and	alkaline	phosphatase	may	
be	raised	in	conjunction	with	systemic	lactic	acidosis.	However,	these	laboratory	markers	are	rarely	raised	in	
mild	 cases	 and	 are	 typically	 raised	 in	 severe	 cases	 that	 present	 late	 in	 the	 clinical	 course.	 Typically,	 plain	
abdominal	radiographs	are	nonspecific	and	insensitive	in	the	diagnosis	of	ischaemic	colitis.111	Barium	enema	
may	demonstrate	findings	suggestive	of	bowel	ischaemia	in	up	to	75%	of	patients,	however	it	is	non-specific	
and	 is	 commonly	 present	 in	 a	 variety	 of	 inflammatory	 bowel	 conditions.	 The	 use	 of	 luminal	 contrast	
mediums	however,	renders	subsequent	endoscopic	or	angiographic	evaluation	more	challenging,	due	to	the	
inevitable	 residual	 contrast	material,	which	 influences	 interpretation	and	 therefore	 is	not	 typically	used	 in	
the	 modern	 clinical	 setting.110,111	 Angiography	 has	 previously	 been	 proven	 in	 various	 studies	 to	 possess	
sensitivities	of	74-100%	and	a	specificity	of	100%	for	mesenteric	arterial	occlusion.112	However	angiography	
is	 highly	 invasive,	 unsuitable	 for	 critically	 ill	 patients	 and	 is	 not	 readily	 available	 in	 an	 emergency	 setting,	
thereby	 inducing	delay	 in	management	and	has	a	nephrotoxic	effect.	Due	to	 these	reasons	angiography	 is	
not	typically	used	in	modern	clinical	practice.113	Computed	Tomography	Angiogram	(CT-A)	is	a	valuable	tool	
for	 the	assessment	of	bowel	 ischaemia,	allowing	detailed	multi-array	 spiral	examination	of	 the	bowel	and	
mesenteric	 vessels,	 with	 volumetric	 analysis	 of	 the	 entire	 abdomen.	 However,	 CT	 lacks	 specificity	 and	
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sensitivity	in	the	early	stages	of	the	disease	process,	it	is	helpful	however	in	excluding	other	intra-abdominal	
pathologies.	 The	 diagnostic	modality	 has	 proven	 to	 be	 very	 helpful	 in	 later	 stages	 of	 the	 disease	 process	
often	 demonstrating	 signs	 in	 keeping	with	 bowel	 wall	 necrosis.	 In	 this	 advanced	 clinical	 setting,	multiple	
studies	have	cited	sensitivities	of	96-100%	and	specificities	of	89-94%.114		
Colonoscopy	or	flexible	sigmoidoscopy	has	become	the	diagnostic	modality	of	choice	in	many	centres,	due	
to	 its	 greater	 sensitivity	 for	 identifying	mucosal	 changes.	 Endoscopic	 findings	 are	dependent	on	 the	 stage	
and	severity	of	ischaemia,	with	early	stages	characterised	by	pale	oedematous	mucosa	and	advanced	stages	
characterised	by	dusky	or	black	mucosa.115	These	 initial	 findings	are	not	solely	specific	 to	bowel	 ischaemia	
and	its	use	is	limited	to	centres	that	have	access	to	emergency	endoscopy.	Colonoscopy	in	such	critically	ill	
patients	is	also	associated	with	a	significantly	higher	morbidity.	116,117	There	exists	no	current	modality	that	
allows	an	accurate,	safe,	non-invasive	pathological	diagnosis	that	is	highly	selective	and	specific	in	identifying	
bowel	ischaemia	in	its	early	stages.		
Initial	 treatment	 directives	 are	 based	 on	 supporting	 cardiac	 and	 haemodynamic	 function,	with	 aggressive	
and	 judicious	 fluid	 management,	 oxygen	 supplementation	 and	 monitoring	 of	 acid-base	 balance.	
Approximately	 20%	 of	 patients	 will	 deteriorate	 despite	 supportive	 regimes	 and	 progress	 to	 surgical	
intervention.118,119	 During	 exploratory	 laparotomy,	 all	 nonviable	 ischaemic	 bowel	 segments	 are	 resected,	
with	 close	 inspection	 of	 margins	 to	 identify	 healthy	 and	 viable	 mucosa.	 Typically,	 an	 end	 colostomy	 is	
fashioned	with	 the	 proximal	 limb	 of	 the	 colon,	whilst	 the	 distal	 limb	 is	 either	 closed	 or	 exteriorised	 as	 a	
mucous	fistula.91	A	primary	anastomosis	is	rarely	created	due	to	the	high	risk	of	dehiscence	and	anastomotic	
leak.120	Even	after	prompt	resection,	mortality	rates	surpass	50%	in	this	cohort	of	patients	with	a	number	of	
patients	requiring	a	second	look	laparotomy.121	
1.5.4 Ischaemic	colitis	after	AAA	repair	
A	significant	complication	following	open	repair	of	abdominal	aortic	aneurysms	(AAA)	is	the	development	of	
ischaemic	 bowel.	 Ischaemic	 bowel	 in	 this	 cohort	 of	 patients	 has	 an	 incidence	 of	 up	 to	 42%,	 with	 a	 re-
operation	 rate	 of	 up	 to	 73%	 and	 is	 associated	with	 a	 significantly	 high	morbidity	 and	mortality.78,79,122,123	
Numerous	risk	factors	have	been	identified,	however	hypoperfusion	of	the	splanchnic	bed	appears	to	be	the	
most	 prevalent	 pathological	 mechanism.	 The	 IMA	 is	 often	 divided	 during	 aortic	 aneurysm	 repair,	 which	
reduces	 splanchnic	 arterial	 flow.	 Athero-embolisation	 of	 the	 hindgut	 has	 also	 been	 implicated	 in	 the	
aetiology	of	 ischaemic	colitis	 following	aortic	 surgery.124	Athero-embolisation	can	also	affect	other	 remote	
organ	 systems,	 such	 as	 the	 kidneys,	 small	 bowel	 and	 spinal	 cord.	 Intra-operative	 hypotension,	 retractor	
trauma,	poor	collateral	development	and	retrograde	flow	in	the	meandering	artery	of	Moskowitz	have	also	
all	been	identified	as	predisposing	factors	for	the	development	of	ischaemic	colitis	after	AAA	repair	
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Organ	 systems	 within	 the	 hindgut,	 midgut	 and	 foregut	 territories	 possess	 an	 extensive	 collateral	 arterial	
supply	 as	 previously	 described,	 this	 safeguards	 against	 the	 development	 of	 ischaemia	 when	 perfusion	 is	
disturbed	 by	 disease	 or	 surgical	 intervention.	 However,	 patients	 with	 atherosclerotic	 occlusive	 or	
aneurysmal	disease	often	possess	stenoses	or	occlusions	within	their	collateral	supply,	and	are	therefore	at	
risk	 of	 ischaemia	 following	 intervention. Ischaemic	 colitis	 is	 more	 commonly	 associated	 with	 arterial	
aneurysmal	 pathology	 than	 arterial	 occlusive	 disease.	 The	 chronicity	 of	 the	 latter	 encourages	 greater	
collateral	formation	over	a	period	of	time.124	Greenwald	et	al	developed	a	pathological	classification	system	
for	patients	with	colonic	ischaemia	following	aortic	surgery,	allowing	for	stratification	of	the	ischaemic	injury	
as	 reversible	 or	 irreversible.	 Patients	 can	 be	 further	 classified	 by	 the	 presence	 of	 submural	 or	 intramural	
ischaemia,	transient	colitis,	fulminant	colitis,	presence	of	strictures,	ulcers	or	gangrene.125	More	than	60%	of	
cases	involve	transmural	ischaemia	leading	to	infarction	and	perforation,	with	the	most	frequent	site	being	
in	the	sigmoid	colon	secondary	to	IMA	ligation.126 
A	high	 index	of	 clinical	 suspicion	can	 facilitate	an	early	diagnosis	of	bowel	 ischaemia	 following	AAA	 repair	
and	can	potentially	prevent	fatal	sequelae.	Severe	ischaemic	bowel	is	evident	in	2%	of	patients	undergoing	
elective	infra-renal	AAA	repair	and	up	to	42%	of	patients	following	emergency	repair	of	ruptured	AAA127-129	
Prospective	 observational	 studies	 performing	 colonoscopy	 identified	 limited	mucosal	 ischaemia	 in	 35%	of	
patients	 undergoing	 elective	 repair	 and	 up	 to	 60%	 of	 patients	 with	 emergency	 repairs	 for	 ruptured	
aneurysms.130,131	The	majority	of	 these	patients	do	not	progress	 to	develop	clinical	signs	and	symptoms	of	
bowel	ischaemia,	therefore	it	remains	a	clinical	challenge	to	attempt	to	stratify	and	identify	the	patients	that	
are	at	risk	and	have	insufficient	collateral	supply	to	maintain	bowel	viability.	 
Ischaemic	 bowel	 is	 classically	 described	 as	 presenting	 with	 bloody	 diarrhoea	 post-operatively.	 However	
numerous	investigators	have	shown	this	to	be	an	insensitive	and	a	poor	clinical	predictor,	with	between	29-
36%	of	patients	with	documented	 ischemic	bowel	exhibiting	this	sign.132,133	Whilst	 infrequent	 in	 incidence,	
the	 presence	 of	 bloody	 diarrhoea	 is	 a	 poor	 prognostic	 indicator	 and	 often	 heralds	 transmural	 colonic	
infarction.	Other	signs	 include	abdominal	pain,	hypotension,	 fever,	anuria,	 leukocytosis	and	 lactic	acidosis.	
These	symptoms	are	non-specific	and	often	expected	in	the	post-operative	period	following	complex	major	
vascular	surgery.		This	in	turn	makes	the	diagnosis	of	ischaemic	bowel	difficult	to	make	in	this	clinical	setting.	
Hypovolaemia,	hypotension	and	the	subsequent	hypoperfusion	of	the	colon	in	the	postoperative	period	are	
major	causes	of	morbidity	 following	aneurysm	repair.	 In	 the	event	of	 IMA	 ligation,	 the	collateral	 supply	 is	
vulnerable	to	periods	of	hypotension	and	therefore	monitoring	 fluid	status	utilising	pulmonary	wedge	and	
central	 venous	 pressures	 is	 pivotal	 in	 high-risk	 patients.	 An	 alternative	 method	 to	 reduce	 the	 risk	 of	
developing	 ischaemic	 colitis	 after	 aneurysm	 repair	 is	 to	 re-implant	 the	 IMA	 when	 found	 to	 be	 patent.	
Welborn	et	al	in	a	three-year	prospective	study,	re-implanted	the	IMA	in	151	patients	undergoing	open	AAA	
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repair.	 In	 this	series,	none	of	 the	patients	developed	signs	or	symptoms	 in	keeping	with	colonic	 ischaemia	
and	of	the	mortalities	no	deaths	were	attributable	to	colonic	ischaemia	at	the	time	of	autopsy.134	
The	 diagnosis	 can	 be	 confirmed	 with	 flexible	 sigmoidoscopy,	 colonoscopy	 or	 CT	 angiograms.	 Serial	
endoscopic	examinations	can	verify	clinical	resolution	or	disease	progression.	Endoscopic	examination	up	to	
40	cm	proximal	to	the	anal	verge	to	inspect	the	colonic	mucosa	will	be	able	to	detect	ischaemic	changes	in	
up	 to	95%	of	patients	with	 ischaemic	colitis.129	 Isolated	 right	 sided	or	 transverse	colon	 ischaemia,	without	
descending	 colon	 involvement	 is	 rare	 and	 therefore	 endoscopic	 examination	 of	 the	 left	 colon	 typically	
suffices.116,131	 Other	 modalities	 have	 been	 investigated	 for	 the	 early	 prediction	 of	 colonic	 ischaemia.	
Schiedler	 et	 al	 investigated	 the	 use	 of	 transluminal	 pH	 (pHt)	 mucosal	 monitoring.
135	 The	 investigators	
demonstrated	that	anaerobic	metabolism	secondary	to	ischaemia	can	be	detected	by	demonstrating	low	pH	
in	the	gastric	or	colonic	mucosa.	Bjorck	et	al	demonstrated	that	sigmoid	acidosis,	with	a	pHt	of	less	than	7.1	
is	a	predictor	of	major	mortality	if	not	corrected	within	a	two	hour	window	following	AAA	repair.136	The	use	
of	 other	modalities	 has	 been	 examined,	 such	 fluorescein	 injection,	 pulse	 oximetry,	 colonic	 serosal	 photo	
plethysmography,	 inferior	 mesenteric	 artery	 stump	 pressure	 and	 Doppler	 ultrasound,	 in	 experimental	
models	of	bowel	 ischaemia.	However,	none	of	these	modalities	have	been	shown	to	be	either	sensitive	or	
accurate	 in	 the	diagnosis	of	bowel	 ischaemia	 in	 the	clinical	 setting.137	 The	most	 important	 factor	 that	 can	
reduce	the	mortality	associated	with	this	complication	is	early	diagnosis	and	prompt	intervention.	However,	
there	is	often	a	late	presentation,	with	the	systemic	signs	and	symptoms	of	ischaemic	bowel	in	an	intubated	
and	unconscious	patient	often	heralding	significant	bowel	 ischaemia,	with	 impending	mural	 infarction	and	
perforation.			
The	early	diagnosis	of	bowel	 ischaemia	 following	AAA	 repair	 is	 therefore	dependent	on	a	 subjective,	high	
index	 of	 clinical	 suspicion,	 followed	 by	 rapid	 action	 to	 optimise	 the	 patient’s	 fluid	 balance	 and	
haemodynamic	 status.	 Patients	 are	 likely	 to	progress	 to	 laparotomy	and	direct	 examination	of	 the	bowel,	
with	 potential	 resection	 and	 de-functioning	 with	 an	 end	 colostomy.	 Whilst	 an	 early	 diagnosis	 is	 key	 to	
reducing	mortality,	 it	 is	clear	that	a	safe,	accurate	and	effective	tool	 is	required	to	detect	and	monitor	this	
clinical	complication	at	the	bedside	in	the	early	post-operative	period.	
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1.6 IN-VIVO	DETECTION	OF	GASTRO-INTESTINAL	ANASTOMOTIC	
LEAKS	
Postoperative	 complications	 and	 the	 associated	morbidity	 and	mortality	 constitute	 a	 significant	 risk	 to	 all	
patients	undergoing	major	elective	or	emergency	gastro-intestinal	surgery.	These	complications	are	diverse	
and	numerous	 in	nature,	with	 incidence	varying	depending	on	the	type	of	surgery	and	the	patient	 related	
risk	factors.	The	absence	of	unifying	consensus	on	grading	and	classification	of	postoperative	complications	
has	 greatly	 hindered	 the	 risk	 evaluation	 of	 surgical	 procedures.	 One	 frequently	 used	 classification	 tool,	
developed	 by	 Clavien	 and	 Dindo,	 is	 based	 on	 the	 type	 of	 intervention	 required	 and	 is	 a	 simple	 and	
reproducible	tool	for	post-operative	management.138	
Overall	post-operative	complications	are	very	common	with	an	incidence	of	greater	than	10%.		Including,	but	
not	limited	to	ileus,	infective	collections,	haematoma	formation,	wound	dehiscence	and	infection,	visceral	or	
enteric	iatrogenic	injury	and	of	course	anastomotic	leaks.	A	gastrointestinal	(GI)	anastomotic	leak	is	a	major	
and	 serious	 complication	 following	bowel	 resection	 and	 formation	of	 an	 anastomosis.	 It	 is	 defined	 as	 the	
exudation	of	 intestinal	 fluid	and	contents	from	the	site	of	the	surgical	 joining	of	two	segments	of	bowel.80	
This	 complication	 is	 associated	with	a	 significant	 increase	 in	morbidity,	mortality,	prolongation	of	hospital	
stay,	and	a	risk	of	local	recurrence	in	colorectal	cancer	resections.139,140		
Whilst	there	is	no	current	unifying	system	to	categorise	leaks,	there	is	a	commonly	used	stratification	based	
on	 the	 presentation	 of	 the	 leaks.80	 A	 minor	 leak	 can	 be	 described	 as	 a	 leak	 with	 no	 systemic	 clinical	
manifestations,	 but	 with	 radiological	 evidence	 of	 extravasation	 of	 small	 volumes	 of	 contrast	 outside	 the	
lumen	of	 the	GI	 tract.	 These	 leaks	often	 require	 little	or	no	 intervention.	A	major	 leak	will	 typically	 cause	
systemic	 signs	 and	 symptoms,	 such	 as	 tachycardia,	 hypotension,	 rise	 in	 temperature,	 fever,	 rigors	 or	
evidence	of	peritonitis	on	clinical	examination	of	the	abdomen.	Major	leaks	are	characterised	by	an	obvious	
radiological	defect	in	the	continuity	of	the	anastomoses,	with	free	extravasation	of	contrast	in	the	peritoneal	
or	 thoracic	cavity.	The	 faecal	 soiling	 that	 typically	accompanies	 such	 leaks	 inevitably	 results	 in	generalised	
peritonitis	and	is	associated	with	a	significant	increase	in	morbidity	and	mortality.	
There	are	many	series	that	report	variable	rates	of	anastomotic	leaks	ranging	between	3-15%,	with	mortality	
rates	associated	with	clinically	significant	leaks	varying	in	the	range	of	6-40%.	82,165,169,171	Strategies	to	reduce	
the	 incidence	 of	 post-operative	 complications	 have	 led	 to	 the	 recognition	 of	 a	 number	 of	 procedure	 and	
patient	related	risk	factors	by	numerous	investigators.	Whilst	some	investigators,	go	further	to	suggest	that	
that	post-operative	complications	such	as	anastomotic	 leaks	are	 inevitable	 in	major	resectional	GI	surgery.	
Whilst	 type,	 technique	 and	 timing	 of	 surgery	 can	 be	mitigated	 for,	 patient	 related	 risk	 factors	 are	 often	
unavoidable.140-142		
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Numerous	 risk	 factors	 have	 been	 identified	 that	 increase	 the	 risk	 of	 complications,	 and	 in	 particular,	
anastomotic	 leaks.	 Patient-related	 factors	 include	 the	 presence	 of	 diabetes,	 malnutrition,	 anaemia,	
inflammatory	 bowel	 disease	 and	 the	 use	 of	 corticosteroids.	Operative	 factors	 include	 the	 type	of	 surgical	
technique	used,	location	of	anastomosis,	presence	of	tension	on	the	anastomosis,	distal	obstruction	and	the	
absence	of	adequate	blood	supply.143	Colorectal	anastomoses,	and	in	particular	low	rectal	anastomoses,	are	
at	high	risk	of	anastomotic	dehiscence	and	leak.	A	multivariate	analysis	by	Vignali	et	al,	considered	operative	
variables	 including	 indication	 for	 surgery,	 co-morbidities,	 bowel	 preparation,	 and	 intraoperative	 events	
showed	that	a	distance	of	7cm	or	less	from	the	anal	verge	is	a	significant	risk	factor	for	the	development	of	
anastomotic	dehiscence	and	subsequent	leak.143	
Karanjia	 et	 al	 showed	 that	 sepsis,	 postoperative	 blood	 transfusions,	 bowel	 obstruction,	 peritonitis	 and	
hypoalbuminaemia	 are	 independent	 risk	 factors	 for	 developing	 a	 leak	 in	 a	 stapled	 low	 anastomosis	 after	
total	mesorectal	 excision	 for	 carcinoma	 of	 the	 rectum.144	 In	 a	 publication	 in	 The	New	 England	 Journal	 of	
Medicine,	 the	authors	of	 the	Surgical	Therapy	Group	showed	 that	performing	 laparoscopic	 resections	and	
anastomoses	does	not	increase	the	risk	of	developing	anastomotic	leaks.	In	a	Cochrane	review,	the	authors	
demonstrated	that	the	technique	of	automatic	stapling	was	not	superior	to	hand	sutured	anastomoses	nor	
did	 it	 demonstrate	 an	 increase	 in	 the	 risk	 of	 anastomotic	 leaks.145	 A	 state	 of	 malnutrition	 is	 however	
associated	with	an	 increased	risk	of	anastomotic	 leak,	with	a	serum	albumin	of	<30	g/dl	and	acute	weight	
loss	of	>5	kg	as	 strong	positive	 indicators.81	 	 Early	 feeding	 following	 surgery	 is	 typically	 advocated,	having	
been	shown	to	reduce	recovery	time	with	no	evidence	of	an	increased	risk	of	anastomotic	leaks.	The	use	of	
bowel	preparation,	whilst	historically	advocated	pre-operatively,	has	been	confirmed	in	numerous	studies	to	
have	 no	 affect	 on	 rates	 of	 anastomotic	 leaks,	 but	 rather	 an	 increased	 incidence	 of	 dehydration	 and	
electrolyte	imbalance.146,147	
It	 is	 commonly	 accepted	 that	 the	 key	 principles	 of	 anastomosis	 formation	 are	 the	 absence	 of	 distal	
obstruction	and	tension	within	the	join,	with	sufficient	blood	perfusion	to	the	proximal	and	distal	limbs.	An	
adequate	blood	supply	ensures	appropriate	oxygen	delivery	to	meet	the	metabolic	demands	of	the	healing	
tissue.	 It	 is	 therefore	 widely	 considered	 that	 localised	 ischaemia	 is	 the	 most	 significant	 factor	 that	
predisposes	an	anastomosis	to	leak.80-82,144	Further	investigation	into	the	role	of	ischaemia	and	the	challenge	
of	developing	a	tool	to	monitor	and	detect	 leaks	 in	the	peri-operative	period,	 forms	the	foundation	of	the	
research	presented	within	this	thesis.			
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1.6.1 Diagnosis	and	management	of	anastomotic	leaks	
Clinical	 deterioration	 with	 signs	 of	 sepsis	 may	 raise	 suspicion	 of	 an	 anastomotic	 leak.	 The	 signs	 and	
symptoms	associated	with	a	leak	are	varied	and	non-specific,	and	include	fever,	non-resolution	or	worsening	
pain,	prolonged	ileus,	acute	renal	failure,	and	rising	serum	inflammatory	markers	such	as	c-reactive	protein	
(CRP)	and	white	cell	count	(WCC).82	Clinical	parameters	serving	as	a	primary	diagnostic	tool	to	identify	leaks	
has	 a	 low	 sensitivity.82,148,149	 Several	 investigators	 have	 developed	 scoring	 systems	 for	 the	 diagnosis	 of	
anastomotic	leaks,	however	none	of	these	have	been	validated	in	clinical	studies.150,151	Clinical	markers	of	an	
anastomotic	 leak	 are	 vague,	 indistinct	 and	 lack	 sensitivity,	 thereby	 precluding	 an	 early	 diagnosis	 and	
resulting	in	a	clinically	significant	delay	in	starting	treatment.152	
Radiological	imaging	may	be	useful	in	confirming	the	diagnosis	when	clinical	assessment	is	inconclusive.	CT	
scanning	with	enteral	contrast	is	considered	the	gold	standard.82,149,152,153	Whilst	abdominal	CT	scanning	and	
water	 soluble	 contrast	 enemas	 undoubtedly	 have	 a	 role	 in	 the	 diagnosis	 of	 anastomotic	 leaks,	 their	
sensitivity	 in	 identifying	 leaks	has	been	shown	to	be	 low	in	a	recent	systematic	review	by	Kornmann	et	al.	
Some	authors	have	further	suggested	that	the	high	false-negative	rates	associated	with	CT	scanning	for	the	
diagnosis	 of	 anastomotic	 leaks	 may	 result	 in	 delayed	 surgical	 exploration	 and	 potentially	 adverse	
outcomes.154-156	 Such	 delays	 allow	 for	 the	 development	 of	 significant	 sepsis,	 peritonitis,	 multiple	 organ	
failure	and	increases	the	risk	of	death.		
If	a	small	anastomotic	leak	is	identified	on	a	CT	scan	with	water-soluble	contrast,	and	if	contained	within	a	
small	 cavity,	 it	 is	 typically	 treated	 conservatively	with	 intravenous	 antibiotics.	 A	 leak	within	 a	 large	 cavity	
necessitates	 percutaneous	 drainage	 under	 radiologic	 guidance	 and	 has	 shown	 to	 be	 80%	 successful.157	
Failing	this,	operative	intervention	is	required.	Patients	who	develop	major	anastomotic	leaks	with	resulting	
faecal	 peritonitis,	will	 be	 septic,	 have	developed	 SIRS	 and	may	be	 cardiovascularly	 unstable.	 They	 require	
aggressive	 resuscitation	 with	 intravenous	 fluids,	 antibiotics	 and	 careful	 monitoring	 in	 the	 intensive	 care	
setting.	 Once	 stabilised,	 these	 patients	 undergo	 emergency	 laparotomy,	 washout	 and	 formation	 of	 a	
defunctioning	stoma.	
It	 is	 evident	 that	 an	 accurate,	 reliable	 and	 safe	 tool	 that	 would	 allow	 for	 the	 early	 diagnosis	 of	 an	
anastomotic	leak	-	before	the	development	of	clinical	sequelae	-	would	reduce	morbidity,	mortality,	hospital	
stay	 and	 the	 intervention	 costs	 that	 are	 associated	 with	 the	 development	 of	 anastomotic	 leaks.	 Utilising	
rapid	sampling	microdialysis	as	a	quantitative	tool	to	monitor	a	GI	anastomoses	and	potentially	detect	a	leak	
is	one	of	the	central	aims	of	this	research.	
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1.6.2 Microdialysis	in	the	monitoring	of	a	gastrointestinal	anastomosis	
Matthiessen	 et	 al,	 in	 a	 small	 prospective	 study,	 utilised	 offline	 microdialysis	 in	 the	 detection	 of	
intraperitoneal	peri-anastomotic	ischaemia	after	anterior	resection	of	the	rectum.148	The	authors	found	that	
the	lactate/pyruvate	ratio	was	significantly	higher	in	the	patients	that	developed	a	symptomatic	anastomotic	
leak	 than	 the	 patients	 that	 had	 an	 uncomplicated	 postoperative	 recovery	 with	 no	 evidence	 of	 an	
anastomotic	 leak.	 These	 results	 help	 to	 confirm	 the	 role	 of	 microdialysis	 in	 the	 in-vivo	monitoring	 of	 an	
intestinal	anastomosis.	The	authors	did	not	identify	any	complications	related	to	the	microdialysis	catheter	
insertion.	The	study	was	however	small	(n=23)	and	had	a	proportionally	high	anastomotic	leak	rate	(n=7).	A	
30%	anastomotic	leak	rate	is	higher	than	rates	reported	in	the	literature	and	therefore	asks	questions	of	the	
study	design,	methodology	and	relevance	of	these	results.	Clearly	further	investigation	is	warranted	with	a	
large	definitive	study.	
Tenhunen	et	al	demonstrated	that	microdialysis	can	be	utilised	to	quantify	 ischaemic	metabolites	within	a	
porcine	colon	model	with	surgically	created	ischaemia	and	reperfusion.158	Hirata	et	al	followed	this	study,	by	
using	offline	microdialysis	monitoring	to	 identify	changes	 in	hydroxide	concentration	 in	a	bowel	 ischaemia	
reperfusion	model.159	Numerous	investigators	have	deployed	microdialysis	catheters	intramurally,	within	the	
bowel	wall,	utilising	different	fixation	techniques.	The	procedure	is	however	operator	dependent,	requiring	
skill	 and	 training	 to	ensure	 that	measurements	are	accurate	and	 to	 reduce	 the	 risk	of	 complications.160,161	
The	 risks	 associated	 with	 this	 include	 perforation	 of	 the	 bowel	 wall	 and	 strangulation	 of	 the	 bowel	
mesentery	around	the	catheter.		
Intraluminal	deployment	within	the	colon	is	potentially	less	traumatic,	and	theoretically	more	accurate,	due	
to	 the	 fact	 that	 the	 intestinal	 mucosa	 is	 sensitive	 to	 ischaemia	 and	 it	 often	 displays	 the	 first	 signs	 of	
ischaemic	 injury.	During	 ischaemic	 events,	 the	mucosal	 endothelium	 increases	 permeability	 and	 lactate	 is	
sequestered	 into	 the	 lumen,	 this	 in	 turn	 can	 be	 sampled.162,163	 Whilst	 distal	 colonic	 sampling	 may	 be	 a	
feasible	 option,	 proximal	 or	 small	 bowel	 monitoring	 would	 be	 logistically	 challenging.	 Sommer	 et	 al	
demonstrated	that	intraluminal	monitoring	to	be	inferior	to	intramural	or	intraperitoneal	monitoring,	due	to	
loss	 of	 definition	 from	 artefact	 movement	 within	 the	 lumen	 and	 the	 washout	 of	 metabolites	 by	 faecal	
material.163	 The	 investigators	 also	 demonstrated	 that	 intraperitoneal	 and	 intramural	 microdialysis	
monitoring	in	a	porcine	bowel	ischaemia	model,	yielded	similar	and	comparable	results.	
Much	 investigation	and	 the	 focus	of	my	 research	has	moved	 towards	 the	prediction	or	early	detection	of	
these	 complications.	 This	 is	 particularly	 relevant	 to	 anastomotic	 leaks,	 where	 inherent	 limitations	 in	
diagnostic	tools,	 late	clinical	presentation	and	a	lack	of	specific	biological	markers	result	 in	a	 late	diagnosis	
and	high	mortality	rates.139,164	Prompt	and	early	intervention	is	vital	to	reduce	the	associated	morbidity	and	
mortality	 following	 the	 development	 of	 all	 post-surgical	 complications,	 as	 well	 as	 anastomotic	 leaks.165	 A	
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number	 of	 investigators	 utilising	 intraperitoneal	 microdialysis	 to	 detect	 and	 monitor	 for	 the	 presence	 of	
peritoneal	 lactate,	 have	 demonstrated	 encouraging	 results	 regarding	 its	 role	 in	 predicting	 postoperative	
complications.166,167	
Tissue	ischaemia	is	a	risk	factor	for	postoperative	complications	and	plays	a	major	role	in	the	development	
of	 anastomotic	 leaks.164,167,168	 Verdant	 et	 al	 demonstrated	 greater	 lactate-pyruvate	 (L/P)	 ratios	within	 the	
peritoneum,	 in	patients	with	postoperative	 complications.169	 Pedersen	et	 al	 demonstrated	 that	peritoneal	
L/P	 ratios	 were	 raised	 prior	 to	 the	 development	 of	 colorectal	 anastomotic	 leaks.167	 Lactate	 remains	 an	
encouraging	potential,	in	the	search	for	a	biomarker	for	the	early	diagnosis	of	post-operative	complications.	
Whilst	 key	 parenchymal	 data	 can	 be	 obtained	 by	 in-vivo	 analysis	 of	 the	 anastomosis	 with	 tissue	 and	
extracellular	matrix	sampling,	it	is	technically	difficult	and	potentially	hazardous	to	the	patient.	The	need	for	
continuous	‘in	vivo’	monitoring	has	also	meant	that	cadaveric	tissue	that	is	commonly	used	for	mechanical	
bowel	anastomotic	testing	is	not	suitable	in	this	setting.	
The	 routine	 use	 of	 abdominal	 drains	 after	 laparotomy	 allows	 for	 the	 sampling	 of	 the	 peritoneal	
environment.	 Therefore,	 ex-vivo	microdialysis	monitoring	of	peritoneal	 lactate	 concentration,	by	 sampling	
drain	 fluid,	 can	 potentially	 replicate	 the	 results	 demonstrated	 by	 in-vivo	 studies.	 The	 routine	 use	 of	
peritoneal	drains	following	gastrointestinal	surgery,	provides	easy,	cheap	and	quick	access	to	peritoneal	fluid	
thereby	mitigating	the	need	for	microdialysis	catheters.	
Numerous	studies	have	quantified	different	pathological	biomarkers	in	peritoneal	drains,	such	as	cytokines,	
enzymes	 and	 the	 presence	 of	microorganisms.170,171	 However,	 few	 have	 investigated	 peritoneal	 lactate	 in	
drain	fluid	as	a	biomarker	of	post-operative	complications.	DeLaurier	et	al	 in	a	canine	and	a	clinical	model,	
demonstrated	higher	peritoneal/blood	 lactate	ratios	 in	patients	with	acute	abdomens.172,173	The	paucity	of	
research	on	peritoneal	 lactate	profiling,	serves	as	motivation	to	further	understand	the	metabolic	patterns	
and	 concentration	 changes	 in	 lactate	 during	 complicated	 and	 uncomplicated	 gastrointestinal	 surgery.	
Further	clarification	is	key	to	developing	a	tool	with	predictive	capability	in	the	early	post-operative	period.	
	
	
	 	
	 50	
1.7 ALLOGRAFT	VIABILITY	ASSESSMENT	DURING	THE	
PRESERVATION	PERIOD	UTILISING	ONLINE	RAPID	SAMPLING	
MICRODIALYSIS	
Over	the	past	100	years,	advances	in	surgical	technique	and	immunobiology	have	contributed	to	successful	
clinical	applications	 in	organ	transplantation.	Presently	 transplantation	of	 the	kidney,	 liver	and	pancreas	 is	
considered	standard	treatment	for	failure	of	these	organs.		During	the	period	of	April	2015	to	April	2016,	a	
total	of	3,139	kidney	transplants	and	888	liver	transplants	were	performed	in	the	United	Kingdom,	however	
the	 number	 of	 patients	 registered	 for	 a	 transplant	 continues	 to	 increase.174	The	 growth	 in	 the	 number	 of	
patients	waiting	for	a	transplant	has	outpaced	the	supply	of	available	organs.	As	of	the	end	of	March	2015,	
there	were	 6,943	 patients	waiting	 for	 a	 transplant	 in	 the	 UK.	 Of	 these	 patients,	 429	 patients	 died	whilst	
waiting	and	a	further	807	were	removed	due	to	deteriorating	health.	The	mismatch	of	demand	and	supply	is	
not	limited	to	the	UK;	it	is	a	growing	challenge	in	many	international	health	systems.	In	the	US	for	example,	
approximately	121,000	patients	are	currently	waiting	for	a	life-saving	organ	transplantation	with	an	average	
of	22	patients	per	day	dying	whilst	on	the	active	waiting	list.175	Each	year,	more	patients	are	placed	on	the	
waiting	lists	than	receive	transplants,	resulting	in	waiting	times	further	increasing.	Given	this	global	trend,	it	
is	crucial	that	further	research	is	conducted	to	reduce	complications	and	failure	rates	of	transplants,	whilst	
also	identifying	methods	to	increase	the	number	of	viable	organs	available.	
Renal	transplantation	provides	improved	long-term	survival	and	quality	of	life	and	is	a	relatively	more	cost-
effective	care	plan.		It	 is	therefore	the	treatment	of	choice	for	the	vast	majority	of	patients	with	end	stage	
renal	disease,	particularly	with	the	incidence	of	renal	failure	with	an	aging	population.83,84,176,177	
During	all	stages	of	transplantation	the	graft	sustains	varying	degrees	of	injury.85	Much	of	this	is	unavoidable,	
however	 the	 significant	 ischaemic	 injury	 that	develops	during	 the	 retrieval,	preservation	and	 implantation	
period	 is	 one	 phenomenon	 that	 is	 potentially	 amenable	 to	 a	 therapeutic	 modality.	 Given	 the	 scarcity	 of	
viable	organs,	methods	of	improving	graft	and	patient	survival	are	an	important	area	of	research.	Ischaemia	
occurs	when	blood	flow	and	hence	tissue	perfusion	and	oxygenation	ceases	 following	 ligation	of	 the	renal	
artery	 and	 vein	 and	 removal	 of	 the	 organ	 from	 the	 donor.	 Inefficient	 anaerobic	 metabolism	 of	 glucose	
ensues,	which	results	in	the	reduction	in	the	synthesis	of	adenosine	triphosphate	(ATP)	and	accumulation	of	
metabolic	waste	products	 such	as	 inorganic	phosphate,	protons	and	 lactate	within	cells.178,	179	This	 further	
results	in	disruption	of	energy	dependent	processes,	such	as	the	sodium-potassium	pump,	and	activates	the	
immune	and	non-immune	pathways.	The	degradation	of	ionic	homeostasis	causes	cellular	oedema,	swelling	
and	finally	results	in	apoptosis.180		
The	 ischaemic	 injury	occurs	 in	 two	distinct	 time	periods	during	 the	process	of	clinical	 transplantation.	The	
first,	 known	 as	 the	 warm	 ischaemic	 time	 (WIT),	 is	 used	 to	 describe	 ischaemia	 of	 cells	 and	 tissues	 under	
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normothermic	 conditions	 (i.e.	 at	 body	 temperature).	 WIT	 is	 further	 differentiated	 into	 two	 distinct	 time	
periods.	 The	 first	 time	 period	 is	 the	 duration	 between	 the	 cessation	 of	 blood	 flow	 at	 asystole,	 or	 cross-
clamping,	and	 flushing	of	 the	organ	with	cold	preservative	solution.	The	second	time	period	occurs	as	 the	
organ	is	removed	from	cold	storage	and	begins	to	warm	during	the	implantation	process,	at	which	point	it	is	
reperfused	with	recipient	blood.		
The	second	important	period	that	results	in	significant	ischaemic	injury	is	the	cold	ischaemia	time	(CIT).	This	
is	 the	period	between	 flushing	of	 the	organ	with	cold	preservation	solution,	 transport	of	 the	organ	 to	 the	
recipient,	and	removal	of	the	organ	out	of	ice	prior	to	transplantation.	Numerous	studies	have	shown	that	a	
prolonged	CIT	 is	 associated	with	 increased	 incidence	of	delayed	graft	 function,	 reduced	graft	 survival	 and	
increased	 patient	 morbidity.	 There	 remains	 a	 great	 clinical	 need	 to	 reduce	 the	 duration	 of	 the	 CIT	 and	
minimise	the	extent	of	injury	during	this	period.181-186	
This	 clinical	 need	 has	 led	 to	 the	 development	 of	 preservation	 techniques	 that	 aim	 to	minimise	 ischaemic	
damage	 and	 thus	 maintain	 graft	 viability	 during	 this	 period.	 There	 are	 currently	 two	 clinically	 accepted	
techniques	employed	in	the	preservation	of	renal	allografts	from	deceased	donors:	static	cold	storage	(SCS)	
and	 hypothermic	 machine	 perfusion	 (HMP).	 In	 SCS	 the	 kidney	 is	 cooled	 by	 flushing	 it	 with	 a	 cold	
preservation	solution	and	then	it	is	placed	on	ice.187	The	resultant	hypothermia	reduces	the	rate	of	physical	
and	metabolic	cellular	processes	and	ensures	that	the	effect	of	the	ischaemic	injury	is	minimised.188	Similarly	
HMP,	 in	 which	 the	 kidney	 is	 artificially	 perfused	with	 a	 continuous	 or	 pulsatile	 flow	 of	 cold	 preservation	
solution,	relies	on	hypothermia	as	its	main	mechanism	of	cellular	protection.180,188,189	In	addition,	HMP	also	
supplies	 metabolic	 substrates	 and	 removes	 waste	 products	 from	 the	 graft	 as	 well	 as	 providing	 several	
perfusion	 parameters	 for	 use	 in	 organ	 viability	 assessment.190-193	 Whilst	 a	 few	 studies	 have	 sought	 to	
compare	the	effect	of	SCS	and	HMP	on	clinical	outcomes,	none	have	utilised	novel	monitoring	 techniques	
such	as	microdialysis	to	directly	characterise	and	compare	the	effects	of	each	on	renal	metabolic	activity	and	
ischaemic	 injury	 during	 preservation	 in	 real	 time.194-197	 The	 ischaemic	 injury	 that	 develops	 during	 the	
different	 processes	 of	 transplantation	 are	 associated	with	 poor	 graft	 survival,	 therefore	 a	 tool	 capable	 of	
detecting	 and	 quantifying	 such	 injury	 on	 a	 biochemical	 level	may	 have	 a	 role	 in	 assessing	 the	 viability	 of	
allografts	destined	for	clinical	use.		
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1.7.1 Renal	transplantation	
Renal	 transplantation	 is	 considered	 the	 gold	 standard	 treatment	 for	 end	 stage	 renal	 failure	 (ESRF),	 with	
longer	patient	survival	and	superior	quality	of	life	compared	to	long-term	dialysis	therapy.176,198,199	Due	to	the	
undersupply	of	suitable	organs,	a	greater	incentive	has	been	placed	on	the	use	of	‘marginal’	donors,	such	as	
donation	after	 circulatory	death	 (DCD)	and	expanded	criteria	donors	 (ECD).	Despite	being	associated	with	
higher	 rates	 of	 early	 graft	 dysfunction	 and	 reduced	 graft	 survival,	 these	 organs	 remain	 a	 vital	 source	 of	
organs	for	transplantation	due	to	the	overall	mismatch	in	organ	demand	and	supply.	Deceased	organ	donors	
fall	into	three	categories,	standard	criteria	donors	(SCD),	donation	after	circulatory	death	(DCD)	donors	and	
extended	criteria	donors	(ECD).		
Standard	 criteria	 donation	 takes	 place	 after	 a	 deceased	 donor	 is	 declared	 brain	 dead	 following	 an	 acute	
intracerebral	 brain	 injury,	 with	 irreversible	 loss	 of	 the	 function	 of	 the	 brain	 and	 is	 thus	 also	 termed	 a	
donation	after	brain	death	(DBD)	donor.	Donation	after	circulatory	death	typically	takes	place	from	donors	
after	the	cessation	of	circulation	due	to	a	cardiac	arrest.	Organs	retrieved	from	DCD	donors	are	considered	
‘marginal’	due	 to	 the	presence	of	 a	 significant	warm	 ischaemic	 injury	 that	develops	prior	 to	preservation.	
The	WIT	and	subsequent	injury	can	lead	to	irreversible	damage,	resulting	in	graft	dysfunction	and	reduced	
graft	survival.	Five	categories	of	organs	from	DCD	donors	exist,	proposed	by	the	International	Workshop	on	
DCD	donation	 in	Maastricht.	 They	are	 collectively	 termed	 the	Maastricht	 classification	and	 the	organs	are	
categorised	based	on	the	circumstances	of	death.200	
Maastricht	type	1	donors	are	patients	that	have	been	pronounced	dead	on	arrival	by	the	Emergency	Medical	
Services,	 whilst	 Maastricht	 type	 2	 donors	 typically	 undergo	 unsuccessful	 in-hospital	 resuscitation	 before	
dying.	Both	 subsets	of	 patients	have	 typically	 died	 from	a	 sudden	cardiac	 event	or	major	 trauma	and	are	
usually	 based	 in	 the	 Accident	 &	 Emergency	 department.	 Once	 formally	 pronounced	 dead,	 5	 minutes	 is	
allowed	to	 lapse	before	the	organs	are	perfused	in-situ	via	wide-bore	aortic	cannulas	 inserted	through	the	
femoral	arteries.201	Both	subtypes	of	DCD	organs	are	considered	to	be	retrieved	in	an	uncontrolled	process.	
Maastricht	type	3	patients	are	typically	based	on	the	intensive	care	following	a	severe	intracerebral	 injury,	
however	they	do	not	meet	the	criteria	for	brain	stem	death	and	will	maintain	spontaneous	ventilation.	They	
undergo	a	planned	and	controlled	withdrawal	of	treatment,	when	it	is	deemed	that	there	is	no	possibility	of	
recovery.	 After	 cardiac	 arrest,	 the	 patient	 is	 transferred	 to	 the	 operating	 theatre	 and	 the	 organs	 are	
retrieved	 after	 in-situ	 cooling.	 Maastricht	 category	 4	 donors	 undergo	 a	 cardiac	 arrest	 following	 the	
determination	of	brain	stem	death.	Typically,	the	restoration	of	cardiac	activity	is	first	attempted,	however	if	
this	fails,	the	protocol	of	donation	takes	place	in	an	uncontrolled	manner	
The	 term	 ‘extended	 criteria	 donor’	 (ECD)	 has	 been	 used	 to	 identify	 donor	 organs	with	 an	 expected	 poor	
outcome.	ECDs	are	defined	as	an	organ	donor	over	the	age	of	60	years	old	or	over	the	age	of	55	years	with	
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two	or	more	of	the	following	criteria;	Hypertension,	a	terminal	serum	creatinine	greater	than	132μmol/L,	or	
a	 death	 resulting	 from	 an	 intracranial	 haemorrhage.	 It	 is	 likely	 that	 ECD	 kidneys	 are	more	 susceptible	 to	
ischaemic	injury	than	SCDs	and	demonstrate	>1.7	times	the	risk	for	graft	loss	than	SCD.202	However	this	is	in	
part	due	to	the	fact	that	such	kidneys	are	frequently	allocated	to	high-risk	older	recipients.	
The	 outcomes	 of	 ECD	 kidneys	 are	 heavily	 influenced	 by	 the	 practice	 of	 allocating	 them	 to	 high-risk	
recipients.	The	understandable	practice	of	allocating	low-risk	organs	to	younger	patients	with	few	or	no	co-
morbidities	means	that	high-risk	organs	are	intrinsically	linked	to	high-risk	recipients.	Therefore,	dissociating	
the	risks	between	SCDs	and	ECDs	is	difficult,	as	a	portion	of	the	apparent	donor	risks	are	actually	recipient	
risks.	 The	 perioperative	 course,	 the	 surgical	management	 and	 the	 presence	 of	 delayed	 graft	 function	 can	
also	 have	 a	 profound	 effect	 on	 graft	 survival	 and	 long	 term	 success	 following	 renal	 transplantation.	
Numerous	other	factors	have	been	identified	that	can	influence	graft	outcomes,	 including	recipient	factors	
such	as	age,	co-morbidities	and	sensitisation	status,	donor	characteristics	such	as	age,	creatinine	clearance,	
history	of	hypertension,	as	well	as	the	cold	ischaemia	time	(CIT)	and	the	length	of	the	warm	ischaemia	time	
(WIT)	 in	 DCD	 donors,	 have	 all	 been	 described	 as	major	 determinants	 of	 graft	 function	 and	 survival.203	 Of	
these	factors,	the	CIT	is	a	potentially	modifiable	factor,	which	has	a	significant	effect	on	graft	outcome.		
The	 mechanism	 that	 underpins	 hypothermic	 preservation	 is	 based	 on	 the	 principle	 that	 cooling	 tissue	
reduces	the	rate	of	enzymatic	processes.	With	every	10oC	fall	in	tissue	temperature	there	is	a	concomitant	2-
3-fold	reduction	in	metabolism.204,205	The	previously	described	depletion	of	ATP,	a	characteristic	of	anaerobic	
metabolism	in	hypoxic	conditions,	leads	to	the	formation	of	lactic	acid	with	increased	levels	of	intracellular	
adenosine,	 inosine	 and	 hypoxanthine.85	 The	 resulting	 reduction	 in	 intracellular	 pH	 causes	 lysosomal	
instability	 and	 activation	 of	 lytic	 enzymes.206	 Depletion	 of	 ATP	 also	 results	 in	 inactivation	 of	 the	 Na+/K+	
ATPase	pump	and	accumulation	of	sodium,	calcium	and	water	with	subsequent	cellular	swelling.207	
In	hypothermic	conditions	 the	depletion	of	ATP	 in	hypoxia	 is	significantly	 reduced,	however	 the	metabolic	
rate	remains	at	approximately	10%	of	baseline,	therefore,	over	time,	hypoxia	continues	to	cause	significant	
cold	 ischaemic	 injury.	 Following	 reperfusion	 of	 the	 kidney,	 the	 cold	 ischaemic	 injury	 and	 the	 ischaemia	
reperfusion	injury	results	in	renal	tubular	and	vascular	damage,	with	subsequent	reduction	of	blood	flow	and	
reduction	 in	 urine	 output	 after	 transplantation.	Whilst	 the	 kidney	 can	 withstand	 up	 to	 48	 hours	 of	 cold	
ischaemia,	 significant	efforts	are	made	 to	 reduce	 this	and	on	average	cold	 ischaemia	 is	below	24	hours	 in	
most	transplant	units.	Numerous	studies	have	demonstrated	that	the	duration	of	cold	ischaemia	can	directly	
influence	 graft	 function.	 Transplant	 graft	 function	 is	 typically	measured	 by	 the	 incidence	 of	 delayed	 graft	
function	(DGF)	and	is	defined	as	the	requirement	for	dialysis	within	the	first	week	following	transplantation.	
Acute	tubular	necrosis	secondary	to	ischaemic	injury	is	the	main	cause	of	DGF	and	is	associated	with	acute	
rejection,	increased	fibrosis	and	reduced	long	term	graft	survival.208,209	
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Rates	of	DGF	 in	deceased	donor	kidney	transplants	range	 from	5-40%,	whilst	 in	 live	donor	transplantation	
rates	are	significantly	less,	between	2-5%,	in	part	due	to	the	shortened	cold	ischaemia	time	and	in	part	due	
to	 the	healthy	 younger	donor.210,211	 In	 clinical	models	 the	 cold	 ischaemia	 time	has	 clearly	 shown	 to	be	an	
independent	risk	factor	for	DGF	and	by	reducing	the	cold	ischaemia	time	the	incidence	of	DGF	can	also	be	
reduced.	Numerous	studies	have	demonstrated	that	cold	ischaemia	times	greater	than	6	hours	can	result	in	
injury.212,213	 Ojo	 et	 al	 in	 a	 cohort	 analysis	 of	 over	 37,000	 DBD	 renal	 transplants	 found	 the	 risk	 of	 DGF	
increases	by	23%	for	every	6	hours	of	cold	ischaemia,	whilst	Locke	et	al	 in	a	similar	cohort	analysis	of	over	
170,000	 transplant	 recipients	 demonstrated	 that	 limiting	 the	 cold	 ischaemia	 time	 to	 less	 than	 12	 hours	
reduced	 the	 risk	 of	 DGF	 by	 approximately	 15%.214,215	 A	 prolonged	 cold	 ischaemia	 time	 is	 considered	 an	
independent	risk	factor	for	DGF,	whilst	DGF	is	associated	with	reduced	graft	survival	and	acute	rejection.216-
219	
1.7.2 Organ	preservation	
Experimental	studies	in	the	1950s	by	Lapchinsky	in	the	Soviet	Union	showed	that	the	ischaemic	injury	could	
be	 reduced	 by	 lowering	 the	 temperature,	 whilst	 Calne	 et	 al	 extended	 the	 preservation	 time	 by	 utilising	
hypothermic	 conditions	 and	 successfully	 transplanting	 canine	 kidneys	 after	12	hours	of	preservation.220,221	
These	 initial	 experiments	 and	 subsequent	 studies	 led	 to	 the	application	and	development	of	 preservation	
techniques	and	 solutions	 that	are	utilised	 today.	 Static	 cold	 storage	 (SCS)	 is	 the	 simplest	and	most	widely	
used	 clinical	 method	 of	 hypothermic	 preservation.	 Following	 retrieval,	 the	 kidney	 is	 flushed	 with	 cold	
preservation	solution	 to	 flush	out	blood	 from	the	vasculature	and	 initiate	cooling	of	 the	parenchyma.	The	
kidney	is	then	stored	in	cold	preservation	solution	within	a	sterile	bag,	which	is	surrounded	by	crushed	ice,	
to	maintain	a	temperature	between	0oC	and	4oC.	The	preservation	solutions	that	are	used	in	clinical	practice	
have	 been	 specifically	 designed	 to	 counteract	 the	 injurious	 effects	 of	 cold	 ischaemia.	 The	 commercially	
available	solutions	maintain	similar	basic	characteristics.	They	 include	an	 impermeable	osmotic	agent	such	
as	glucose	or	mannitol	that	act	to	minimise	cellular	swelling	and	stability	to	the	cell.	The	solutions	contain	a	
buffering	 agent	 such	 as	 citrate	 or	 histidine,	 as	 well	 as	 a	 balanced	 electrolyte	 composition	 to	 prevent	
intracellular	acidosis	and	further	reduce	cellular	oedema.		
In	1969,	Geoffrey	Collins	developed	the	first	preservation	solution,	termed	Collins	solution,	which	contained	
relatively	 high	 concentrations	 of	 potassium	 and	 glucose.	 This	 was	 subsequently	 modified	 to	 replace	 the	
glucose	 with	 mannitol,	 lowering	 the	 viscosity	 and	 providing	 better	 osmotic	 properties.	 The	 solution	 was	
renamed	Euro	Collins	solution	and	was	initially	used	widely	amongst	the	transplant	community.	
In	 the	 1970s	 an	 alternative	 to	 Collins	 solution	was	 developed.	Hyperosmolar	 citrate	 (HOC)	 also	 known	 as	
Soltran	or	Marshall’s	solution	was	formulated	with	a	high	potassium	content,	containing	citrate	as	a	buffer	
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and	 having	 hypertonic	 qualities	 to	 reduce	 cellular	 oedema.	 It	 is	 commonly	 used	 in	 some	 renal	 transplant	
programmes,	 however	 it	 is	 not	 recommended	 for	 DCD	 or	 ECD	 kidneys.	 Researchers	 at	 the	 University	 of	
Wisconsin	 developed	 a	 complex	 solution,	 with	 a	 high	 potassium	 concentration	 thereby	 maintaining	
intracellular	 ionic	 balance,	 containing	 trisaccharide	 raffinose	 and	 lactabionate	 as	 osmotic	 impermeants,	 a	
phosphate	buffer	and	anti-oxidants	to	scavenge	oxygen	free	radicals.	The	solution	also	contains	allopurinol	
to	 block	 the	 activity	 of	 ATP	 precursors	 and	 colloid	 hydroxyethyl	 starch	 (HES)	 to	 prevent	 cellular	 oedema	
formation.222	 The	 solution	 is	 termed	 University	 of	 Wisconsin	 (UW)	 solution	 and	 is	 considered	 the	 ‘gold	
standard’	 preservation	 solution	 for	 clinical	 use	 currently.	 The	 composition	 of	 UW	 prefers	 a	 significant	
advantage	when	compared	to	other	preservation	solutions,	allowing	kidneys	to	be	stored	for	longer	periods	
with	better	function	and	less	histological	ischaemic	injury	following	transplantation.	
New	 solutions	 such	histidine-tryptophan-ketoglutarate	 (HTK)	 and	Celsior	were	 initially	 designed	 for	 use	 in	
cardiac	transplantation,	but	have	been	adopted	for	clinical	preservation	of	the	kidney,	liver	and	pancreas.223-
226	HTK	is	considered	an	extracellular	solution	utilising	mannitol	as	an	impermeant	and	histidine	as	a	buffer.	
HTK	 contains	 several	 amino	 acids,	 tryptophan,	 which	 acts	 to	 stabilise	 cellular	 membranes	 and	 oxidative	
damage,	 and	 ketoglutararate,	 a	 substrate	 to	 support	 anaerobic	 metabolism.	 Concerns	 have	 been	 raised	
regarding	 its	 use	 for	 the	 preservation	 of	 ECD	 and	 DCD	 kidneys,	 with	 an	 increased	 risk	 of	 primary	 non-
function	 and	 early	 graft	 loss.227,228	 Celsior	 similarly	 is	 an	 extracellular	 solution,	 containing	 a	 high	 sodium	
concentration	 with	 histidine	 to	 buffer,	 mannitol	 to	 prevent	 cellular	 swelling	 and	 glutathione	 as	 an	
antioxidant.	Celsior	has	proved	beneficial	as	a	preservation	solution	in	multi-organ	transplantation.229	
Many	experimental	 studies	have	compared	the	various	preservation	solutions,	comparing	 the	efficacy	and	
effect	on	graft	survival,	with	the	majority	of	studies	demonstrating	that	UW	solution	 is	 the	most	superior.	
However	HTK,	Celsior	and	UW	appear	to	demonstrate	similarly	low	rates	of	DGF.	Euro	Collins	solution	is	not	
widely	used	and	is	regarded	as	inferior	with	higher	risk	of	DGF.230	Since	the	introduction	and	evolution	of	SCS	
techniques,	 there	 has	 been	 much	 debate	 on	 the	 best	 method	 of	 kidney	 preservation,	 SCS	 or	 HMP.	 The	
simplicity	 and	 inexpensive	 nature	 of	 SCS	 has	 an	 advantage	 over	 HMP.	 However	 HMP	 is	 thought	 to	 be	
superior	 method	 of	 preservation	 in	 that	 it	 allows	 a	 continual	 flush	 of	 the	 vasculature,	 preventing	 the	
accumulation	of	waste	products	and	intravascular	thrombosis.231		A	machine	perfusion	system	incorporates	
an	 automatic	 pump	 that	 continuously	 perfuses	 the	 kidney	 with	 a	 sterile	 and	 cold	 preservation	 solution.	
Immediately	after	retrieval,	 the	kidney	 is	attached	to	the	machine	via	the	renal	artery	ensuring	an	airtight	
seal.	 Circulation	 of	 the	 perfusate	 is	 achieved	 by	 a	 peristaltic	 pump	 that	 generates	 either	 a	 continuous	 or	
pulsatile	 flow.	 The	 kidney	 is	 perfused	 with	 a	 hypothermic	 preservation	 solution	 via	 the	 renal	 artery,	
maintaining	a	temperature	between	0oC	and	4oC,	providing	a	continuous	supply	of	nutrients	with	or	without	
oxygen,	 whilst	 simultaneously	 eliminating	 any	 toxic	 substrates	 and	 free	 radicals	 produced	 during	 the	
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ischaemic	period.	 In	 1967,	 Folker	Belzer	developed	a	machine	equipped	with	 a	pulsatile	pump	 to	perfuse	
and	preserve	the	kidney	for	72	hours.	He	utilised	cryoprecipitate	and	oxygenated	plasma	at	low	pressures	at	
a	 temperature	 between	 6oC	 and	 10oC.232,233	 With	 the	 introduction	 of	 SCS,	 which	 was	 inexpensive	 and	
simpler,	there	was	little	further	development	of	the	technique	of	HMP.	However,	with	the	increasing	use	of	
DCD	 and	 ECD	 kidneys	 over	 the	 last	 decade,	 there	 has	 been	 renewed	 interest	 into	 the	 use	 of	 HMP.	 New	
simpler	and	cheaper	systems	have	been	developed,	of	which	there	are	two	main	devices	that	are	commonly	
used.	The	LifePort	kidney	transporter	(Organ	Recovery	System,	Chicago,	U.S)	and	The	Waters	Medical	RM3	
(Rochester,	Minnesota,	U.S).	The	LifePort	is	a	portable	machine	perfusion	system	that	is	capable	of	perfusing	
a	single	kidney	without	supervision.	The	Waters	RM3	preservation	system	is	not	portable,	but	is	capable	of	
perfusing	two	kidneys	under	supervision.			
Many	 advantages	 of	 HMP	 have	 been	 demonstrated	 in	 various	 experimental	 studies.	 HMP	 provides	 the	
surgeon	with	biometric	parameters,	 such	as	 flow	rate,	 resistance,	 temperature	and	pressure,	allowing	 the	
evaluation	of	ischaemic	damage	and	organ	viability	as	predictors	of	outcome	following	transplantation.195,234	
It	 appears	 that	 HMP	 may	 reduce	 vasospasm,	 whilst	 allowing	 the	 surgeon	 to	 improve	 graft	 quality	 by	
pharmacological	 modulation	 or	 gene	 transfer	 therapies.235,236	 Numerous	 experimental	 studies	 have	
demonstrated	 that	 HMP	 is	 a	 better	 preservation	 tool	 and	 improves	 the	 quality	 of	 the	 kidney.188,205	 The	
largest	multicentre	 randomised	 control	 trial	 conducted	 in	 Europe	 comparing	 the	 use	 of	 SCS	 and	 HMP	 in	
deceased	donors	found	that	HMP	reduced	the	risk	of	DGF	by	6%	compared	to	SCS	(20.8%	vs	26.5%,	adjusted	
odds	ratio,	0.57;	P=0.01)	and	 improved	1	(94%	vs.	90%,	P=0.04)	and	3	year	 (91%	vs.	87%;	adjusted	hazard	
ratio	for	graft	failure,	0.60;	P=0.04)	graft	survival.195,237		
In	contrast	to	this,	Watson	et	al	 in	a	UK-based	randomised	multicentre	trial	comparing	HMP	versus	SCS	of	
DCD	kidneys,	found	no	beneficial	effects	of	HMP.197	The	authors	demonstrated	DGF	rates	of	58%	vs	56%	in	
the	HMP	and	SCS	groups	respectively.	However	this	trial	has	been	criticised	for	its	study	design,	protocol	and	
small	 number	 of	 patients.238,239	 The	 advantages	 of	 HMP	 versus	 SCS	 are	 still	 debated.	Monbaliuet	 al	 in	 a	
study	 of	 HMP	 of	 porcine	 livers	 demonstrated	 an	 increased	 risk	 of	 endothelial	 injury	 and	 trauma	 to	 the	
vessels,	 as	 well	 as	 questions	 on	 the	 cost	 effectiveness	 of	 the	 technique	 compared	 to	 traditional	 SCS	
techniques	 in	 other	 reviews	 and	 economic	modelling.240,241	 	 The	 experimental	 evidence	 strongly	 suggests	
that	 HMP	 is	 capable	 of	 reducing	 cold	 ischaemic	 injury	 compared	 to	 SCS,	 and	 growing	 clinical	 evidence	
demonstrates	that	HMP	is	the	preferred	technique	of	preservation.	However,	the	evidence	is	not	conclusive	
and	the	technique	in	not	universally	accepted.	There	is	clear	need	for	further	experimental	and	clinical	study	
to	determine	the	superior	method	of	preservation.	
The	use	of	microdialysis	for	in	vivo	tissue	viability	assessment	has	been	validated	in	a	variety	of	research	and	
clinical	scenarios,	 including	monitoring	of	cerebral	 ischaemia,	bowel	ischaemia,	free	flap	surgery,	and	post-
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operatively	in	kidney	and	liver	transplantation.26,242,243	There	are	limited	reports	of	the	use	of	microdialysis	as	
a	 tool	 for	 organ	 viability	 assessment	 during	 SCS	 or	 HMP,	 however,	 the	 clear	 need	 for	 greater	 tissue	
assessment	compels	us	to	propose	that	microdialysis	can	effectively	quantify	the	development	of	ischaemic	
injury	during	this	period.	Recent	studies	using	conventional	microdialysis	demonstrate	that	renal	ischaemia	
leads	 to	 significant	 increases	 in	 cortical	 lactate	 concentration	 in	 both	 animals	 and	humans.57,244,245	This,	 in	
combination	with	our	existing	knowledge	of	its	role	in	anaerobic	metabolism,	formed	our	rationale	of	using	
lactate	concentration	as	a	surrogate	marker	of	tissue	ischaemia	in	the	kidney.	
With	this	in	mind,	we	have	developed	a	novel	online	rapid	sampling	microdialysis	(rsMD)	analyser	capable	of	
measuring	the	concentration	of	markers	of	tissue	ischaemia,	such	as	lactate,	at	30-second	intervals.	To	date,	
no	 such	 system	 has	 been	 used	 to	 directly	 characterise	 and	 compare	 the	 effects	 of	 SCS	 and	 HMP	 on	
parenchymal	 metabolic	 activity	 and	 the	 ischaemic	 injury	 sustained	 during	 preservation	 in	 real	 time.	 If	
capable	of	accurately	monitoring	 tissue	 ischaemia	during	organ	preservation,	 rsMD	may	have	a	promising	
future	role	in	graft	viability	assessment.	
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1.8 HYPOTHESES	&	AIMS	
1.8.1 In-vivo	detection	of	colonic	ischaemia	following	abdominal	aortic	
aneurysm	repair	
Colonic	ischaemia	is	a	recognised	and	serious	complication	of	abdominal	aortic	aneurysm	(AAA)	repair	with	
an	incidence	of	up	to	42%.78,116	The	mortality	in	these	patients	can	be	up	to	90%	when	transmural	infarction	
is	 present,	 resulting	 in	 gangrene	 and	 perforation.132	 The	 clinical	 difficulty	 in	 establishing	 the	 diagnosis	
combined	with	the	patient’s	poor	physiological	status	is	often	associated	with	a	fatal	outcome.	
I	hypothesise	 that	microdialysis	 can	be	utilised	as	 an	effective	 tool	 in	 the	early	diagnosis	 and	 subsequent	
monitoring	 of	 colonic	 ischaemia	 in	 the	 post-operative	 period	 following	 AAA	 repair.	 I	 aim	 to	 assess	 the	
feasibility	of	using	on-line	rapid	sampling	microdialysis	in	the	detection	of	colonic	ischaemia	by	sampling,	in	
real	time,	the	metabolic	markers	of	ischaemic	within	the	colon	in	patients	following	AAA	repair.	
1.8.2 In-vivo	detection	of	gastro-intestinal	anastomotic	leaks	
The	 prompt	 diagnosis	 of	 post-operative	 complications	 such	 as	 anastomotic	 leaks	 can	 reduce	 morbidity,	
mortality,	 hospital	 stay	 and	 intervention	 costs.	 Complications	 following	 gastrointestinal	 surgery	 have	 an	
incidence	 of	 up	 to	 30%	 and	 can	 include	 serious	 complications	 such	 as	 anastomotic	 leaks,	 which	 possess	
mortality	 rates	 of	 up	 to	 39%.80,141,165	 Complications	 lead	 to	 poor	 surgical	 outcomes,	 increased	morbidity,	
prolonged	hospital	stay	and	potentially	increased	mortality.	
Although	a	number	of	risk	factors	predisposing	patients	to	anastomotic	leaks	and	other	complications	have	
been	identified,	an	absence	of	information	exists	on	the	biochemical	changes	that	occur	at	the	anastomotic	
site.	81,246,247	There	is	a	clear	role	for	a	monitoring	device	which	allows	real	time,	continuous	in-vivo	sampling	
of	 specific	 biomarkers	 in	 the	 post-operative	 phase.	 Online	 rsMD	 may	 allow	 investigators	 to	 better	
understand	 the	 intra-abdominal	 metabolic	 processes	 that	 take	 place,	 allowing	 for	 the	 early	 detection	 of	
post-operative	complications	such	as	anastomotic	leaks.	
I	hypothesise	that	online	rsMD	can	be	effectively	utilised	in	the	monitoring	of	patients	undergoing	major	GI	
surgery,	for	the	early	detection	of	post-operative	complications	such	as	anastomotic	leaks.	
To	conclusively	prove	this	hypothesis	would	 likely	 require	multiple	studies.	As	a	 first	step	my	primary	aim	
was	 to	 perform	 a	 feasibility	 study	where	 I	 sample	 peritoneal	 fluid,	 examine	 peritoneal	 lactate	 profiles	 of	
patients	undergoing	GI	surgery	and	correlate	 these	 findings	with	clinical	progress	and	the	development	of	
post-operative	complications	such	as	anastomotic	leaks.	
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There	 currently	 exists	 no	 validated	 protocol	 for	 peritoneal	 lactate	 quantification	 in	 patients	 undergoing	
major	GI	surgery,	therefore	my	secondary	aim	is	to	establish	and	validate	an	ex-vivo	microdialysis	protocol	
for	peritoneal	lactate	quantification.	This	will	allow	for	further	future	examination	and	concordance	with	in-
vivo	microdialysis	monitoring	of	complications	such	as	anastomoses.	
1.8.3 Allograft	viability	assessment	during	the	preservation	period	
utilising	online	rapid	sampling	microdialysis	
With	 the	 number	 of	 patients	waiting	 for	 a	 renal	 transplant	 ever	 increasing,	 transplant	 programmes	 have	
sought	to	increase	the	donor	pool	by	including	ECD	and	DCD	kidneys.	Therefore,	stratagems	are	needed	to	
assess	and	potentially	modify	the	parenchymal	environment	of	organs	from	‘marginal’	donors,	allowing	the	
surgeon	 to	 stratify	potential	 outcomes	and	 improve	graft	 survival.	Hypothermic	machine	perfusion	 (HMP)	
has	possible	advantages	 for	 the	preservation	of	kidneys	compared	to	static	cold	storage	 (SCS),	 resulting	 in	
improved	 immediate	 post-transplant	 graft	 function,	 better	 survival	 rates	 and	 superior	 preservation	 of	
microcirculatory	integrity.191,248,249	At	present	however,	there	are	no	accepted	indicators	that	can	determine	
organ	viability	and	potential	post-operative	function	before	an	organ	is	transplanted,	and	12-18%	of	kidneys	
are	 discarded	 due	 to	 concerns	 about	 their	 suitability	 for	 transplantation.	 A	 comprehensive	 assessment	 of	
both	 renal	 tissue	 viability	 and	 ex	 vivo	 function	 during	 preservation	 would	 facilitate	 a	 greater	 level	 of	
discrimination	 in	 identifying	 those	organs	which	are	at	higher	 risk	of	delayed	graft	 function.	 It	would	also	
enable	a	more	accurate	selection	of	kidneys	which	are	suitable	for	transplantation.		
I	hypothesise	 that	online	 rapid	sampling	microdialysis	can	be	utilised	 for	organ	viability	assessment	 in	 the	
preservation	 period	 with	 the	 real-time	measurement	 of	 parenchymal	 lactate	 concentration,	 thereby	 also	
allowing	metabolic	profiles	to	be	demonstrated	during	both	SCS	and	HMP.	
My	aims	were	three-fold:		 	
1 Assess	 the	 use	 of	 cortical	 lactate	 concentration	 as	 a	 biomarker	 for	 ischaemic	 injury	 with	 a	 view	 to	
determining	 the	 potential	 role	 of	 rsMD	 in	 the	 viability	 assessment	 of	 kidney	 allografts	 during	
preservation.	
2 Assess	the	feasibility	of	using	rsMD	to	monitor	changes	in	lactate	concentration	within	the	renal	cortex	
and	medulla	during	SCS	and	HMP	in	a	porcine	model.	
3 Once	I	have	validated	the	technique	of	online	rsMD,	I	aim	to	compare	the	effects	of	SCS	and	HMP	on	
renal	cellular	metabolism	and	ischemia	during	the	preservation	period.		
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2 CHAPTER	2	–	MATERIALS	&	METHODS	
2.1 ONLINE	RAPID	SAMPLING	MICRODIALYSIS	ANALYSER	
The	online	rapid	sampling	microdialysis	analyser	(rsMD)	was	designed,	assembled,	modified	and	optimised	
in	conjunction	with	the	Department	of	Bioengineering,	Imperial	College	London.	The	aim	in	constructing	the	
analyser	 was	 to	 allow	 simultaneous	 and	 automatic	 analysis	 of	 the	 dialysate	 from	 the	 outlet	 of	 the	
microdialysis	catheter.	The	system	consists	of	multiple	components,	which	when	working	together	allow	the	
biosensor	assay	to	detect	the	metabolic	markers	of	ischaemia	online	and	in	high	resolution.	
	
Figure	5	–	Schematic	of	online	rapid	sampling	microdialysis	analyser	
Illustration	by	author	–	SD	
Figure	5	illustrates	the	different	components	of	the	biosensor	assay	system.	A	multiport	microdialysis	pump	
injects	 a	 physiological	 perfusion	 solution	 into	 the	microdialysis	 catheter,	which	 is	 inserted	 into	 the	 target	
tissue.	The	catheter	outlet	is	connected	to	an	alternating	valve,	which	directs	the	dialysate	in	to	one	of	two	
reactor	 chambers.	 The	 oxidising	 reaction	 takes	 place	within	 these	 reactors,	which	 releases	 electrons.	 The	
reactors	are	coupled	to	radial	flow	cell	electrodes,	where	an	electrical	current	is	created	and	is	proportional	
to	 the	 concentration	 of	 the	 analyte.	 This	 current	 is	 held	 at	 a	 constant	 potential	 by	 the	 potentiostat	 and	
recorded	by	the	PowerlabTM	software.	A	ferrocene	buffer	is	also	pumped	through	the	system,	which	contains	
the	mediator	molecule	for	the	enzyme-based	reaction	that	occurs	within	the	reactor	beds.	
2.0	μL/min
Microdialysis	pump
Switching	
valve
Microdialysis	probe
Target	tissue
HPLC	pump
Ferrocene	buffer
Lactate	
sensor
Glucose	
sensor
Electrode
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PowerBook	display
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2.1.1 Catheter	design	&	Construction	
A	microdialysis	 probe	 (CMA	 12	MD	Probe	 -	 Figure	 6),	which	was	 used	 in	 all	 animal	models,	 consists	 of	 a	
tubular	dialysis	membrane	closed	at	its	distal	end,	an	inlet	tube	for	supplying	perfusion	fluid	into	the	body	of	
the	 dialysis	 membrane	 and	 an	 outlet	 tube	 for	 the	 exit	 of	 perfusion	 fluid	 from	 the	 body	 of	 the	 dialysis	
membrane.	The	semi	permeable	membrane	is	glued	between	the	tip	of	the	inner	steel	tubing	and	the	outer	
steel	shaft.	The	perfusion	fluid	enters	the	membrane	space	through	two	holes	in	the	inner	channel,	flowing	
into	the	outlet	shaft.	A	clinical	microdialysis	catheter	(such	as	the	CMA	61	Hepatic	Microdialysis	Catheter	-	
Figure	7),	which	was	used	in	all	clinical	in-vivo	models,	consists	of	a	concentric	tube.	Within	the	outer	wall	is	
30mm	semi-permeable	membrane,	which	allows	a	high	recovery	of	substances	from	the	extracellular	fluid.	
The	 membrane	 cut-off	 is	 approximately	 20,000	 Daltons,	 this	 limits	 the	 size	 of	 the	 molecules	 diffusing	
through,	 thereby	 increasing	 the	 selectivity	 of	 the	 technique.	 In	 clinical	 use,	 this	 has	 the	 added	 benefit	 of	
preventing	the	passage	of	microorganism,	viruses	or	prions	and	the	enzymes	that	may	degrade	the	analytes	
being	measured.		
2.1.2 Connection	to	the	rsMD	assay	
Two	 connections	 are	 required	 for	 a	 microdialysis	 catheter	 or	 probe	 to	 function	 within	 the	 rsMD	 assay.	
Firstly,	 a	 connection	 is	 needed	 between	 the	 inlet	 of	 the	microdialysis	 catheter	 or	 probe	 and	 then	 to	 the	
microdialysis	pump.	This	allows	the	perfusion	solution	to	be	delivered	at	a	constant	and	predetermined	rate.	
The	second	connection	that	 is	required	 is	between	the	outlet	of	the	catheter	and	the	assay	 itself,	to	allow	
the	dialysate	to	be	analysed	in	real	time.	The	catheter	inlet	is	connected	to	a	microdialysis	pump	via	a	sterile	
1.5m	 long	 extension	 tube	 (Alaris	 Medical®	 systems,	 Ohio,	 U.S.)	 with	 a	 0.4ml	 capacity.	 The	 outlet	 of	 the	
catheter	 is	 attached	 to	 a	 sterile,	 1.5m	 long	 fine	 fluorinated	 ethylene	 propylene	 (FEP)	 tubing	 (CMA	
Microdialysis	AB,	Stockholm,	Sweden),	which	is	in	turn	attached	to	the	analyser	via	a	needle	adaptor	(Needle	
22	gauge,	0.75	 inches	 from	Hamilton,	GR,	Switzerland).	The	needle	adaptor	 is	 inserted	 into	an	aperture	 in	
the	dual	switching	valve,	thereby	delivering	the	dialysate	directly	into	the	analyser.	
	
Figure	6	–	CMA	12	MD	probe	
Courtesy	of	CMA	Microdialysis.		
Inlet
Distal	 tip
Dialysis	 membrane
Outlet
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Figure	7	–	Schematic	of	#61	Hepatic	Microdialysis	Catheter	
Courtesy	of	CMA	Microdialysis	
2.1.3 High-pressure	liquid	chromatography	pump			
The	assay	 in	the	rsMD	employs	a	 ferrocene	buffer	that	accelerates	the	dialysate	fluid	through	the	enzyme	
reactors,	after	it	travels	from	the	outlet	tubing	of	the	microdialysis	catheter.	The	ferrocene	buffer	is	pumped	
through	 the	 assay	 by	 a	 high-pressure	 liquid	 chromatography	 pump	 (HPLC,	 Flux	 Instruments,	 Rheos	 2000,	
Reinach	BL	Switzerland).	The	flask	(Anachem	Ltd,	Bedfordshire,	UK)	that	stores	the	ferrocene	buffer	contains	
a	 perforated	 membrane	 that	 acts	 to	 filter	 the	 solvent	 as	 it	 travels	 through	 transparent	 PEEKTM	 tubing	
(Thames	Restek,	Buckinghamshire,	UK)	via	capillary	action.	The	dual	switching	valve	and	the	HPLC	pump	are	
connected	with	green	PEEKTM	tubing	(Anachem	Ltd,	Bedfordshire,	UK).	The	connections	between	the	valve	
and	 the	 reactors	 are	 created	 with	 yellow	 PEEKTM	 tubing	 (Anachem	 Ltd,	 Bedfordshire,	 UK),	 whilst	 the	
connections	between	the	reactors	and	the	electrodes	utilise	red	PEEKTM	tubing	(Anachem	Ltd,	Bedfordshire,	
UK).	 Flow	 of	 ferrocene	 from	 the	 HPLC	 pump	 is	 divided	 into	 two	 independent	 streams	 using	 a	 t-shaped	
connector	(Thames	Restek,	Buckinghamshire,	UK)	(Figure	8).	
 1.  Microvial (polystyrene + santoprene)
 2.  Luer lock connection (polycarbonate)
 3.  Inlet tube (polyurethane)
 4.  Vial holder (polycarbonate)
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1. Microvial (polystyrene	+	santoprene)	
2. Luer lock	connection	 (polycarbonate)	
3. Inlet	tube	(polyurethane)	
4. Vial	holder	 (polycarbonate)	
5. Outlet	tube	(polyurethane)	
6. Liquid	 cross	(polysulfone)	
7. Protection	 tube	(polyethylene)	
8. Inner	Shaft	(polyurethane)	
9. Outer	Shaft	(polyurethane)	
10. Suture	(braided	 polyester	suture,	 5-0,	non-resorbable)
11. Dialysis	membrane	(polyarylethersulphone,	 PAES,	OD	0.6	mm)	
12. Gold	thread	 within	the	catheter	 membrane	tip	(OD	0.13	mm,	length	3	mm)
13. Fixating	device	(PEBAX®)
14. Splitable Introducer
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Component Material
Length	
mm
Ø
mm
Inner	shaft Polyurethane 310 0.9
Outer	shaft Polyurethane 280 1.5
Membrane
Polyaryl-ether	
Sulphone 30 0.6
Inlet	tube Polyurethane 400 1.0
Outlet	tube Polyurethane 70 1.0
Membrane	cut-off	20.000	Daltons
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Figure	8	–	T-connector	from	Restek	
The	device	splits	the	flow	of	ferrocene	buffer	
2.1.4 Faraday	Box		
The	 Faraday	 box	 (RS,	Northants,	UK)	 (Figure	9)	 is	 formed	 from	 aluminium	 and	 allows	 blocking	 of	 external	
static	 and	 non-static	 electric	 fields.	 It	 contains	 the	 valves,	 enzyme	 reactors,	 electrodes	 and	 all	 the	
connections	that	allow	analysis	of	the	dialysate.			 
	
Figure	9	–	Faraday	box	containing	the	valve,	reactors,	electrodes	and	connections 
In	the	centre	of	the	Faraday	box	is	the	dual	switching	valve	(1),	which	introduces	the	dialysate	fluid	sample	
into	independent	lactate	and	glucose	reactors.	The	ferrocene	buffer,	which	is	a	key	component	in	the	flow	
injection	analysis	(FIA)	is	injected	by	the	HPLC	pump	into	the	green	PEEKTM	tubing	(2).	On	either	side	of	the	
dual	switching	valve	are	the	two	enzyme	reactors	(3	–	left	reactor	labelled),	where	the	dialysate	flows	into	
Chapter 2: Common Materials and Methods 
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• Animal Surgery: during the entire procedure the clinician can visually inspect and 
verify the probe implantation site. 
• Patient Intensive Care: unfortunately, there are not means for inspection of the 
probe site after implantation during intensive care treatment. An MRi scan could 
locate the probe using the gold marker in the probe tip. However, a scan was not 
routinely performed on this patient group. 
2.2.2 HPLC Pump 
The assay system uses a ferrocene buffer that accelerates the dialysate fluid coming from 
the microdialysis outlet through the valve into the enzymes reactors. In order to pump this 
buffer an HPLC pump (Flux Instruments, Rheos 2000, Reinach BL Switzerland) is used. A 
transparent PEEKTM tubing (Thames Restek, Buckinghamshire, UK) 1/8” external diameter 
is connected from the pump to a solvent filter, working on the principle of capillary, in the 
bottle. The bottle, being of specific shape, (Anachem Ltd, Bedfordshire, UK) encloses a lid 
with perforations to hold the filter with the tubing in. The connections between the valve and 
the pump are green PEEKTM tubing (Anachem Ltd, Bedfordshire, UK) 0.030 inch internal 
diameter and 1/16 inch external diameter, and 0.007 inch internal diameter yellow and 
0.005 inch internal diameter red PEEKTM tubing for the connections between the valve and 
the reactors and between the reactor and the electrodes, respectively, to reduce the dead 
volume. Fittings are Sealtight TM (Upchurch Scientific, WA, USA). 
The green tubing coming from the pump is divided in two streams before entering the valve. 
This is been usually a normal t-shape connector (Thames Restek, Buckinghamshire, UK). 
However, for this new assay system, Valco retailers provided us with a custom adjustable 
connector, previously discussed with them. This also consists of a t-shape union with flat 
bottom ports and flangeless fittings for a tight seal. The nut with a T (see figure 2.3) turns to 
right or left, leading the flow to the side that is turned and blocking the flow in the other 
direction. 
 
Figure 2.3: New T-connecto  from Valco.  
The connector splits the flow coming from the black ferrule to the green one on the left and the blue one on the 
right. Turning the nut with the T permit us to lead the flow stream to each side without disassembling the 
connections.  
This new connector will result in a highly helpful tool in the construction of the reactors (see 
section 2.5). 
	
Figure	6	- Farad y	box	containing	the	 ,	reactors,	 lectrodes	and	connections 
In	the	centre	of	the	Faraday	box	is	the	dual	switching	valve	(1),	which	introduces	the	
dialysate	fluid	sample	into	independent	lactate	and	glucose	reactors.	The	ferrocene	
buffer,	which	is	a	key	component	in	the	flow	injection	analysis	(FIA)	is	injected	by	the	
HPLC	pump	into	the	green	PEEKTM	tubing	(2).	On	either	sides	of	the	dual	switching	
valve	 are	 the	 two	 enzyme	 reactors	 (3	 –	 left	 reactor	 labeled),	 where	 the	 dialysate	
flows	 into	 and	 generates	 a	 current,	which	 is	 detected	 further	 down	 stream	at	 the	
electrodes	(4).	The	electrodes	are	coupled	to	analysis	instrumentation	(5)	for	further	
examination	of	the	collected	data.	
Dual	channel	switching	injection	valve		
A	1.5	m	length	of	FEP	tubing	(1.2	μl/10	cm,	Thames-Restek,	Buckinghamshire,	UK)	is	
attached	to	the	outlet	of	 the	microdialysis	catheter.	The	distal	end	of	 the	tubing	 is	
attached	to	the	connection	port	of	 the	customised	valve	 (0.2	μl	dual	 internal	 loop,	
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2.2.3 Faraday Box 
The Faraday box holds the valve connected to each enzyme reactors that then are coupled 
to the electrodes.  
Box 
The box (RS, Northans, UK) needed to be custom modified to place the injection valve, the 
enzyme reactors and the radial flow cell electrodes in one compartment and the motor and 
the automatic system of the valve in another. It was then ordered and delivered to a 
mechanic workshop at Kingʼs College Hospital.  
 
 
Figure 2.4: The Faraday Box. 
The valve, the reactors and the flow cell electrodes connected to the potentiostats are visible when the lid is 
open, while the motor of the valve is hidden behind. 
The lid that covers the box can be open showing only the valve and the reactors 
compartment. The box provides an excellent isolation as well as a perfect place to keep the 
electronics in order. 
4 
1 
3 
2 
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and	 generates	 a	 current,	which	 is	 detected	 further	 downstream	 at	 the	 electrodes	 (4).	 The	 electrodes	 are	
coupled	to	analysis	instrumentation	(5)	for	further	examination	of	the	collected	data.	
2.1.5 Dual	channel	switching	injection	valve	
A	1.5m	length	of	FEP	tubing	(1.2μl/10	cm,	Thames-Restek,	Buckinghamshire,	UK)	is	attached	to	the	outlet	of	
the	microdialysis	catheter.	The	distal	end	of	the	tubing	is	attached	to	the	connection	port	of	the	customised	
valve	(0.2μl	dual	 internal	 loop,	Valco	 Instruments,	Switzerland)	via	a	22-gauge	needle	adaptor	 (0.75inches,	
Hamilton,	GR,	Switzerland).	The	dialysate	travels	within	the	lumen	of	the	tubing	and	is	delivered	directly	to	
the	valve.	The	calibrations	standards	can	also	be	injected	directly	into	the	valve	through	the	same	port	using	
a	 specially	 designed	 1ml	 calibrated	 syringe	 (Hamilton,	 GR,	 Switzerland).	 The	 customised	 valve	 (Figure	 10)	
comprises	of	six	individual	ports	with	the	following	function:	
1	 Injection	of	dialysate	fluid	
2	 Removal	of	dialysate	waste	
3	+	4	 Injection	of	external	ferrocene	buffer	solution	
5	+	6	 Outlet	to	enzyme	reactors	
	
Figure	10	–	Injection	Valve	system	
Two	 independent	 injecting	positions,	 the	valve	alternates	between	Position	A,	directing	the	 flow	to	 the	Lactate	enzyme	reactor	and	Position	B,	
directing	the	flow	to	the	glucose	reactor.	
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2.1.6 Enzyme	reactors	
The	rsMD	assay	contains	two	enzyme	reactors	(Figure	11),	one	for	lactate	and	one	for	glucose.	Each	reactor	
holds	a	6mm	circular	membrane	with	a	preloaded	enzyme	bed.	They	are	custom	created from	novel	in-line	
biocompatible	 filters	 (Anachem	 Ltd,	 Bedfordshire,	 UK)	 and	 comprise	 of	 a	 stainless-steel	 body	 with	 two	
adjustable	 caps	made	 from	 a	 non-reactive	 plasticised	 polymer.	 The	 dialysate	 is	 directly	 delivered	 to	 each	
reactor	by	the	dual	switching	valve	and	then	travels	to	the	electrode	for	detection	of	electrons.	
	
Figure	11	–	Enzyme	Reactor	
The	 polymer	 cap	 holds	 the	 enzyme	 membrane	 and	 the	 arrow	 on	 the	 body	 demonstrates	 the	 flow	 of	 dialysate	 through	 the	 reactors	 whilst	
facilitating	orientation	when	assembling	the	assay.	
2.1.7 Enzyme	bed		
Each	enzyme	bed	has	 two	 layers	of	 enzymes	absorbed	onto	a	 circular	 cellulose	membrane,	which	 is	 then	
enclosed	 into	 a	 steel	 enzyme	 reactor.	 The	 first	 layer	 contains	 the	 oxidase	 enzyme,	 either	 in	 the	 form	 of	
glucose	oxidase	(GOx)	or	lactate	oxidase	(LOx),	depending	on	which	analyte	is	being	sensed	for.	The	second	
layer	contains	the	peroxidase	enzyme	 in	the	 form	of	horseradish	peroxidase	 (HRP).	They	are	sensitive	and	
stable	for	up	to	five	days	of	continuous	use.	
The	enzyme	beds	are	created	in	the	following	manner:	
1. Lactate	 oxidase,	 glucose	 oxidase	 and	 horseradish	 peroxidase	 (LOx	 2mg,	 GOx	 1mg	 and	 HRP	 0.5mg,	
Genzyme	Diagnostics,	UK)	are	individually	dissolved	in	filtered	ferrocene	buffer	(1ml).	
2. Each	enzyme	solution	is	pumped	five	times	through	nano-porous	mixed	cellulose	membranes	(0.025μm	
pores,	25mm	discs,	VSWP02500,	Millipore	UK	membrane)	to	allow	maximum	loading	of	the	membrane	
with	the	enzymes. 
3. 6mm	circular	discs	are	punched	out	of	the	cellulose	membrane	and	stored	in	the	ferrocene	at	4oC.	The	
circular	 punch,	 tweezers	 for	 handling	 and	 the	pumping	 syringe	 are	 treated	with	methanol	 solution	 to	
prevent	any	contamination	between	enzymes	substrates. 
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Injection Valve 
The dialysate liquid collected from the ECF is carried through a FEP tube (1.2 µl/10 cm, 
Thames-Restek, Buckinghamshire, UK) attached to the outlet of the probe and to a needle 
(22 gauge, 0.75 inches, Hamilton, GR, Switzerland) at the other end. This needle is 
connected into the port of a custom valve made for us by Valco Instruments (Schenkon, 
Switzerland USA) with a 0.2 µl dual internal loop (Figure 2.4). Standards for the calibration 
are injected also into the valve manually using a 1 ml Hamilton Syringe (Hamilton, GR, 
Switzerland).  
 
Figure 2.5: Injection Valve Scheme. 
The valve has two injecting positions, the dialysate is connected to the loading port, the valve then switches to 
direct the flow to the lactate reactor (left), returning to reload position to then inject to the glucose reactor (right). 
The custom valve consisted of 6 ports valve, one port where the collection of the dialysate 
is directed, with its respective waste. Two others are the inlets of the external buffer and the 
two remaining ports are the outlets to each respective reactor.  
Enzyme Reactors 
The reactors are used to hold a 6 mm disc membranes where the enzyme has been 
previously loaded.  
 
Figure 2.6: Reactor for the enzymatic recognition. 
The enzymatic reactors are made from in-line biocompatible filter components. It consists of a steel body and 
two end fittings where the enzyme membranes will be held. The arrow of the body helps orientating the reactor 
in the direction of the flow. 
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4. The	 oxidase	 and	 peroxidase	 enzyme	 discs	 are	 placed	 in	 the	 centre	 of	 the	 high	 pressure	 in-line	 filter	
reactors,	 thereby	 maximising	 surface	 area	 for	 contact	 and	 preventing	 unwanted	 build-up	 of	 back	
pressure.	It	is	important	that	the	oxidase	enzyme	is	in	the	first	layer	and	the	peroxidase	enzyme	is	in	the	
second	layer,	in	order	that	the	correct	sequence	of	reactions	takes	place	as	the	dialysate	flows	through	
the	reactor. 
5. The	reactors	are	pressure	adjusted	to	allow	equal	distribution	of	the	dialysate	when	split	by	the	valve. 
6. The	reactors	are	filled	with	the	ferrocene	buffer	solution	and	stored	at	4oC	when	not	in	use. 
2.1.8 Radial	flow	cell	electrode		
The	rsMD	assay	contains	two	radial	flow	cell	electrodes	(BAS,	IN,	USA).	One	electrode	detects	the	electrons	
produced	by	 the	 reduction	of	 the	mediator	 in	 the	 glucose	 reactor	 and	 the	other	 electrode	detects	 at	 the	
lactate	reactor.	Each	electrode	comprises	a	stainless-steel	jet	auxiliary	electrode	through	which	the	dialysate	
flows	from	the	valve	to	the	reactor.	The	flow	is	then	directed	onto	the	3mm	glassy	carbon	working	electrode	
that	 is	 embedded	 into	a	polymer	unit	 and	 fixed	 to	 the	electrode.	 The	 reference	electrode	Ag/AgCl	 is	 also	
embedded	 in	 the	 polymer	 unit	 and	 is	 in	 close	 proximity	 to	 the	 glassy	 carbon	working	 electrode,	which	 is	
separated	from	the	auxiliary	electrode	by	a	16μm	thin	Teflon	gasket. 
		
Figure	12	–	Radial	flow	cell	electrode	
The	individual	auxiliary,	reference	and	working	electrodes	can	be	seen,	which	together	form	the	radial	flow	electrode	
2.1.9 Hardware	and	software		
Each	electrode	is	attached	to	and	controlled	by	one	of	two	potentiostats	(ADInstruments,	E.	Sussex,	UK).	The	
currents	 detected	 by	 the	 electrodes	 are	 converted	 to	 current	 peaks	 by	 Powerlab	 8/SP	 A/D	 converter	
(ADInstruments,	 E.	 Sussex,	 UK)	 and	 displayed	 on	 an	 Apple	 Mac	 (G4	 PowerBook,	 Cupertino,	 US)	 running	
ChartTM	 5.5.6	 software	 (ADInstruments).	 Valve	 switching	 and	 the	 HPLC	 pump	 are	 also	 controlled	
electronically	with	software	JaneiroTM.	
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These are built from novel in-line biocompatible filters components (Anachem Ltd, 
Bedfordshire, UK) that consisted of three sections, a stainless steel body and two end 
fittings made of 100% PEEKTM. The reactors are settled between the valve, through which 
the sample is injected alternatively, and each respective electrode where the detection 
occurs. 
2.2.4 Radial Flow Cell 
The electrodes named above are two radial flow cells (BAS, IN, USA) one for glucose and 
one for lactate. These radial flow cells consist of a stainless steel jet auxiliary electrode 
through which the flow from the valve passes. It then hits the glassy carbon working 
electrode, embedded in the other part of the radial flow cell. The reference electrode 
Ag/AgCl covers a small area beside the 3 mm glassy carbon electrode of the flow cell. The 
working electrode is separated (16 µm) from the auxiliary electrode by a thin Teflon gasket. 
 
Figure 2.7: Radial flow cell electrode. 
The auxiliary electrode is the stainless steel jet, the working electrode can be seen in the other part as a 3 mm 
glassy carbon area and the reference electrode is the Ag/AgCl dot next to the working electrode. 
Working electrode 
The working electrode is positioned opposite to the auxiliary electrode and separated by a 
gasket a distance of 16 µm. 
 
Figure 2.8: Schematic radial flow cell gap between auxiliary and working electrodes. 
The possibility that a molecule of ferrocene that is oxidised on the working electrode, diffused to the auxiliary 
electrode and reduced there to then be oxidised again on the working electrode is depicted. 
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Figure	13	–	On-line	rapid	sampling	microdialysis	system	
All	 the	various	components	of	 the	 rsMD	assay	are	placed	on	a	 trolley,	with	 the	HPLC	and	back-up	power	 source	 (UPS)	on	 the	 lowest	 shelf	and	
Powerlab	with	the	potentiostats	on	a	higher	shelf.	The	controlling	Apple	Mac	and	microdialysis	pump	are	situated	on	the	highest	shelf,	with	the	
Faraday	box	situated	laterally	on	an	adjustable	extension	arm.	
Solutions	and	Standards		
In	order	to	operate	the	rsMD	assay	efficiently	and	to	achieve	an	accurate	and	sensitive	assay,	a	number	of	
important	liquid	components	were	needed.		
2.1.9.1 Ferrocene	Buffer	
The flow	injection	analyser	(FIA)	consists	of	a	 low-pressure	dialysate	stream	with	a	 low	flow	rate	which	 is	
introduced	into	a	high-pressure,	high	flow	rate	analysis	stream.	A	ferrocene	buffer	is	required	in	the	FIA	to	
provide	the	appropriate	biochemical	and	electrochemical	environment.	It	was	important	in	our	experiments	
that	there	was	no	contamination	of	the	ferrocene,	as	the	presence	of	microorganisms	may	unduly	affect	our	
analysis.	Therefore,	a	fresh	volume	of	ferrocene	was	synthesized	and	stored	at	4oC	prior	to	each	experiment. 
	
pump	 are	 also	 controlled	 electronically	 with	 software	 JaneiroTM.
	
Figure	10	–	On-line	rapid	sampling	microdialysis	system	
All	the	various	components	of	the	rsMD	assay	are	placed	on	a	trolley,	with	the	HPLC	and	back	up	power	
source	(UPS)	on	the	lowest	shelf	and	Powerlab	with	the	potentiostats	on	a	higher	shelf.	The	controlling	
Apple	Mac	and	microdialysis	pump	are	situated	on	the	highest	shelf,	with	the	Faraday	box	situated	
laterally	on	an	adjustable	extension	arm.					
Solutions	and	Standards		
In	 order	 to	 operate	 the	 rsMD	 assay	 efficiently	 and	 to	 achieve	 an	 accurate	 and	
sensitive	assay,	a	number	of	important	liquid	components	were	needed.	 
Ferrocene	Buffer		
Faraday	Box	
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The	constituents	of	the	ferrocene	buffer	solution	are	detailed	below:	
Substrate	 Volume	(mls)	 Action	
Ferrocene	Monocarboxylic	Acid	
Fluka	46264,UK	 1.5	
Mediator	for	the	transduction	process	in	the	
biosensor		
Ethylene	Diamine	Tetra	Acetic	acid	(EDTA)		
Sigma	S4641,	UK	 1	
Chelating	agent	applied	to	reduce	
interference	of	divalent	and	trivalent	ions	
Sodium	Chloride	
SigmaS7653,UK	 150	
Maintain	the	concentration	of	chloride	at	the	
reference	electrode	
Sodium	Citrate		
SigmaS4641,UK	 0.1	
Buffer	solution	at	a	neutral	pH	to	allow	
optimum	enzyme	activity	
Kathon	biocide	(Chloro-methyl	Isothiazoline)	
Rohn	and	Hass,	UK	 	 Protects	against	bacterial	scavenging	
Ultra	pure	water	 1000	 Solvent	
	
Table	1	–	Constituents	of	the	ferrocene	buffer	solution 
The	procedure	to	prepare	and	operate	a	ferrocene	based	FIA	stream	(1	litre),	is	detailed	below:	
1. The	constituents	(Table	1)	are	dissolved	into	a	solution	and	stirred	continuously	
2. The	 solution	 is	 then	 filtered	using	 a	 vacuum	pump	 through	47mm	anodised	membrane	 (0.02	 -	 0.1μm	
pore	size,	Whatman	International,	UK)	
3. The	ferrocene	can	be	sealed	and	stored	at	4oC	for	later	use.	
4. The	 ferrocene	 buffer	 solution	 is	 pumped	 through	 a	 backpressure	 regulator	 and	 the	 FIA	 using	 the	
computer	controlled	HPLC	pump	at	a	rate	of	200μL/min,	which	is	the	optimum	rate	for	a	sensitive	and	
stable	assay.	
5. The	HPLC	pump	can	be	monitored	and	controlled	by	the	JaneiroTM	software	on	the	Apple	Mac.	
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2.1.9.2 Dialysate	Solution	
To	allow	for	molecules	to	diffuse	along	concentrations	gradients,	it	vital	that	the	dialysate	solution	possess	
the	 same	macro	and	molecular	 chemical	 structure	as	normal	physiological	extracellular	 fluid.	With	 that	 in	
mind	 we	 used	 a	 commercially	 pre-prepared	 physiological	 saline	 solution	 (Perfusion	 fluid	 T1,	 CMA	
microdialysis,	Stockholm,	Sweden).	The	ionic	concentrations	of	the	dialysate	are	shown	in	Table	2.		
Ion	 Concentration	
(mmol/L)	
Na+	 147	(mmol/L)	
K+	 4	(mmol/L)	
Ca2+	 2.3	(mmol/L)	
Cl-	 156	(mmol/L)	
	
Table	2	–	Ionic	concentration	of	the	sterile	dialysate	solution	
Perfusion	fluid	T1,	CMA,	Stockholm,	Sweden	
2.1.9.3 Glucose	and	Lactate	calibration	standards		
The	use	of	calibration	standards	 is	 imperative	 in	the	analysis	and	 interpretation	of	 the	data.	Calibration	of	
the	assay	allows	us	to	correlate	the	electrode-produced	amperometric	signal	to	a	specific	concentration	of	
the	analyte.	Numerous	standards	are	required	to	allow	correlation	with	different	analyte	concentrations.  
Glucose	(0.5M,	Sigma,	Aristar	grade)	and	Lactic	acid	(0.5M,	Sigma,	Aristar	grade)	substrates	are	dissolved	in	
a	 solution	 that	 is	 ionically	 identical	 to	 the	 dialysate	 being	 used.	 New	 standards	 are	 created	 for	 each	
experiment	 and	 stored	 at	 4oC.	 Solutions	 of	 glucose	 and	 lactate	 are	 made	 with	 differing	 concentrations,	
ranging	from	10mM	to	50μM	and	are	created	by	diluting	with	saline.	
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2.1.10 Data	analysis	
The	 raw	 data	 is	 collected	 using	 the	 Powerlab	 Chart®	 program	 which	 directly	 interprets	 and	 displays	 the	
concentrations	of	the	analytes	as	current	peaks	on	a	continuous	running	trace	over	time.		
	
Figure	14	–	Online	rsMD	analyser	amphometric	current	signal	over	time	
This	is	a	typical	5-minute	recording	of	the	output	of	the	assay	as	visualised	by	the	chart	programs.	Current	peaks	(amp)	for	glucose	are	shown	in	
red	and	the	equivalent	for	lactate	in	green.	Each	peak	and	its	corresponding	amplitude	is	proportional	to	the	concentrations	of	the	metabolite	in	
the	dialysate	fluid.	
The	trace	seen	 in	Chart®	shows	a	red	trace	representing	glucose	detection	and	a	green	trace	representing	
lactate	detection.	Figure	14	is	typical	of	a	combined	trace	in	Chart.	
Each	peak	visible	represents	a	current	(mA)	generated	at	the	electrode	as	a	result	of	a	redox	reaction	when	
either	glucose	or	lactate	is	detected	within	the	biosensor.		
To	be	able	 to	accurately	equate	 the	amplitude	of	 the	current	peaks	 to	a	concentration	 (mM),	we	need	 to	
compare	to	calibration	standards.	The	system	is	calibrated	at	the	beginning	of	each	assay,	with	standards	of	
glucose	and	 lactate	solutions	of	0.5,	1,	2	and	4mM	concentrations.	These	standards	are	manually	 injected	
into	the	system	and	their	corresponding	current	peaks	measured.	Each	concentration	is	injected	three	times	
into	the	assay	to	provide	three	current	peaks,	and	an	average	of	these	is	recorded.	For	a	given	concentration	
of	a	specific	metabolite	we	now	know	what	the	current	amplitude	will	be.	Conversely	a	linear	regression	can	
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be	fitted	for	both	glucose	and	lactate	calibrations	that	allow	accurate	correlation	between	current	amplitude	
(mA)	 and	 concentration	 (mM).	 The	 gradient	 of	 this	 correlation	 is	 the	 conversion	 factor	 of	 amplitude	 to	
concentration	of	lactate	or	glucose.	The	current	amplitude	value	can	be	divided	by	the	conversion	factor	and	
this	results	in	a	value	that	represents	the	concentration	of	the	analyte	(mM).	These	values	can	be	plotted	on	
a	trace	over	time.	
To	 analyse	 the	 calibration	 data	 the Powerlab	 ChartTM	 software	 is	 utilised.	 The	 peaks	 generated	 from	 the	
injection	 of	 the	 calibration	 standards	 are	 selected	manually	 using	 the	 ʻPeak	 Parametersʼ	 extension	 in	 the	
software.	This	captures	 important	measurements	 for	each	peak	 in	 the	software’s	 ‘data	pad’,	 such	as	peak	
amplitude,	baseline,	width	and	area.	 
	
Figure	15	–	Screen	capture	from	Powerlab	ChartTM	software	
A)	Shows	the	peak	parameters	window.	Generates	key	measurements	for	each	peak.	B)	Data	storage.	Captures	specific	parameters	in	each	pre-set	
column	
Once	 the	peaks	were	measured,	 the	data	 can	be	 transferred	 to	Microsoft	 Excel	 and	a	 calibration	 trace	of	
current	versus	concentration	can	be	fitted	(Figure	17).	
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An extension set with clamp (Alaris medical system, Hampshire, UK, 150 cm, 0.4 ml) was 
connected to the lock connection of the inlet tubing of the probe through one end and the 
other end to a sterile syringe containing the ionic saline solution. A FEP tubing extension 
was used in this case for the outlet tubing, the end of which is connected to the on-line 
system. The perfusion fluid was delivered at a rate range from 2 to 4 µl/min, depending on 
the tissue to monitor and the distance added by the FEP tubing from the tissue to the 
assay. For longer distance, the time of dialysate to reach the analyser will be longer, and 
therefore higher flow rates were necessary. However, other parameters, like microdialysis 
recovery are of importance. This will be clarified further in ch pter 3.  
2.7 Data Analysis 
Subsequent to the monitoring, the analysis of the peaks is required in order to plot the 
graphs and present the data. When needed de-rippling and de-noise signal processing was 
executed. [230]  
For the analysis of the peaks, Chart TM, the software used for the recording was e ployed. 
For the analysis of the calibration data, peaks were selected manually using the ʻPeak 
Parametersʼ extension. The peak amplitude, width, area and baseline were determined and 
stored in the data pad. 
 
a)
 
b)
 
Figure 2.16: Peak Parameters window and data pad from Chart TM 5.5.6 for Mac. 
a) Peak parameters window. Different options can be sel cted in the preferences f this window, which re 
displayed here and can be stored for further analysis, b) snapshot of data storage. Each column has been 
selected with a specific parameter that is stored when the peak is selected. 
Once the peaks ere easured, the data was transferred to Excel and the analysis was 
completed. In this case the construction of the calibration curve was required in order to 
then fit the current peak results and obtain the concentration for glucose and lactate.  
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Figure	16	–	Calibration	raw	data	
Each	peak	represents	a	signal	obtained	from	injection	of	calibration	standard	of	known	concentration	of	lactate	(green)	and	glucose	(blue)		
 
 
 
	
Figure	17	–	Current	(µA)	versus	concentration	(mM)	trace	
A	 fitted	 linear	 regression	 for	 both	 glucose	 and	 lactate	 calibrations	 concentrations	 allows	 further	 calculation	 of	 dialysate	 concentrations	 from	
ischaemic	tissue	
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Successful	 calibration	 allows	 analysis	 of	 the	 dialysate	 peaks,	 by	 running	 semi-automatic	 peak	 allocation	
algorithm	within	ChartTM.	The	‘peak	parameters’	are	stored	within	the	‘data	pad’.	The	appearance	of	the	raw	
data	in	real	time	monitoring	is	shown	in	Figure	18.	
Once	the	raw	data	is	corrected	for	time	lag	between	the	time	the	catheter	is	inserted	into	the	target	tissue	
and	the	appearance	of	the	first	dialysate	peak,	each	peak	amplitude	is	converted	into	a	concentration.	The	
analysed	glucose	and	lactate	concentrations	can	then	be	plotted	on	a	trace.	
	
Figure	18	–	Screen	capture	of	Chart	TM	for	Apple	Mac	
Demonstrates	data	collection	and	real	time	signal	capture	from	glucose	(red)	and	lactate	(green)	sensing	
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After the calibration was obtained the analysis of every peak was performed with the ʻFindʼ 
option from Chart TM, a semi-automatic option that selects the peaks. The peak amplitude, 
width, area and baseline were determined and were stored also in the data pad. 
The appearance of the raw data while the recording is happening is shown in figure 2.19.  
 
 
Figure 2.19: Chart TM 5.5.6 for Mac screen snapshot of data collection. 
The Chart TM program appears in the computer screen divided in two channels, one for glucose (red) and one 
for lactate (green). The left hand side of the screen shows peaks every 30 seconds for over a period of 1 hour, 
while the right hand side shows the peaks occurring at that precise moment. 
A snapshot of the screen while the assay is running was taken to show the typical 
appearance of the raw data. The screen for the Chart TM program is divided in two. The right 
side shows the peaks that are being monitored at that instance and the left side shows the 
entire recording; having a scroll bar to observe changes on time. 
The raw data is corrected for the lag time between dialysate leaving the probe and the 
peak-current measured. When the surgeon inserted the microdialysis probe a mark was 
noted at that time in the monitoring. When the first measurement was observed the time lag 
could be measured, being the time between the probe implantation and the first peak 
observed. This time lag could be extracted at the end of the monitoring from the entire data.  
Once the raw data was analysed, glucose and lactate dialysate levels could be plotted 
versus time axis. The time lag due to the outlet tube extension had to be taken into 
consideration to place the marked events at the right time. A representative example of 
analysed data is presented in figure 2.20. 
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Chapter	3	–	In-Vivo	Detection	of	Colonic	
Ischaemia	Following	Abdominal	Aortic	
Aneurysm	Repair	
Chapter	3	focuses	on	my	first	study,	the	in-vivo	detection	of	colonic	 ischaemia	in	the	postoperative	period	
following	AAA	repair.	 I	provide	 the	specific	methodology	 for	 this	 study,	detailing	 the	study	design,	patient	
recruitment,	analyser	set	up	and	catheter	modification,	in-vivo	and	ITU	protocols.	In	Chapter	3,	I	discuss	the	
results	and	their	interpretation	for	each	patient	recruited.	 	
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3 CHAPTER	3	—	IN-VIVO	DETECTION	OF	COLONIC	ISCHAEMIA	
FOLLOWING	ABDOMINAL	AORTIC	ANEURYSM	REPAIR	
3.1 HYPOTHESES	&	AIMS	
Colonic	ischaemia	is	a	serious	and	potentially	fatal	complication	of	AAA	repair,	especially	in	the	presence	of	
transmural	 infarction	 leading	 to	 gangrene	 and	 perforation.	 The	 clinical	 difficulty	 in	 establishing	 an	 early	
diagnosis	 combined	with	 the	 patient’s	 poor	 physiological	 status	 is	 often	 associated	with	 a	 fatal	 outcome.	
Early	 diagnosis	 and	 prompt	 intervention	 is	 the	 key	 to	 reducing	 the	 mortality	 from	 this	 devastating	
complication.	It	is	clear	that	a	safe,	accurate	and	effective	tool	is	required	to	detect	and	monitor	this	clinical	
entity	at	the	bedside	in	the	early	post-operative	period.	
I	 hypothesise	 that	 microdialysis	 can	 be	 utilised	 as	 an	 effective	 and	 safe	 tool	 in	 the	 early	 diagnosis	 and	
subsequent	 monitoring	 of	 colonic	 ischaemia	 in	 the	 post-operative	 period	 following	 AAA	 repair.	 I	 aim	 to	
assess	the	feasibility	of	using	on-line	rapid	sampling	microdialysis	 in	the	detection	of	colonic	 ischaemia,	by	
sampling	in	real	time,	the	metabolic	markers	of	ischaemic	within	the	colon	in	patients	following	AAA	repair.	
3.2 METHODOLOGY	
3.2.1 Ethical	Approval	
This	study	was	granted	ethical	approval	by	the	St	Mary	Research	Ethics	Committee	Ref:	06/Q0403/160	(see	
appendix).	
3.2.2 Study	design	
This	was	a	prospective	observational	study	enrolling	all	elective	patients	who	presented	with	infra	or	 juxta	
renal	abdominal	aortic	aneurysms,	Type	II,	III,	or	IV	thoracoabdominal	aortic	aneurysms.	Patients	with	Type	I	
thoracoabdominal	 aortic	 aneurysm	 and	 patients	with	 abdominal	 aortic	 aneurysm	with	 purely	 supra	 renal	
components	 were	 excluded	 from	 this	 study.	 This	 exclusion	 is	 based	 on	 the	 fact	 that	 the	 repair	 of	 such	
aneurysms	does	not	compromise	the	IMA	and	therefore	the	risk	of	ischaemic	bowel	is	reduced.	
All	 suitable	 patients	 were	 enrolled	 after	 written	 informed	 consent	 was	 obtained.	 A	 copy	 of	 the	 consent	
document	(see	appendix)	was	filed	 into	the	hospital	notes,	a	further	copy	given	to	the	patient	alongside	a	
patient	information	sheet	(see	appendix)	and	a	final	copy	of	the	consent	retained	by	the	author.	
All	 study	 participants	 were	 followed	 up	 on	 a	 daily	 basis	 until	 discharge	 whilst	 demographic	 data	 was	
recorded.	Clinical	data	including	vital	signs,	blood	test	results,	radiological	test	reports,	clinical	review	notes	
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and	 complications	 were	 also	 recorded	 prospectively	 using	 a	 standardised	 data	 collection	 pro-forma.	
Patients’	details	were	anonymised	using	patient	specific	randomised	codes	to	protect	patient	confidentiality.			
During	 the	 operative	 procedure,	 following	 repair	 of	 the	 aneurysm	 prior	 to	 closure	 of	 the	 abdomen,	 a	
microdialysis	catheter	(CMA	#61	MD	catheter,	CMA,	Sweden)	was	tunnelled	 into	the	mesenteric	border	of	
the	 sigmoid	colon	close	 to	 the	 seromuscular	 layer	of	 the	colon	and	 then	 tunnelled	outside	 the	abdominal	
cavity	 in	 a	 similar	 fashion	 to	 that	 of	 a	 normal	 surgical	 drain.	 After	 transfer	 to	 ITU,	 the	 rsMD	 analyser	 is	
connected	to	the	microdialysis	catheter	for	sampling	for	48	hours	post-operatively.	
3.2.2.1 Catheter	choice	
There	 are	 a	 range	of	 sterile,	 CE	marked	microdialysis	 catheters	 available	 for	 clinical	 use	 in	humans	 (CMA,	
Sweden):		
Microdialysis	Clinical	Catheter	 Code	 Typical	use	
Hepatic	MD	catheter		 #61	 Monitoring	of	hepatic	tissue	following	resection	or	transplantation		
Gastrointestinal	MD	catheter		 #62	 Metabolic	peritoneal	monitoring	after	G.I.	surgery	
MD	catheter		 #63	 Monitoring	of	adipose	tissue	and	resting	skeletal	muscle	
Linear	MD	catheter		 #64	 Monitoring	of	skin,	adipose	tissue	and	resting	skeletal	muscle	
Brain	MD	catheter		 #70	 Implantation	during	open	neurosurgery	or	through	a	burr	hole		
Table	3	–	Various	clinical	microdialysis	catheters	available		
CMA,	Sweden	
The	#61	Hepatic	MD	Catheter	was	 chosen	 in	 favour	over	 the	#62	Gastrointestinal	MD	catheter	due	 to	 its	
longer	shaft	length	(Table	3)	The	#61	Hepatic	MD	Catheter	is	a	sterile,	single	use	microdialysis	catheter,	with	
a	 shaft	 length	 of	 310mm	 and	 a	 membrane	 length	 of	 30mm.	 The	 dialysing	 membrane	 of	 the	 61	 Hepatic	
Microdialysis	Catheter	 is	designed	 to	allow	excellent	diffusion	characteristics,	achieving	a	high	 recovery	of	
substances	from	the	extracellular	fluid.	The	catheter	has	a	reinforced	shaft	and	contains	a	gold	thread	at	the	
tip,	which	is	visible	on	a	CT	scan	in	the	event	that	the	tip	fractures	and	is	retained	within	the	patient.	
The	extra	length	is	important	to	allow	tension	free	implantation	into	the	mesentery	of	the	descending	colon,	
externalisation	through	the	anterior	abdominal	wall	and	to	compensate	for	the	fact	that	the	colon	is	mobile.		
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3.2.2.2 Catheter	implantation	&	fixation	
Once	 the	 graft	 is	 sutured	 in	 place,	 the	 aortic	 cross	 clamp	 is	 released	 and	 the	 surgeon	 ensures	 there	 is	
adequate	haemostasis,	the	microdialysis	catheter	is	then	implanted	into	the	descending	colon	mesentery,	at	
the	 junction	 of	 the	 mesentery	 and	 the	 mesenteric	 border	 of	 the	 colon.	 This	 is	 performed	 under	 sterile	
conditions	and	is	supervised	by	the	consultant	vascular	surgeon.		
The	steps	for	this	procedure	are:	
1 The	author	‘scrubs’	and	prepares	just	as	in	any	surgical	case.	This	includes	the	systematic	washing	of	the	
hands	 and	 forearms	 with	 an	 antibacterial	 cleansing	 wash,	 followed	 by	 donning	 sterile	 gloves	 and	 a	
gown.	
2 The	circulating	nurse	opens	the	CMA	61	Hepatic	MD	catheter	into	the	sterile	field.	
3 The	 removable	 protective	 sleeve	 of	 the	 catheter,	 is	 separated	 from	 the	 catheter	 and	 is	 cut	 to	
approximately	10	cm	to	allow	adequate	length	for	tunnelling	through	the	abdominal	wall.	
4 The	fixation	suture	that	is	pre-attached	to	the	catheter	is	cut	and	discarded.	
5 The	 sleeve	 of	 the	 catheter	 is	 tunnelled	 through	 the	 abdominal	 wall	 in	 the	 left	 iliac	 fossa.	 This	 is	
performed	 by	making	 a	 2mm	 skin	 incision	 and	 blunt	 dissection	 through	 the	 anterior	 abdominal	wall	
with	a	Robert’s	clip.	Using	the	clip,	the	sleeve	is	then	passed	through	the	anterior	abdominal	wall.	
6 The	catheter	is	passed	through	the	sleeve	into	the	abdominal	cavity.	
7 The	sigmoid	and	descending	colon	mesentery	is	identified	
8 An	 18-Gauge	 angiocath	 (Abott	 laboratories,	 US)	 is	 tunnelled	 under	 the	 visceral	 peritoneal	 layer	 that	
overlies	the	colonic	mesentery,	with	the	tip	of	the	needle	exiting	the	peritoneal	surface.		
9 The	needle	is	then	withdrawn	and	the	plastic	angiocath	left	in-situ.	
10 The	microdialysis	catheter	is	threaded	into	the	distal	end	of	the	angiocath	
11 The	angiocath	is	withdrawn	leaving	the	microdialysis	catheter	within	the	tissue	
12 The	catheter	is	not	fixed	to	the	mesentery	to	allow	risk	free	removal	after	the	cessation	of	monitoring	
13 The	colon	is	replaced	into	the	left	iliac	fossa	in	its	anatomical	position	
14 The	 catheter	 is	 fixed	 to	 the	 skin	 outside	 the	 abdominal	 cavity,	 to	 reduce	 the	 risk	 of	 accidental	 and	
premature	catheter	removal		
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Figure	19	–	The	MD	catheter	following	implantation,	fixation	&	connection	of	the	extension	tubing	
3.2.2.3 ITU	Monitoring	
The	microdialysis	analyser	 is	 set	up	 in	 the	 ITU	next	 to	 the	patient’s	 left	 side	and	 is	 calibrated	with	pre-set	
standards	of	1mM,	2mM	and	4mM	of	glucose	and	lactate	solutions.	The	catheter	exits	the	abdomen	on	the	
left	 side	 and	 therefore	 it	 is	 more	 appropriate	 to	 place	 the	 rsMD	 analyser	 on	 the	 left.	 	 The	microdialysis	
catheter	 is	 attached	 to	 the	 analyser	 as	 previously	 described	 in	 Chapter	 2.	 The	 T1	 perfusion	 fluid	 (CMA,	
Stockholm,	Sweden)	is	drawn	into	a	2.5ml	syringe,	connected	to	the	extension	tubing	(0.4ml,	Alaris	Medical,	
California)	and	then	inserted	in	to	the	perfusion	pump	(CMA	microdialysis	pump	400,	Stockholm,	Sweden).	
The	extension	tubing	is	flushed	with	the	perfusion	solution	to	dispel	air	bubbles	and	then	connected	to	the	
inflow	 tubing	 of	 the	microdialysis	 catheter	 (Figure	 19).	 The	 perfusion	 fluid	 is	 initially	 injected	 at	 a	 rate	 of	
10μL/min	for	a	period	of	approximately	10	minutes	to	allow	fluid	to	appear	 in	the	outflow	catheter.	Once	
fluid	 appears	 in	 the	 outflow	 catheter,	 this	 indicates	 that	 the	 catheter	 is	 primed	 and	 ready	 for	 use.	 The	
outflow	catheter	is	then	attached	to	the	connecting	bell	adaptor.	The	connection	bell	is	further	connected	to	
a	FEP	extension	tubing	 (1.2m,	CMA	Microdialysis	AB,	Stockholm,	Sweden).	The	distal	end	of	 the	extension	
tubing	is	directed	into	the	analyser	via	a	22	gauge-adaptor	needle	(Hamilton,	GR,	Switzerland).		A	period	of	
approximately	 12	 minutes	 is	 needed	 for	 the	 dialysate	 to	 reach	 the	 analyser,	 following	 this	 the	 rate	 of	
perfusion	is	reduced	to	2μl/min	to	allow	for	adequate	recovery,	dialysis	and	dialysate	delivery	into	the	valve.	
Bell	adaptor	attached	to	outlet
Microdialysis catheter
Inflow	&	outflow	
tubing
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sleeve and ready for deploying in the seromuscular layer of the sigmoid colon. An area of the 
sigmoid is designated, and an 18 Gauge angiocath (Abott labrotories, Il) is used to tunnel the 
catheter in place. The angiocath is tunneled in the seromuscular layer from one side to the other 
on the mesenteric border of the colon just where the mesentery meets the colon wall. The needle 
is withdrawn and the plastic angiocath is left in place to thread the catheter through it and then 
withdraw it from the other end to keep the catheter in place in the colon wall. The catheter along 
with the sigmoid are tucked in the left iliac fossa and covered by the omentum, and the catheter 
outside is secured in the following fashion. The PEBAX fixating device is clipped on the catheter 
in its sleeve just as it outtakes from the skin and two 2/0 vicryl ties are tied around it just to keep 
it in place so that it does not snap out from around the catheter sleeve. Then two 2/0 silk sutures 
are taken to fix the PEBAX to the skin hence fixing the catheter in place as it goes out from the 
abdominal wall. The catheter is then dresses and the operation continued by closing the 
laparotomy in the usual running fashion. It takes the nursing staff about 30-45 minutes to transfer 
the patient from the operating table to the ITU bed and the nurses settle the patient in ITU. It is 
only after all the nursing care has been completed that we come in. 
 
Figure 4.3. The catheter   as   it   appears   out   of   the   patient’s   abdomen  after   implantation  
and fixation 
Extension	tubing
Bell	adaptor
Outflow	tubing
Adaptor	needle	
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The	assay	is	capable	of	automatic	sampling,	performing	alternating	sampling	between	glucose	and	lactate	at	
30	seconds	 intervals.	The	system	can	effectively	continue	to	sample	for	11	hours	before	the	syringe	pump	
needs	to	be	refilled.	The	analysis	is	displayed	and	captured	in	Chart	TM	programme	and	can	be	monitored	on	
a	portable	computer	which	is	left	at	the	bedside	(Figure	20).	
	
Figure	20	–	Laptop	screen	displaying	Glucose	and	Lactate	peaks	
Over	 a	 period	 of	monitoring	 the	 efficiency	 of	 the	 enzyme	 bed	 is	 degraded	 resulting	 in	 a	 loss	 of	 activity,	
therefore	the	enzyme	beds	are	calibrated	three	times	a	day.	They	are	replaced	with	fresh	enzyme	beds	on	a	
daily	basis.	The	analyser	is	allowed	to	monitor	for	48	consecutive	hours.	Upon	completion	of	the	monitoring,	
the	microdialysis	catheter	is	removed	from	the	abdominal	cavity	by	cutting	the	fixation	sutures	and	applying	
gentle	 traction	 on	 the	 catheter.	 The	 catheter	 is	 examined	 in	 its	 entirety	 for	 any	 evidence	 of	 damage	 or	
fracture.	
	
Figure	21	–	A	typical	patient	being	monitored	in	ITU	
The	inflow	and	outflow	tubes	highlighted	in	yellow	and	red	respectively	splinted	together	near	the	patient.	
directed	 into	 the	 analyser	 via	 a	 22	 gauge-adaptor	 needle	 (Hamilton,	 GR,	
Switzerland).	
	
Figure	7	-	Adaptor	connection	bell	and	needle 
  
A	period	of	about	12	minutes	is	needed	for	the	dialysate	to	reach	the	analyser,	
following	this	the	rate	of	perfusion is	reduced to	2μl/ i 	to	allow	for	adequate	
recovery,	dialysis	and	dialysate	delivery	into	the	valve.	The	assay	is	capable	of	
automatic	sampling,	performing	alternating	sampling	between	glucose	and	lactate	at	
30	seconds	intervals.	The	system	can	effectively	continue	to	sample	for	11	hours	
before	the	syringe	pump	needs	to	be	refilled.	The	analysis	is	displayed	and	captured	
in	Chart	TM	programme	and	can	be	monitored	on	a	portable	computer	which	is	left	at	
the	bedside	(Figure	8). 
	
Figure	8	-	Laptop	screen	displaying	Glucose	and	Lactate	peaks	
Over	a	period	of	monitoring	the	efficiency	of	the	enzyme	bed	is	degraded	resulting	in	
a	loss	of	activity,	therefore	the	enzyme	beds	are	calibrated	three	times	a	day.	They	
Bell	adaptor	attached	to	outlet	
Adaptor	needle		
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A period of about 12 minutes is needed for the dialysate to reach the analyzer, and the 
CMA pump rate was then decreased to   2μ/min   to   allow   for   adequate   dialysis   and   dialysate  
delivery into the valve. Usually one syringe full of 2.5ml of perfusate lasts for 11 hours in the 
pump. The system is left to run on automatic sampling every one minute for glucose and lactate 
and the data is collected with the Chart program.  
 
Figure 4.8. The Laptop displaying the glucose and lactate peaks over 48hrs. 
The beds in the analyzer are calibrated three times a day and are changed to new ones 
with the sys em re-calibrated when the old beds lose their activity. This i  left to run for 
approximately 48 hours, with short periods of interrupted data where the patient was repositioned 
in bed, the system calibrated, or where there has been a period of inadvertent detachment of the 
tubes.  
Glucose peaks 
(red) and lactate 
peaks (green) as 
Chart displays 
them every 
minute. 
Glucose	
Lactate	
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Figure 4.9. The patient in ITU monitored by the rs-analyzer. The inflow and outflow 
tubes hi hlighted in yellow and red respectively splinted together near the patient. 
 
4.1.4 The analysis: 
Data was analyzed in a similar manner to the previous two studies. The peak amplitude 
was converted to concentration according to the conversion coefficient method explained earlier. 
However, in this study, because the beds were used for extended periods of time, they lost part of 
their reactivity. To accommodate for that, we used a formula that would account for the change 
in coefficient and we applied it at four hourly intervals in the data analysis: 
 
Where tf is the time final, t0 is the time 0 at the beginning of the 4-hour interval, and t is the time 
at that point in time, with their respective slopes. So, at any one time the slope at that time was 
calculated to accommodate for the change in bed reactivity at that time.  
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3.2.3 Data	analysis	
As	 previously	 described	 part	 of	 the	 enzyme	 reactors	 sensitivity	 and	 function	 is	 degraded	with	 continuous	
use.	Periodic	calibrations	with	known	concentrations	of	lactate	and	glucose	will	account	for	this	degradation,	
however	 it	 was	 not	 possible	 to	 calibrate	 overnight.	 Therefore,	 calculating	 the	 data	 by	 using	 calibrations	
immediately	before	the	night	period	and	the	calibrations	 in	 the	early	morning,	would	 introduce	errors.	To	
accommodate	for	this,	we	applied	a	formula	at	four	hourly	intervals	in	the	data	analysis	that	would	account	
for	the	change	in	coefficient.	The	slope	of	a	calibration	curve	at	a	time	(tt)	was	calculated:	
  
Where:	tt	=	time	of	calculation,	tf	=	time	of	 first	overnight	calibration,	t0	=	time	of	 last	pre-night	calibration,	
slope	tt	=	slope	for	calculation,	slope	tf	=	slope	of	first	overnight	calibration,	slope	t0	=	slope	of	last	pre-night	
calibration.	 Therefore,	 with	 slope	 at	 time	 (tt)	 the	 current	 was	 converted	 into	 glucose	 and	 lactate	
concentrations. After	 conversion,	 a	 three-point	 weighted	 average	 was	 calculated	 for	 each	 data	 point	 to	
allow	 smoothing	 of	 the	 data	 curve	 away	 from	 any	 outlier	 points.	 Each	 patient	 had	 routine	 arterial	 blood	
sampling	by	the	ITU	team.	These	arterial	blood	gases	(ABG’s)	provided	the	blood	concentration	of	the	two	
key	metabolites	and	was	subsequently	recorded.	
3.3 RESULTS	
As	per	the	original	research	proposal,	my	aim	was	to	recruit	a	total	of	10	patients	into	this	study.	Over	the	
study	period	I	approached	a	total	of	17	patients	to	discuss	potentially	enrolling	into	the	study.		
All	patients	were	admitted	in	the	morning	of	the	day	of	surgery.	It	was	therefore	only	possible	to	discuss	the	
nature	and	potential	risks	of	the	study	on	the	day	of	the	surgery.	After	some	consideration,	it	was	decided	
that	due	to	the	complexity	of	the	study	that	any	discussions	with	the	patient	and	the	process	of	consenting,	
should	 take	place	 in	 person,	 rather	 than	on	 the	 telephone	or	 via	 a	 formal	 letter.	However,	 this	 approach	
does	potentially	place	further	stress	and	decision	making	on	patients,	who	may	already	be	very	anxious	as	
they	prepare	to	undergo	major	surgery.	Within	this	context,	a	number	of	patients	that	I	initially	approached	
proceeded	to	refuse	consent	(n=2).	They	appeared	understandably	anxious	and	decided	not	to	proceed	with	
the	 study.	 The	 remaining	 patients	 (n=15)	 decided	 to	 enrol	 into	 the	 study	 after	 the	 consenting	 process.	 A	
further	 subset	 of	 patients	 (n=3)	 having	 consented	 and	deemed	 suitable	 for	 enrolment,	 unfortunately	 had	
their	 procedures	 cancelled	 on	 the	 day	 and	 did	 not	 subsequently	 proceed	 to	 aneurysm	 repair	 within	 the	
study	 period.	 Another	 patient	 (n=1)	 proceeded	 to	 surgery,	 however	 during	 surgery	 developed	 graft	
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The microdialysis probe did not cause any interference in the patientʼs postoperative care 
or subsequent recovery, however the tunnelling of the catheter in the bowel caused a mild 
hematoma. This was minimised by the technique mastered by the clinician in charge of the 
study, and the use of the tunneller (plastic Angiocath Gauge 18). 
Analysis of Data 
The data was processed as explained in chapter 2. Since the monitoring was, in general, 
continuous during 48h, the rea tors lost s nsitivity ov r that period of time. A calibration 
was carried out periodically, however, the overnight period, approximately 12 hours, 
occurred without calibrations. Calculating the data with either the last pre-night calibration 
or the first overnight calibration introduced errors, hence the slope of a calibration curve at a 
time (tt) was calculated. 
€ 
Slope tt( ) = Slope t0( )−
tt − t0( )
t f − t0( )
× Slope t
0( )− Slope t f( )( )
 
 
 
 
 
 
 
 
 (6.1) 
where, tt= time of calculation, tf= time of first overnight calibration, t0= time of last pre-night 
calibration, slope tt= slope for calculation, slope tf= slope of first overnight calibration, slope 
t0= slope of last pre-night calibration 
Hence, with slope at time (tt) the current was transformed into concentration. 
Once the concentration was calculated a 3 points weighted moving average was performed 
to smooth the data curve from any outlier. Data recording missing for technical or other 
reasons was also plotted, i.e. the gap appears as a blank in the concentration plot. 
The glucose and lactate plasma levels were taken from the patient records during the ICU 
stay. The nurses recorded these and other physiological measurements every few hours.  
In order to construct a graph comparing plasma and dialysate levels, 5 minutes of dialysate 
levels, at the time of the plasma measurement, were averaged and plotted versus plasma 
levels. Linear regression analysis for the study of th  correlation f these two variables was 
applied and regression coefficient (r2) and p values were obtained. 
6.3 In vivo Recovery (variable-flow-rate method) 
Microdialysis probe recovery has been an important factor of study throughout this work. 
For safety and regulation issues it was more difficult to perform the no-net flux in vivo 
calibration method us d before (Chapter 5). How ver, another in vivo me hod to measure 
recovery was applied, the variable-flow-rate method.  
The method was carried out in patient 1, following 24 hours of on-line mo itoring and when 
all the clinical parameters were stable indicating a successful recovery of the patient. Flow 
rates as low as 0.1 µL/min or less were typically used, however, due to the long times 
required for the sample to travel down the extension tube, the lowest flow rate used here 
(Figure 6.3) was 0.3-µl/min. Nevertheless, the long membrane (3 cm) used in this trial, 
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thrombosis,	 cardiac	 instability	 and	 had	 an	 intra-operative	 cardiac	 arrest.	 This	 all	 took	 place	 during	 the	
surgical	procedure	and	before	the	microdialysis	catheter	would	normally	be	implanted	to	allow	monitoring.	
After	discussion	with	the	senior	vascular	surgeon	it	was	decided	that	we	would	not	proceed	with	implanting	
the	microdialysis	 catheter	 and	 hence	 not	 commence	 the	 study	 in	 this	 patient.	 Primarily	 it	was	 not	 in	 the	
patient’s	 best	 interest	 to	 have	 a	 prolonged	 operative	 time,	 or	 to	 be	 exposed	 to	 any	 further	 risk	 (even	 if	
relatively	small)	and	secondly	any	data	analysed	from	these	patients	would	have	been	difficult	to	interpret	
due	 to	 the	 massive	 global	 ischaemia	 that	 developed	 during	 the	 cardiac	 arrest.	 One	 patient	 (n=1)	 who	
proceeded	to	surgery,	underwent	a	successful	aneurysm	repair	and	microdialysis	monitoring	commenced	as	
per	the	standardised	study	protocol.	Data	was	successfully	collected,	however	at	the	time	of	dismantling	the	
experimental	 setup	 and	 disconnecting	 the	 Apple	Mac	 (G4	 PowerBook,	 Cupertino,	 US)	 from	 the	 Powerlab	
converter,	the	Apple	Mac’s	operating	system	crashed.	This	resulted	in	the	loss	of	all	data	from	the	hard	drive	
of	 the	 Apple	 Mac,	 despite	 the	 best	 efforts	 of	 the	 engineers	 from	 the	 IT	 department,	 Imperial	 College.	
Unfortunately,	the	raw	data	for	this	patient,	and	only	this	patient,	was	lost.	Prior	to	this	event,	all	collected	
data	for	each	case	was	backed	up	en-masse	at	the	end	of	monitoring,	and	stored	securely	in	a	portable	hard	
drive.	However,	we	subsequently	changed	the	protocol	for	the	remaining	cases,	whereby	we	backed	up	the	
data	 periodically	 and	 at	multiple	 times	 during	 each	 case	 and	 purchased	 newer	 hardware	 (Apple	Mac	 G4	
PowerBook,	Cupertino,	US).	No	further	events	such	as	this	took	place	for	the	remaining	patients	that	were	
monitored.	 All	 the	 patients	 that	were	 approached	 and	 considered	 for	 enrolling	within	 the	 study	 and	 the	
subsequent	study	outcomes	for	each	patient	are	shown	in	Table	4.	
	
Table	4	–	All	patients	approached	and	study	outcomes	
Patient
Consent	
given?
Enrolled	in	
study?
Monitoring	
commenced?
Data	
analysed? Other	details
Incorporated	
in	thesis?
2009012SMHSD
2009333SMHSD
2009715SMHSD
2009682SMHSD
Refused	consent
Operation	cancelled	on	the	day
MD	catheter	not	implanted	(intra-operative	
complications,	cardiac	instability)
Operation	cancelled	on	the	day
2009541SMHSD Data	lost	due	to	HD	crash
2009834SMHSD Operation	cancelled	on	the	day
2009394SMHSD Refused	consent
2009389SMHSD
2009278SMHSD
2009312SMHSD
2009938SMHSD
2009785SMHSD
2009562SMHSD
2009943SMHSD
2009672SMHSD
2009453SMHSD
2009134SMHSD
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Excluding	 several	 of	 the	 patients	 discussed	 previously,	 we	 were	 able	 to	 recruit	 the	 proposed	 number	 of	
patients	(n=10).	All	patients	underwent	successful	aneurysm	repair	with	subsequent	commencement	of	the	
study	 protocol	 and	 microdialysis	 monitoring.	 All	 patients	 underwent	 a	 standardised	 data	 analysis,	 as	
previously	 described,	 and	 have	 been	 included	within	 this	 thesis.	 Table	 5	 below	 shows	 the	 demographics,	
such	as	age,	diagnosis,	diabetic	status	and	surgical	procedure	carried	out.			
	
Table	5	–		Summary	of	all	patients	recruited	in	to	study.	
Of	the	patients	recruited	the	majority	were	diagnosed	with	Type	IV	thoraco-abdominal	aneurysms	(n=9)	and	one	patient	had	a	Type	III	thoraco-	
abdominal	 aneurysm	 (n=1).	 All	 patients	 underwent	 hybrid	 procedures	 with	 endovascular	 stent	 repairs	 of	 their	 aneurysms	 with	 open	
revascularisation	of	the	visceral	vessel.	
Our	study	protocol,	with	the	accompanying	ethical	approval,	allowed	us	to	monitor	each	patient	for	up	to	48	
hours	postoperatively	in	the	ITU,	converting	the	raw	data	of	the	current	detected	at	the	electrode	within	the	
analyser	into	glucose	and	lactate	concentrations	using	the	established	conversion	coefficients.	The	real	time,	
metabolic	 profiles	 of	 the	 gastrointestinal	 interstitium	 for	 each	 patient	 following	 AAA	 repair	 are	 shown	 in	
figures	 below,	 as	 traces	 of	 the	 dialysate	 concentration	 of	 each	 metabolite	 over	 time.	 The	 green	 trace	
represents	 the	 dialysate	 lactate	 concentration	 and	 the	 dark	 blue	 trace	 represents	 the	 dialysate	 glucose	
concentrations.	Throughout	this	study	we	use	the	term	“dialysate	concentration”	and	“tissue	concentration”	
interchangeably.	 The	 tip	 of	 the	microdialysis	 catheter	 is	 placed	within	 the	 target	 tissue,	 and	 therefore	 is	
sampling	 the	 fluid	 in	 the	 interstitium	 of	 the	 tissue.	 Therefore,	 the	 dialysate	 concentration	 is	 a	 direct	
reflection	and	representation	of	the	tissue	concentration	for	a	given	analyte.	
	 	
Patient Age Diagnosis
Hybrid	repair	
performed?* Elective? Co-morbiditiesDiabetes?
*	Hybrid	endovascular	repair	of	thoraco-abdominal	aneurysm	with	open	four	vessel	visceral	revascularisation
Smoker?
Patient	1 81 9.2	cm	Type	IV	TAAA Hypertension,	Hypercholesterolaemia,	Myelodysplasia 80	pack	yr
Patient	5 67 5.9	cm	Type	IV	TAAA CKD	stage	3,	Hypertension,	Hypercholesterolaemia 30	pack	yr
Patient	6 48 6.0	cm	Type	IV	TAAA
Hypertension,	Hypercholesterolaemia,	Congestive	
cardiac	failure,	Ischaemic	heart	disease 30	pack	yr
Patient	2 74 8.0	cm	Type	IV	TAAA Peripheral	vascular	disease,	hypertension 40	pack	yr
Patient	7 37 6.5	cm	Type	IV	TAAA Marfan’s disease,	Hypertension
Patient	3 75 7.1	cm	Type	IV	TAAA Hypertension,	Hypercholesterolaemia Ex-smoker;	stopped	15	yrs ago,	20	pack	yr
Patient	10 78 7.1	cm	Type	III	TAAA Hypertenion,	Osteoarthritis Ex-smoker;	stopped	2	mths ago,	25	pack	yr
Patient	9 69 8.2	cm	Type	IV	TAAA Hypertension,	Benign	prostatic	hypertrophy Ex-smoker;	stopped	3	yrs ago,	30	pack	yr
Patient	8 67 7.8	cm	Type	IV	TAAA Ischaemic	heart	disease,	Quadruple	CABG,	Hypertension,	Hypercholesterolaemia
Ex-smoker;	stopped	6	
mths ago,	40	pack	yr
Patient	4 65 8.0	cm	Type	IV	TAAA COPD,	Hypertension
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3.3.1 Patient	1	
The	 first	 patient	 enrolled	 into	 our	 study	was	 an	 81-year-old	male	with	 9.2	 cm	 Type	 IV	 thoracoabdominal	
aortic	 aneurysm	who	 presented	with	 symptoms	 suggestive	 of	 intestinal	 angina.	 The	 patient	 underwent	 a	
hybrid	 endovascular	 repair	 of	 the	 thoracoabdominal	 aneurysm	 with	 open	 four	 vessel	 visceral	
revascularisation	 of	 the	 coeliac	 artery,	 SMA	 and	 both	 renal	 arteries.	 At	 the	 end	 of	 the	 procedure	 a	
microdialysis	catheter	was	introduced	into	the	mesentery	of	the	colon	as	per	the	protocol.	The	patient	was	
transferred	 from	 the	 operating	 room	 directly	 to	 the	 ITU,	 which	 allowed	 immediate	 commencement	 of	
microdialysis	monitoring	for	48	hours.	At	the	start	of	monitoring	in	the	ITU,	calibration	standards	are	directly	
injected	 into	 the	 assay.	 By	 using	 known	 concentrations	 of	 glucose	 and	 lactate,	 we	 can	 then	 record	 the	
amplitude	 of	 the	 current	 at	 the	 electrode	 for	 each	 analyte,	 which	 allows	 us	 then	 to	 determine	 the	
concentration	of	each	sample	once	the	monitoring	starts.	Table	6	shows	the	calibration	data	for	the	glucose	
standards.	 For	each	known	concentration,	a	number	of	 readings	are	 taken,	which	allows	us	 to	 take	mean	
values.	Once	the	mean	amplitudes	are	established	for	a	known	concentration,	they	can	be	plotted	on	a	trace	
(Figure	22)	and	linear	regression	carried	out.	As	described	in	Chapter	2,	the	gradient	of	this	correlation	is	the	
conversion	factor	of	amplitude	to	concentration	of	analyte.	
	
Table	6	–	Patient	1	–	Glucose	Calibration	data	T	=	0	
	
Figure	22	–	Patient	1	–	Glucose	Calibration	trace	with	linear	regression	T	=	0	
Concentration*of*standard*(mM) 6 4 2 1 0.5 0.25
Current*at*electrode*(μA) 1.893 1.192 0.641 0.263 0.12 0.071
Current*at*electrode*(μA) 1.806 1.122 0.606 0.266 0.122 0.077
Current*at*electrode*(μA) 1.806 0.61 0.126
Mean*current*(μA) 1.84 1.16 0.62 0.26 0.12 0.07
Standard*deviation 0.05 0.05 0.02 0.00 0.00 0.00
y"="0.30x"
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A	similar	process	is	carried	out	for	lactate	with	standards	of	known	concentration.	Table	7	shows	the	lactate	
calibration	 data	 and	 Figure	 23	 shows	 the	 trace	 of	 the	 calibration	 data	 with	 linear	 regression	 to	 allow	
calculation	of	the	conversion	factor.		
	
Table	7	–	Patient	1	–	Lactate	Calibration	data	
	
	
Figure	23	–	Patient	1	–	Lactate	Calibration	trace	with	linear	regression	
Table	8	 and	Table	9	below	 show	a	 sample	of	 the	data	 that	 is	 generated	 for	 each	 analyte	 and	 the	 further	
analysis	that	takes	place.	The	10-minute	sample	displayed	represents	the	start	of	the	monitoring	period	at	
T=0,	and	shows	the	actual	real	time	that	each	sample	was	taken.	The	assay	samples	at	30	second	intervals	
and	 alternates	 between	 analytes.	 There	 is	 therefore	 a	 1-minute	 interval	 between	 the	 sampling	 of	 each	
analyte.	 The	 sample	 below	 displays	 the	 amplitude	 of	 the	 current	 generated	 at	 each	 sample	 and	 the	
concentration	 of	 the	 analyte	 after	 application	 of	 the	 initial	 conversion	 factor.	 As	 explained	 previously,	 a	
complex	calibration	is	then	applied,	which	allows	consideration	of	changing	calibrations	with	degradation	of	
the	 enzyme	 biosensor	 with	 time.	 This	 changing	 calibration	 curve	 is	 demonstrated	 in	 the	 table	 and	 the	
resultant	calibrated	dialysate	concentration.	
Concentration*of*standard*(mM) 6 4 2 1 0.5 0.25 0.1
Current*at*electrode*(μA) 5.583 3.879 1.913 1.037 0.533 0.316 0.128
Current*at*electrode*(μA) 5.389 3.878 1.834 1.024 0.558 0.331 0.109
Current*at*electrode*(μA) 5.322 1.994 0.646 0.061 0.12
Current*at*electrode*(μA) 0.08
Mean*current*(μA) 5.43 3.88 1.91 1.03 0.58 0.20 0.12
Standard*deviation 0.14 0.00 0.08 0.01 0.06 0.15 0.01
y"="0.93x"
R²"="1.00"
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Table	8	–	Patient	1	–	Sample	of	the	Glucose	dialysate	analysis	
Demonstrates	 current	 (µA)	 detected	 at	 the	 electrode,	 the	 raw	 dialysate	 concentrations	 (mM),	 the	 calibration	 co-efficient	 and	 the	 calibrated	
dialysate	concentration	(mM)	
	
Table	9	–	Patient	1	–	Sample	of	the	Lactate	dialysate	analysis	
Demonstrates	 current	 (µA)	 detected	 at	 the	 electrode,	 the	 raw	 dialysate	 concentrations	 (mM),	 the	 calibration	 co-efficient	 and	 the	 calibrated	
dialysate	concentration	(mM).	
At	the	end	of	the	monitoring	period	all	the	data	is	analysed	and	the	final	calibrated	dialysate	concentrations	
can	be	plotted	on	a	trace.		
Figure	 24	 below	 shows	 the	 lactate	 and	 glucose	 traces	 during	 the	 48-hour	 period	 for	 patient	 1.	 Table	 10	
demonstrates	the	results	of	the	arterial	blood	gas	samples	that	were	taken	throughout	the	48-hour	period	of	
monitoring	and	Figure	25	graphically	displays	the	trends	for	blood	glucose	and	blood	lactate	concentrations.	
By	comparing	the	dialysate	concentrations	with	the	blood	concentrations	and	any	subsequent	trending	we	
can	confirm	whether	concentrations	changes	are	confined	locally	or	are	a	systemic	feature.	
We	 can	 see	 that	 there	 is	 data	 missing	 over	 two	 separate	 periods,	 on	 the	 first	 occasion	 this	 was	 due	 to	
detachment	of	the	outflow	connection	from	the	catheter	to	the	valve	and	on	the	second	occasion	was	due	
Time%
(mins)
Real%Time%
(mins)
Current%at%
Electrode%(µA)
Dialysate%
Conc%(mM)
Calibration%
curve
Calibrated%Dialysate%
Conc%(mM)
0 22:47:15 0.338 1.1248 0.3005 1.1248
1 22:48:15 0.526 1.7504 0.3003 1.7516
2 22:49:15 0.591 1.9667 0.3001 1.9693
3 22:50:15 0.49 1.6306 0.2999 1.6338
4 22:51:15 0.635 2.1131 0.2997 2.1186
5 22:52:15 0.628 2.0899 0.2995 2.0967
6 22:53:15 0.563 1.8735 0.2993 1.8809
7 22:54:15 0.673 2.2396 0.2991 2.2498
8 22:55:15 0.682 2.2696 0.2989 2.2814
9 22:56:15 0.69 2.2962 0.2987 2.3097
10 22:57:15 0.663 2.2063 0.2986 2.2207
Glucose
Time%
(mins)
Real%Time%
(mins)
Current%at%
Electrode%(µA)
Dialysate%Conc%
(mM)
Calibration%
curve
Calibrated%Dialysate%
Conc%(mM)
0 22:47:15 0.799 0.858585859 0.9306 0.858585859
1 22:48:15 0.834 0.896196003 0.929857407 0.896911713
2 22:49:15 0.937 1.006877283 0.929114815 1.008486772
3 22:50:15 1.019 1.094992478 0.928372222 1.097620088
4 22:51:15 0.896 0.962819686 0.92762963 0.965902739
5 22:52:15 1.036 1.113260262 0.926887037 1.117719807
6 22:53:15 0.925 0.993982377 0.926144444 0.998764292
7 22:54:15 1.048 1.126155169 0.925401852 1.132480984
8 22:55:15 1.187 1.275521169 0.924659259 1.283716124
9 22:56:15 1.122 1.205673759 0.923916667 1.214395238
10 22:57:15 1.094 1.175585644 0.923174074 1.185041945
Lactate
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to	 a	 leak	 in	 the	buffer	 pump.	 These	 issues	where	 addressed	 and	 the	 faults	 fixed	 allowing	 continued	data	
collection.		
Analysing	the	data,	we	can	see	that	the	glucose	and	lactate	dialysate	traces	show	some	interesting	trends.	At	
the	beginning	of	the	monitoring,	which	is	upon	completion	of	the	surgical	procedure,	we	can	see	that	blood	
glucose	is	high	(10mM),	whilst	dialysate	glucose	concentration	is	much	lower	(4mM).	This	can	be	explained	
by	the	production	of	stress	hormones	peri-operatively	due	to	the	high	stress	placed	on	the	biochemical	and	
physiological	systems.	In	particular,	glucagon	is	secreted	from	the	pancreas,	resulting	in	the	mobilisation	of	
glucose	stores	during	periods	of	stress,	allowing	greater	delivery	and	utilisation	of	energy	by	the	vital	organs.	
However,	 the	 lower	 concentration	 within	 the	 dialysate	 would	 suggest	 that	 this	 does	 not	 seem	 to	 occur	
within	 the	 colon	 wall.	 After	 eight	 hours	 of	 monitoring	 we	 see	 a	 significant	 drop	 in	 the	 blood	 glucose	
concentration	 (5mM),	 however	 there	 is	 only	 a	 small	 drop	 in	 the	 dialysate	 concentration	 (3.4mM).	 The	
decrease	in	the	two	concentrations	does	not	directly	mirror	each	other.	It	would	seem	that	the	local	changes	
in	glucose	concentration	within	the	colon	wall	could	be	attributed	to	regional	blood	flow	changes	that	meet	
the	metabolic	demands	of	the	colon	irrespective	of	global	systemic	changes.	
	
Figure	24	–Patient	1	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	two	periods	of	missing	data	are	depicted	in	
red	(1	+	2)	
It	is	clear	that	the	blood	lactate	concentration	is	high	immediately	after	the	procedure	has	been	completed,	
this	can	be	explained	by	the	ischaemic	effects	within	the	lower	limbs,	after	intra-operative	cross	clamping	of	
the	aorta.	At	 the	 start	 of	monitoring	 the	blood	 lactate	 concentration	 is	 2.25mM	but	 then	decreases	 after	
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four	hours	of	monitoring	to	1.12mM.	The	concentration	decreases	as	lactate	molecules	are	broken	down	by	
enzymes	processes	and	relatively	less	lactate	is	produced,	due	to	the	fact	that	the	ischaemic	process	within	
the	 lower	 limbs	 is	 stopped	 as	 the	 aortic	 cross	 clamp	 is	 released.	We	 see	 a	 similar	 initial	 pattern	with	 the	
dialysate	lactate	concentrations.	The	concentration	drops	from	1.8mM	at	the	start	to	1.1mM	within	the	first	
4	hours	of	monitoring,	but	then	slowly	 increases	to	a	stable	1.7mM.	This	 is	compared	to	the	blood	 lactate	
level,	 which	 at	 this	 point	 is	 now	 1.12mM.	 The	 difference	 between	 the	 two	 levels	 is	 maintained	 fairly	
constantly	 throughout	 the	 period	 of	 monitoring.	 This	 would	 indicate	 that	 the	 local	 lactate	 concentration	
within	the	bowel	is	independent	of	the	systemic	plasma	lactate	concentrations.	The	difference	between	the	
two	 concentrations	 cannot	 be	 attributed	 to	 a	 recovery	 effect,	 due	 to	 the	 fact	 that	 the	 dialysate	
concentration	is	higher	than	the	plasma	concentration.	If	a	recovery	effect	were	evident,	then	it	would	result	
in	a	lower	dialysate	concentration	when	compared	to	the	blood	concentration.		
	
Figure	25	–	Patient	1	–	Arterial	blood	gas	sampling	over	time.	
Trace	shows	trend	of	the	arterial	blood	concentrations	of	lactate	(green)	and	glucose	(blue)	at	time	(min)	intervals	throughout	the	entire	period	of	
monitoring	
Table	10	–	Patient	1	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	intervals	
By	 calculating	 the	 dialysate	 lactate/glucose	 (L/G)	 ratio	 for	 each	 data	 point	 obtained,	 we	 can	 assess	 for	
changes	 in	 the	 concentration	 of	 each	 analyte	 in	 relation	 to	 each	 other.	 For	 example,	 a	 rise	 in	 dialysate	
lactate	 concentrations,	 with	 a	 fall	 in	 dialysate	 glucose	 concentrations	 and	 subsequent	 increase	 in	 the	
dialysate	 L/G	 ratio	 is	 highly	 suggestive	 of	 an	 ischaemic	 event.	 Figure	 26	 demonstrates	 the	 calculated	 L/G	
ratio	for	the	period	of	monitoring	for	patient	1.	
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2441 4.7 1.38
2604 4.7 1.19
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Figure	26	–	Patient	1	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	
Demonstrates	the	two	periods	(Red	1+2)	of	monitoring	that	were	lost	due	to	logistical	failures.	
The	calculated	L/G	ratio	provides	a	valuable	metric	when	utilised	in	comparative	studies.	An	increasing	L/G	
ratio	 reflects	 a	 sustained	 lactate	 production	 driven	 by	 hypoxia	 induced	 hyperglycolysis	 and	 is	 therefore	 a	
useful	marker	of	on-going	ischaemia.	The	graph	below	shows	the	L/G	ratio	over	time	for	the	entire	period	of	
monitoring.	It	is	clear	that	the	trace	is	stable	throughout	the	monitoring,	with	a	minor	increase	from	0.6	at	
T=1500	to	a	mean	of	0.704	±0.26	(from	T=1500	to	T=1919).	This	 increase	 is	not	 likely	 to	correlate	with	an	
ischaemic	 event.	 Previous	 studies	 performed	 by	 Deeba	 et	 al,	 in	 this	 institution	 using	 the	 same	 analyser,	
showed	that	clinically	confirmed	bowel	ischaemia,	induced	by	ligating	the	mesenteric	vessels,	resulted	in	an	
increase	in	the	L/G	ratio	of	approximately	16-fold	from	the	baseline.	
To	 further	 explore	 the	 possibility	 of	 a	 recovery	 artefact,	 we	 can	 look	 at	 the	 results	 in	 greater	 detail	 by	
examining	a	shorter	time	period.	Figure	27	below	displays	the	dialysate	glucose	(dark	blue)	concentration,	
the	dialysate	 lactate	concentration	 (green)	and	 the	L/G	ratio	 (light	blue)	between	 the	60	minute	and	240-
minute	mark	of	monitoring.	The	red	shaded	areas	demonstrate	periods	where	the	L/G	ratio	 increases	and	
the	 blue	 shaded	 areas	 represent	 areas	 where	 there	 is	 a	 decrease	 in	 the	 L/G	 ratio.	 These	 areas	 also	
demonstrate	the	inverse	trends	between	the	dialysate	lactate	and	glucose	concentrations	that	give	rise	to	an	
increase	or	decrease	in	the	L/G	ratio.	
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Figure	27	–	Patient	1	–	Online	rapid	sampling	microdialysis	monitoring	60-240	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	60	mins	to	240	mins.	
The	red	areas	demonstrate	periods	where	the	L/G	ratio	increases	and	the	blue	areas	represent	areas	where	there	is	a	decrease	in	the	L/G	ratio.	
The	shaded	areas	also	demonstrate	the	inverse	trends	between	the	dialysate	lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	
decrease	in	the	L/G	ratio	
By	examining	the	red	shaded	areas	(1,	2	and	3)	we	can	see	that	there	is	an	increase	in	the	dialysate	lactate	
concentrations	and	a	corresponding	increase	in	the	dialysate	glucose	concentration	but	to	a	 lesser	degree.	
The	net	result	here	is	that	there	is	an	increase	in	L/G	ratio	potentially	indicating	a	transient	ischaemic	event.	
Localised	autoregulation	of	blood	flow	in	this	region	has	resulted	in	an	increase	in	glucose	delivery,	however	
the	increasing	local	levels	of	lactate	might	suggest	that	this	increase	in	glucose	is	not	sufficient	to	supply	the	
local	metabolic	needs.		The	unmatched	increasing	metabolic	demands	has	resulted	in	anaerobic	metabolism.	
These	 events	 are	 self-limiting,	 transient	 and	 occur	 over	 a	 significant	 period	 of	 time	 (15	 minutes)	 and	
therefore	are	not	likely	to	be	artefacts.	The	red	shaded	areas	(5	and	11)	show	the	typically	envisaged	signs	of	
ischaemia,	 with	 an	 increase	 in	 lactate	 concentration,	 decrease	 in	 glucose	 concentration	 and	 subsequent	
increase	in	L/G	ratio.	The	blue	shaded	areas,	inversely	show	a	decrease	in	the	L/G	ratio,	caused	by	increased	
glucose	delivery,	representative	of	increased	blood	flow	and	a	move	from	anaerobic	metabolism	to	aerobic	
metabolism,	with	 resultant	 reduction	 in	 lactate	production.	 It	 important	 to	note	how	 these	 transient	 self-
limiting	 events	 of	 hypoperfusion	 and	 hyperperfusion	 alternate.	 Figure	 28	 further	 demonstrates	 these	
transient	 events.	 The	 red	 arrows	 show	 periods	 of	 the	monitoring	 where	 the	 peaks	 in	 the	 L/G	 trace	 also	
reflects	where	the	trend	of	the	dialysate	lactate	and	glucose	trace	progresses	in	an	inverse	direction,	this	is	
represented	 by	 inversed	 gradients	 for	 each	 trace.	 For	 example,	 we	 can	 see	 that	 the	 dialysate	 glucose	
concentration	 decreases	 and	 the	 lactate	 concentration	 increases	 at	 the	 first	 red	 arrow	mark.	 This	 further	
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suggests	that	the	changes	identified	are	representative	of	actual	local	metabolic	changes	rather	than	a	result	
of	recovery	artefact.		
	
Figure	28	–	Patient	1	–	Online	rapid	sampling	microdialysis	monitoring	240-400	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	240	mins	to	400	mins.	
The	red	arrows	identify	areas	where	there	is	a	significant	 increase	in	the	L/G	ratio,	such	that	we	see	inverse	trends	 in	the	relationship	between	
dialysate	lactate	and	glucose	concentrations	
To	 investigate	 any	 possible	 relationship	 between	 the	 blood	 and	 local	 tissue	 dialysate	 concentrations,	
correlations	were	created	that	allowed	for	regression	analysis.	As	previously	demonstrated,	each	patient	had	
serial	 arterial	 blood	 gas	 sampling,	 where	 blood	 glucose	 and	 lactate	 concentrations	 were	 analysed	 and	
recorded.	For	each	blood	sample	at	a	particular	time,	five	individual	samples	(which	equates	to	five	minutes	
of	monitoring)	of	corresponding	dialysate	concentrations	were	averaged	together.	These	were	then	plotted	
and	 any	 correlation	 examined	 for.	 Figure	 29	 demonstrates	 that	 there	was	 no	 linear	 relationship	 between	
blood	 glucose	 concentration	 and	 dialysate	 glucose	 concentrations,	with	 a	 R2	 close	 to	 zero	 (R2=0.000053).	
However,	there	are	three	outlying	data	points,	which	are	depicted	in	red.	To	examine	if	these	outlier	points,	
which	likely	represent	abnormally	high	blood	glucose	levels	and	not	within	normal	physiological	parameters,	
unduly	affected	the	linear	regression,	we	manually	removed	these	points	and	recalculated	the	correlation	in	
Figure	 30.	 The	 newly	 calculated	 correlation	 shows	 a	 moderate	 positive	 linear	 relationship	 (R2=0.649).	
Assuming	we	have	sufficient	data	points	 to	accept	 this,	 this	suggests	 that	systemic	glucose	concentrations	
may	potentially	affect	local	glucose	concentrations.	However,	there	are	limited	number	of	data	points	here,	
so	 it	 is	 difficult	 to	 accept	 this	 fully.	 Figure	 31	 demonstrates	 that	 there	 is	 no	 effective	 linear	 relationship	
(R2=0.0619)	 between	 local	 and	 systemic	 lactate	 concentrations.	 Therefore,	 in	 the	 further	 analysis	 of	 the	
changes	in	lactate	concentration,	we	can	confidently	exclude	the	effect	of	systemic	blood	lactate	changes	on	
the	local	tissue	levels	of	 lactate.	Patient	1	had	an	uncomplicated	postoperative	course	and	did	not	present	
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with	 signs	 or	 symptoms	 suggestive	 of	 bowel	 ischaemia.	 Patient	 1	was	 stepped	down	 from	 the	 ITU	 to	 the	
vascular	ward	at	the	third	postoperative	day.	He	discharged	home	on	the	seventh	postoperative	day.	
	
Figure	29	–	Patient	1	–	Correlation	between	blood	glucose	concentration	(mM)	&	dialysate	glucose	concentration	(mM)	
Linear	regression	shown	in	green.	Outliers	shown	in	red	
	
Figure	30	–	Patient	1	–	Correlation	between	blood	glucose	concentration	(mM)	&	dialysate	glucose	concentration	(mM)	
Linear	regression	shown	in	green.	Previously	demonstrated	outliers	removed	
	
Figure	31	–	Patient	1	–	Correlation	between	blood	lactate	concentration	(mM)	and	dialysate	lactate	concentration	(mM)	
Linear	regression	shown	in	green	
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3.3.2 Patient	2	
The	 second	 patient	 enlisted	 in	 to	 the	 study,	 was	 a	 74-year-old	 male,	 who	 presented	 to	 his	 general	
practitioner	 with	 back	 pain	 and	 thigh	 claudication,	 with	 a	 walking	 distance	 of	 100metres.	 On	 further	
investigation,	 he	 was	 diagnosed	 with	 an	 8cm	 Type	 IV	 thoracoabdominal	 aneurysm	 and	 subsequently	
underwent	an	elective	repair.		
Monitoring	was	initiated	in	the	same	manner	as	previously	described.	Table	11	and	Figure	32	demonstrate	
the	 dialysate	 glucose	 calibration	 data	 and	 trace,	 and	 Table	 12	 and	 Figure	 33	 demonstrate	 the	 dialysate	
lactate	calibration	data	and	trace.	
	
Table	11	–	Patient	2	–	Glucose	Calibration	data	
	
Figure	32	–	Patient	2	–	Glucose	Calibration	trace	with	linear	regression	
	
Concentration*of*standard*(mM) 6 4 2 0.25
Current*at*electrode*(μA) 2.198 1.477 0.559 0.079
Current*at*electrode*(μA) 2.34 1.53 0.611 0.083
Current*at*electrode*(μA) 2.145 1.317 0.607 0.069
Mean*current*(μA) 2.23 1.44 0.59 0.08
Standard*deviation 0.10 0.11 0.03 0.01
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Table	12	–	Patient	2	–	Lactate	Calibration	data	
	
Figure	33	–	Patient	2	–	Lactate	Calibration	trace	with	linear	regression	
Figure	34	below	display	the	microdialysis	monitoring	for	patient	2.	Dialysate	lactate	values	are	displayed	in	
green,	dialysate	glucose	concentration	are	shown	 in	blue,	and	an	area	of	 interest	 is	highlighted	 in	 red	 (1).	
This	area	refers	to	missing	data	due	to	technical	failures.	Table	13	displays	the	results	of	the	arterial	blood	
gas	 sampling	 and	 the	 same	 concentrations	 are	 graphically	 displayed	 in	 Figure	 35	 to	 allow	 examination	 of	
trends	and	compare	with	dialysate	values.	
	
Concentration*of*standard*(mM) 6 4 2 0.25
Current*at*electrode*(μA) 4.559 2.757 1.187 0.216
Current*at*electrode*(μA) 4.418 2.69 0.915 0.235
Current*at*electrode*(μA) 2.557 1.172 0.335
Current*at*electrode*(μA) 0.08
Mean*current*(μA) 4.49 2.67 1.09 0.22
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Figure	34	–	Patient	2	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	period	of	missing	data	is	shown	in	red	(1)	
	
	
Figure	35	–	Patient	2	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	13	–	Patient	2	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	interval	
Due	to	a	technical	fault	with	the	analyser	there	was	no	recordable	data	in	the	first	6	hours.	The	fault	was	due	
to	a	malfunctioning	glucose	enzyme	bed.	Once	this	was	realised	monitoring	continued	with	ongoing	lactate	
concentrations.	 However,	 the	 glucose	 sampling	 was	 not	 restarted	 for	 approximately	 12	 hours	 following	
sourcing	of	new	parts.	
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We	can	see	that	the	initial	lactate	concentration	range	is	between	1.5-2.5mM	between	the	6th	and	8th	hour	
of	monitoring.	 This	 is	maintained	over	 the	 first	 12	hours	of	monitoring	and	 then	gradually	decreases	 to	a	
lower	 range	 of	 0.5-1.5mM	 at	 the	 24-hour	 mark.	 We	 can	 see	 parallel	 changes	 with	 the	 serum	 lactate	
concentrations.	 Initial	 serum	 lactate	concentrations	are	 in	 the	 range	of	4-5	mM,	 this	 then	decreases	 to	2-
3mM	at	around	the	6-hour	mark,	when	online	monitoring	commences	again.	There	is	a	gradual	reduction	in	
the	serum	lactate	concentration	which	mirrors	that	of	the	colonic	lactate	concentrations.	We	expect	to	see	
an	initial	high	concentration	of	lactate	due	to	the	ischaemia	rendering	effects	of	the	aortic	cross	clamping,	it	
is	then	expected	that	the	lactate	concentration	decreases	in	the	absence	of	further	ischaemic	processes,	as	
the	lactate	is	metabolised	by	systemic	and	local	enzyme	action.			
On	 closer	 examination,	 we	 can	 see	 an	 irregular	 trend	 in	 the	 lactate	 concentration	 at	 the	 16th	 hour	 of	
monitoring	 (1,000	 mins).	 We	 can	 see	 that	 the	 dialysate	 lactate	 concentration	 increases	 from	 1.6mM	 to	
2.3mM,	 however	 there	 is	 no	 discernible	 rise	 in	 the	 serum	 lactate	 concentration	 at	 this	 time.	 This	
phenomenon	is	self-limiting	and	last	for	only	1-2	hrs.		This	transient	event	can	be	explained	by	local	changes	
in	the	blood	flow,	with	regulatory	mechanisms	shunting	blood	away	from	the	splanchnic	circulation	to	other	
more	vital	organs	such	as	brain,	heart	and	kidneys.	This	transient	hypoperfusion	and	subsequent	subclinical	
ischaemia	may	cause	the	observed	increase	in	the	dialysate	lactate	concentration.		
At	approximately	the	36th	hour	of	monitoring	(2,000	mins),	we	can	clearly	observe	that	the	dialysate	lactate	
concentration	decreases	 to	 the	 same	 level	 to	 that	 of	 the	 serum,	between	0.5-1.0	mmol.	 Perfusion	 to	 the	
colon	 has	 been	 re-established	 to	 that	 of	 normal	 levels,	 which	 reduces	 lactate	 producing	 anaerobic	
metabolism.		
The	glucose	trace	is	difficult	to	interpret	due	to	periods	without	data.	At	the	16th	hour	of	monitoring	(1000	
mins)	 we	 see	 the	 already	 described	 rise	 in	 the	 dialysate	 lactate	 concentration,	 likely	 secondary	 to	
hypoperfusion.	 This	 transient	 phenomenon	 also	 coincides	 with	 an	 increase	 in	 the	 dialysate	 glucose	
concentration.	This	could	be	secondary	to	local	regulatory	changes	that	are	employed	to	increase	perfusion	
of	the	bowel	in	response	to	hypoperfusion	caused	by	systemic	shunting	of	the	blood	into	vital	organs.	This	
localised	 increase	 in	glucose	and	 therefore	perfusion	 reverses	 the	 ischaemic	process	and	ensures	 that	 the	
metabolic	 changes	 are	 transient.	We	 see	 this	 occurrence	 again	 at	 the	 30th	 hour	 of	monitoring,	where	 an	
increase	 in	 the	 lactate	 dialysate	 concentration	 is	 mirrored	 by	 an	 increase	 in	 the	 glucose	 dialysate	
concentration	 to	 counteract	 on-going	 ischaemic	 processes,	 followed	 by	 a	 drop	 in	 both	 concentrations.	
During	 these	 two	 identified	 phenomenon,	 the	 serum	 concentration	 of	 both	 lactate	 and	 glucose	 remain	
stable	 and	 do	 not	 reflect	 the	 changes	 seen	 within	 the	 colon.	 This	 would	 indicate	 that	 the	 dialysate	
concentration	changes	reflect	localised	colonic	metabolic	changes	and	not	systemic	global	changes.	
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Examining	 the	 L/G	 ratio	 (Figure	 36)	 throughout	 the	 period	 of	 monitoring	 allows	 for	 the	 identification	 of	
periods	of	worsening	ischaemia.	Due	to	the	absence	of	the	initial	glucose	monitoring,	the	L/G	trace	starts	at	
time	1000	mins,	when	glucose	monitoring	begins.	 Ignoring	 the	artefact	at	 the	beginning	of	 the	 trace,	 it	 is	
clear	that	overall	the	L/G	ratio	is	stable	between	0.5	and	1.5	with	no	significant	deviations.	This	reflects	the	
clinical	progress	of	the	patient.	The	patient	had	an	uncomplicated	post-operative	course	with	no	evidence	of	
clinical	bowel	ischaemia.	
	
Figure	36	–	Patient	2	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)		
A	 combined	 trace	of	 L/G	 ratio,	 dialysate	 lactate	 concentration	 and	dialysate	 glucose	 concentration	 allows	
direct	comparison	of	the	trends	seen	in	a	particular	period	(Figure	37	and	Figure	38).	The	red	shaded	areas	
demonstrate	an	increase	in	the	L/G	ratio	that	is	sustained	for	a	significant	period	of	time.	Areas	1,	2	and	3	
display	a	transient	 increase	in	L/G	ratio	for	an	hour	each.	In	this	period	the	dialysate	lactate	concentration	
increase	however	the	dialysate	glucose	concentration	and	hence	glucose	delivery	is	constant.		
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Figure	37	–	Patient	2	–	Online	rapid	sampling	microdialysis	monitoring	1080-1280	mins	
Combined	trace	of	dialysate	glucose	 (blue),	dialysate	 lactate	 (green)	and	 lactate/glucose	 (light	blue)	 ratio	during	the	period	1080	mins	to	1280	
mins.	 The	 red	 areas	 demonstrate	 periods	 where	 the	 L/G	 ratio	 increases.	 The	 shaded	 areas	 also	 demonstrate	 the	 inverse	 trends	 between	 the	
dialysate	lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
	
Figure	38	–	Patient	2	–	Online	rapid	sampling	microdialysis	monitoring	1280	–	1480	mins	
Combined	trace	of	dialysate	glucose	 (blue),	dialysate	 lactate	 (green)	and	 lactate/glucose	 (light	blue)	 ratio	during	the	period	1280	mins	to	1480	
mins.	 The	 red	 areas	 demonstrate	 periods	 where	 the	 L/G	 ratio	 increases.	 The	 shaded	 areas	 also	 demonstrate	 the	 inverse	 trends	 between	 the	
dialysate	lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
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As	 we	 saw	 with	 patient	 1,	 there	 appears	 to	 be	 no	 correlation	 (Figure	 39	 and	 Figure	 40)	 between	 blood	
glucose	 and	 dialysate	 glucose	 concentrations,	 as	 well	 between	 blood	 lactate	 and	 dialysate	 lactate	
concentration.	
	
Figure	39	–	Patient	2	–	Correlation	between	blood	glucose	concentration	(mM)	&	dialysate	glucose	concentration	(mM)	
Linear	regression	shown	in	green	
	
	
Figure	40	–	Patient	2	–	Correlation	between	blood	lactate	concentration	(mM)	&	dialysate	lactate	concentration	(mM).		
Linear	regression	shown	in	green	
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3.3.3 Patient	3	
The	third	patient	enrolled	into	the	study	was	a	75-year-old	gentleman	who	presented	to	his	GP	for	a	routine	
examination	and	was	discovered	to	have	a	palpable	and	pulsatile	mass	in	his	abdomen.	A	CT	confirmed	a	7.1	
cm	Type	IV	thoracoabdominal	aortic	aneurysm	and	underwent	an	elective	repair.	Monitoring	was	initiated	in	
the	same	manner	previously	described.		
The	table	and	graph	below	demonstrate	the	dialysate	glucose	calibration	data	and	trace,	and	Table	15	and	
Figure	42	demonstrate	the	dialysate	lactate	calibration	data	and	trace.	
	
Table	14	–	Patient	3	–	Glucose	Calibration	data	
	
Figure	41	–	Patient	3	–	Glucose	Calibration	trace	with	linear	regression	
	
Table	15	–	Patient	3	–	Lactate	Calibration	data	
Concentration*of*standard*(mM) 6 4 2 1
Current*at*electrode*(μA) 2.655 1.508 0.643 0.242
Current*at*electrode*(μA) 2.502 1.487 0.617 0.231
Current*at*electrode*(μA) 1.458 0.64 0.25
Mean*current*(μA) 2.58 1.48 0.63 0.24
Standard*deviation 0.11 0.03 0.01 0.01
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Concentration*of*standard*(mM) 6 4 2 1
Current*at*electrode*(μA) 5.302 2.484 1.251 0.662
Current*at*electrode*(μA) 5.064 2.477 1.256 0.612
Current*at*electrode*(μA) 2.368 1.144 0.635
Current*at*electrode*(μA)
Mean*current*(μA) 5.18 2.44 1.22 0.64
Standard*deviation 0.17 0.07 0.06 0.03
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Figure	42	–	Patient	3	–	Lactate	Calibration	trace	with	linear	regression	
Due	to	technical	errors,	microdialysis	monitoring	only	took	place	for	approximately	5	hours	postoperatively.	
Despite	 adequate	 fixation	 of	 the	microdialysis	 catheter	 to	 the	 anterior	 abdominal	wall,	whilst	 the	 patient	
was	being	transferred	from	theatre	to	ITU,	undue	tension	was	applied	to	the	catheter.	This	resulted	in	the	
catheter	 being	 displaced	 by	 approximately	 15cms	 with	 the	 tip	 of	 the	 catheter	 still	 located	 within	 the	
abdomen.	It	is	not	likely	that	the	microdialysis	analyser	was	sampling	metabolites	from	the	extracellular	fluid	
in	the	colon	mesentery	as	intended,	but	rather	the	peritoneal	fluid.	At	around	the	5th	hour	the	catheter	had	
become	completely	dislodged	from	the	patient	and	hence	monitoring	stopped.	Figure	43displays	the	results	
of	 the	 microdialysis	 monitoring	 for	 patient	 3.	 Dialysate	 lactate	 values	 are	 displayed	 in	 green,	 dialysate	
glucose	concentrations	are	shown	in	blue.	The	red	numbered	markers	demonstrate	three	key	events	during	
the	monitoring	and	the	subsequent	effects	on	the	dialysate	traces.	
At	the	highlighted	time	point	(1),	at	approximately	60	minutes	the	 lactate	concentration	dramatically	 falls,	
this	is	the	point	where	the	microdialysis	catheter	is	displaced	from	the	colonic	mesentery	into	the	peritoneal	
cavity.	The	operative	procedure	does	 require	 incising	 the	peritoneum	and	 thus	 it	 is	expected	 to	see	some	
glucose	 and	 lactate	 from	 the	 damaged	 peritoneum,	 where	 there	 will	 be	 small	 microscopic	 areas	 of	
ischaemia.	 At	 the	 280th	 minute	 mark,	 time	 event	 highlighted	 (2),	 we	 see	 another	 dramatic	 drop	 in	 the	
dialysate	lactate	and	glucose	concentrations	where	the	catheter	is	completely	dislodged	from	the	abdomen.	
The	concentrations	subsequently	drop	to	zero	and	the	monitoring	is	stopped	at	time	event,	highlighted	(3).	
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Figure	43	–	Patient	3	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	three	important	events	are	marked	in	red	(1,	2	
and	3)	
Figure	 44	 	 demonstrates	 the	 L/G	 ratio	 for	 this	 patient,	 whilst	 the	 overall	 trend	 is	 stable,	 excluding	 the	
artefact	from	280th	minute	onward,	which	represents	data	when	the	catheter	was	outside	the	abdomen,	the	
initial	phase	 (1)	of	monitoring	 shows	 lower	 levels	 than	phase	 (2).	Phase	 (1)	 represents	 colonic	monitoring	
and	phase	(2)	represents	peritoneal	monitoring.	This	may	be	due	to	the	fact	that	in	colonic	monitoring	the	
microdialysis	catheter	can	assess	glucose	delivery	more	accurately,	due	to	the	fact	that	it	is	embedded	into	
tissue.	However,	when	the	catheter	 is	essentially	placed	freely	 in	 the	peritoneal	cavity	and	sampling	takes	
place	 from	 free	 fluid,	 it	 is	 able	 to	 detect	 the	 lactate	 that	 is	 sequestered	 into	 the	 cavity	 from	 the	 surgical	
dissection,	but	it	is	not	able	to	assess	glucose	delivery,	as	there	is	technically	no	glucose	being	delivered	into	
the	free	fluid.	Therefore	it	would	appear	that	the	L/G	ratio	increase	as	lactate	increases.	
	
Figure	44	–	Patient	3	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min).		 	
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3.3.4 Patient	4	
The	 forth	patient	 that	was	enrolled	 into	 the	study	was	a	65-year-old	gentleman	who	presented	with	back	
pain.	 Further	 investigations	 identified	 an	 8	 cm	 Type	 IV	 thoracoabdominal	 aneurysm	 that	 resulted	 in	 an	
elective	 repair.	 Following	 the	 successful	 implantation	 of	 the	 catheter,	 monitoring	 with	 rapid	 sampling	
microdialysis	 analyser	 was	 started	 as	 per	 the	 previous	 cases.	 However,	 6	 hours	 in	 to	 the	monitoring	 the	
software	that	operates	the	HPLC	pump	crashed	and	stopped	the	pump	from	functioning.	This	resulted	in	the	
cessation	 of	 the	 pumping	 of	 the	 buffer	 solution	 through	 the	 enzyme	 beds	 and	 resulted	 in	 no	 data	 being	
generated	or	 recorded.	This	happened	overnight	and	 therefore	 the	malfunction	was	not	 corrected	 till	 the	
morning,	which	resulted	in	significant	data	loss.	The	monitoring	was	recommenced,	however	the	following	
night	at	approximately	1200mins	the	catheter	was	accidentally	pulled	out	by	the	nursing	staff	as	they	were	
moving	the	patient.	Monitoring	stopped	at	this	point.	
Calibration	was	performed	in	the	same	manner	as	previously	described.	Table	16	and	Figure	45	demonstrate	
the	 dialysate	 glucose	 calibration	 data	 and	 trace,	 and	 Table	 17	 and	 Figure	 46	 demonstrate	 the	 dialysate	
lactate	calibration	data	and	trace.	
	
Table	16	–	Patient	4	–	Glucose	Calibration	data	
	
Figure	45	–	Patient	4	–	Glucose	Calibration	trace	with	linear	regression	
Concentration*of*standard*(mM) 6 4 2 0.5
Current*at*electrode*(μA) 2.296 1.578 0.723 0.143
Current*at*electrode*(μA) 2.109 1.743 0.796 0.145
Current*at*electrode*(μA) 2.273 1.514 0.749 0.126
Mean*current*(μA) 2.23 1.61 0.76 0.14
Standard*deviation 0.10 0.12 0.04 0.01
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Table	17	–	Patient	4	–	Lactate	Calibration	data	
	
Figure	46	–	Patient	4	–	Lactate	Calibration	trace	with	linear	regression	
	
Figure	 47	 displays	 the	 results	 of	 the	 microdialysis	 monitoring	 for	 patient	 4.	 Dialysate	 lactate	 values	 are	
displayed	in	green,	dialysate	glucose	concentrations	are	shown	in	blue.	The	red	highlighted	area	(1)	reflects	
the	period	where	monitoring	temporarily	stopped.		
As	 monitoring	 is	 commenced,	 both	 the	 lactate	 and	 glucose	 dialysate	 concentrations	 show	 a	 similar	
tangential	increase.	In	the	initial	period	this	may	be	due	to	the	increasing	recovery	within	the	microdialysis	
catheter.	On	 implantation,	 the	 catheter	 flow	 rate	 is	 initially	 high	 (10μL/min)	 to	 allow	 adequate	 and	quick	
priming	of	the	catheter	and	the	FEP	tubing.	Once	dialysate	 is	present	the	flow	rate	 is	significantly	reduced	
(2μL/min),	 which	 results	 in	 an	 increased	 recovery	 and	 higher	 dialysate	 concentration	 values.	 The	 glucose	
dialysate	 concentration	 increases	 from	3.2	 to	 5.7mM,	 it	 then	 stabilises	 and	drops	down	2.6mM,	 at	which	
point	monitoring	was	 interrupted.	Once	monitoring	 resumes	 the	dialysate	 concentration	 is	at	2.4mM.	We	
see	 a	 similar	 pattern	with	 the	 lactate	 dialysate	 concentration,	with	 starting	 values	 around	 2.3mM,	which	
then	increases	to	3.1mM.	However,	we	do	not	see	a	drop	in	the	lactate	concentration,	like	we	do	with	the	
Concentration*of*standard*(mM) 6 4 2 0.5
Current*at*electrode*(μA) 7.876 4.756 2.304 0.309
Current*at*electrode*(μA) 7.929 4.661 2.126 0.316
Current*at*electrode*(μA) 4.736 2.236
Current*at*electrode*(μA)
Mean*current*(μA) 7.90 4.72 2.22 0.31
Standard*deviation 0.04 0.05 0.09 0.00
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glucose	concentration,	unfortunately	 the	monitoring	stops	at	 this	point.	 It	 is	 impossible	 to	speculate	what	
happens	 to	 either	 trace	 in	 this	 period,	 however	 on	 restarting	 of	 the	 monitoring	 the	 lactate	 dialysate	
concentration	is	unchanged.			
	
Figure	47	–	Patient	4	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair.		
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	periods	of	missing	data	are	shown	in	red	(1)	
Table	 18	 displays	 the	 results	 from	 the	 serial	 arterial	 blood	 gas	 analyses;	 these	 are	 further	 displayed	 on	 a	
trace	 in	 Figure	 48.	 The	 blood	 glucose	 and	 lactate	 concentrations	 follow	 a	 similar	 pattern	 to	 the	 tissue	
dialysate	 concentrations	 at	 the	 same	 corresponding	 times.	We	 see	 overall	 both	 blood	 analytes	 have	 high	
concentrations	 (Glucose	 =	 9.1mM	 and	 Lactate	 =	 3.6mM).	 However,	 as	 monitoring	 proceeds	 these	
concentrations	normalise,	the	blood	 lactate	concentrations	drop	down	to	baseline	 levels	faster	than	blood	
glucose	 concentrations.	 This	 is	 in	 an	 indicator	 that	 all	 the	 potentially	 ischaemic	 processes	 affecting	 organ	
systems	(renal,	G.I,	muscle	and	cardiac)	during	this	procedure,	are	temporary	and	improving	in	this	patient.	
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Figure	48	–	Patient	4	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	18	–	Patient	4	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	intervals	
Figure	49	demonstrates	the	L/G	ratio	for	patient	4	for	the	entire	period	of	monitoring,	whilst	displaying	the	
period	of	the	monitoring,	which	is	lost	due	to	the	technical	malfunction.	It	would	appear	that	either	side	of	
this	 period	 the	 L/G	 ratio	 is	 stable,	 excluding	 the	 artefact	 data	 at	 the	 1000th	 minute,	 where	microdialysis	
monitoring	was	restarted.		
	
Figure	49	–	Patient	4	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	
Demonstrates	the	period	(red	-	1)	of	monitoring	that	was	lost	due	to	logistical	failures.	
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On	further	examination	of	the	initial	period	of	monitoring	in	Figure	50	we	can	see	that	in	the	red	highlighted	
area	(1)	both	lactate	and	glucose	are	very	low,	this	is	likely	to	represent	recovery	artefact,	as	the	immediate	
molecules	 are	 depleted	 by	 the	 dialysis	 process,	 and	 it	 would	 appear	 on	 analysis	 that	 the	 concentration	
drops.	We	can	see	that	following	this,	within	approximately	20	minutes	the	concentration	of	both	analytes	
increases	to	a	steady	date.	However	even	within	this	steady	state,	there	are	periods	(2	+	3)	of	the	trace	that	
appear	to	have	the	characteristics	of	transient	ischaemia,	with	a	decrease	in	dialysate	glucose	concentration,	
increase	in	dialysate	lactate	concentration	and	subsequent	increase	in	L/G	ratio.	
	
Figure	50	–	Patient	4	–	Online	rapid	sampling	microdialysis	monitoring	0-180	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	0	mins	to	180	mins.	
The	red	areas	demonstrate	periods	where	the	L/G	ratio	increases.	The	shaded	areas	also	demonstrate	the	inverse	trends	between	the	dialysate	
lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
With	the	recommencement	of	monitoring	at	approximately	the	1000th	minute,	there	are	several	features	of	
interest	 in	 Figure	 51.	 The	 initial	 highlighted	 area	 (1)	 demonstrates	 a	 large	 spike	 in	 the	 L/G	 trace.	 This	
corresponds	with	a	large	fall	in	dialysate	glucose	concentration,	which	is	a	marker	of	glucose	delivery	and	a	
smaller	fall	in	dialysate	lactate	concentration.	It	is	not	clear	if	this	represents	a	transient	ischaemic	event	or	
changing	recovery	of	the	probe.	Whilst	the	drop	in	lactate	concentration,	all	be	it	smaller	than	the	drop	in	
glucose,	 is	 not	 typical	 of	 an	 ischaemic	 event,	 it	 is	 important	 to	 remember	 that	 tissue	 metabolism	 and	
concentration	of	analytes	are	 in	constant	 flux.	A	given	concentration	of	an	analyte	 is	a	 result	of	processes	
that	create	versus	processes	that	breakdown.	So,	whilst	a	concentration	may	appear	to	decrease,	it	may	in	
fact	represent	an	increase,	which	has	not	overcome	enzymes	processes	that	act	to	clear	the	analyte.	In	this	
case,	it	is	likely	that	the	change	demonstrated	in	the	L/G	ratio	is	likely	due	to	changing	recovery	properties	of	
the	 probe.	 The	 other	 highlighted	 areas	 (2	 +	 3)	 are	more	 in	 keeping	with	 transient,	 self-limiting	 ischaemic	
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events.	 We	 see	 large	 spikes	 in	 dialysate	 lactate	 concentrations,	 with	 decreases	 in	 dialysate	 glucose	
concentration.		
	
Figure	51	–	Patient	4	–	Online	rapid	sampling	microdialysis	monitoring	1000-1160	mins	
Combined	trace	of	dialysate	glucose	 (blue),	dialysate	 lactate	 (green)	and	 lactate/glucose	 (light	blue)	 ratio	during	the	period	1000	mins	to	1160	
mins.	 The	 red	 areas	 demonstrate	 periods	 where	 the	 L/G	 ratio	 increases.	 The	 shaded	 areas	 also	 demonstrate	 the	 inverse	 trends	 between	 the	
dialysate	lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
Figure	52	 shows	a	mild	positive	 linear	 relationship	 (R2	 =	0.318)	between	blood	glucose	 concentration	and	
dialysate	 glucose	 concentration,	 however	 the	 relationship	may	 be	 overstated	 due	 to	 the	 presence	 of	 an	
outlying	 data	 point.	 As	 per	 the	 previously	 monitored	 patients	 there	 appear	 to	 be	 no	 apparent	 linear	
relationship	between	blood	 lactate	concentration	and	dialysate	 lactate	concentrations	 (Figure	53),	with	R2	
close	 to	 zero	 (R2	 =	 0.1123).	 The	 patient	 made	 an	 uncomplicated	 recovery	 and	 did	 not	 develop	 sign	 or	
symptoms	suggestive	of	bowel	ischaemia.	
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Figure	52	–	Patient	4	–	Correlation	between	blood	glucose	concentration	(mM)	&	dialysate	glucose	concentration	(mM)	
Linear	regression	shown	in	green	
	
Figure	53	–	Patient	4	–	Correlation	between	blood	lactate	concentration	(mM)	&	dialysate	lactate	concentration	(mM)	
Linear	regression	shown	in	green	
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3.3.5 Patient	5	
The	fifth	patient	that	enrolled	 into	the	study	was	a	67-year-old	 lady	who	presented	with	back	pain	and	an	
ischaemic	toe.	The	ischaemic	toe	was	as	a	result	of	a	distal	embolic	phenomenon	secondary	to	a	5.9cm	type	
IV	thoracoabdominal	aneurysm.	She	underwent	an	uncomplicated	elective	open	repair.	
Calibration	with	known	standards	was	performed	in	the	same	manner	as	previously	described.	Table	19	and	
Figure	 54	 demonstrate	 the	 dialysate	 glucose	 calibration	 data	 and	 trace,	 and	 Table	 20	 and	 Figure	 55	
demonstrate	the	dialysate	lactate	calibration	data	and	trace.	
	
Table	19	–	Patient	5	–	Glucose	Calibration	data	
	
Figure	54	–	Patient	5	–	Glucose	Calibration	trace	with	linear	regression	
	
Concentration*of*standard*(mM) 1 0.5 0.25
Current*at*electrode*(μA) 0.68 0.303 0.161
Current*at*electrode*(μA) 0.732 0.334 0.149
Current*at*electrode*(μA) 0.678 0.185
Mean*current*(μA) 0.70 0.32 0.17
Standard*deviation 0.03 0.02 0.02
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Table	20	–	Patient	5	–	Lactate	Calibration	data	
	 	
Figure	55	–	Patient	5	–	Lactate	Calibration	trace	with	linear	regression	
Figure	 56	 displays	 the	 results	 of	 the	 microdialysis	 monitoring	 for	 patient	 5.	 Dialysate	 lactate	 values	 are	
displayed	in	green	and	dialysate	glucose	concentrations	are	shown	in	blue.	The	red	shaded	area	(numbered	
1)	demonstrates	a	period	of	no	data	capture.	
At	the	beginning	of	the	monitoring	we	see	a	familiar	pattern	of	unstable	results	due	to	the	high	perfusion	
rate	through	the	catheter.	The	concentration	profiles	start	to	stabilise	as	the	perfusion	rate	is	reduced	to	a	
level	that	allows	optimum	recovery	and	resolution.	However,	unfortunately	early	on	during	the	monitoring	
(178	mins)	the	signal	is	lost	as	the	nursing	staff	accidentally	disconnected	the	FEP	tubing	(Red	shaded	area).	
The	 error	 is	 not	 identified	over	 night	 by	 the	nursing	 staff,	 until	 the	 following	morning	when	 the	 research	
team	arrive	and	reconnect	the	tubing.	
	
Concentration*of*standard*(mM) 1 0.5 0.25
Current*at*electrode*(μA) 1.476 0.729 0.338
Current*at*electrode*(μA) 1.426 0.726 0.354
Current*at*electrode*(μA) 1.45 0.406
Mean*current*(μA) 1.45 0.73 0.37
Standard*deviation 0.03 0.00 0.04
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Figure	56	–	Patient	5	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	period	of	missing	data	is	shown	in	red	(1)	
Once	microdialysis	monitoring	recommenced	in	the	12th	hour,	dialysate	glucose	concentrations	were	found	
within	a	range	between	1.5mM	and	3.5mM	and	lactate	between	0.5mM	and	2mM.	The	oscillatory	pattern	
that	is	seen	mirrors	that	which	is	seen	in	previous	patients	that	were	monitored.	
Both	dialysate	glucose	and	lactate	concentrations,	and	serum	glucose	and	lactate	concentrations	decrease	in	
parallel	 with	 each	 other	 until	 approximately	 the	 1500th	 minute	 of	 monitoring.	 Following	 this	 point	 the	
dialysate	 glucose	 concentrations	 increase	 whilst	 the	 dialysate	 lactate	 concentration	 fall.	 This	 indicates	
increasing	and	adequate	splanchnic	perfusion,	with	greater	aerobic	metabolism	in	the	tissue	surrounding	the	
microdialysis	catheter.		
Table	 21	 displays	 the	 results	 from	 the	 serial	 arterial	 blood	 gas	 analyses;	 these	 are	 further	 displayed	 on	 a	
trace	in	Figure	57.	As	seen	in	the	previous	patients	and	is	likely	secondary	to	aortic	cross	clamping	the	blood	
lactate	and	blood	glucose	concentrations	are	initially	high	and	decrease	to	steady	state	values.	However,	at	
approximately	900	minutes	the	blood	 lactate	concentration	 increases	significantly	(2.74mM	at	1110	mins),	
almost	as	high	as	the	starting	values.	The	glucose	similarly	increases,	but	to	lesser	a	degree.	We	see	a	similar	
increase	 in	dialysate	 lactate	concentration	 (2.1mM	at	1000	mins)	but	with	overall	 stable	dialysate	glucose	
concentrations.	It	is	unclear	as	to	whether	the	increasing	dialysate	lactate	concentration	causes	or	is	a	result	
of	 the	 raised	 blood	 lactate.	 This	 patient	 made	 a	 good	 post-operative	 recovery	 and	 there	 was	 no	 clinical	
evidence	 of	 ischaemia,	 and	 therefore	 we	 cannot	 attribute	 causation	 and	 sequence.	 Whilst	 out	 with	 the	
scope	and	protocol	of	this	study,	it	is	possible	that	flexible	sigmoidoscopy	performed	at	that	time	may	have	
demonstrated	mild	mucosal	ischaemia.				
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Figure	57	–	Patient	5	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	21	–	Patient	5	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	intervals	
Figure	58	demonstrates	the	L/G	ratio	for	patient	5	for	the	entire	period	of	monitoring	and	the	period	of	the	
monitoring	(shaded	in	red),	which	is	lost	due	to	the	disconnection.	
Calculating	the	L/G	ratio	we	see	mean	values	0.55	±	0.17	at	178	minutes.	Following	the	disconnection,	the	
mean	 value	 drops	 to	 0.25	 ±	 0.12	 at	 the	 1500	minutes	 of	monitoring.	 During	 this	 period,	we	 can	 observe	
better	 the	oscillatory	 configuration	of	 the	profile.	 The	overall	 drop	 in	 the	 L/G	 ratio	most	 likely	 represents	
improved	 perfusion	 of	 the	 colon	 possibly	 due	 to	 the	 utilisation	 of	 increased	 collateral	 flow	 within	 the	
mesentery.		
By	focusing	on	short	time	periods	within	the	monitoring	and	combining	the	dialysate	lactate	concentrations,	
dialysate	glucose	concentrations	and	the	L/G	ratios	 in	 the	 trace	we	are	able	 to	 identify	 interesting	 trends.	
The	traces	below	demonstrate	the	previously	seen	phenomenon,	whereby	both	analyte	concentrations	are	
low,	as	the	molecules	are	sampled	out	of	the	extracellular	fluid	by	the	dialysing	property	of	the	catheter,	the	
levels	 slowly	 increase	 as	 the	 molecules	 diffuse	 from	 surrounding	 areas	 and	 concentration	 gradients	 are	
established	 which	 results	 in	 the	 achievement	 of	 the	 appearance	 of	 steady	 state.	 We	 can	 see	 in	 the	
highlighted	 area	 (1)	 that	 there	 is	 a	 rise	 in	 the	 L/G	 ratio,	 with	 a	 small	 spike	 in	 the	 dialysate	 lactate	
concentration.	This	is	likely	artefact	as	the	analyte	concentrations	reach	equilibrium	and	the	duration	of	the	
event	 is	small	enough	to	exclude	it	as	a	non-event.	Overall	the	trend	in	this	time	period	is	stable,	with	the	
presence	of	small	spikes	 in	the	L/G	ratio	 in	the	highlighted	area	(2).	 	The	oscillatory	pattern	evident	 in	the	
highlighted	area	(3)	 is	unlikely	to	represent	transient	 ischaemia	but	rather	changing	recovery	properties	of	
the	probe.	We	do	not	see	the	typical	increasing	dialysate	lactate	and	decreasing	glucose	concentrations.	
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Figure	58	–	Patient	5	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	
Demonstrates	the	period	(red	-	1)	of	monitoring	that	was	lost	due	to	logistical	failures.	
	
Figure	59	–	Patient	5	–	Online	rapid	sampling	microdialysis	monitoring	0-180	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	0	mins	to	180	mins.	
The	red	areas	demonstrate	periods	where	the	L/G	ratio	increases.	The	shaded	areas	also	demonstrate	the	inverse	trends	between	the	dialysate	
lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
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On	further	examination	of	a	similar	trace	(Figure	60)	in	the	period	of	monitoring	between	800	minutes	and	
1100	minutes,	 we	 see	 similarly	 oscillating	 pattern	 in	 the	 L/G	 ratio	 which	 may	 be	 secondary	 to	 changing	
recovery	 properties	 of	 the	 catheter	 or	 artefact	 from	 the	 bowel.	 The	 bowel	 will	 continue	 to	 undergo	
peristalsis	and	may	cause	an	oscillatory	artefact	as	seen	in	the	highlighted	area	(2).	There	is	a	period	of	the	
L/G	 ratio	 that	 does	 however	 appear	 characteristic	 of	 transient	 ischaemia	 in	 the	 highlighted	 area	 (3).	 This	
event	lasts	approximately	30	minutes	and	represents	an	increase	in	the	L/G	ratio,	with	concomitant	rise	in	
the	dialysate	lactate	concentration	and	drop	in	the	dialysate	glucose	concentration.	To	assess	for	potential	
relationships	between	 systemic	blood	 concentrations	 and	 local	 dialysate	 concentrations,	 correlations	with	
linear	 regression	 analysis	 was	 performed.	 Figure	 61	 demonstrates	 that	 there	 is	 no	 discernible	 linear	
relationship	between	blood	glucose	and	dialysate	glucose	concentrations,	with	a	R2	close	to	zero	(R2=0.072).	
Figure	62	demonstrated	a	weak	positive	 relationship	 (R2=0.227)	between	blood	 lactate	 concentration	and	
dialysate	 lactate	concentrations.	 It	 is	 likely	that	the	high	blood	lactate	and	dialysate	 lactate	concentrations	
between	the	900th	and	1200th	minutes	that	were	previously	discussed	affected	the	regression.	
	
Figure	60	–	Patient	5	–	Online	rapid	sampling	microdialysis	monitoring	800-1100	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	800	mins	to	1100	mins.	
The	red	areas	demonstrate	periods	where	the	L/G	ratio	increases.	The	shaded	areas	also	demonstrate	the	inverse	trends	between	the	dialysate	
lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
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Figure	61	–	Patient	5	–	Correlation	between	blood	glucose	concentration	(mM)	&	dialysate	glucose	concentration	(mM)	
Linear	regression	shown	in	green	
	
Figure	62	–		Patient	5	–	Correlation	between	blood	lactate	concentration	(mM)	&	dialysate	lactate	concentration	(mM)	
Linear	regression	shown	in	green	
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3.3.6 Patient	6	
Patient	 6	 was	 48-year-old	 gentleman,	 who	 presented	 with	 a	 large	 expansile	 abdominal	 mass	 and	 mild	
lumbar	 back	 pain.	 A	 CT	 scan	 identified	 a	 6cm	 type	 IV	 thoracoabdominal	 aneurysm	 and	 underwent	 an	
expedited	 elective	 repair.	 The	 microdialysis	 catheter	 was	 inserted	 as	 per	 the	 protocol	 and	 monitoring	
commenced	when	the	patient	arrived	in	ITU.	Monitoring	continued	for	48	hours	with	two	separate	relatively	
short	periods	of	data	loss	due	to	disconnections	of	the	tubing.		
Figure	 63	 displays	 the	 results	 of	 the	 microdialysis	 monitoring	 for	 patient	 6.	 Dialysate	 lactate	 values	 are	
displayed	 in	 green	 and	 dialysate	 glucose	 concentrations	 are	 shown	 in	 blue.	 The	 two	 red	 shaded	 areas	
demonstrate	 the	periods	of	missing	data.	 The	 first	 period	 (1)	 starts	 at	 the	650th	minute	 and	 continues	 for	
approximately	 200	minutes,	whilst	 the	 second	 shorter	 interruption	 commences	 at	 the	 1120th	minute	 and	
continues	for	approximately	150	minutes.	The	 lactate	concentrations	start	relatively	high	at	approximately	
0.9mM.	This	then	gradually	decreases	overnight	to	0.35mM	at	the	500th	minute,	then	stabilises	to	a	steady	
state	of	0.5mM	towards	the	end	of	the	monitoring	period.	The	lactate	and	glucose	concentrations	start	at	a	
similar	 level	 at	 the	 beginning	 of	 the	 monitoring,	 however	 as	 time	 progresses	 the	 lactate	 concentration	
declines	as	previously	described.	However	the	glucose	concentration	profile	is	very	different.	Whilst	there	is	
an	 initial	 gradual	drop	 in	 the	 concentration	 in	parallel	with	 the	 lactate	 concentration,	 after	 approximately	
1000	minutes	of	monitoring	we	 see	 rise	 in	 the	glucose	 concentration,	 approximately	doubling	 that	of	 the	
starting	concentration.	
	
Figure	63	–	Patient	6	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	two	periods	of	missing	data	are	in	red	(1	+	2)	
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Table	 22	 displays	 the	 results	 from	 the	 serial	 arterial	 blood	 gas	 analyses,	 these	 are	 further	 displayed	 on	 a	
trace	in	Figure	64.	Both	blood	glucose	and	lactate	concentrations	are	initially	high	and	drop	to	a	steady	state.	
There	 is	 notable	 variability	 with	 the	 blood	 glucose,	 however	 the	 blood	 lactate	 concentration	 is	 stable	
between	0.8	-	1.2	mM	for	the	majority	of	the	period	of	monitoring.		
	
Figure	64	–	Patient	6	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	22	–	Patient	6	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	intervals	
Figure	65	demonstrates	the	L/G	ratio	for	patient	6	for	the	entire	period	of	monitoring,	and	the	two	periods	
of	the	monitoring	which	are	lost	due	to	the	disconnection	of	the	tubing.		
There	is	a	gradual	but	constant	decrease	in	the	ratio,	starting	at	0.8	and	reducing	to	0.2	at	the	end	of	the	48	
hours	of	monitoring.	This	further	demonstrates	the	gradual	 increase	 in	the	glucose	concentration	with	the	
inverse	decrease	in	lactate	concentration.	Lactate	production	secondary	to	anaerobic	metabolism	ceases	to	
be	the	primary	source	of	energy	production	after	un-clamping	of	the	abdominal	aorta	allows	reperfusion	of	
the	 colon.	 This	 is	 demonstrated	 by	 the	 gradual	 increase	 in	 glucose	 concentration,	 which	 facilitates	 the	
increasing	utilisation	of	aerobic	metabolism.	The	patient’s	clinical	progress	confirms	these	tissue	metabolic	
findings,	as	they	made	a	full	recovery	with	no	clinical	evidence	of	bowel	ischaemia.	
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Figure	65	–	Patient	6	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	
Demonstrates	the	two	periods	(Red	1+2)	of	monitoring	that	were	lost	due	to	logistical	failures.	
Figure	66	demonstrates	the	 initial	4	hours	of	monitoring,	with	dialysate	glucose	concentration	(dark	blue),	
dialysate	 lactate	 concentration	 (green)	 and	 L/G	 ratio	 (light	blue)	 traces.	Overall	 the	 L/G	 ratio	has	 a	 stable	
trace,	 with	 slight	 oscillations	 around	 the	 baseline.	 The	 stability	 in	 the	 L/G	 ratio	 is	 caused	 by	 the	 parallel	
changes	 in	both	dialysate	 lactate	and	glucose,	with	 increases	and	decreases	mirroring	each	other.	The	red	
highlighted	areas	(1	-	6)	show	significant	increases	in	both	dialysate	lactate	and	dialysate	glucose,	however	
as	these	changes	are	in	parallel	with	each	other,	the	net	effect	is	a	stable	L/G	ratio.	Figure	67	shows	a	similar	
combined	trace,	with	L/G	ratio	(light	blue),	dialysate	glucose	(dark	blue)	and	lactate	(green)	concentrations	
detected	during	the	monitoring	of	patient	6	during	the	4th	and	8th	hour.	The	red	arrows	identify	peaks	in	the	
dialysate	 lactate	 trace,	which	 are	 typically	 of	 20-30	minutes’	 duration.	 These	 oscillations	 are	 not	 likely	 to	
represent	artefact	or	noise	from	the	analyser,	due	to	the	fact	that	during	these	events,	the	concentrations	
are	 elevated	 for	 long	 periods	 of	 time.	 These	 events	 are	 not	 representative	 of	 changing	 concentrations	 of	
analytes	 across	 the	 dialysis	membrane	 or	 ischaemic	 events	 due	 to	 the	 fact	 that	 the	 increase	 in	 lactate	 is	
mirrored	by	a	similar	increase	in	dialysate	glucose.	It	is	likely	that	these	events	represent	changing	properties	
of	the	microdialysis	catheter.	
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Figure	66	–	Patient	6	–	Online	rapid	sampling	microdialysis	monitoring	10-240	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	0	mins	to	240	mins.	
The	red	areas	demonstrate	periods	where	the	L/G	ratio	increases.	The	shaded	areas	also	demonstrate	the	inverse	trends	between	the	dialysate	
lactate	and	glucose	concentrations	that	give	rise	to	an	increase	or	decrease	in	the	L/G	ratio	
	
Figure	67	–	Patient	6	–	Online	rapid	sampling	microdialysis	monitoring	240-480	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	240	mins	to	480	mins.	
The	red	arrows	 identify	areas	where	there	 is	a	significant	 increase	 in	 the	dialysate	 lactate	concentrations	and	parallel	 changes	 in	 the	dialysate	
glucose	concentrations	
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3.3.7 Patient	7	
The	 seventh	patient	 enrolled	 into	 the	 study	was	 a	 37-year-old	 lady	diagnosed	with	Marfan’s	 syndrome,	 a	
connective	tissue	disorder	characterised	by	a	deficit	in	a	key	gene	which	encodes	for	the	proper	formation	of	
elastin	fibres.	She	was	identified	to	have	a	AAA	on	CT	scan.	
The	microdialysis	catheter	was	introduced	into	the	tissue	as	per	the	other	cases	and	monitoring	started	as	
per	the	protocol.	After	20	hours	of	monitoring	the	patient	was	deemed	appropriate	for	discharge	back	to	the	
ward,	due	to	a	significant	clinical	 improvement.	Our	remit	of	monitoring	extended	only	to	ITU	and	not	the	
ward	 setting,	 therefore	 the	 nursing	 staff	 removed	 the	 catheter	 without	 the	 researcher’s	 knowledge,	
fortunately	there	were	no	complications	as	a	result	and	the	catheter	was	intact	on	inspection.	
Figure	68	displays	the	results	of	the	microdialysis	monitoring	for	patient	7.	Dialysate	lactate	concentrations	
are	displayed	in	green	and	dialysate	glucose	concentrations	are	displayed	in	blue.	The	two	short	periods	of	
missing	 data	 are	 shown	 and	 are	 highlighted	 in	 red	 (1	 +	 2).	 The	 first	 period	 of	 missing	 data	 is	 due	 to	 a	
technical	 fault	with	 the	HPLC	 pump.	Once	 this	was	 rectified,	monitoring	 commenced	 for	 approximately	 3	
hours.	A	further	interruption	in	the	monitoring	took	place	as	the	nursing	staff	accidentally	disconnected	the	
tubing.	Luckily	the	nursing	staff	realised	this	and	informed	the	research	team,	who	were	able	to	reconnect	
the	 tubing.	 The	 first	 period	 of	 monitoring	 shows	 stable	 dialysate	 concentrations	 for	 both	 analytes,	 with	
glucose	being	 particularly	 high	 (10-12mM).	 It	 is	 likely	 that	 due	 to	 the	 patient	 young	 age,	 she	was	 able	 to	
produce	 an	 aggressive	 adrenergic	 response	 to	 the	 surgery,	 which	 resulted	 in	 high	 levels	 of	 circulating	
glucose.	 In	 the	second	period	of	monitoring	 the	dialysate	glucose	concentrations	 remains	high,	but	 slowly	
decreased	down	to	a	baseline	of	approximately	8mM.	The	starting	lactate	concentration	was	in	keeping	with	
the	other	cases,	however	the	starting	glucose	concentration	was	significantly	higher	than	other	cases,	by	a	
factor	 of	 10	 compared	 to	 others.	 These	 concentrations	 accurately	 reflect	 the	metabolic	 conditions	 of	 the	
tissue	at	the	time	of	monitoring	and	do	not	represent	faults	within	the	assay.	We	know	this	is	the	case,	as	
the	 calibrations	 are	 carried	 out	 using	 standards	 of	 known	 concentrations	 and	 that	 the	 amplitude	 of	 the	
current	peaks	was	significantly	larger	than	in	other	cases.	The	high	dialysate	glucose	concentrations	directly	
reflect	glucose	delivery,	and	 therefore	 it	 is	 important	 to	notes	 that	 levels	were	significantly	higher	 than	 in	
the	other	cases.	The	rest	of	the	patients	that	were	enrolled	into	the	study	were	elderly	patients,	where	the	
pathogenesis	of	 the	aneurysm	is	secondary	to	atheromatous	disease.	 It	 likely	that	these	patients	will	have	
atheroma	in	the	arterial	cascade	that	primarily	supply	the	colon	as	well	as	the	collateral	arterial	supply.	 In	
addition,	 these	patients	have	a	 limited	 cardiac	 reserve	and	due	 to	physiological	 shunting	 in	hypovolaemic	
states,	perfusion	to	secondary	organs	such	as	the	kidneys,	gastrointestinal	tract	and	skin	will	be	reduced	in	
order	 to	maximise	perfusion	 to	 vital	 tissues	 such	as	 the	myocardium	and	brain.	 The	 lack	of	 these	 limiting	
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factors	 in	 a	 young	 patient,	 whose	 pathogenesis	 for	 aneurysm	 development	 is	 secondary	 to	 a	 connective	
tissue	disorder,	results	in	much	greater	splanchnic	perfusion	and	glucose	delivery.	
	
Figure	68	–	Patient	7	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	two	periods	of	missing	data	are	in	red	(1	+	2)	
Table	 23	 displays	 the	 results	 from	 the	 serial	 arterial	 blood	 gas	 analyses;	 these	 are	 further	 displayed	 on	 a	
trace	in	Figure	69,	which	demonstrates	how	the	blood	glucose	and	blood	lactate	concentrations	reflect	those	
of	 the	 dialysate	 concentrations.	 The	 initial	 low	 blood	 glucose	 concentration,	 may	 be	 spurious,	 as	 the	
concentration	then	increases	to	8mM	within	one	hour,	reaching	a	peak	at	10.9mM	10	hour	after	the	start	of	
monitoring.	 Figure	 70	 demonstrates	 the	 L/G	 ratio	 for	 patient	 7	 for	 the	 entire	 period	 of	 monitoring	 and	
displaying	 the	 two	 periods	 of	 the	monitoring	which	 are	 lost	 due	 to	 the	 disconnection	 of	 the	 tubing.	 The	
initial	period	of	monitoring	yields	a	very	stable	L/G	ratio,	with	only	very	minor	 fluctuations	away	from	the	
baseline	 of	 0.18.	 The	 monitoring	 recommences	 after	 the	 interruption,	 with	 an	 L/G	 ratio	 that	 is	 low	 and	
slowly	 increases	 over	 a	 period	 of	 3	 hours	 to	 a	 plateau.	 This	 initial	 rise	 in	 L/G	 ratio	 appears	 secondary	 to	
persistently	high	dialysate	glucose	and	slow	two-fold	rise	in	dialysate	lactate	(0.8	to	1.6mM).		
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Figure	69	–	Patient	7	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	23	–	Patient	7	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	intervals	
	
Figure	70	–	Patient	7	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	
Demonstrates	the	two	periods	(Red	1+2)	of	monitoring	that	were	lost	due	to	logistical	failures.	
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A	 combined	 trace	of	 L/G	 ratio,	 dialysate	 lactate	 concentration	 and	dialysate	 glucose	 concentration	 allows	
direct	 comparison	 of	 the	 trends	 seen	 in	 a	 particular	 period	 as	 shown	 in	 Figure	 72.	 In	 the	 time	 period	
between	 the	200th	and	300th	minute,	we	can	see	 that	all	 the	 traces	are	 largely	 stable	however	each	 trace	
demonstrates	fine	oscillations	along	a	stable	and	flat	baseline.	The	L/G	ratio	alternates	between	positive	and	
negative	 inclinations	within	a	 range	of	0.15-0.2.	 The	dialysate	glucose	and	 lactate	 concentrations	 vacillate	
similarly	between	a	range	of	10-12mM	and	1.5-2.0mM	respectively.	These	patterns	demonstrate	very	stable	
traces	within	a	narrow	concentration	range.		
	
Figure	71	–	Patient	7	–	Online	rapid	sampling	microdialysis	monitoring	200-300	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	200	mins	to	300	mins.	
The	red	arrows	demonstrate	periods	of	the	monitoring	that	are	characterised	by	an	increase	in	the	dialysate	
lactate	 concentration	 with	 concomitant	 decrease	 in	 the	 dialysate	 glucose	 concentration.	 The	 result	 is	 a	
series	of	peak	within	the	L/G	ratio.	Each	of	these	peaks	represents	a	period	of	the	monitoring	that	is	typical	
of	 the	 episodes	 of	 transient	 ischaemia	 that	we	 have	 seen	 previously.	However	 they	 appear	 to	 take	 place	
over	 short	 time	periods	 (5-10	minutes),	 it	 is	 important	 to	 recognise	 that	 changes	over	 very	 short	periods,	
consisting	of	a	few	data	points	may	be	erroneous	and	represent	artefact.	However,	events	over	a	10-minute	
time	period	will	 consist	of	20	data	points,	 so	consistently	 raised	or	 lowered	analyte	concentrations	 in	 this	
frame	 can	be	 recognised	 as	 ‘real’.	 Figure	 73	demonstrates	 the	monitoring	 between	 the	 650th	minute	 and	
1150th	minute	in	patient	7,	with	L/G	ratio	(light	blue),	dialysate	 lactate	concentration	(green)	and	dialysate	
glucose	 (lactate)	concentration.	The	dialysate	glucose	concentration	 is	 stable	commencing	at	10.0mM	and	
finishing	at	9.0mM.	
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Figure	72	–	Patient	7	–	Online	rapid	sampling	microdialysis	monitoring	200-300	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	200	mins	to	300	mins.	
The	red	arrows	 identify	areas	where	there	 is	a	significant	 increase	 in	the	dialysate	 lactate	concentrations	and	decrease	 in	the	dialysate	glucose	
concentrations	with	concomitant	increase	in	the	L/G	ratio	
The	 dialysate	 lactate	 concentration	 is	 similarly	 stable,	 with	 no	 major	 peaks	 or	 troughs,	 however	 does	
demonstrates	a	gradual	decease.	The	 initial	dialysate	concentration	 in	this	period	of	monitoring	 is	1.5mM,	
which	progressively	drops	down	to	0.7mM,	which	results	in	a	parallel	gradual	drop	in	the	L/G	ratio.	
	
Figure	73	–	Patient	7	–	Online	rapid	sampling	microdialysis	monitoring	650-1150	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	of	650	mins	to	1150	
mins.	
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Figure	74	displays	a	weak	negative	correlation	between	blood	glucose	concentration	and	dialysate	 lactate	
concentration,	 with	 r2=0.163.	 The	 blood	 glucose	 levels	 are	 much	 higher	 in	 this	 patient,	 as	 previously	
discussed.	The	presence	of	a	single	data	point,	which	is	significantly	 lower	and	likely	to	be	erroneous,	may	
have	 unduly	 affected	 the	 regression.	 Figure	 75	 demonstrates	 that	 there	 is	 no	 correlation	 between	 blood	
lactate	 concentration	and	dialysate	 lactate	 concentrations,	with	 r2	 close	 to	 zero	 (r2=0.013),	 the	 regression	
demonstrates	a	near	flat	line	and	the	data	points	display	the	typical	shot	gun	pattern.	
	
Figure	74	–	Patient	7	–	Correlation	between	blood	glucose	concentration	(mM)	&	dialysate	glucose	concentration	(mM)	
Linear	regression	shown	in	green	
	
Figure	75	–	Patient	7	–	Correlation	between	blood	lactate	concentration	(mM)	&	dialysate	lactate	concentration	(mM)	
Linear	regression	shown	in	green.		
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3.3.8 Patient	8	
The	eighth	patient	enrolled	into	the	study	was	a	67-year-old	lady	who	had	an	incidental	finding	of	a	7.8cm	
type	 IV	 thoracoabdominal	 aneurysm	 with	 a	 short	 angulated	 neck	 that	 was	 technically	 not	 suitable	 for	
endovascular	repair.	She	was	a	high-risk	surgical	candidate,	with	a	previous	history	of	a	quadruple	coronary	
artery	bypass	graft	for	ischaemic	heart	disease,	and	had	subsequently	developed	ischaemic	cardiomyopathy	
and	had	 an	 implanted	 cardiac	 defibrillator.	 Following	 lengthy	discussion	with	 the	 surgeons,	 she	opted	 for	
surgery	to	repair	the	aneurysm.	She	underwent	open	aneurysm	repair	through	a	subcostal	 incision,	with	a	
medial	 visceral	 rotation	 performed	 to	 allow	 a	 cross	 clamp	 to	 be	 applied	 to	 the	 distal	 thoracic	 aorta	 just	
proximal	to	the	coeliac	artery.	A	24mm	oblique	Dacron	graft	was	anastomosed	within	the	aneurysm	sac.	The	
cross-clamp	time	was	approximately	29	minutes	and	resulted	in	5.5	litres	of	blood	loss.	The	patient	made	a	
good	post-operative	recovery	with	no	evidence	of	bowel	ischaemia.		The	microdialysis	catheter	was	inserted	
as	per	the	protocol	and	monitoring	commenced	when	the	patient	arrived	in	ITU.	Monitoring	continued	for	
48	 hours	 with	 two	 separate	 relatively	 short	 periods	 of	 data	 loss	 due	 to	 disconnections	 of	 the	 tubing.	
Monitoring	was	initiated	in	the	same	manner	previously	described.		Table	24	and	Figure	76	demonstrate	the	
dialysate	glucose	calibration	data	and	trace,	and	Table	25	and	Figure	77	demonstrate	the	dialysate	 lactate	
calibration	data	and	trace.	
	
Table	24	–	Patient	8	–	Glucose	Calibration	data	
	
Figure	76	–	Patient	8	–	Glucose	Calibration	trace	with	linear	regression	
Concentration*of*standard*(mM) 4 2 0.5 0.25 0.125
Current*at*electrode*(μA) 2.2829556 0.91632192 0.11475927 0.03895525 0.00412551
Current*at*electrode*(μA) 2.3248076 0.94472566 0.11479117 0.05401142 0.02837928
Current*at*electrode*(μA) 2.4313399 0.89661376 0.11530309 0.03835767 0.02502055
Mean*current*(μA) 2.35 0.92 0.11 0.04 0.02
Standard*deviation 0.08 0.02 0.00 0.01
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Table	25	–	Patient	3	–	Lactate	Calibration	data	
	 	
Figure	77	–	Patient	8	–	Lactate	Calibration	trace	with	linear	regression	
Figure	 78	 displays	 the	 results	 of	 the	 microdialysis	 monitoring	 for	 patient	 8.	 Dialysate	 lactate	 values	 are	
displayed	 in	 green	 and	dialysate	 glucose	 concentrations	 are	displayed	 in	 blue.	Also	demonstrated	 are	 the	
two	 short	 periods	 of	missing	 data,	which	 are	 highlighted	 in	 red	 (1+2).	 Both	 periods	 of	missing	 data	were	
secondary	 to	 unintentional	 disconnection	 of	 the	 tubing	 from	 the	 catheter	 by	 the	 nursing	 staff	 as	 they	
attempted	 to	 move	 the	 patient	 in	 the	 bed.	 Each	 time	 this	 was	 noticed	 reasonably	 quickly	 and	 the	
connections	were	reattached,	limiting	the	amount	of	data	loss.	
The	dialysate	glucose	concentration	is	initially	low,	but	then	increases	quickly	as	equilibrium	is	reached	to	a	
steady	 state.	Within	 this	 steady	 state	 there	 are	 oscillations,	 with	 peaks	 and	 troughs	 between	 a	 range	 of	
3mM.	Following	the	second	interruption,	the	dialysate	glucose	initially	within	a	range	of	6.0-9.0mM,	drops	to	
significantly	 lower	level	(5.0-3.0mM).	There	is	a	slight	 increase	to	a	baseline	of	between	5.0-6.0mM,	which	
then	plateaus.	With	the	dialysate	lactate	concentration	trace	we	see	initially	high	concentrations	within	the	
tissue,	which	is	typical	of	a	patient	following	aortic	cross	clamping.	As	we	have	seen	with	the	other	patients,	
the	 lactate	 concentration	 progressively	 decreases	 from	 3.0mM	 to	 1.0mM.	 Unfortunately,	 the	 data	
interruption	 takes	 place	 at	 a	 key	 point,	 as	 it	 appears	 that	 dialysate	 glucose	 concentrations	 drops	 and	
dialysate	 lactate	 concentration	 increases.	 At	 the	 1300th	 minute	 there	 is	 reversal	 in	 the	 trend,	 with	 the	
Concentration*of*standard*(mM) 2 0.5 0.25 0.125
Current*at*electrode*(μA) 0.56400157 0.08244733 0.10663556 0.17081686
Current*at*electrode*(μA) 0.51943796 0.07552444 0.10328947 0.15780969
Current*at*electrode*(μA) 0.51921556 0.0770687 0.1020041 0.16928135
Current*at*electrode*(μA) 0.55818712
Mean*current*(μA) 0.54 0.08 0.10 0.17
Standard*deviation 0.02 0.00 0.00 0.01
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glucose	 delivery	 increasing	 and	 the	 lactate	 production	 deceasing.	 The	 preceding	 event	 is	 typical	 of	 an	
ischaemic	event,	which	 then	 resolves	 spontaneously	at	 the	1300th	minute.	 This	 transient	 ischaemic	event,	
differs	from	the	previous	events	as	it	takes	place	over	a	much	longer	time	frame	(500	minutes	in	total).	To	
postulate	 why	 this	 takes	 place	 approximately	 13	 hours	 following	 the	 procedure	 is	 difficult.	 Perhaps	 a	
hypotensive	 period	 developed,	 due	 to	 hypovolaemia	 or	 cardiac	 insufficiency,	 which	 resulted	 in	 reduced	
glucose	 delivery,	 increased	 anaerobic	metabolism	 and	 increased	 lactate	 production.	 This	metabolic	 event	
has	 been	 reversed	 by	 increasing	 the	 glucose	 delivery.	 This	 could	 be	 due	 to	 several	 reasons	 including:	
increasing	 autoregulation	 of	 the	 microvasculature,	 increased	 arterial	 shunting	 through	 major	 collateral	
branches	or	increased	external	support	(blood	transfusions,	inotropic	support	etc.).	Figure	79	demonstrates	
the	L/G	ratio	for	patient	7	for	the	entire	period	of	monitoring,	and	the	two	periods	of	the	monitoring	which	
are	 lost	 due	 to	 the	 disconnection	 of	 the	 tubing.	 The	 initial	 period	 of	 the	 monitoring	 yields	 a	 stable	 and	
progressively	 reducing	 L/G	 ratio.	 There	 is	 a	 large	 increase	 in	 the	 L/G	 ratio,	 which	 is	 in	 keeping	 with	 the	
findings	in	the	dialysate	glucose	and	lactate	traces.	The	L/G	ratio	then	gradually	drops	to	a	steady	state	level.	
A	 combined	 trace	of	 L/G	 ratio,	 dialysate	 lactate	 concentration	 and	dialysate	 glucose	 concentration	 allows	
direct	 comparison	 of	 these	 initial	 trends	 (Figure	 80).	 Once	 equilibrium	 is	 reached	 at	 approximately	 10	
minutes,	 dialysate	 glucose	 concentrations	 reaches	 a	 stable	 plateau,	 this	 is	 accompanied	 by	 a	 gradual	
decrease	 in	 dialysate	 concentrations	 and	 L/G	 ratio.	 Figure	 81	 shows	 a	 stable	 L/G	 ratio,	 however	 both	
dialysate	 lactate	 and	 glucose	 concentration	 traces	 demonstrate	 significant	 oscillations.	 These	 changes	
parallel	 with	 each	 other	 and	 the	 result	 is	 a	 stable	 L/G	 ratio.	 They	 are	 therefore	 not	 in	 keeping	 with	 the	
previously	 demonstrated	 transient	 ischaemic	 events,	 instead,	 they	 represent	 changes	 in	 recovery	 of	 the	
catheter.	
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Figure	78	–	Patient	8	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	two	periods	of	missing	data	are	in	red	(1	+	2)	
	
	
	
Figure	79	–	Patient	8	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	
Demonstrates	the	two	periods	(Red	1+2)	of	monitoring	that	were	lost	due	to	logistical	failures.	
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Figure	80	–	Patient	8	–	Online	rapid	sampling	microdialysis	monitoring	0-240	mins.		
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	0	mins	to	240	mins.	
	
	
	
Figure	81	–	Patient	8	–	Online	rapid	sampling	microdialysis	monitoring	240-480	mins	
Combined	trace	of	dialysate	glucose	(blue),	dialysate	lactate	(green)	and	lactate/glucose	(light	blue)	ratio	during	the	period	240mins	to	480	mins.	
The	red	areas	demonstrate	periods	of	parallel	changes	in	the	dialysate	lactate	and	glucose	concentrations	that	gives	rise	to	a	stable	L/G	ratio	 	
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3.3.9 Patient	9	
The	ninth	patient	enrolled	 into	 the	 study	was	a	69-year-old	 gentleman	who	was	 referred	by	his	GP,	 after	
having	a	routine	examination	was	discovered	to	have	an	8.2cm	Type	 IV	thoraco-abdominal	aneurysm.	The	
patient	underwent	aneurysm	repair	through	a	midline	laparotomy	and	required	visceral	re-implantation.	The	
visceral	implantation	consisted	of	10mm	Dacron	grafts	anastomosed	proximally	to	the	main	aortic	graft	and	
distally	to	each	of	the	visceral	arteries	(coeliac	artery,	SMA,	right	and	left	renal	arteries).	It	important	to	note	
that	the	IMA	is	not	routinely	re-implanted	in	this	procedure.	There	was	a	very	high	risk	of	bowel	ischaemia	in	
this	patient	and	therefore	important	to	include	in	the	study	protocol.	Intraoperative	examination	was	made	
of	the	sigmoid	colon	following	removal	of	the	aortic	clamp	to	assess	for	potential	ischaemia.	The	bowel	was	
deemed	pink,	healthy	and	viable.		
The	microdialysis	catheter	was	 inserted	as	per	 the	protocol	and	monitoring	commenced	when	the	patient	
arrived	in	ITU.	Monitoring	continued	for	48	hours	with	two	separate	relatively	short	periods	of	data	loss	due	
to	disconnections	of	the	tubing.	Monitoring	was	initiated	in	the	same	manner	as	previously	described.	Table	
26	and	Figure	82	demonstrate	the	dialysate	glucose	concentration	calibration	data	and	trace,	and	Table	27	
and	Figure	83	demonstrate	the	dialysate	lactate	calibration	data	and	trace.	
	
Table	26	–	Patient	9	–	Glucose	Calibration	data	
	
Figure	82	–	Patient	9	–	Glucose	Calibration	trace	with	linear	regression	
Concentration*of*standard*(mM) 4 2 0.5 0.25 0.125
Current*at*electrode*(μA) 4.1997926 2.0191138 0.45068789 0.204367 0.08623446
Current*at*electrode*(μA) 4.2526328 1.9834995 0.401457 0.19452603 0.07640237
Current*at*electrode*(μA) 4.397651 0.43026119 0.09178216
Mean*current*(μA) 4.28 2.00 0.43 0.20 0.08
Standard*deviation 0.10 0.03 0.02 0.01
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Table	27	–	Patient	9	–	Lactate	Calibration	data	
	
Figure	83	–	Patient	9	–	Lactate	Calibration	trace	with	linear	regression	
Figure	 84	 displays	 the	 results	 of	 the	 microdialysis	 monitoring	 for	 patient	 9.	 Dialysate	 lactate	 values	 are	
displayed	 in	green	and	dialysate	glucose	concentrations	are	displayed	 in	blue.	Unfortunately,	 the	catheter	
was	accidentally	displaced	by	 the	nursing	 staff	early	on	 following	commencement	of	monitoring	and	 then	
subsequently	completely	removed	from	the	patient	shortly	after	by	the	nursing	staff	as	 they	were	moving	
the	patient.	The	patient	made	a	complete	recovery	following	the	procedure	and	there	was	no	evidence	of	
colonic	 ischaemia.	 The	 two	 key	 events,	 highlighted	 in	 red,	 can	 be	 seen,	 where	 the	 catheter	 is	 partially	
displaced	 (1)	 and	 then	 completely	 removed	 from	 the	 patient	 (2).	 It	 is	 likely	 that	 following	 the	 partial	
displacement	of	the	catheter,	the	catheter	was	sampling	from	peritoneal	fluid	as	seen	in	patient	3.	
	
	
	
	
Concentration*of*standard*(mM) 2 0.5 0.25 0.125
Current*at*electrode*(μA) 2.4318168 0.6401934 0.41377567 0.21216753
Current*at*electrode*(μA) 2.5854434 0.61353928 0.4238338 0.202518
Current*at*electrode*(μA) 2.5065418 0.37987917 0.20694011
Mean*current*(μA) 2.507934 0.62686634 0.40582955 0.20720855
Standard*deviation 0.08 0.02 0.02 0.00
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Figure	84	–	Patient	9	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	three	important	events	are	marked	in	red	(1,	2	
and	3)	
Table	 28	 displays	 the	 results	 from	 the	 serial	 arterial	 blood	 gas	 analyses;	 these	 are	 further	 displayed	 on	 a	
trace	in	Figure	85.	We	can	see	that	for	the	first	10	hours	of	the	postoperative	period	both	blood	glucose	and	
blood	lactate	concentrations	are	stable.	
	
Figure	85	–	Patient	9	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	28	–	Patient	9	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)		
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3.3.10 Patient	10	
The	tenth	and	last	patient	enrolled	into	the	study	was	a	78-year-old	lady	with	a	known	previous	history	of	
endometriosis	 and	 presented	 to	 her	 GP	 with	 long	 standing	 lower	 abdominal	 pain.	 Routine	 clinical	
examination	elicited	a	palpable	pulsating	mass	 in	 the	abdomen.	The	patient	was	subsequently	 referred	 to	
the	vascular	surgeons	and	underwent	a	CT	aortogram,	which	 identified	a	7.1cm	Type	III	 thoracoabdominal	
aortic	 aneurysm.	 Like	 the	 previous	 patient,	 she	 underwent	 open	 aneurysm	 repair	 with	 visceral	
revascularisation,	 consisting	of	10	mm	Dacron	grafts	anastomosed	 individually	 from	 the	main	body	of	 the	
aortic	graft	to	the	coeliac	artery,	SMA,	right	and	left	renal	arteries.	The	microdialysis	catheter	was	inserted	
as	per	the	protocol	and	monitoring	commenced	when	the	patient	arrived	in	ITU.	Monitoring	continued	for	
48	hours	with	a	period	of	data	loss	on	the	first	postoperative	night	due	to	inadvertent	disconnection	of	the	
FEP	tubing	by	the	nursing	staff.		Figure	86	displays	the	results	of	the	microdialysis	monitoring	for	patient	10.	
Dialysate	 lactate	values	are	displayed	 in	green	and	dialysate	glucose	concentrations	are	displayed	 in	blue.	
Also	demonstrated	are	 the	periods	of	missing	data,	which	 is	highlighting	 in	 red	 (1).	At	 commencement	of	
monitoring	 the	dialysate	 lactate	 concentration	 appear	 high	 at	 2.8mM,	progressively	 decreasing	 to	 1.7mM	
within	4	hours.	A	parallel	trace	is	seen	with	dialysate	glucose	concentration,	as	initial	anaerobic	metabolism	
following	aortic	cross	clamping	and	the	surge	of	glucogenolytic	stress	hormones	resolves.	At	this	point	the	
tubing	 is	unfortunately	accidentally	disconnected	by	 the	nursing	 staff	 and	 the	data	 is	 lost.	 The	 catheter	 is	
reconnected	later	in	the	morning	by	the	research	team.	Following	this	we	can	see	that	both	dialysate	lactate	
and	 glucose	 have	 increased	 to	 stable	 steady	 state,	 between	 a	 concentration	 range	 of	 2.7-3.3mM	 for	
dialysate	lactate	and	2.8-5mM	for	dialysate	glucose.	
	
Figure	86	–	Patient	10	–	Online	rapid	sampling	microdialysis	monitoring	of	the	colon	following	AAA	repair	
Dialysate	concentrations	(mM)	is	shown	over	time	(min),	for	Lactate	(green)	and	Glucose	(blue).	The	period	of	missing	data	is	shown	in	red	(1)	
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Table	 29	 displays	 the	 results	 from	 the	 serial	 arterial	 blood	 gas	 analyses;	 these	 are	 further	 displayed	 on	 a	
trace	in	Figure	87.	Both	blood	glucose	and	blood	lactate	concentrations	are	initially	high	and	slowly	decrease	
down	to	stable	levels.	This	mirrors	the	changes	that	we	see	in	the	local	tissue	concentrations	of	each	analyte.	
	
Figure	87	–	Patient	10	–	Arterial	blood	gas	sampling	over	time	
Trace	 shows	 trend	 of	 the	 arterial	 concentrations	 of	 lactate	 (green)	 and	 glucose	 (blue)	 at	 time	 (min)	 intervals	 throughout	 the	 entire	 period	 of	
monitoring	
Table	29	–	Patient	10	–	Arterial	blood	gas	analysis	
Blood	glucose	and	lactate	concentrations	are	shown	at	time	(min)	intervals	
Figure	88	demonstrates	the	L/G	ratio	for	patient	10	for	the	entire	period	of	monitoring,	displaying	the	long	
period	overnight	where	the	monitoring	is	lost	due	to	the	disconnection	of	the	FEP	tubing.	The	initial	period	
of	the	monitoring	yields	a	stable	and	flat	L/G	ratio	trace.	Whilst	the	dialysate	lactate	and	dialysate	glucose	
concentrations	 both	 decreased	 in	 this	 period,	 the	 drop	 in	 concentration	 took	 place	 in	 parallel	 with	 each	
other	and	therefore	the	result	is	a	flat	L/G	ratio	trace.	There	is	a	gradual	increase	in	the	L/G	ratio	following	
the	 interruption	from	approximately	0.7mM	to	1.2mM,	but	this	 is	unlikely	to	reflect	 tissue	 ischaemia.	This	
patient	made	a	good	clinical	recovery	and	did	not	develop	any	evidence	of	bowel	ischaemia.	
	
Figure	88	–	Patient	10	–	Dialysate	Lactate/Glucose	ratio	(blue)	of	the	colon	following	AAA	repair	over	time	(min)	 	
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3.4 DISCUSSION	
My	aim	was	to	assess	the	feasibility	of	using	the	online	rsMD	analyser	to	detect	colonic	 ischaemia,	by	real	
time	sampling	of	 lactate	and	glucose	to	test	 the	hypothesis	 that	microdialysis	can	be	effectively	utilised	 in	
the	detection	of	colonic	ischaemic	after	AAA	repair.	
My	results	have	demonstrated	numerous	findings.	We	see	consistently	high	blood	concentrations	of	glucose	
in	the	immediate	post-operative	periods,	with	much	lower	dialysate	glucose	concentrations.	The	initial	high	
glucose	 concentrations	 can	 be	 explained	 by	 the	 production	 of	 gluconeogenic	 stress	 hormones	 in	 the	
presence	of	acidosis.	The	dialysate	glucose	concentrations	and	therefore	the	tissue	concentrations	appear	to	
be	 independent	 of	 this	 with	 lower	 concentrations	 in	 most	 of	 the	 cases.	 This	 could	 be	 either	 due	 to	
physiological	shunting	with	blood	being	redistributed	to	vital	areas	such	as	the	brain	and	heart	in	response	
to	hypovolaemia,	or	pathological	due	to	atherosclerosis	and	a	disruption	of	the	vascular	supply	to	the	colon,	
as	marker	 of	 ischaemia.	 It	may	 also	 be	 a	 combination	 of	 the	 two,	 however	we	 do	 see	 the	 tissue	 glucose	
concentrations	normalise	after	a	period.	This	period	of	tissue	hypoglycaemia	 is	 likely	caused	by	splanchnic	
hypoperfusion,	however	 this	 is	 transient	and	 it	 appears	 that	 the	 colonic	 tissue	 is	 able	 to	auto	 regulate	by	
slowly	increasing	blood	flow	and	thereby	delivering	more	glucose	to	the	region.	This	is	further	confirmed	by	
the	 fact	 that	 initially	 after	 the	 procedure	 tissue	 concentrations	 of	 lactate	 in	 all	 patients	 appear	 high	 and	
normalise	 after	 a	 period.	 These	 findings	 also	 correlate	 with	 the	 fact	 the	 none	 of	 the	 patients	 studied	
developed	clinical	signs	of	fulminant	bowel	ischaemia.		
We	 see	 in	 several	 patients,	 at	 certain	 points	 during	 the	monitoring	 the	 tissue	 lactate	 concentrations	 are	
higher	than	blood	lactate	concentrations.	This	demonstrates	a	few	things.	It	allows	us	to	assert	that	at	that	
point	tissue	and	blood	concentrations	are	independent	of	each	other.	This	is	an	important	distinction	as	it	is	
imperative	 that	 the	 analyte	 being	measured	 by	 the	 rsMD	 reflects	 only	 tissue	 levels	 rather	 than	 systemic	
concentrations	 that	 secondarily	 affect	 local	 concentrations.	 Developing	 a	 systemic	 lactic	 acidosis	 after	
surgery	 is	an	expected	consequence,	however	 if	we	 identify	that	there	 is	a	higher	concentration	of	 lactate	
within	 the	 bowel	 tissue,	we	 can	 assert	 that	 this	 lactate	 is	 produced	 by	 the	 colon,	which	may	 suggest	 an	
ongoing	 ischaemic	 process.	 This	 data	 would	 suggest	 that	 rsMD	 can	 be	 effectively	 used	 in	 the	 clinical	
detection	of	bowel	ischaemia	after	AAA	repair.	None	of	the	patients	enrolled	into	the	study	have	proceeded	
to	develop	clinically	evident	 ischaemic	colitis	during	the	peri-operative	period,	 this	 is	 further	confirmed	by	
stable	L/G	ratios	in	all	patients.	There	are	periods	in	all	the	patients	monitoring	where	we	see	a	transient	rise	
in	their	L/G	ratios,	however	this	is	never	greater	than	a	three-fold	increase	from	the	baseline.	As	shown	by	
Deeba	et	al	 and	Corcoles	et	al	 in	previous	work	using	 the	 same	 rapid	 sampling	microdialysis	 analyser,	we	
would	expect	the	L/G	ratio	to	increase	by	up	to	16-fold	when	clinically	evident	ischaemia	is	present.	56,250		
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The	 periods	 of	 monitoring	 whereby	 we	 see	 a	 self-limiting	 rise	 in	 the	 L/G	 ratio	 are	 highly	 suggestive	 of	
transient	 episodes	 of	 ischaemia.	 The	 L/G	 ratio	 will	 increase	 when	 there	 is	 a	 rise	 in	 the	 lactate	 tissue	
concentration	with	a	drop	in	the	glucose	concentration.	During	periods	of	ischaemic	stress,	we	would	expect	
to	 see	 localised	 lactic	 acidosis	 triggered	 by	 a	 fall	 in	 glucose	 delivery,	 this	 is	 clearly	 represented	 in	 these	
traces.	 However,	 following	 these	 episodes,	 which	 are	 highly	 suggestive	 of	 ischaemia,	 there	 is	 a	 rebound	
increase	in	glucose	delivery,	fall	in	lactate	concentration	and	subsequent	drop	in	L/G	ratio.	It	would	suggest	
that	 the	 reversal	of	 ischaemia	during	 these	events	 is	 secondary	 to	 localised	autoregulation	of	metabolism	
and	possibly	due	to	increased	perfusion	and	blood	flow,	which	would	explain	the	increased	glucose	delivery	
and	 decrease	 in	 regional	 lactic	 acidosis.	 The	 decrease	 in	 lactate	 concentration	 could	 be	 secondary	 to	
enzymatic	breakdown,	however	this	would	not	necessarily	explain	the	increase	in	glucose	delivery	within	the	
tissue.	These	transient	episodes	are	present	in	all	the	patients	examined	and	are	frequently	encountered.	By	
pooling	all	the	data	sets	from	each	patient	and	displaying	the	data	at	hourly	intervals	with	box	and	whisker	
plots,	we	are	able	 to	 see	 the	distributional	 characteristics	of	our	datasets.	 Figure	89	 shows	all	 the	pooled	
data	 for	each	patient	displaying	the	dialysate	glucose	concentrations	at	hourly	 intervals	within	the	 first	24	
hours,	 whilst	 Figure	 90	 demonstrates	 the	 distribution	 of	 all	 the	 dialysate	 lactate	 concentrations	 for	 each	
patient	at	hourly	intervals.	Examining	the	distribution	of	tissue	glucose	and	lactate	concentrations	for	all	ten	
patients	we	can	see	that	the	mean	of	each	data	group	is	very	stable	with	little	fluctuation	above	and	below	
the	baseline.	The	lactate	and	glucose	tissue	concentrations	over	the	period	of	monitoring	rarely	go	beyond	
1mM	away	from	mean.	Whilst	there	are	occasional	outliers,	 this	 is	 to	be	expected	 in	such	a	 large	dataset,	
however	 the	 mean	 and	 median	 values	 are	 closely	 arranged	 in	 the	 majority	 of	 the	 hourly	 intervals,	
demonstrating	 a	 close	 to	 symmetrical	 distribution	with	minimal	 skewing	of	 the	data	 set.	On	 those	hourly	
intervals	where	the	median	and	mean	are	not	closely	applied,	we	can	see	that	for	tissue	glucose	there	is	a	
positive	 non-parametric	 skew,	where	 the	mean	 is	 typically	 higher	 than	 the	median	 and	 greater	 spread	of	
values	 in	 the	3rd	and	4th	quartile	groups.	With	 the	 tissue	 lactate	concentrations,	 there	are	hourly	 intervals	
where	the	mean	is	less	than	the	median,	displaying	a	negative	skew,	with	a	greater	distribution	and	spread	
of	data	points	in	the	1st	and	2nd	quartiles.	The	glucose	tissue	concentrations	show	the	greatest	spread	within	
the	 first	 14	 hours,	 in	 particular	 between	 hour	 4	 and	 14,	 following	 this	 period	 the	 glucose	 concentrations	
stabilise	 with	minimal	 spread.	 The	 initial	 period	 following	 surgery	 represents	 the	 greatest	 metabolic	 and	
physiological	instability,	with	homeostasis	mechanisms	working	hardest	to	normalise	function.	Perhaps	this	
chaotic	 pattern	 in	 glucose	 delivery	 to	 the	 tissue	 is	 a	 reflection	 of	 this	 instability.	 Whilst	 there	 is	 less	
distribution,	 spread	 and	 skew	within	 the	 tissue	 lactate	 concentrations,	 overall	 both	 analytes	 display	 data	
points	within	the	upper	and	lower	quartiles	with	minimal	spread	over	a	short	concentration	range,	close	to	
the	 median.	 These	 findings	 correlate	 clearly	 with	 the	 clinical	 observation	 that	 none	 of	 the	 patients	
developed	bowel	ischaemia	after	AAA	repair.	
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Figure	89	–	All	patients	–	Mean	dialysate	glucose	concentrations	per	hour	for	the	first	24	hours	of	monitoring	the	colon	with	rsMD	after	AAA	repair	
Each	 box	 and	whisker	 plot	 demonstrates	 the	median,	mean,	maximum	 and	minimum	 outliers,	maximum	 and	minimum	 range,	 first	 and	 third	
quartiles	and	the	interquartile	range	
	
	
Figure	90	–	All	patients	–	Mean	dialysate	lactate	concentrations	per	hour	for	the	first	24	hours	of	monitoring	the	colon	with	rsMD	after	AAA	repair.	
Each	 box	 and	whisker	 plot	 demonstrates	 the	median,	mean,	maximum	 and	minimum	 outliers,	maximum	 and	minimum	 range,	 first	 and	 third	
quartiles	and	the	interquartile	range	
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Figure	91	and	Figure	92	demonstrates	the	distribution	of	dialysate	glucose	and	lactate	concentrations	within	
the	first	hour,	at	10-minute	intervals	for	all	10	patients.	For	both	analytes,	the	mean	and	median	are	closely	
applied,	with	minimal	 skew.	We	see	 steady	 lactate	concentrations	during	 this	period	with	minimal	 spread	
away	 from	the	baseline	and	a	stable	mean.	The	dialysate	glucose	concentration	 is	also	stable,	however	as	
previously	described	we	see	lower	levels	from	the	outset	that	gradually	increase	over	the	next	hour.		
	
Figure	91	–	All	patients	–	Mean	dialysate	glucose	concentrations	per	10	minute	period	in	the	first	hour	of	monitoring	the	colon	with	rsMD	after	
AAA	repair	
Each	 box	 and	whisker	 plot	 demonstrates	 the	median,	mean,	maximum	 and	minimum	 outliers,	maximum	 and	minimum	 range,	 first	 and	 third	
quartiles	and	the	interquartile	range	
	
	
Figure	92	–	All	patients	–	Mean	dialysate	lactate	concentrations	per	10	minutes	period	in	the	first	hour	of	monitoring	the	colon	with	rsMD	after	
AAA	repair	
Each	 box	 and	whisker	 plot	 demonstrates	 the	median,	mean,	maximum	 and	minimum	 outliers,	maximum	 and	minimum	 range,	 first	 and	 third	
quartiles	and	the	interquartile	range	
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The	analysis	of	the	data	for	Patients	7	demonstrates	interesting	findings.	Here	we	see	the	highest	dialysate	
glucose	and	blood	glucose	concentrations	of	any	of	the	patients.	There	could	be	numerous	potential	causes	
for	this.	It	is	a	possibility	that	the	patient	had	undiagnosed	or	early	diabetes	mellitus,	lack	of	insulin	or	insulin	
resistance	that	would	undoubtedly	results	in	systemic	and	tissue	hyperglycaemia.	Interestingly	this	patient’s	
blood	results	all	returned	to	normal	without	the	need	for	insulin,	subsequent	tests	did	not	identify	features	
consistent	 with	 diabetes.	 A	 more	 likely	 theory	 is	 that	 due	 to	 the	 patient’s	 young	 age,	 she	 was	 able	 to	
produce	 an	 aggressive	 adrenergic	 response	 to	 the	 surgery,	 triggering	 a	 glycogenolytic	 cascade,	 which	
resulted	in	high	concentrations	of	circulating	glucose.	These	concentrations	accurately	reflect	the	metabolic	
conditions	of	the	tissue	at	the	time	of	monitoring	and	do	not	represent	faults	within	the	assay.	We	know	this	
is	 the	 case,	 as	 the	 calibrations	 are	 carried	 out	 using	 standards	 of	 known	 concentrations	 and	 that	 the	
amplitude	 of	 the	 current	 peaks	 were	 significantly	 larger	 than	 in	 other	 cases.	 The	 high	 dialysate	 glucose	
concentrations	 directly	 reflect	 glucose	 delivery,	 and	 therefore	 it	 is	 important	 to	 notes	 that	 levels	 were	
significantly	higher	than	in	the	other	cases.	The	rest	of	the	patients	that	were	enrolled	into	the	study	were	
elderly	 patients,	where	 the	 pathogenesis	 of	 the	 aneurysm	 is	 secondary	 to	 atheromatous	 disease.	 It	 likely	
that	these	patients	will	have	atheroma	in	the	arterial	cascade	that	primarily	supply	the	colon	as	well	as	the	
collateral	arterial	supply.	In	addition,	these	patients	have	a	limited	cardiac	reserve	and	due	to	physiological	
shunting	 in	hypovolaemic	 states,	perfusion	 to	 secondary	organs	 such	as	 the	kidneys,	 gastrointestinal	 tract	
and	skin	will	be	reduced	in	order	to	maximise	perfusion	to	vital	tissues	such	as	the	myocardium	and	brain.	
The	 lack	 of	 these	 limiting	 factors	 in	 a	 young	 patient,	 whose	 pathogenesis	 for	 aneurysm	 development	 is	
secondary	to	a	connective	tissue	disorder,	results	in	much	greater	splanchnic	perfusion	and	glucose	delivery.	
The	previously	described	 calibration	data	and	 linear	 traces	 that	 are	 subsequently	produced	are	 important	
when	accurately	converting	the	peaks	generated	at	 the	electrodes	 into	analyte	concentrations.	During	the	
monitoring	of	Patient	7,	resulting	glucose	dialysate	concentrations	were	greater	than	that	of	the	calibration	
samples	 concentrations.	 At	 its	 peak	 glucose	 concentration	 reaches	 approximately	 12mM,	 however	 when	
calibrating	the	system	we	only	used	samples	of	6mM	of	glucose.	During	the	monitoring,	the	peaks	generated	
at	 the	 electrode	 during	 this	 period	were	 larger	 than	 that	 of	 the	 calibrations	 samples,	 indicating	 that	 the	
concentrations	are	indeed	higher	and	not	artefact.	However,	Corcoles	et	al	using	the	rsMD	in	previous	work	
examining	 ischaemic	 porcine	 bowel,	 demonstrated	 that	 calibration	 traces	 possess	 a	 linear	 relationship	 at	
concentrations	below	10mM.	250	
	Concentrations	 above	 this	 demonstrate	 a	 plateauing	 flattened	 curve.	 Corcoles	 et	 al	 anticipated	 higher	
values	of	lactate,	due	to	the	presence	of	frank	ischaemia	after	arterial	vessels	were	clamped	in	their	animal	
model.	In	doing	so	the	authors	undertook	an	extended	calibration,	with	concentrations	up	to	30mM	for	both	
lactate	 and	 glucose.	 In	 our	 study,	 we	 use	 a	 maximum	 concentration	 of	 6mM,	 and	 therefore	 higher	
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concentrations	are	calculated	on	the	assumption	that	the	liner	calibration	trace	is	maintained.	It	is	likely	that	
this	is	not	the	case	for	very	high	concentrations,	such	as	encountered	in	Patient	7.	The	result	is	that	the	value	
demonstrated	 may	 be	 an	 over	 estimation,	 with	 actually	 lower	 concentrations	 in	 reality.	 This	 is	 a	 clear	
limitation	of	this	study	as	several	assumptions	are	made,	without	corroborating	evidence.	
As	 previously	 described,	 dialysate	 lactate	 concentration	 is	 typically	 high	 at	 the	 start	 of	 monitoring,	 then	
progressively	drops	to	a	steady	state.	The	warm	ishchaemia	that	develops	results	 in	anaerobic	metabolism	
with	increased	tissue	and	systemic	lactate	concentrations.	This	is	demonstrated	by	the	initially	high	dialysate	
lactate	 concentration,	which	 accurately	 reflects	 local	 bowel	 lactate	 production.	 The	 anticipated	 increased	
systemic	 lactate	production	 is	 reflected	by	the	high	blood	 lactate	concentrations	demonstrated	on	arterial	
blood	gas	sampling.	We	typically	see	that	blood	lactate	concentrations	(Figure	93	and	Figure	94)	are	higher	
than	local	dialysate	 lactate	concentrations,	as	the	former	represents	the	ischaemic	response	from	multiple	
organs	 and	 systems,	whereas	 the	 latter	 reflects	 local	 changes.	 This	 is	 the	 case	when	we	have	 sub-clinical	
ischaemia,	 however	 in	 the	 presence	 of	 progressive	 fulminant	 ischaemia	 of	 the	 bowel,	 it	 is	 likely	 that	 the	
dialysate	lactate	concentrations	would	be	initially	significantly	higher	than	blood	values.	
	
Figure	93	–	All	patients	–	Mean	blood	glucose	conc	at	1,	2	or	3	hourly	periods	for	the	entire	period	of	monitoring	
Each	 box	 and	whisker	 plot	 demonstrates	 the	median,	mean,	maximum	 and	minimum	 outliers,	maximum	 and	minimum	 range,	 first	 and	 third	
quartiles	and	the	interquartile	range	
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Figure	94	–	All	patients	–	Mean	blood	lactate	conc	at	1,	2	or	3	hourly	periods	for	the	entire	period	of	monitoring	
Each	 box	 and	whisker	 plot	 demonstrates	 the	median,	mean,	maximum	 and	minimum	 outliers,	maximum	 and	minimum	 range,	 first	 and	 third	
quartiles	and	the	interquartile	range	
3.4.1 Measuring	the	L/G	ratio	
The	 L/G	 ratio	 provides	 a	 valuable	 metric	 when	 utilised	 in	 comparative	 studies.	 An	 increasing	 L/G	 ratio	
reflects	a	sustained	 lactate	production	driven	by	hypoxia	 induced	hyperglycolysis	and	 is	 therefore	a	useful	
marker	of	on-going	ischaemia.	
Monitoring	 lactate	as	a	metabolic	marker	of	 ischaemia	affords	the	 investigator	key	 information	on	oxygen	
delivery,	oxygen	demand,	tissue	viability	and	cellular	damage.	However,	numerous	studies	have	previously	
demonstrated	that	the	measurement	of	 lactate	alone	is	not	a	good	marker	of	tissue	ischaemia,	as	any	rise	
may	be	the	result	of	hypermetabolism	as	well	as	ischaemia.251	Parkin	et	al	and	Ungerstedt	et	al	emphasised	
the	 importance	 of	 measuring	 local	 tissue	 glucose	 in	 order	 to	 accurately	 interpret	 oxygen	 and	 glucose	
delivery	in	various	clinical	model	utilising	microdialysis.25,252	
Goodman	et	 al	 have	 utilised	 the	measurement	 of	 L/G	 ratio	 to	 demonstrate	 adverse	 outcomes	 associated	
with	 traumatic	brain	 injury,	whilst	Zauner	et	al	presented	data	 that	 revealed	a	L/G	ratio	of	greater	 than	4	
was	 related	 to	 cerebral	 hypoxic	 events.253,254	 Sorensen	 et	 al	 whilst	 studying	 ischaemic	 jejunal	 flaps,	
demonstrated	that	a	L/G	ratio	of	greater	than	10	fold	when	compared	to	viable	flaps,	was	characteristic	of	
ischaemic	 nonviable	 flaps.63	 On	 further	 examination	 of	 the	 data	 from	 the	 monitoring	 of	 the	 10	 patients	
enrolled,	we	can	see	various	trends	in	the	L/G	ratio	traces.	We	see	initially	a	self-limiting	rise	in	the	L/G	ratio,	
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typically	 within	 1	 unit	 from	 the	 baseline	 rate.	 This	 progressively	 increases	 over	 the	 course	 of	monitoring	
within	the	first	24	hours,	reaching	a	steady	state	at	approximately	2	units	from	the	baseline.	Over	the	next	
period	of	monitoring	we	see	the	L/G	ratio	gradually	decline	down	to	baseline.	
Most	 patients	 demonstrated	 this	 trend,	 with	 an	 overall	 reduction	 in	 the	 L/G	 ratio	 during	 the	 period	 of	
monitoring,	 indicating	 a	 resolution	 of	 the	 temporal	 ischaemia	 that	 initially	 developed	 through	 increasing	
perfusion,	oxygenation	and	glucose	delivery.	
Spontaneously	 resolving,	 transient	 metabolic	 changes	 can	 be	 interpreted	 as	 temporal	 ischaemic	 events.	
These	 changes	 are	 recognised	 by	 an	 increase	 in	 dialysate	 lactate	 concentration	 coupled	 with	 a	 parallel	
decrease	 in	dialysate	glucose	concentration.	The	L/G	ratio	 is	an	alternative	measurement	 for	 these	events	
and	 they	 are	 observed	 as	 a	 transient	 increase	 in	 the	 ratio	 levels.	 As	 previously	 described	 most	 patients	
display	 a	 gentle	 decline	 in	 the	 L/G	 ratio	 over	 the	 period	 of	 monitoring,	 however	 there	 were	 numerous	
periods	 in	the	monitoring	where	a	significant	 increase	 in	the	L/G	ratio	was	demonstrated.	These	 increases	
never	 exceeded	 more	 than	 2	 units	 from	 the	 baseline.	 Parkin	 et	 al	 and	 Boutelle	 et	 al	 have	 previously	
demonstrated	similar	transient	ischaemic	events	in	patients	undergoing	microdialysis	monitoring	of	hypoxic	
injury	following	traumatic	brain	injury.24,255			
3.4.2 Relationship	between	blood	and	dialysate	concentrations	
To	 investigate	 any	 possible	 relationship	 between	 the	 blood	 and	 local	 tissue	 dialysate	 concentrations,	
correlations	were	 created	 that	 allowed	 for	 regression	 analysis.	 As	 previously	 described,	 each	 patient	 had	
serial	 arterial	 blood	 gas	 sampling,	 where	 blood	 glucose	 and	 lactate	 concentrations	 were	 analysed	 and	
recorded.	For	each	blood	sample	at	a	particular	time,	5	 individual	samples	(which	equates	to	5	minutes	of	
monitoring)	 of	 corresponding	 dialysate	 concentrations	 were	 averaged	 together.	 These	were	 then	 plotted	
and	 examined	 for	 any	 potential	 correlation.	We	 have	 demonstrated	 for	 each	 patient,	 that	 there	 was	 no	
significant	 correlation	between	dialysate	 and	blood	 concentrations	 for	 lactate,	with	R2	 close	 to	 zero	 in	 all	
cases	 (Figure	 95).	 With	 glucose,	 there	 existed	 in	 a	 few	 cases	 minor	 correlations	 (R2	 between	 0.1-0.3)	
between	blood	and	dialysate	 concentrations,	when	 the	 glucose	 concentrations	were	high	 (Figure	96).	We	
also	 demonstrated	 in	 these	 patients,	 that	 by	 omitting	 these	 high	 values	 the	 correlation	 subsequently	
becomes	negligible.	 
The	absence	of	a	 linear	relationship	between	blood	and	dialysate	concentrations	(Figure	97	and	Figure	98)	
for	both	lactate	and	glucose	in	the	data,	confirms	that	the	rsMD	assay	monitors	and	reflects	local	metabolic	
changes	rather	than	systemic	conditions.		
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We	can	therefore	conclude	that	in	the	presence	of	subclinical	bowel	ischaemia,	the	measurement	of	blood	
glucose	and	lactate	is	a	poor	indicator	of	localised	tissue	ischaemia.	When	assessing	and	comparing	dialysate	
lactate	concentrations,	we	do	not	need	to	normalise	for	blood	lactate	concentrations.	Whilst	the	same	can	
be	stated	for	dialysate	glucose	concentrations,	our	data	would	suggest	that	at	higher	concentration	dialysate	
glucose	 is	 sensitive	 to	 systemic	 blood	 concentrations	 and	 therefore	 blood	 glucose	 sampling	 is	 useful	 for	
interpretation.	
	
Figure	95	–	All	patients	–	Correlation	between	blood	lactate	conc	(mM)	&	dialysate	lactate	conc	(mM)	
Linear	regression	shown	in	green	
	
	
Figure	96	–	All	patients	–	Correlation	between	blood	glucose	conc	(mM)	&	dialysate	glucose	conc	(mM).		
Linear	regression	shown	in	green	
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Figure	97	–	All	patients	–	Correlation	between	blood	glucose	concentration	(mM)	&	blood	lactate	concentration	(mM).		
Linear	regression	shown	in	green	
	
	
Figure	98	–	All	patients	–	Correlation	between	dialysate	glucose	conc	(mM)	&	dialysate	lactate	conc	(mM).		
Linear	regression	shown	in	green	
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3.4.3 Summary	of	findings	
This	 is	the	first	study	of	 its	kind,	utilising	a	rsMD	biosensor	assay	to	determine	the	metabolic	properties	of	
bowel	following	AAA	repair	and	in	the	context	of	subclinical	ischaemia.		
Four	key	findings	have	been	demonstrated	by	this	study:	
1. Ten	 patients	 were	 monitored	 with	 the	 rsMD	 assay	 following	 thoraco-abdominal	 aneurysm	 repairs,	
successfully	confirming	that	none	of	the	patients	developed	colonic	ischaemia.	
2. I	 confirmed	 that	 L/G	 ratio	 is	 a	 reliable	 measurement	 of	 colonic	 ischaemia	 and	 a	 key	 parameter	 in	
comparative	clinical	studies.	
3. That	blood	and	dialysate	concentrations	of	the	metabolic	markers	of	ischaemia	do	not	share	a	significant	
correlation	at	lower	concentrations,	however	do	exhibit	mild	correlations	at	higher	concentrations.	
4. The	presence	of	 spontaneously	 resolving	 transient	 ischaemic	 periods	would	 suggest	 that	 the	bowel	 is	
capable	of	auto-regulating	glucose	delivery	whilst	in	a	subclinical	ischaemic	environment.		
I	have	not	been	able	 to	 identify	 the	changes	 that	signify	 fulminant	bowel	 ischaemia,	but	 rather	 the	subtle	
changes	in	the	bowel	that	are	not	clinically	evident	and	may	progress	to	progressive	ischaemia.		
The	 identification	 of	 ischaemic	 bowel	 in	 the	 clinical	 setting,	 once	 transmural	 infarction	 has	 developed,	 is	
relatively	 easy.	 The	 clinical	 signs	 and	 symptoms	 of	 irreversible	 infarction	 are	 relatively	 easy	 to	 elicit	 and	
arguably	too	 late	 in	doing	so.	However,	 to	be	able	to	clinically	detect	the	early,	subtle	signs	that	a	patient	
may	 potentially	 develop	 worsening	 ischaemia,	 is	 difficult	 and	 is	 something	 that	 has	 eluded	 previous	
investigators.	Our	study	has	shown	that	the	rsMD	assay	is	sensitive	and	selective	enough	to	be	able	to	detect	
and	 monitor	 for	 sub-clinical	 ischaemia,	 and	 can	 potentially	 warn	 surgeons	 prior	 to	 the	 development	 of	
potentially	 fatal	 complications.	 Further	 work	 is	 required	 to	 stabilise	 the	 system,	 develop	 a	 protocol	 that	
limits	 data	 loss	 and	 the	 enrolment	 of	 more	 patients	 to	 allows	 characterisation	 of	 a	 trace	 that	 reflects	
worsening	fulminant	bowel	ischaemia	in	a	clinical	setting.	
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Chapter	4	–	Online	rapid	sampling	
microdialysis	for	the	in-vivo	detection	of	
bowel	anastomotic	leaks	
Chapter	 4	 is	 centred	 on	my	 second	 study:	 utilising	 online	 rsMD	 for	 the	 early	 detection	 of	 post-operative	
complications	such	as	anastomotic	leaks	and	other	post-operative	complications	following	major	GI	surgery.	
In	this	chapter,	I	clearly	set	out	my	hypothesis	and	aim,	whilst	also	describing	the	methodology	of	the	study.	
I	describe	and	examine	my	results	and	their	interpretations.	 	
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4 CHAPTER	4	–	ONLINE	RAPID	SAMPLING	MICRODIALYSIS	FOR	
THE	IN-VIVO	DETECTION	OF	BOWEL	ANASTOMOTIC	LEAKS	
4.1 HYPOTHESIS	&	AIM	
The	 prompt	 diagnosis	 of	 post-operative	 complications	 such	 as	 anastomotic	 leaks	 can	 reduce	 morbidity,	
mortality,	 hospital	 stay	 and	 the	 intervention	 costs.	 Complications	 following	 major	 GI	 surgery	 are	 very	
common,	 serious	complications	such	as	anastomotic	 leaks	are	associated	with	high	mortality	 rates.80,141,165		
Much	 investigation	and	 the	 focus	of	my	 research	has	moved	 towards	 the	prediction	or	early	detection	of	
these	 complications.	 This	 is	 particularly	 relevant	 to	 anastomotic	 leaks,	 where	 inherent	 limitations	 in	
diagnostic	 tools,	 a	 late	 clinical	 presentation	 and	 a	 lack	 of	 specific	 biological	 markers,	 results	 in	 a	 late	
diagnosis	 and	 high	 mortality	 rates.139,164	 Prompt	 and	 early	 intervention	 is	 vital	 to	 reduce	 the	 associated	
morbidity	and	mortality.165	I	hypothesise	that	that	online	rsMD	can	be	effectively	utilised	in	the	monitoring	
of	 patients	 undergoing	major	 GI	 surgery,	 for	 the	 early	 detection	 of	 post-operative	 complications	 such	 as	
anastomotic	 leaks.	The	frequent	use	of	 intra-abdominal	drains	after	major	GI	surgery	allows	easy	and	safe	
access	 to	 sample	 the	 peritoneal	 environment.	 Therefore,	 an	 ex-vivo	microdialysis	 protocol	 for	 peritoneal	
lactate	quantification,	by	sampling	drain	 fluid	can	potentially	replicate	the	results	demonstrated	by	 in-vivo	
studies,	thereby	mitigating	the	need	for	microdialysis	catheters	in	the	initial	phase.	Sampling	a	small	volume	
of	fluid	from	a	surgical	drain,	exposes	the	patient	to	minimal	risk	and	complication,	whilst	providing	valuable	
data	as	to	the	biochemical	processes	taking	place	within	the	surgical	field.	Positive	correlations	would	allow	
me	 to	 design	 the	 second	 phase	 in	 this	 investigation,	 utilising	 in-vivo	monitoring.	 It	 is	 likely	 that	multiple	
studies	are	required	to	prove	my	hypothesis.	Therefore,	my	primary	aim	was	to	perform	an	initial	feasibility	
study	where	I	sample	peritoneal	fluid,	examine	peritoneal	lactate	profiles	of	patients	undergoing	GI	surgery	
and	 correlate	 these	 findings	 with	 clinical	 progress	 and	 the	 development	 of	 post-operative	 complications	
such	 as	 anastomotic	 leaks.	 Whilst	 the	 early	 detection	 of	 anastomotic	 leaks	 following	 GI	 surgery,	 is	 the	
primary	 focus	 of	 this	 research,	 post-operative	 complications	 as	 a	 collection	 of	 clinical	 entities	 are	 both	
commonplace	 and	 associated	 with	 significant	 morbidity.	 Therefore,	 complications	 such	 as	 infective	
collections,	 iatrogenic	 injuries,	 ileus	 and	 haematomas	 are	 clinically	 important	 and	 warrant	 further	
investigation.	This	experiment	is	a	feasibility	study	and	the	results	will	allow	me	to	determine	the	suitability	
of	progressing	to	in-vivo	clinical	studies	with	the	rsMD.	In	light	of	the	exploratory	nature	of	this	study,	 it	 is	
appropriate	 to	 expand	 the	 clinical	 outcomes	 under	 investigation	 to	 consider	 different	 post-operative	
complications.	There	currently	exists	no	validated	protocol	 for	peritoneal	 lactate	quantification	 in	patients	
undergoing	 major	 GI	 surgery,	 therefore	 my	 secondary	 aim	 is	 to	 establish	 and	 validate	 an	 ex-vivo	
microdialysis	protocol	for	peritoneal	lactate	quantification.	This	will	allow	for	further	future	examination	and	
concordance	with	in-vivo	microdialysis	monitoring	of	complications	such	as	anastomoses.	
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4.2 METHODOLOGY	
4.2.1 Ethical	approval	
The	 study	 protocol	 was	 approved	 by	 the	 St.	 Mary’s	 Hospital	 Local	 Regional	 Ethics	 Committee	 (Ref:	
06/Q0403/160).	
4.2.2 Study	design	
This	was	a	prospective	observational	study	recruiting	eligible	patients	from	the	General	Surgery	department	
of	St	Marys	Hospital,	London,	UK.	I	aimed	to	recruit	20	patients	into	this	study	over	a	three-month	period.	
Eligibility	 criteria	 consisted	of	patients	undergoing	emergency	or	elective,	upper	or	 lower	GI	 surgery.	Only	
patients	who	were	deemed	 likely	 to	have	 a	GI	 anastomoses	 created	 and	 an	 intra-abdominal	 drain	placed	
were	 recruited	 into	 the	 study.	 All	 eligible	 patients	 were	 enrolled	 after	 written	 informed	 consent	 was	
obtained.	A	copy	of	the	consent	document	(see	appendix)	was	given	to	the	patient	and	a	copy	was	retained	
by	 the	 author.	 The	 final	 copy	 was	 not	 filed	 in	 the	 notes	 until	 after	 the	 procedure	 had	 been	 completed.	
Operating	 surgeons	were	 not	 informed	 of	 a	 patient’s	 involvement	with	 the	 study,	 to	 prevent	 the	 study’s	
protocol	 from	 unduly	 affecting	 the	 surgical	 procedure.	 Peri-operative	 management	 and	 surgical	 decision	
making,	in	terms	of	whether	the	surgeon	decided	to	create	an	anastomosis	or	insert	a	drain,	was	completely	
independent	of	the	researchers.	All	consultant	surgeons	had	been	approached	prior	to	the	commencement	
of	 the	 study	period,	were	aware	of	 the	 study	protocols	 and	had	given	permission	 for	 their	patients	 to	be	
involved.	 They	 were	 not	 aware	 of	 which	 individual	 patients	 were	 recruited.	 Recruited	 patients	 who,	
following	 the	 procedure,	 did	 not	 have	 a	GI	 anastomoses	 created	 or	 intra-abdominal	 drains	 inserted	were	
excluded	 in	 the	post-operative	period.	All	 patients	 received	general	 anaesthesia	 regimens	 in	 keeping	with	
local	policies	and	post-operative	management	of	each	patient	was	consistent	with	departmental	protocols.	
Recruited	patients	were	monitored	daily,	following	their	procedures	until	discharge.	Patients	admitted	under	
the	emergency	surgical	team	were	cross-referenced	with	recruited	patients	that	were	discharged,	to	identify	
any	 study	 participants	 that	 may	 have	 been	 re-admitted	 with	 potential	 complications.	 Key	 demographics	
were	documented	for	all	participants.	Clinical	information	such	as	pulse	rate,	blood	pressure,	temperature,	
oxygen	saturation,	blood	test	results,	reports	of	radiological	investigations,	surgeon’s	clinical	notes	and	the	
development	 of	 complications	 were	 all	 prospectively	 documented	 using	 a	 standardised	 pro-forma	
specifically	 designed	 for	 this	 study	 (see	 Figure	 99).	 Participant’s	 demographics	 and	 clinical	 data	 were	
anonymised	by	utilisation	of	patient	specific	codes,	thereby	maintaining	confidentiality	of	all	patients.		
The	diagnosis	of	post-operative	complications	was	made	by	 the	 surgeons	and	documented	 in	 the	medical	
notes.	 Post-operative	 complications	 were	 graded	 using	 the	 Clavien-Dindo	 classification	 of	 surgical	
complications,	by	the	author	and	recorded	in	the	data	collection	sheet.138	
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Figure	99	–	Example	of	the	standardised	pro-forma	used	to	collect	patient	demographics	and	to	chart	clinical	progress	
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4.2.2.1 Sample	collection	
Peritoneal	drain	 fluid	was	sampled	from	 intra-abdominal	drains.	Sampling	took	place	every	6	hours	during	
the	day,	 and	every	12	hours	 through	 the	night,	 resulting	 in	4	 samples	 in	a	24-hour	period.	This	 collection	
protocol	was	considered	satisfactory	for	potential	detection	of	trends,	whilst	maintaining	practicality	for	the	
investigators	 and	 ensuring	 minimal	 disruption	 to	 patients	 and	 nursing	 staff.	 Drains	 were	 sampled	
immediately	post-operatively	and	until	the	drain	was	removed.	The	decision	to	remove	the	intra-abdominal	
drain	 was	 taken	 by	 the	 surgeons.	 Following	 sampling,	 vials	 containing	 the	 drain	 fluid	 was	 labelled,	
catalogued	and	frozen	at	–80oC	for	further	batch	analysis.	
4.2.2.2 Ex-vivo	microdialysis	protocol	
Prior	 to	analysis,	 samples	were	 thawed	at	ambient	 room	temperature	 (25OC-27OC).	Each	sample	was	 then	
centrifuged	at	3000	RPM	for	12	minute	to	separate	all	cellular	debris.	A	standardised	ex-vivo	microdialysis	
protocol	was	designed	and	developed	for	the	analysis	of	drain	samples,	by	utilisation	and	modification	of	an	
in-vivo	 microdialysis	 methodology.	 In	 typical	 fashion,	 the	 microdialysis	 inlet	 tubing	 was	 attached	 to	 the	
perfusion	pump	whilst	 the	outlet	was	attached	 to	 the	 rsMD	assay.	The	 tip	of	 the	microdialysis	probe	was	
suspended	 in	 the	 drain	 samples.	 Samples	 were	 slowly	 stirred	 using	 magnetised	 stirrers,	 allowing	 even	
distribution	 and	 efficient	 sampling	 of	 lactate	 molecules.	 Analysis	 took	 place	 in	 tubular	 glass	 vials	 with	 a	
custom	drilled	hole	in	the	caps	to	allow	insertion	of	the	microdialysis	probe.	The	ex-vivo	assay	is	illustrated	
below	Figure	100.	
	
Figure	100	–	Custom	design	of	the	ex-vivo	microdialysis	assay	setup	
Illustration	by	author	-	SD	
A	perfusion	rate	of	1.5ml/min	was	chosen	after	initial	experiments	demonstrated	a	Relative	Recovery	(RR)	of	
72%	whilst	still	allowing	for	reasonably	fast	analysis.	RR	was	calculated	by	using	a	2mM	lactate	solution	at	
Perfusion	fluid	 Analyser
Microdialysis	
probe
Drain	fluid
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the	adopted	perfusion	rate	at	room	temperature.	The	percentage	proportion	of	the	concentration	of	lactate	
recovered	was	equal	to	the	RR	of	the	probe.	
Peritoneal	drain	fluid	analysis	took	place	in	batches,	each	containing	multiple	sample	of	drain	fluid.	This	was	
a	more	 efficient	 process,	 and	 it	 allowed	 for	 the	 standardisation	 of	 analysis	 and	 reduction	 of	 errors.	 Each	
batch	analysis	took	place	on	different	days,	and	therefore	prior	to	this	enzyme	beds	were	replaced	and	the	
assay	calibrated	with	standards	of	known	concentrations	of	lactate	(0.5mM,	1mM	and	2mM).	
For	 each	 known	 concentration	 of	 lactate,	 the	 corresponding	 amplitude	 of	 the	 current	 detected	 at	 the	
electrode	was	recorded.	This	was	repeated	5	times	for	each	concentration	and	the	mean	of	these	values	was	
recorded.	
Linear	regression	of	dialysate	lactate	concentrations	versus	the	corresponding	mean	amplitude	of	detected	
current	provided	a	linear	equation.	As	described	in	Chapters	2	and	3,	the	gradient	of	this	correlation	is	the	
conversion	factor	of	amplitude	to	concentration	of	analyte.	Figure	101	illustrates	the	calibration	data	for	the	
8	 batch	 analyses	 that	were	 performed.	 Figure	 102	 demonstrates	 a	 single	 sample	 lactate	 calibration	 trace	
with	linear	regression.	
	
Figure	101	-	Calibration	data	for	each	batch	analysis	
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Current	(μA)
0.5 0.708 0.5 0.696 0.5 0.548 0.5 0.442
1 1.396 1 1.193 1 1.035 1 0.842
2 2.612 2 2.132 2 2.087 2 1.589
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0.5 0.369 0.5 0.895 0.5 0.373 0.5 0.271
1 0.794 1 1.903 1 0.736 1 0.536
2 1.643 2 3.218 2 1.484 2 1.038
	Analysis	Batch	8	Analysis	Batch	7	Analysis	Batch	6	Analysis	Batch	5
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Figure	102	–	Batch	1	–	Lactate	calibration	trace	with	linear	regression	
4.2.2.3 Materials	
A	high	grade,	 commercially	 available,	 10	mm	membrane	microdialysis	probe	 (MAB	11.35.4,	Microbiotech,	
Stockholm,	 Sweden)	 was	 utilised	 in	 this	 study.	 Perfusion	 was	 facilitated	 by	 utilising	 a	 high	 performance,	
microdialysis	pump	(CMA	400	pump;	CMA	microdialysis	AB,	Stockholm,	Sweden)	with	isotonic	T1	perfusate	
solution	(CMA	microdialysis	AB,	Stockholm,	Sweden).	The	perfusate	contained	147mM	Na,	4mM	K,	2.3mM	
Ca	and	156mM	Cl.	
4.2.2.4 Protocol	validation	
With	the	ex-vivo	microdialysis	protocol,	sampling	of	peritoneal	lactate	fluid	may	potentially	take	place	many	
hours	 after	 the	 fluid	 is	 sequestered	 into	 the	 peritoneum	 and	 subsequently	 into	 the	 drain.	 There	 is	 also	
approximately	one	hour	between	the	thawing	and	analysing	of	the	sample.	There	was	a	concern	that	these	
two	 lags	may	 introduce	errors	 in	 the	 results	 due	 to	enzyme	or	bacterial	 breakdown	of	 lactate	during	 this	
period.	 To	 address	 this	 potential	 imitation,	 a	 protocol	 validation	 experiment	was	developed	 to	 assess	 the	
stability	 of	 peritoneal	 lactate	 in	 the	 ex-vivo	 setting.	 Two	 samples	 of	 drain	 fluid	 were	 left	 at	 room	
temperature	 and	 their	 lactate	 concentrations	 measured	 hourly	 for	 6	 hours	 using	 the	 adopted	 analysis	
parameters	of	room	temperature	and	perfusion	rate	of	1.5µL/min.	Figure	103	shows	the	peritoneal	lactate	
concentrations	over	the	6	hours	of	monitoring.	The	results	demonstrate	that	the	peritoneal	dialysate	lactate	
concentration	 remained	 stable	 throughout	 period	 of	 monitoring.	 All	 drain	 samples	 for	 patients	 recruited	
were	analysed	within	this	time	period	of	6	hours.	
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Figure	103	–	Ex-vivo	protocol	validation	–	Test	Sample	1	&	2	
Measuring	the	peritoneal	lactate	concentration	(mM)	
4.2.2.5 Statistical	analyses	
As	 this	 was	 a	 feasibility	 study	 and	 exploratory	 in	 nature,	 it	 was	 deemed	 that	 a	 power	 calculation	 was	
unnecessary.	Data	analysis	was	performed	using	Microsoft	Excel	for	Mac	and	SPSS	version	16	for	Windows.	
Absolute	 dialysate	 lactate	 concentration	 for	 each	 patient	were	 initially zeroed	 to	 allow	 demonstration	 of	
changes	 and	 account	 for	 variability	 from	 baseline	 concentrations.	 This	was	 performed	 by	 subtracting	 the	
starting	concentration	from	all	subsequent	values.	
Results	 are	 displayed	 as	 a	 median	 of	 the	 concentration	 or	 median	 change	 in	 concentrations.	 Baseline	
characteristics	 between	 each	 cohort	 were	 compared	 using	 Welch	 Two	 Sample	 t-test	 for	 the	 numerical	
variables	and	Fishers	exact	test	for	the	nominal	variables.	Any	observed	trends	were	modelled	using	linear	
regression.	A	Wald	t-test	was	utilised	to	confirm	that	time	variables	had	a	significant	effect	on	changes	in	the	
lactate	concentration.	To	allow	fitting	of	the	ideal	representative	model	to	the	dataset,	analysis	of	variance	
(ANOVA)	 was	 utilised	 to	 compare	 simple	 linear,	 quadratic	 and	 cubic	 linear	 regression	 models.	 A	 best-fit	
model	was	used	based	on	observed	significance,	whilst	Mann	Whitney	U-test	was	employed	to	compare	the	
first	 post-operative	 day’s	 median	 concentration	 between	 each	 group.	 In	 our	 study	 a	 P<0.05	 value	 was	
considered	statistically	significant.	
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4.4 RESULTS	
As	per	my	original	research	proposal,	 I	aimed	to	recruit	20	patients	 into	this	study.	 I	 initially	approached	a	
total	 of	 33	 patients.	 Several	 patients	 (n=7)	 consented	 to	 being	 enrolled	 into	 the	 study	 and	 subsequently	
underwent	their	surgical	procedures,	however	it	was	not	deemed	necessary	to	either	create	an	anastomosis	
or	 insert	an	intra-abdominal	drain.	These	patients	were	consequently	excluded	from	the	study	in	the	post-
operative	 period.	 	 Another	 patient	 (n=1)	 meeting	 the	 criteria	 for	 eligibility	 and	 having	 consented	 to	
participate,	 was	 also	 excluded	 in	 the	 early	 post-operative	 period,	 as	 the	 surgical	 drain	 was	 accidentally	
removed	by	a	member	of	the	nursing	staff.	One	patient	who	was	approached	felt	anxious	and	decided	not	to	
participate	 in	 the	 research	 study.	 Two	 patients	who	met	 the	 initial	 criteria	 and	were	 initially	 approached	
were	 acutely	 confused	 and	 it	was	 therefore	 decided	 inappropriate	 to	 attempt	 to	 consent	 these	 patients.	
Several	 patients	 (n=3)	 had	 their	 procedures	 cancelled	 on	 the	 day	 despite	 consenting	 to	 participate	 in	 the	
research	study.		
All	 the	 patients	 that	were	 approached	 and	 considered	 for	 enrolling	within	 the	 study	 and	 the	 subsequent	
study	outcomes	for	each	patient	are	shown	below.	
Excluding	 several	of	 the	patients	discussed	previously,	 I	 recruited	a	 total	of	19	patients.	All	 these	patients	
(n=19)	 were	 eligible	 to	 partake,	 consented	 and	 proceeded	 to	 a	 surgical	 procedure	 that	 resulted	 in	 a	 GI	
anastomosis	and	had	intra-abdominal	drains	inserted.	These	patients	were	monitored	in	the	post-operative	
period	and	underwent	drain	sampling,	as	per	our	research	protocol.	Table	31	presents	a	summary	of	the	19	
patients	 recruited	 into	 the	 study,	 providing	 basic	 demographics,	 diagnosis	 and	 surgical	 procedure	 carried	
out,	type	of	anastomosis	carried	out,	number	of	drains	and	the	total	monitoring	length.	
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Table	30	–	All	patients	approached	and	study	outcomes	
Patient Eligible?
Consent	
given?
Enrolled	
in	study?
Proceed	to	
surgery?
Drain	
inserted?	
Anastamosis
created?	
201103021200SMHDO
Monitoring	
commenced?
Data	
analysed?	
Incorporated	
into	thesis? Other	details
201103030815SMHDO
201103066534SMHDO
201103080915SMHDO
2011030806738MHDO
201103080830SMHDO
201103099012SMHDO
201103092000SMHDO
201103101800SMHDO
201103146236SMHDO
201103171030SMHDO
201103216743SMHDO
201103225609SMHDO
201103210730SMHDO
201103127743SMHDO
201103110937SMHDO
201103107710SMHDO
201103101045SMHDO
201103230800SMHDO
201103241400SMHDO
201103215189SMHDO
201103034199SMHDO
201103311000SMHDO
201103261209SMHDO
201104061000SMHDO
201104071372SMHDO
201104031678SMHDO
201104071015SMHDO
201104161000SMHDO
201104161005SMHDO
201104180943SMHDO
201104193001SMHDO
201104201000SMHDO
No	anastomosis
Procedure	cancelled
Refused	consent
Acutely	confused
Drains	removed	prematurely
No	anastomosis
No	drain	inserted
No	drain	inserted
Procedure	cancelled
No	drain	inserted
Acutely	confused
No	anastomosis
Procedure	cancelled
No	drain	inserted
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Table	31	–	Summary	of	recruited	patient's	demographics
Patient Gender Age Diagnosis Surgical	Procedure Anastomosis	type Co	morbidities
No.	of	
drains
Monitoring	
period	
(days)
No.	of	
samples
1 M 80 Mid-transverse	colon	carcinoma Subtotal	colectomy	+	loop	ileostomy Ileo-rectal GORD 1 8 16
Marfan's	syndrome
Epilepsy
3 M 62 Mid	rectal	carcinoma Low	anterior	resection	+		loop	ileostomy Rectal Smoker 1 7 14
Hypertension
Hepatitis	B
Smoker
COPD
Asthma
Ischaemic	heart	disease
6 F 80 Complicated	sigmoid	diverticular	disease Laparoscopic	anterior	resection	+		loop	ileostomy Rectal Ischaemic	heart	disease 3 4 6
Atrila	fibrilation	
Hypertension
CKD
8 M 66 Oesophageal	adenocarcinoma Ivor	Lewis	Oesophagectomy Oesophageal High	cholesterolaemia 1 6 11
NIIDM
Hypertension
10 F 78 Metastatic	colon	carcinoma	-	small	bowel	deposits Small	bowel	resection Small	bowel Lung	metastases 1 4 9
Paget's	disease
Atrila	fibrilation	
Hiatus	hernia
AAA
PVD
COPD
NIDDM
Hypertension
Asthma
14 M 75 Low	rectal	carcinoma Ultra	low	anterior	resection	+		loop	ileostomy Rectal Smoker 1 4 7
15 F 67 Mid	rectal	carcinoma Low	anterior	resection	+		loop	ileostomy Rectal 1 3 6
IDDM
Hypertension
COPD
Autoimmune	haemolytic	anaemia
Asthma
Smoker
Ischaemic	heart	disease
Atrila	fibrilation	
Hypertension
Hypertension
NIDDM
1 3 619 F 74 Mid	rectal	carcinoma Open	anterior	resection	+	loop	ileostomy Rectal
8
17 M 74 Gastric	adenocarcinoma Total	gastrectomy		+	Roux	-en	-Y	&	D2	radical	lymphadenectomy Oesophago-jejunal 3 7 38
7 15
12 M 83 Gastric	adenocarcinoma Subtotal	gastrectomy	&	D2		lymphadenectomy Gastro-jejunal 2 3
1
18 M 46 Metastatic	colon	carcinoma	-	Pelvic	wall	deposits	 Open	small	bowel	resection	&	appendicectomy Small	bowel 1
26
11 M 79 Low	rectal	carcinoma Ultra	low	anterior	resection	+		loop	ileostomy Rectal 4 6
7 14
7 F 80 Gastric	adenocarcinoma Subtotal	gastrectomy	&	D2		lymphadenectomy Gastro-jejunal 3 6
1 3 6
5 F 72 Low	rectal	carcinoma Ultra	low	anterior	resection	+		loop	ileostomy Rectal 1
4 F 58 Appendiceal	adenocarcinoma Right	hemicolectomy Colonic
9
16 M 58 Diverticular	stricture	of	colon Open	anterior	resection	+	loop	ileostomy Rectal 1 3 5
5 11
13 F 51 Low	rectal	carcinoma ultra	low	anterior	resection	(anal	verge)	+	defuntioning	ileostomy Rectal 1 5
3 11 26
9 F 74 Low	rectal	carcinoma Ultra	low	anterior	resection	+		loop	ileostomy Rectal 1
2 M 51 Oesophageal	adenocarcinoma Ivor-Lewis	oesophagectomy	&	lymphadenectomy Gastro-oesophageal
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Results	from	the	19	patients	are	reported	below.	52.6%	of	the	study	participants	were	male	(n=10).	
The	mean	age	of	all	participants	was	69.	A	 total	of	239	samples	of	peritoneal	 fluid	were	collected	
from	19	patients,	with	a	mean	of	13	samples	per	patient.	Each	sample	was	analysed	three	times,	the	
results	were	 recorded	and	 the	mean	calculated	 for	each	 sample.	A	 total	of	717	 separate	analyses	
were	done.	The	patients’	data	was	analysed	into	two	defined	groups.	The	presence	of	complications	
and	the	absence	of	complications.	This	distinction	was	made	according	to	the	previously	discussed	
Clavien-Dindo	classification	for	surgical	complications.	138	
Nine	 patients	 in	 total	 (n=9,	 47%)	 developed	 post-operative	 complications,	 the	 remaining	 patients	
had	uncomplicated	post-operative	 recoveries.	 	Baseline	 characteristics	 for	 the	 two	defined	groups	
are	 shown	 in	Table	32,	whilst	 Table	33	below	displays	 the	patients	 that	developed	post-operative	
complications,	the	associated	surgical	procedure,	the	Clavien-Dindo	grading	of	the	complication	and	
treatment	outcome.		
	
Table	32	–	Data	expressed	as	means	and	proportions	
Statistical	testing:	Welch’s	T-test	and	Fishers	exact	test	
Patient characteristics
Complications	
(n=9)
No-complications	
(n=10)
Mean Age (Range) P=0.194 65.2	± 10 75	± 12
Gender (%)P=1.00 Male 5	(55.6) 5	(50)
Female 4	(44.4) 5	(50)
Indication for surgery [n (%)]
P=0.370
Oesophageal adenocarcinoma 2	(22.2) 0	(0)
Gastric adenocarcinoma 1	(11.1) 2	(20)
Appendiceal Adenocarcinoma 1	(11.1) 0	(0)
Diverticular disease 0	(0) 2	(20)
Colon cancer 1	(11.1) 3	(30)
Rectal adenocarcinoma 4	(44.4) 3	(30)
Surgical procedure [n (%)]
P=0.598
Ivor Lewis Oesophagectomy 2	(22.2) 0	(0)
Gastrectomy 1	(11.1) 2	(20)
Low anterior resection 5	(55.6) 5	(50)
Hemicolectomy 1	(11.1) 0	(0)
Subtotal colectomy 0	(0) 1	(10)
Small bowel resection 0	(0) 2	(20)
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Table	33	–	Summary	of	patients	that	developed	post-operative	complications	and	the	outcome	
In	 consideration	of	one	 the	original	 study	objectives,	 to	 correlate	peritoneal	 lactate	 concentration	
with	 the	 development	 of	 post-operative	 complications,	 coupled	with	 the	 fact	 that	 there	was	 only	
one	confirmed	case	of	an	anastomotic	leak,	I	analysed	the	data	from	this	study	into	two	groups:	the	
presence	of	complications	and	the	absence	of	complications.	
I	 compared	 the	peritoneal	dialysate	 lactate	concentrations	 in	 the	 first	24	hours,	by	pooling	all	 the	
patient	 data	 in	 to	 their	 respective	 groups,	 at	 6	 hourly	 time	 intervals.	 The	 results	 can	 be	 seen	 in	
Figure	 104.	 There	 was	 no	 significant	 difference	 between	 the	 complication	 group	 and	 non-
complication	group	in	the	first	24	hours,	when	sampling	peritoneal	lactate	concentrations.	P	values	
of	P=0.323,	P=0.926,	P=0.270,	P=0.503	were	obtained	and	confirm	this	finding.	Examining	the	data	
further,	 there	 appears	 to	 be	 great	 inter-patient	 variability	when	 utilising	 absolute	 concentrations,	
which	 restricts	 our	 ability	 to	 inspect	 for	 correlations	 between	 the	 two	 groups	 and	 hence	 draw	
meaningful	 conclusions.	 A	 more	 appropriate	 method	 of	 examining	 the	 peritoneal	 lactate	
concentration	data	would	be	to	calculate	the	change	in	concentration.	This	can	be	done	by	‘zeroing’	
the	 initial	 concentration,	 thereby	 establishing	 a	 baseline,	 and	 subsequently	 subtracting	 this	 value	
from	successive	concentrations.		The	results	of	this	analysis	can	be	seen	in	Figure	105.	
Patient	
No.
Procedure Complication
Clavien	
Dindo	
Grade
Outcome
2 Oesophagectomy Pneumonia 2 Treated with IV antibiotics
3 Low anterior resection Anastomotic leak 3a Radiological drainage
4 Right Hemicolectomy Pneumonia 2 Treated with IV antibiotics
5 Ultra-low anterior resection Wound infection 2 Treated with IV antibiotics
9 Ultra-low anterior resection Intra-abdominal collection 3a Radiological drainage
11 Ultra-low anterior resection Ileus 1 Conservatively managed
13 Low anterior resection Wound dehiscence 3b Theatre for washout & closure
17 Subtotal gastrectomy Sub- clinical leak 3a Radiological drainage
19 Low anterior resection Ileus 1 Conservatively managed
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Figure	104	–	Pooled	peritoneal	lactate	concentration	at	6	hourly	intervals,	over	the	first	post-operative	day	
Comparisons	via	Mann	Whitney	U	test.	P>0.05	for	both	groups	
	
Figure	105	–	Median	change	in	lactate	concentration	during	post-operative	period	
Best	 fitting	 model	 fitted	 after	 comparison	 using	 ANOVA	 without	 forcing	 through	 zero.	 Complications	 =	 quadratic	 model,	 No	
complications	=	simple	linear	model	
0
2
4
6
8
10
12
14
16
18
20
0 0 6 6 12 12 24 240 6 12 24
Time	(hours)
La
ct
at
e	
(m
M
)
2
6
No	complicaton
Complication
Max	outlier
P	=	0.323
P	=	0.926
P	=	0.270 P	=	0.503
Pooled	peritoneal	lactate	concentration
Complications	vs	No	complications
-3
-2
-1
0
1
2
3
0 20 40 60 80 100 120
Time	(hours)
M
ed
ia
n	
ch
an
ge
	in
	la
ct
at
e	
co
nc
en
tr
at
io
n	
(m
M
)
-2
-1
0
1
2
No	complicaton
Complication
Median	changes	in	lactate	concentration
Complications	vs	No	complications
-3
3
24 48 72 96 120
	 162	
Participants	in	the	no-complications	group	demonstrated	a	declining	linear	trend	in	their	peritoneal	
lactate	 concentrations	 over	 time	 as	 illustrated	 in	 Figure	 105	 in	 (R2	 =0.578).	 In	 contrast	 to	 this,	
patients	 in	 the	 complications	 group	 displayed	 an	 initial	 increasing	 trend	 followed	 by	 a	 gradual	
decline	 towards	 a	 steady	 state	 after	 48	 hours	 (R2=0.530).	 The	 direction	 of	 change	 suggested	 that	
lactate	increased	in	the	complications	group	and	decreased	in	“no-	complications”	group.	
Comparison	of	 change	between	peritoneal	 lactate	 concentrations,	 serum	C–reactive	protein	 (CRP)	
and	 serum	white	 cell	 count	 (WCC)	 in	 the	 complications	 groups	 showed	 that	both	 lactate	and	CRP	
rose	very	early	in	the	complicated	post-operative	period	(Figure	105)	The	fastest	rise	occurred	within	
the	first	post-operative	24	hours.	Lactate	appeared	to	rise	more	consistently	after	the	first	24	hours	
compared	to	CRP.	WCC	exhibited	a	delayed	response	to	complications	when	compared	to	lactate	(48	
hours	late).		
One	 definite	 case	 of	 anastomotic	 leakage	with	 abdominal	 collection	was	 encountered	 during	 the	
study	 period.	 The	 patient	 developed	 a	 symptomatic	 leak	 following	 a	 lower	 anterior	 resection	 for	
rectal	adenocarcinoma.	Symptomatic	presentation	(fever	and	abdominal	pain)	occurred	on	the	6th	
post-operative	day.	The	 leakage	was	 later	diagnosed	 radiologically	on	 the	10th	post-operative	day	
via	 CT	 scan	 and	 contrast	 studies.	A	 rise	 in	 peritoneal	 dialysate	 lactate	was	 apparent	 from	 the	3rd	
post-operative	 day	 onwards	 (Figure	 106).	Unfortunately,	 the	 drain	was	 removed	 on	 the	 5th	 post-
operative	day	hence	no	peritoneal	dialysate	samples	were	collected	during	the	symptomatic	period.	
Nevertheless,	 the	 observed	 lactate	 rise	 occurred	 7	 days	 before	 diagnosis,	 a	 deviation	 from	 the	
previously	declining	trend.	
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Table	34	–	Median	change	in	lactate	and	inflammatory	markers	during	complicated	post-operative	period	
Y-axis	on	right	belongs	to	CRP.	
	
Figure	106	–	Lactate	concentration	patterns	in	a	case	of	anastomotic	leak	
62-year-old	male,	post	low	anterior	resection.	Arrow	indicates	point	of	symptomatic	presentation.	Radiological	diagnosis	was	made	on	
post-operative	day	10.	
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4.5 DISCUSSION	
Numerous	 studies	 have	 sought	 biomarkers	 that	 can	 aid	 the	 early	 detection	 of	 post-operative	
complications.171	 There	 has	 been	 recent	 interest	 in	 peritoneal	 lactate	 as	 one	 such	 biomarker.	 The	
present	 study	 aimed	 to	 investigate	 peritoneal	 lactate	 concentration	 patterns	 during	 the	 post-
operative	period.	The	study	demonstrated	that	lactate	concentrations	exhibited	an	initial	increasing	
trend	during	 complicated	post-operative	 course,	 in	 contrast	 to	a	declining	 trend	 in	uncomplicated	
cases.	 This	 highlights	 potential	 for	 intra-patient	 lactate	 concentration	 changes	 to	 serve	 as	 a	
prediction	 or	 early	 warning	 system	 for	 post-operative	 complications.	 Comparison	 of	 lactate	
concentration	changes	to	that	of	serum	inflammatory	markers	during	complications	also	suggests	a	
comparable	predictive	ability	between	lactate	and	CRP	and	a	superior	responsiveness	compared	to	
WCC.	
An	increase	in	lactate	concentration	preceded	symptomatic	presentation	and	diagnosis	in	a	reported	
case	 of	 anastomotic	 leakage	 thereby	 highlighting	 a	 potential	 predictive	 ability	 for	 peritoneal	
dialysate	 lactate	 in	 anastomotic	 leak	 cases.	 Acquired	 results	 also	 suggest	 that	 absolute	 lactate	
concentrations	 are	 unhelpful	 in	 predicting	 post-operative	 complications	 due	 to	 lack	 of	 significant	
difference	between	complications	and	‘no-complications’	groups.	Also,	high	inter-patient	variability	
in	baseline	concentrations	precludes	such	prediction.	In	addition,	an	ex-	vivo	microdialysis	protocol	
for	 peritoneal	 lactate	 measurement	 was	 successfully	 developed	 during	 the	 study.	 The	 main	
modification	 applied	 to	 the	 template	 in-vivo	 technique	 was	 also	 validated.	 The	 feasibility	 of	 this	
protocol	 is	 apparent	 in	 the	 precision	 of	 acquired	 results	 both	 during	 protocol	 validation	 and	
peritoneal	sample	analysis.	
Due	to	the	exploratory	nature	of	the	present	study,	there	are	very	few	precedent	peritoneal	lactate	
studies	 with	 which	 the	 study	 findings	 can	 be	 compared.	 However,	 all	 the	 trends	 and	 changes	
observed	 in	 this	 study	 are	 in	 agreement	 with	 reported	 findings	 from	 human	 intraperitoneal	
microdialysis	 studies.	 This	 was	 despite	 the	 relatively	 poor	 time	 resolution	 in	 peritoneal	 lactate	
monitoring.167	While	this	observation	was	initially	surprising,	it	does	make	sense	in	the	context	of	the	
protocol	 validation	 results.	 Peritoneal	 lactates	 stability	over	6	hours	 indicates	 that	 time	 resolution	
may	not	be	paramount	when	monitoring	peritoneal	 lactate.	Also,	 the	 rising	 trend	observed	 in	 the	
complications	group	is	in	concordance	with	aforementioned	peritoneal	lactate	study	by	DeLaurier	et	
al.172		
A	 thorough	 search	 of	 the	 literature	 produced	 no	 previous	 studies	 in	which	 changes	 in	 peritoneal	
dialysate	 lactate	 has	 been	 compared	 to	 or	 investigated	 alongside	 that	 of	 serum	 inflammatory	
markers.	 The	 observed	 early	 CRP	 rise	 in	 response	 to	 complications	 is	 well	 supported	 in	 medical	
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literature.	 CRPs	 utility	 for	 early	 detection	 of	 post-operative	 complications	 has	 also	 been	
demonstrated.	However,	its	main	disadvantage	is	poor	specificity.	For	peritoneal	lactate	monitoring	
to	be	considered	superior,	 its	 specificity	 to	GI	 complications	needs	 to	be	demonstrated.	This	 is	an	
important	aim	for	future	studies.	WCC,	on	the	other	hand,	has	been	shown	to	be	poorly	sensitive	to	
post-operative	complications.		
It	 is	 important	 to	 understand	 the	 likely	 reasons	 behind	 the	 observed	 changes	 in	 lactate	
concentration	 as	 this	may	 help	 guide	 future	 study	 designs.	 Lactate	 is	 produced	 from	 pyruvate	 by	
lactate	 dehydrogenase	 during	 anaerobic	 respiration.	 Peritoneal	 lactate	 during	 the	 post–operative	
period	can	rise	in	response	to	both	inflammation	and	ischaemia.	Inflammation	is	a	driver	of	hyper-
metabolism	 which	 leads	 to	 increased	 energy	 requirements.	 This	 causes	 increased	 activation	 of	
glycolytic	 pathways	 and	 a	 simultaneous	 increase	 in	 pyruvate	 and	 lactate	 production.	 In	 contrast,	
ischaemia	causes	oxygen	deficiency	which	leads	to	preferential	conversion	of	pyruvate	to	lactic	acid.	
In	 this	 case,	 higher	 levels	 of	 lactate	 are	 observed	 in	 comparison	 to	 pyruvate.	 GI	 surgery	 usually	
involves	peritoneal	trauma	and	blood	vessel	transections.	Therefore,	 lactate	 levels	rise	 in	response	
to	both	inflammation	and	ischaemia.	Since	different	surgical	procedures	involve	varying	amounts	of	
trauma	and	 ischaemia,	 this	may	explain	 the	variability	 in	baseline	 lactate	concentrations	observed	
during	the	first	post-operative	day.	
The	 present	 study	 focussed	 on	 lactate	measurements.	 Since	 lactate	 levels	 can	 rise	 in	 response	 to	
either	inflammation	or	ischaemia,	differences	in	ischaemia	can	be	masked	by	inflammation	(and	vice	
versa).	 The	 confounding	 influence	 of	 inflammation	 is	 most	 likely	 responsible	 for	 the	 lack	 of	
significant	differences	 in	 1st	 post-operative	peritoneal	 dialysate	 lactate	between	 the	 study	 groups.	
Verdant	 et	 al,	 in	 an	 in-vivo	 microdialysis	 study	 of	 similar	 design	 to	 the	 present	 study,	 observed	
increased	 lactate,	 (but	no	significant	difference)	 in	both	complications	and	no-complications	group	
when	lactate	concentrations	alone	were	compared.	However,	comparison	of	lactate/pyruvate	ratio	
identified	a	 significantly	higher	 ratio	 in	 the	 complicated	group.	The	 simultaneous	measurement	of	
pyruvate	 and	 lactate	 helps	 cancel	 out	 the	 effect	 of	 surgery-associated	 inflammation	 thereby	
rendering	 ischaemic	 differences	 between	 the	 study	 groups	 detectable.	 Absolute	 lactate	
concentrations	are	therefore	not	ideal	for	prediction	of	post-operative	complications.	
The	 interplay	 between	 inflammation	 and	 ischaemia	 also	 provides	 likely	 explanations	 for	 the	
observed	 time	 trends	 in	 lactate	concentration.	 Intraperitoneal	microdialysis	 study	by	 Janssen	et	al	
found	 a	 simultaneous	 reduction	 and	 correlation	 between	 peritoneal	 lactate/pyruvate	 ratio	 and	
cytokines	 during	 an	 uneventful	 post-operative	 course.256	 This	 suggests	 that	 as	 inflammatory	
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response	 to	 surgical	 trauma	attenuates,	hypermetabolic	 lactate	production	 reduces	 leading	 to	 the	
falling	trend	in	the	non-complications	group.	
Conversely,	 the	 rising	 peritoneal	 lactate	 trend	 in	 the	 complications	 group	 suggests	 ongoing	
ischaemia,	inflammation,	or	both.	These	are	recognised	risk	factors	for	post-operative	complications.	
Peritoneal	 cytokines	 also	 exhibit	 a	 similar	 trend	 during	 complications.	 This	 explains	 the	 rationale	
behind	 concurrent	 research	 interest	 in	 peritoneal	 cytokines	 potential	 to	 predict	 post-operative	
complications.	 The	 pre-symptomatic	 lactate	 rise	 in	 the	 presented	 anastomotic	 leak	 case	 further	
implicates	 ischaemia	 and	 inflammation	 in	 the	 pathophysiology	 of	 anastomotic	 dehiscence	 while	
corroborating	findings	in	in-vivo	studies.	
This	 study	 greatly	 benefited	 from	 regular	 sample	 collection	 especially	 since	 most	 studies	
investigating	 biomarkers	 in	 peritoneal	 fluid	 only	 sample	 once	 daily.	 Four	 samples	 were	 collected	
within	each	24-hour	period	in	this	study	thereby	allowing	more	opportunities	to	detect	trends	and	
capture	lactate	concentration	changes	during	the	post-operative	period.	
The	concordance	between	the	present	study	and	published	 in-vivo	studies	highlights	 the	potential	
for	regular	peritoneal	lactate	measurement	to	yield	similar	results	to	intra-peritoneal	microdialysis.	
It	 is	certainly	premature	to	make	concrete	conclusions.	However,	confirmation	of	these	findings	by	
larger	studies	may	lead	to	the	use	of	peritoneal	lactate	measurements	as	a	cheaper,	easier	and	more	
accessible	alternative	to	in-vivo	microdialysis.	Since	the	benefits	of	peritoneal	drainage	are	currently	
debated,	 such	 results	 may	 end	 up	 influencing	 opinions	 towards	 routine	 peritoneal	 drainage	
following	major	GI	surgery.	
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Chapter	5	-	Allograft	viability	
assessment	during	the	preservation	
period	utilising	online	rapid	sampling	
microdialysis	
Chapter	 5	 focuses	 on	 my	 final	 study	 within	 this	 thesis:	 allograft	 viability	 assessment	 during	 the	
preservation	 period	 utilising	 online	 rapid	 sampling	 microdialysis.	 I	 previously	 described	 the	
importance	of	 transplant	viability	assessment	and	have	set	 forth	my	aims	and	objectives	with	 this	
work.	In	this	chapter	I	provide	an	experimental	overview	of	the	various	sub-studies	that	I	designed	
and	carried	out.	I	detail	the	experimental	methodology,	retrieval	process	and	technologies	utilised.	I	
present	my	results	and	my	interpretation	of	these	results.	
	 	
	 168	
5 CHAPTER	5	-	ALLOGRAFT	VIABILITY	ASSESSMENT	DURING	
THE	PRESERVATION	PERIOD	UTILISING	ONLINE	RAPID	
SAMPLING	MICRODIALYSIS	
5.1 HYPOTHESES	&	AIMS	
There	exists	a	global	shortage	of	organs	available	for	transplantation,	with	the	number	of	people	on	
the	 waiting	 list	 continuously	 increasing	 and	 patients	 dying	 everyday	 whilst	 waiting	 for	 a	 suitable	
organ.	With	 this	 clinical	 impetus,	 renal	 transplant	programmes	have	 sought	 to	 increase	 the	donor	
pool	 by	 including	 ‘marginal’	 kidneys.	 Strategies	 are	 therefore	 needed	 to	 assess	 and	 potentially	
modify	 the	 parenchymal	 environment	 of	 organs	 from	 ‘marginal’	 donors,	 allowing	 the	 surgeon	 to	
stratify	potential	outcomes	and	 improve	graft	 survival.	Hypothermic	machine	perfusion	 (HMP)	has	
possible	advantages	for	the	preservation	of	kidneys	compared	to	static	cold	storage	(SCS),	resulting	
in	 improved	 immediate	 post-transplant	 graft	 function,	 better	 survival	 rates	 and	 superior	
preservation	of	microcirculatory	integrity.191,248,249	At	present,	there	are	no	accepted	indicators	that	
can	determine	organ	viability	and	potential	post-operative	function	before	an	organ	is	transplanted	
and	12-18%	of	kidneys	are	discarded	due	 to	concerns	about	 their	 suitability	 for	 transplantation.	A	
comprehensive	 assessment	 of	 both	 renal	 tissue	 viability	 and	 ex	 vivo	 function	 during	 preservation	
would	facilitate	a	greater	level	of	discrimination	in	identifying	those	organs	which	are	at	higher	risk	
of	delayed	graft	function	and	would	enable	a	more	accurate	selection	of	kidneys	which	are	suitable	
for	transplantation.		
I	hypothesise	that	online	rapid	sampling	microdialysis	can	be	utilised	for	organ	viability	assessment	
in	 the	preservation	period	with	 the	 real-time	measurement	of	parenchymal	 lactate	concentration,	
thereby	also	allowing	metabolic	profiles	to	be	demonstrated	during	both	SCS	and	HMP.	
My	aims	were	three-fold:		 	
1. Assess	the	use	of	cortical	lactate	concentration	as	a	biomarker	for	ischaemic	injury	with	a	view	
to	determining	the	potential	role	of	rsMD	in	the	viability	assessment	of	kidney	allografts	during	
preservation	
2. To	assess	 the	 feasibility	of	using	 rsMD	 to	monitor	 changes	 in	 lactate	 concentration	within	 the	
renal	cortex	and	medulla	during	SCS	and	HMP	in	a	porcine	model	
3. Once	 I	 have	 validated	 the	 technique	of	 online	 rsMD,	 I	 aim	 to	 compare	 the	effects	 of	 SCS	 and	
HMP	on	renal	cellular	metabolism	and	ischemia	during	the	preservation	period.		
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5.2 EXPERIMENTAL	OVERVIEW	–		SUB-STUDY	1	–	4	
My	primary	objective	is	to	develop	a	tool	that	allows	for	accurate	assessment	of	tissue	metabolism	
and	organ	viability	 in	the	preservation	period.	The	online	rsMD	analyser	 is	a	novel,	 fully	automatic	
custom	 built	 assay,	 that	 is	 capable	 of	 monitoring	 the	 metabolic	 markers	 of	 ischemia	 in	 high	
resolution	and	 in	 real	 time,	every	30	 seconds.	 	To	date,	no	such	system	has	been	used	 to	directly	
characterise	 the	 metabolic	 and	 ischaemic	 processes	 that	 take	 place	 in	 the	 allograft	 during	 the	
preservation	period.	Therefore,	I	hypothesise	that	the	rsMD	can	be	used	for	the	viability	assessment	
of	an	allograft	in	the	pre-transplantation	period.	In	order	to	prove	my	hypothesise,	I	have	designed	a	
series	of	four	experiments	that	will	provide	key	data,	experience	and	validation	of	an	ex-vivo	online	
rsMD	 protocol	 and	 potentially	 lead	 to	 future	 clinical	 in-vivo	 investigations.	 All	 four	 sub-studies	
employ	 an	 experimental	 porcine	 DCD	 renal	model	 to	 determine	 the	 feasibility	 of	 using	 the	 rsMD	
system	for	assessment	of	metabolic	and	ischaemic	profiles	using	an	ex-vivo	monitoring	protocol.	All	
experimental	monitoring	took	place	in	the	laboratories	of	Imperial	College	London,	UK.	
In	my	first	set	of	experiments,	sub-study	1,	I	tested	the	feasibility	of	using	the	rsMD	assay	to	detect	
and	monitor	renal	cortical	 lactate	concentrations,	as	a	marker	for	 ischaemic	injury.	 I	demonstrated	
the	 metabolic	 processes	 taking	 place	 in	 a	 freshly	 retrieved	 porcine	 kidney,	 by	 immediately	
implanting	 a	 microdialysis	 probe	 into	 the	 renal	 cortex.	 As	 the	 ischaemia	 developed,	 the	 rsMD	
detected	 and	 monitored	 cortical	 lactate	 concentrations,	 providing	 me	 with	 a	 baseline	 ischaemic	
profile	of	 renal	 cortical	 tissue.	The	methodology	and	 results	are	detailed	 later	 in	 this	 chapter.	The	
porcine	 kidneys	 in	 this	 sub-study	 were	 retrieved	 from	 a	 local	 animal	 research	 facility	 and	 then	
transported	back	to	the	laboratory	for	commencement	of	monitoring.	My	results	show	that	key	data	
was	lost	during	this	transit	period,	creating	a	clear	limitation	in	the	study.		
In	sub-study	2,	I	addressed	this	limitation	by	modifying	the	retrieval	process.	After	retrieval,	I	flushed	
the	 organs	 with	 cold	 preservation	 fluid	 and	 transported	 the	 organs	 packed	 on	 ice.	 I	 commenced	
parenchymal	monitoring	of	the	kidney,	whilst	allowing	the	kidney	to	warm	to	room	temperature.		
In	sub-study	3,	to	replicate	clinical	practice,	I	tested	the	impact	of	a	long	CIT	on	parenchymal	lactate	
monitoring	 using	 the	 rsMD	 assay.	 Kidneys	 were	 retrieved	 in	 the	 same	 manner	 as	 sub-study	 2,	
however	monitoring	took	place	in	a	hypothermic	state.	
Having	 previously	 developed	 a	 validated	 ex-vivo	 protocol	 for	 renal	 cortical	 lactate	monitoring,	 in	
sub-study	4	I	utilised	the	assay	to	monitor	changes	in	the	renal	cortex	during	a	short	period	of	SCS	
and	 HMP	 in	 the	 same	 porcine	 model.	 I	 compared	 the	 effects	 of	 SCS	 and	 HMP	 on	 renal	 cellular	
metabolism	and	the	ischaemic	profiles	of	the	cortical	tissue.	
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§ Aim: Lower	metabolism	during	transport;	prevent	data	loss
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§ Kept	kidneys	on	ice	and	monitored	
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3
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§ Aim:	Assess	impact	of	SCS and	HMP on	metabolismSub-study	
4
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5.3 METHODOLOGY	
5.3.1 Microdialysis	probe	
A	sterile,	single	use,	disposable	CMA	12	MD	probe	(CMA	Microdialysis	AB,	Stockholm,	Sweden)	was	
used	 in	 the	 continuous	monitoring	 and	 detection	 of	 local	 changes	 in	metabolism	 following	 organ	
retrieval.	The	probe	has	a	total	length	of	310mm	with	a	30mm	dialysis	membrane.	The	catheter	has	
a	removable	introducer,	which	allows	easy	and	safe	tunnelling	into	tissue.	The	membrane	cut-off	is	
approximately	 20,000	 Daltons,	 this	 limits	 the	 size	 of	 the	 molecules	 diffusing	 through,	 thereby	
increasing	the	selectivity	of	the	technique.	In	clinical	use	this	has	the	added	benefit	of	preventing	the	
passage	of	micro-organism,	viruses	or	prions	and	the	enzymes	that	may	degrade	the	analytes	being	
measured.	We	 used	 normal	 saline	 as	 the	 dialysate	medium.	 The	 fluid	 is	 sterile	 and	 isotonic	 (Na+	
147mmol,	K+	4.0mmol,	Ca2+	2.3mmol,	Cl-	156mmol).	The	perfusion	fluid	was	delivered	at	a	rate	of	2	
µL/min	through	a	CMA	600	microdialysis	pump.	This	rate	is	optimum	for	adequate	recovery	and	fast	
transit	of	dialysate.	
	
Figure	107	–	CMA	12	MD	probe.	Courtesy	of	CMA	Microdialysis	
5.3.2 Online	rapid	sampling	microdialysis	analyser	
The	 online	 rapid	 sampling	 microdialysis	 analyser	 (rsMD)	 was	 designed,	 assembled,	 modified	 and	
optimised	 in	 conjunction	 with	 the	 Department	 of	 Bioengineering,	 Imperial	 College	 London.	 The	
analyser	 allows	 simultaneous	 and	 automatic	 analysis	 of	 the	 dialysate	 from	 the	 outlet	 of	 the	
microdialysis	catheter.	The	system	consists	of	multiple	components,	which	when	working	together	
allow	 the	 biosensor	 assay	 to	 detect	 the	 metabolic	 markers	 of	 ischaemia	 online	 and	 in	 high	
resolution.	This	is	discussed	in	greater	detail	in	chapter	1	and	2.	
Inlet 
Distal	
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The	 custom	 dual	 switching	 injection	 valve	 at	 the	 centre	 of	 the	 analyser	 can	 automatically	 direct	
dialysate	 fluid	 from	 two	 independent	 inflows	 into	 one	 of	 two	 electrodes.	 The	 electrodes	 are	 pre-
loaded	with	enzyme	beds	and	function	as	the	biosensor,	one	for	glucose	and	one	for	lactate.	In	our	
DCD	porcine	models	there	is	no	ongoing	glucose	delivery	into	the	tissue	and	therefore	glucose	is	not	
monitored	 in	 this	 study.	 Instead,	 the	 second	 electrode	 is	 fitted	with	 another	 lactate	 enzyme	bed.	
This	 results	 in	 two	 functioning	 lactate	 channels,	 capable	 of	 monitoring	 one	 kidney	 via	 a	 single	
microdialysis	 catheter	 with	 double	 the	 frequency	 of	 sampling.	 This	 allows	 for	 sampling,	 and	
therefore	 a	 lactate	 concentration	 obtained,	 every	 30	 seconds.	 However,	 given	 that	 the	metabolic	
and	 tissue	processes	do	not	 require	 such	a	high	 resolution	of	monitoring,	 it	may	be	preferable	 to	
have	 two	microdialysis	 probes	 attached	 to	 the	 system,	with	 alternate	 sampling	 every	 60	 seconds.	
This	would	allow	us	to	monitor	a	pair	of	kidneys	at	the	same	time,	or	monitor	a	single	kidney,	but	
with	 one	 probe	 in	 the	 cortex	 and	 one	 in	 the	medulla.	 This	 flexibility	 is	 utilised	 effectively	 in	 our	
various	sub-studies.	
5.3.3 RM3	hypothermic	perfusion	machine		
The	RM3	Renal	Preservation	System	(Waters	Medical	Systems,	Rochester,	US)	 is	a	 lightweight	and	
self-contained	renal	preservation	system.	The	RM3	system	provides	controlled	kidney	perfusion	of	
hypothermic	 physiologic	 solutions,	 monitors,	 displays,	 trends,	 and	 saves	 important	 perfusion	
parameters,	including	perfusate	flow,	temperature,	pressure,	renal	resistance.		
The	RM3	is	a	two-part	system	comprising	a	control	unit	for	perfusion	and	monitoring	of	one	or	two	
kidneys,	and	a	mounted	cassette	used	to	contain	and	circulate	perfusate	 to	 the	kidneys.	The	RM3	
control	unit	regulates	the	pulsatile	perfusion	of	the	perfusate.	The	RM3	perfuses	and	monitors	real-
time	 pressure,	 flow	 and	 temperature	 of	 the	 perfusate.	 The	 control	 unit	 displays	 parameters	 to	
monitor	 perfusion	 activity	 and	 trend	 data	 for	 objective	 evaluation	 of	 the	 kidney	 prior	 to	
transplantation.	The	device	allows	for	an	efficient	method	for	hypothermic	pulsatile	preservation	for	
one	or	two	kidneys	by	maintaining	pressure,	flow	and	temperature.		
The	RM3	cassette	 is	a	gravity	 flow	system	which	allows	perfusate	 to	circulate	 through	 the	kidney.	
The	 perfusate	 is	 pumped	 from	 an	 arterial	 reservoir,	 through	 a	 heat	 exchanger	 to	 a	 bubble	 trap,	
where	it	can	be	delivered	to	a	cannulated	kidney.	The	perfusate	returns	to	the	arterial	reservoir	by	
gravity	through	the	venous	reservoir	and	the	membrane	oxygenator.	The	cassette	is	mounted	on	the	
RM3	 control	 unit,	 allowing	 the	 pressure	 transducer,	 air	 inlet	 tubing,	 temperature	 probe	 and	 flow	
transducers	all	to	be	connected.	A	temperature	probe	controls	a	circulation	pump	within	an	ice	bath	
and	allows	the	thermostatic	control	of	the	perfusate.	Sampling	ports	allow	the	operator	to	regulate	
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perfusate	 levels,	 by	 infusing	 or	withdrawing	 air,	 this	 allows	 accurate	 pressure	measurements	 and	
prevents	damage	to	the	transducer.	 It	allows	the	operator	to	sample	perfusate	 for	analysis	and	to	
introduce	modulating	agents	into	the	perfusate.		
The	RM3	Renal	Preservation	System	(Waters	Medical	Systems,	Rochester,	US)	was	used	in	sub-study	
4	 of	 this	 thesis,	 when	 comparing	 the	 metabolic	 effects	 of	 SCS	 against	 HMP.	 I	 detail	 the	 setup	
procedure	within	the	methodology	of	sub-study	4.		
.
	
Figure	108	–	RM3	Renal	Preservation	System	(Waters	Medical	System,	Rochester,	US)	
Pictured	in	our	laboratory	whilst	undertaking	HMP	of	a	porcine	kidney	
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5.3.4 Organ	procurement	
All	 of	 the	 experiments	 contained	within	 this	 study	 took	 place	 using	 a	 renal	 DCD	 porcine	model.	 I	
chose	kidneys	 for	 the	organ	model	 for	 several	 reasons.	The	 retrieval	process	 is	quicker	and	easier	
than	that	of	 livers,	pancreata	or	hearts.	Kidneys	can	be	retrieved	as	a	pair,	allowing	us	to	perform	
comparative	experiments.	I	can	test	different	tissue	modulators	on	two	genetically	identical	organs,	
which	allows	a	degree	of	biological	concurrence.	Kidneys	are	also	surrounded	by	a	 fibrous	capsule	
that	 prevents	 swelling	 during	 the	 preservation	 processes.	 Kidneys	 are	more	 resilient	 to	 ischaemia	
than	livers	or	pancreata,	and	therefore	our	retrieval	methods	and	transportation	logistics	will	cause	
less	tissue	injury	and	cell	death,	thereby	having	less	of	a	negative	impact	on	our	results.	
5.3.4.1 Department	of	Medical	Science,	St	Mark’s	Hospital	–	Sub-study	1	
In	 sub-study	 1,	 I	 retrieved	 kidneys	 from	 animals	 that	 had	 been	 terminated	 after	 previous	
experimentation	at	the	Department	of	Medical	Science,	St	Mark’s	Hospital,	Harrow,	UK.	All	animal	
experimental	procedures	were	approved	by	the	animal	research	ethics	committee	of	the	Faculty	of	
Medical	 Sciences	of	St.	Mark’s	Hospital.	 The	care	and	handling	of	 the	animals	were	 in	accordance	
with	the	Animals	(Scientific	Procedures)	Act	of	1986.	
Kidneys	were	retrieved	from	large	landrace	pigs	(80-100kg).	All	pigs	were	transported	to	the	facility	
seven	days	prior	to	the	commencement	of	any	experimentation.	This	allowed	the	pigs	to	acclimatise	
to	the	new	surroundings	and	prevent	a	stress-induced	physical	reaction.		They	were	fed	with	regular	
standard	diet	and	fasted	for	six	hours	prior	to	surgical	procedures.		
All	pigs	were	pre-medicated	with	20mg/kg	ketamine	and	0.5mg/kg	acepromazine	via	intra-muscular	
injection.	The	marginal	ear	vein	was	subsequently	cannulated	and	general	anaesthesia	 induced	by	
intravenous	 injection	 of	 6	 mg/kg	 pentobarbital.	 Endotracheal	 intubation	 was	 performed	 and	
mechanical	 ventilation	 commenced.	 At	 this	 point,	 various	 research	 teams	 would	 undertake	 their	
experimental	studies,	followed	by	chemical	termination	of	the	pig.	Once	the	pig	had	been	confirmed	
dead,	 I	 performed	 a	 rapid	 laparotomy,	making	 an	 incision	 from	 the	 xiphoid	 process	 to	 the	 pubic	
symphysis.	 I	 pulled	 the	 small	 bowel	 out	 of	 the	 abdomen	 to	 allow	 exposure	 to	 the	 colon	 and	
retroperitoneal	 structures.	 I	 quickly	 performed	 a	modified	 right	 and	 left	medical	 visceral	 rotation,	
allowing	exposure	to	both	kidneys.	The	kidneys	were	rapidly	excised	en	bloc,	including	a	portion	of	
the	aorta	and	 inferior	vena	cava	 (IVC).	 I	dissected	the	kidney	out	 individually	on	the	back	table.	 In	
sub-study	1,	I	was	not	perfusing	the	kidneys,	therefore	the	length	of	the	vessels	was	not	important	
and	no	extra	time	was	spent	dissecting	the	vessels.	These	actions	were	performed	quickly	to	allow	
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the	 kidneys	 to	 be	 stored	 at	 room	 temperature	 and	 transported	 to	 the	 laboratory	 to	 start	 the	
microdialysis	monitoring.		
By	utilising	the	resources	at	St	Mark’s	Hospital,	we	had	regular	access	to	kidneys	and	were	able	to	
retrieve	all	the	organs	needed	for	sub-study	1.	An	important	consideration	in	animal	research	is	the	
cost,	however	as	other	research	teams	were	carrying	out	live	experiments	on	the	anaesthetised	pigs,	
they	bore	the	cost	of	this	resource.	I	only	had	access	to	the	pig	once	it	had	been	terminated,	prior	to	
incineration.	 This	was	 beneficial	 as	 I	 had	 a	 very	 small	 research	 budget	 and	 also	 did	 not	 require	 a	
personal	or	project	animal	license.		
St	Mark’s	hospital	is	relatively	close	to	the	laboratory	at	Imperial	College,	therefore	I	could	start	my	
experiments	relatively	quickly	after	retrieval,	which	was	crucial	to	maximise	the	dataset.	There	were	
however	numerous	downsides	to	this	set	up.	Logistically,	I	had	no	control	over	when	and	how	often	I	
could	retrieve	kidneys.	I	was	often	given	very	little	notice,	which	was	challenging	as	the	rsMD	would	
need	to	be	optimised	and	prepared	prior	to	any	monitoring.			
I	was	blinded	to	the	nature	of	the	preceding	studies	and	no	control	over	the	experimental	protocols.	
Occasionally	the	researchers	would	discuss	the	nature	of	their	research,	however	this	was	more	of	a	
professional	 courtesy,	 rather	 than	 a	 requirement.	 I	was	 reassured	 that	 none	 of	 the	 studies	 had	 a	
direct	intervention	or	impact	on	the	kidneys,	however	I	could	not	be	sure	if	there	was	a	direct	effect	
on	 the	 kidneys.	 It	 was	 impossible	 to	 standardise	 for	 this	 potential	 impact,	 as	 different	 research	
teams	were	 present	 undertaking	 different	 studies.	 As	 an	 example,	 one	 of	 the	 preceding	 research	
teams	had	retrieved	the	liver	whilst	the	pig	was	anaesthetised,	with	the	aim	of	creating	an	ex-vivo	
normothermic	perfusion	circuit.	This	required	3	litres	of	oxygenated	blood	to	be	drawn	from	the	pig.	
The	pig	was	hypovolaemic	and	hypotensive	for	a	long	period	prior	to	termination,	which	would	have	
likely	caused	a	significant	amount	of	warm	ischaemia	and	renal	injury.	I	decided	not	to	retrieve	and	
monitor	 these	kidneys.	Overall	 I	was	concerned	about	 the	potential	 impact	 that	 this	 set	up	would	
have	on	my	results	and	the	lack	of	standardisation,	and	therefore	I	decided	to	find	an	alternative.	
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5.3.4.2 Local	abattoir	–	Sub	study	2	-	4		
I	 approached	 the	manager	of	a	 large	abattoir	who	was	willing	 to	help	and	was	considerate	of	 the	
special	requirements	of	my	experimental	protocol.	 I	paid	a	nominal	 fee,	which	was	well	within	my	
research	budget.	I	utilised	this	resource	to	retrieve	all	the	kidneys	for	sub-study	2,	3	and	4.	
In	 this	 setting	 I	 retrieved	 pairs	 of	 kidneys	 from	 large	 landrace	 pigs	 (80-100kg).	 Each	 animal	 was	
stunned	using	a	captive	bolt	pistol,	hung	upside	down	and	sacrificed	by	means	of	exsanguination	via	
transection	 of	 the	 jugular	 veins	 and	 carotid	 arteries.	 At	 the	 time	 of	 death,	 I	 rapidly	 performed	 a	
midline	laparotomy,	allowing	gravity	to	empty	the	abdominal	cavity	of	the	small	bowel.	Using	sharp	
dissection,	 I	 reflected	 the	 colon	 downwards	 and	 excised	 the	 entire	 retroperitoneum	 enbloc,	
including	the	kidneys,	aorta	and	IVC.	This	was	quite	challenging	as	the	pig	was	upside	down,	hanging	
from	hooks.	On	the	back	table,	I	rapidly	exposed	and	divided	the	renal	arteries	close	to	the	origin	of	
the	aorta,	and	divided	the	IVC	length	ways.	Arteries	were	cannulated	sequentially	and	flushed	with	
500ml	of	cold	University	of	Wisconsin	solution	(Viaspan,	Bristol-Myers	Squibb	Pharmaceuticals	Ltd,	
Dublin,	Ireland),	at	low	pressure	(100-cm	H20),	until	the	venous	effluent	was	clear.		
At	 this	point,	 the	kidneys	would	be	placed	on	 ice	and	 I	would	 continue	 the	 rest	of	 the	back-table	
dissection.	With	the	kidneys	having	been	flushed	with	cold	preservation	fluid	and	placed	on	ice,	the	
dissection	could	take	place	at	a	more	leisurely	pace.	Care	was	taken	at	this	point	to	avoid	any	injury	
to	the	kidney	and	to	dissect	the	renal	vessels.	 In	sub-study	4	 it	was	 imperative	that	 I	had	as	much	
length	on	the	renal	arteries	as	possible	as	they	would	be	secured	to	the	tubing	of	the	RM3	perfusion	
device	by	means	of	vicryl	ligatures.	It	was	imperative	that	there	was	enough	length	on	the	artery	to	
allow	me	to	do	so.	Once	completed	the	kidney	were	stored	in	the	remaining	preservation	fluid	and	
sealed	within	 a	 polyethylene	 bag	 and	 placed	 on	 ice	 to	 facilitate	 transportation	 to	 the	 laboratory.	
Overall	warm	ischaemia	time	was	standardised	to	15	minutes.	
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Figure	109	–	Organ	procurement	–	Sub-study	2	–	4	
A)	En	bloc	resection	and	dissection	on	back	table.	B)	Renal	artery	cannulated	and	perfusion	with	UW	solution.	C)	Continued	dissection	of	
renal	vessels	
5.3.5 Data	analysis	
The	analysis	of	the	data	is	discussed	in	greater	detail	in	chapter	2.		
Chart®	software	was	used	for	data	acquisition	allowing	results	to	be	displayed	as	a	trace	of	current	
lactate	 concentration	 levels	 (y-axis)	 versus	 time	 (x-axis),	 with	 peaks	 every	 30-60	 seconds	
corresponding	to	the	sampling	interval.	Using	algorithms	developed	by	Feuerstein	et	al	and	MATLAB	
software	(Version	R2011a,	MathWorks,	Natick,	US)	 I	was	able	to	de-noise	and	clean	excess	spiking	
within	the	data.257	Lactate	concentration	values	were	derived	at	each	time	point,	by	using	calibration	
data	obtained	from	manual	injections	of	known	concentrations	of	lactate	solutions	directly	into	the	
assay.	
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5.4 SUB-STUDY	1	–	FEASIBILITY	ASSESSMENT	OF	RSMD	TO	
MONITOR	ISCHAEMIC	INJURY	
5.4.1 Aim		
My	aim	 in	this	sub-study	was	to	test	 the	feasibility	of	using	the	rsMD	assay	to	detect	and	monitor	
renal	cortical	lactate	concentrations,	as	a	marker	for	ischaemic	injury.	I	wanted	to	develop	a	baseline	
ischaemic	 profile	 of	 a	 freshly	 retrieved	 kidney,	 demonstrating	 the	 metabolic	 processes	 that	 take	
place	during	this	warm	ischaemia	period.		
5.4.2 Method		
I	 used	 an	 experimental	 porcine	 DCD	 renal	 model	 to	 determine	 the	 feasibility	 of	 using	 the	 rsMD	
system	for	assessment	of	metabolic	and	ischaemic	profiles	using	an	ex-vivo	monitoring	protocol.	
Pairs	 of	 kidneys	 were	 retrieved	 from	 animals	 that	 had	 been	 terminated	 after	 previous	
experimentation	 at	 the	 Department	 of	Medical	 Science,	 St	Mark’s	 Hospital,	 Harrow,	 UK	 (detailed	
earlier	 in	this	chapter).	Kidneys	were	transported	at	room	temperature	for	experimentation	to	the	
laboratory	of	the	Department	of	Surgery,	Imperial	College	London,	UK.	The	experiment	was	setup	to	
allow	the	rsMD	to	start	monitoring	the	renal	parenchyma.	A	sterile,	single	use,	disposable	CMA	12	
MD	probe	 (CMA	Microdialysis	AB,	Stockholm,	Sweden)	was	 tunnelled	 into	 the	sub-capsular	 lateral	
renal	cortex	of	each	kidney.		
This	 was	 performed	 in	 a	 similar	 manner	 to	 that	 described	 in	 Chapter	 3	 where	 we	 implanted	
microdialysis	catheters	into	the	bowel	mesentery.	This	technique	was	developed	to	minimise	injury	
to	the	surrounding	structure.	We	used	a	large	gauge	angiocath	to	puncture	the	surface	of	the	kidney	
through	 the	 parenchymal	 tissue	 and	 exiting	 the	 parenchyma	 from	 the	 initial	 puncture.	 The	metal	
needle,	when	withdrawn,	left	the	plastic	cannula	behind.	The	tip	of	the	probe	entered	the	tip	of	the	
cannula	 and	 advanced	 in	 a	 retrograde	 fashion.	 The	 cannula	 was	 removed	 leaving	 behind	 the	
microdialysis	 probe.	 The	 microdialysis	 probe	 was	 packaged	 with	 a	 splitable	 introducer,	 however	
initial	tests	showed	this	to	be	traumatic.	This	technique	is	demonstrated	below	in	Figure	110.	
	
Figure	110	–	Technique	to	implant	MD	probe	
Kidney
AngiocathMD	probe
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Microdialysis	 probes	 were	 connected	 to	 the	 rsMD	 as	 per	 experimental	 protocols	 described	 in	
previous	chapters.	Microdialysis	monitoring	would	commence	within	a	few	minutes	of	initiating	the	
system.	 This	 was	 marked	 by	 the	 appearance	 of	 peaks	 within	 the	 Chart	 software.	 Microdialysis	
measurements	were	 taken	every	60	seconds	 from	each	corresponding	kidney	and	continued	 for	6	
hours	whilst	the	kidney	was	stored	at	room	temperature.	During	this	period,	it	was	not	necessary	to	
change	 the	enzyme	beds,	however	periodic	 calibrations	were	made.	These	were	 factored	 into	 the	
conversion.	 Temperature	monitoring	was	 not	 used	 in	 these	 cases	 as	 all	 kidneys	were	 stored	 and	
monitored	at	room	temperature.	An	overview	of	the	study	protocol	is	provided	in	Figure	111.	
	
Figure	111	–	Experimental	overview	of	sub-study	1	
The	 retrieval	 time,	 transport	 time	and	experimental	 set-up	procedure	 resulted	 in	a	 long	period	of	
time	before	monitoring	was	initiated.	After	a	few	attempts	this	time	was	significantly	reduced.	In	the	
first	 experiment	 (kidney	 1),	 ‘knife	 to	 monitoring	 time’	 was	 close	 to	 240	 mins.	 In	 the	 second	
experiment	(kidneys	2	and	3)	the	‘knife	to	monitoring	time’	was	significantly	less	at	90	mins.	In	the	
first	experiment,	we	only	monitored	one	kidney	as	another	researcher	used	the	contralateral	kidney.	
With	the	exception	of	the	very	first	case,	which	was	aimed	at	testing	and	refining	my	methodology,	
the	experimental	protocol	that	I	designed	aimed	to	monitor	a	pair	of	kidneys	from	the	same	animal	
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simultaneously.	 In	doing	so,	we	could	only	 incorporate	one	microdialysis	probe	 into	each	kidney.	 I	
decided	 that	 I	 would	 measure	 lactate	 concentrations	 within	 the	 renal	 cortex	 in	 preference	 over	
measuring	the	medulla.	
I	 chose	 cortical	 lactate	monitoring	 over	 medulla	 for	 a	 specific	 reason.	 In	 a	 typical	 multi-papillary	
kidney,	 such	 as	 that	 of	 a	 pig	 or	 human,	 in-vivo	 oxygenation	 within	 the	 renal	 parenchyma	 varies	
significantly.258	 The	 renal	 cortex	 has	 the	 highest	 oxygen	 tension	 concentrations,	 whilst	 the	 renal	
medulla	 possesses	 a	 much-reduced	 oxygen	 tension.	 This	 oxygenation	 gradient	 within	 the	 renal	
parenchyma	 is	 a	 result	 of	 the	 counter	 current	 orientation	 of	 the	 arterial	 and	 venous	 vasa	 recta	
within	 the	medulla.259	 Cells	within	each	 region	have	adapted	 to	 function	at	optimum	efficiency	at	
their	 respective	 oxygenation	 level.258	 Epithelial	 cells	within	 the	 renal	 cortex	 predominantly	 use	O2	
dependent	metabolism,	requiring	a	microenvironment	that	is	well	oxygenated	to	function	optimally,	
therefore	 they	are	sensitive	 to	hypoxia	and	susceptible	 to	 ischaemic	 injury.	The	 renal	medulla	can	
use	 O2	 dependent	 metabolism	 or	 use	 glucose	 to	 generate	 ATP	 via	 anaerobic	 glycolysis	 for	 short	
periods	if	changes	within	the	microenvironment	necessitate	it.	These	regions	are	less	susceptible	to	
ischaemia	and	subsequent	injury.	The	greatest	ischaemic	injury	would	likely	take	place	in	the	renal	
cortex,	and	therefore	in	sub-study	1	this	was	the	focus	of	investigation.	
	
	
Figure	112	–	Typical	set	up	of	kidney	monitoring	in	sub-study	1	
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5.4.3 Results	
I	successfully	monitored	7	porcine	kidneys	from	4	large	landrace	pigs,	for	a	period	of	6	hours	each.	
Calibration	 data	 was	 obtained	 at	 the	 start	 of	 monitoring	 and	 continued	 at	 2	 hourly	 intervals.	 A	
sample	of	the	calibration	data	and	trace,	at	the	start	of	monitoring	for	kidney	1	(T=0)	 is	 illustrated	
below	(Figure	113).		
	
	
Figure	113	–	Kidney	1	–	Calibration	data	and	trace	
I	have	presented	the	individual	trace	for	the	first	kidney	(kidney	1	-	Figure	114)	that	I	monitored	in	
sub-study	1.	The	dialysate	lactate	concentrations	are	displayed	as	a	trace.	The	highlighted	blue	areas	
indicate	the	period	of	organ	retrieval	and	transport	to	the	laboratory	for	monitoring.	In	sub	study	1,	
time	zero	equals	time	of	death.		
The	lactate	concentration	is	high	to	start	(0.40mM),	then	rapidly	drops	(0.26mM).	This	initial	sharp	
decline	 is	 secondary	 to	equilibrium	being	reached	within	 the	 tissue	as	 lactate	molecules	diffuse	 to	
the	 microdialysis	 probe,	 this	 typically	 takes	 10	 minutes	 to	 achieve.	 Following	 this	 initial	 sharp	
decline,	 there	 is	 slower	 progressive	 decline	 in	 the	 lactate	 concentration	 during	 the	 period	 of	
monitoring	down	to	0.11mM.	
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Figure	114	–	Sub	study	1	–	Kidney	1	
The	 dialysate	 lactate	 concentration	 (mM)	 is	 shown	 as	 a	 grey	 trace	 during	 the	 period	 of	 monitoring	 (mins).	 The	 blue	 shaded	 area	
represents	the	time	for	retrieving	the	kidney	and	transporting	it	to	the	lab	
Figure	114	demonstrates	that	the	cortical	monitoring	starts	at	the	249th	minute.	The	two	red	arrows	
illustrate	 two	aberrant	peaks	 in	 the	 lactate	dialysate	 concentration.	 The	 first	 irregularity	 coincides	
with	 movement	 of	 the	 probes	 during	manual	 handling	 of	 the	 kidney	 and	 the	 second	 irregularity	
reflects	when	the	probes	accidentally	fell	out	of	the	cortex	and	had	to	be	replaced.	These	increases	
likely	 do	 not	 reflect	 real	 rises	 in	 lactate	 concentration	 rather	 the	 changing	 local	 environment	
surrounding	the	tip	of	the	microdialysis	probe.	As	the	probe	moves	the	molecular	diffusion	gradients	
setup	are	rearranged,	which	may	result	in	more	molecules	reaching	the	probe	and	hence	appear	to	
be	an	increase	in	concentration.		
Figure	115	demonstrates	the	traces	of	all	seven	kidneys	during	monitoring.	Time	zero	(T=0)	equates	
to	 the	 time	of	 death.	 In	 all	 cases,	 except	 for	 kidney	1,	monitoring	was	 started	within	90	minutes.	
Stable	 lactate	 levels	were	achieved	within	10	–	20	minutes	of	starting	the	monitoring	process.	The	
mean	 extracellular	 lactate	 concentration	 was	 212.2	 ±	 48.8mM	 at	 100	 min	 post	 termination.	 I	
successfully	identified	a	subsequent	fall	in	the	lactate	level	to	135.1	±	47.4mM	at	300	min.	
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Figure	115	–	Sub	study	1	–	Kidney	1	–	7	
Each	trace	demonstrates	the	dialysate	lactate	concentration	and	hence	the	metabolic	profile	for	each	kidney	following	termination.	The	
arrows	represent	the	equilibrium	artefact	
Examining	Figure	115,	kidney	2	and	kidney	3,	demonstrate	a	similar	pattern	to	kidney	1.	There	is	a	
relatively	 high	 starting	 dialysate	 lactate	 concentration	 at	 0.26mM	 in	 kidney	 2,	 which	 then	 drops	
quickly	to	0.14mM	within	a	period	of	22	minutes.	The	dialysate	lactate	concentration	progressively	
and	slowly	drops	to	0.08mM	at	its	lowest	point	at	the	end	of	the	period	of	monitoring.	This	second	
phase	shows	a	stable	decrease,	with	only	minor	 fluctuations	off	 the	baseline.	Kidney	 retrieval	and	
transport	 times	 are	 significantly	 reduced	 when	 compared	 to	 the	 first	 experiment	 carried	 out	 in	
kidney	1	(84	mins	vs.	249	mins	respectively).	I	was	able	to	refine	the	methodology	significantly	and	
therefore	 reduce	 this	 time.	 Kidney	 2	 and	 3	 were	 paired	 from	 the	 same	 pig	 (left	 and	 right	
respectively),	interestingly	the	starting	dialysate	lactate	concentration	in	kidney	3	is	similar	to	kidney	
2	(0.25mM	vs.	0.26mM	respectively).	As	seen	before,	the	initial	dialysate	lactate	concentration	drops	
quickly	 from	 0.25mM	 to	 0.14mM	 in	 a	 period	 of	 20	 mins	 as	 equilibrium	 is	 reached.	 There	 is	 a	
subsequent	drop	to	0.0	mM	over	a	much	longer	period	of	monitoring,	which	reflects	the	previously	
identified	 slow	 decrease	 in	 dialysate	 lactate	 concentration.	 The	 traces	 of	 kidney	 2	 and	 3,	 clearly	
display	congruency	in	their	metabolic	profile,	demonstrating	a	close	biological	concordance	between	
syngeneic	 left	 and	 right	 kidneys.	 In	 kidney	 4	 the	 initial	 dialysate	 lactate	 concentration	 start	 at	
0.47mM,	with	a	greater	than	53%	(0.25mM)	drop	 in	the	dialysate	 lactate	concentration	within	the	
first	23	minutes	of	monitoring.	The	rate	of	the	overall	concentration	drop	starts	to	decrease	at	this	
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point,	 as	 the	 trace	 stabilises.	 By	 the	 end	 of	 the	 period	 of	 monitoring,	 the	 dialysate	 lactate	
concentration	 dropped	 to	 0.15mM,	 which	 a	 represents	 a	 68%	 reduction	 in	 the	 starting	 dialysate	
lactate	concentration.	
Kidney	5	and	4	are	paired	organs	 from	the	same	pig.	Therefore,	 the	 retrieval	methodology,	whilst	
standardised	for	all	experiments	within	this	sub	study,	is	identical	for	kidney	4	and	5.	However,	the	
starting	 dialysate	 lactate	 concentration	 is	 slightly	 higher	 at	 0.58mM,	 which	 then	 rapidly	 drops	 to	
0.27mM.	Similar	to	kidney	4,	this	represents	a	53%	drop,	however	the	rate	of	this	reduction	is	faster,	
taking	place	within	10	minutes.	It	is	unclear	why	equilibrium	is	reached	faster	in	kidney	5	than	kidney	
4.	Whilst	the	microdialysis	probes,	the	length	of	FEP	tubing	and	the	rate	of	perfusion	are	all	identical	
in	both	these	experiments,	there	is	room	for	technical	inaccuracies	or	irregularities	within	the	setup.	
It	 is	 also	 possible	 that	 localised	 parenchymal	 differences,	 such	 as	 differing	 levels	 of	
microvascular/macrovascular	thrombosis	or	ischaemia	have	resulted	in	varying	diffusion	capabilities	
within	the	tissue.	
In	 kidney	 6,	 the	 initial	 dialysate	 lactate	 concentration	 is	 high	 at	 0.35mM,	 although	 this	 is	
comparatively	lower	when	compared	to	previous	kidneys.	We	then	see	the	typical	pattern	of	a	rapid	
decrease	as	equilibrium	 is	 reached,	 followed	by	a	sustained	but	slower	decrease	 in	cortical	 lactate	
concentration	 to	 0.13mM.	 The	 arrow	 demonstrates	 a	 period	 where	 monitoring	 was	 temporarily	
stopped	 due	 to	 failure	with	 the	HPLC	 pump,	which	 resulted	 in	 a	 short	 period	 of	 data	 loss.	When	
monitoring	 takes	 place	 under	 normal	 circumstances,	 the	 sampling	 processes	 of	 the	 microdialysis	
technique,	results	 in	a	steady	and	uniform	removal	of	 lactate	molecules.	These	molecules	are	then	
detected	 in	 the	dialysate	stream.	However,	when	 the	sampling	 is	 stopped	abruptly,	 the	molecules	
accumulate	 in	 the	 extracellular	 fluid	 surrounding	 the	 probe	 tip.	 Ongoing	 cellular	 and	 enzyme	
processes	continue	to	produce	lactate,	which	is	present	in	the	extracellular	space.	Once	monitoring	
and	sampling	is	restarted,	it	then	appears	that	there	is	a	high	concentration	of	lactate,	however	this	
artefact	is	secondary	to	accumulation	of	molecules	around	the	probe.	After	a	very	short	period	for	
the	development	of	steady	state	and	equilibrium,	we	can	see	that	the	real	concentration	is	evident.		
Kidneys	 6	 and	 7	 were	 paired	 organs	 from	 the	 same	 animal.	 They	 were	 subjected	 to	 the	 same	
methodology	and	were	analysed	by	the	same	system.	Therefore,	the	previously	seen	period	of	data	
loss	 due	 to	 the	 HPLC	 malfunction	 is	 also	 seen	 in	 this	 kidney’s	 monitoring.	 The	 starting	 dialysate	
lactate	concentration	is	low	at	0.25mM,	which	then	drops	to	a	steady	state	of	0.1mM	by	the	end	of	
monitoring.	
Examining	all	 7	 kidneys,	 the	mean	extracellular	 lactate	 concentration	was	212.2	±	48.8mM	at	100	
min	post	termination,	with	a	decrease	in	the	dialysate	lactate	concentration	to	135.1	±	47.4mM	at	
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300	min.	This	fall	was	not	caused	by	the	microdialysis	process	but	rather	reflected	in	on-going	tissue	
processes,	 specifically	 a	 reduction	 in	anaerobic	metabolism	as	 ischaemia	worsened	and	cells	died.		
This	preliminary	study	partly	provides	evidence	for	a	baseline	ischaemic	profile	for	porcine	kidneys	
whilst	in	part,	validating	the	technique	of	microdialysis	as	a	tool	for	assessing	the	ischaemic	injury	in	
porcine	kidneys.	However,	a	key	limitation	to	this	study	is	the	important	data	missing	in	the	traces,	
within	the	first	90	minutes.	This	represents	the	time	required	to	retrieve	the	organ	and	transfer	to	
the	 laboratory.	Monitoring	 in	 this	 period	 would	 demonstrate	 the	 key	metabolic	 processes	 taking	
place	 at	 the	 initial	 onset	 of	 warm	 ischaemia.	 To	 be	 able	 to	 visualise	 and	 present	 this	 data	 is	
imperative	 in	 order	 to	 validate	 the	 rsMD	 analyser	 for	 organ	 viability	 assessment.	 If	 I	 was	 able	 to	
monitor	the	renal	cortex	 immediately	after	the	point	of	death,	 it	 is	 likely	that	the	dialysate	 lactate	
concentration	 would	 slowly	 rise	 as	 the	 tissue	 becomes	 ischaemic.	 Glucose	 delivery	 stops	 with	
suspension	 of	 arterial	 perfusion	 and	 the	 remaining	 glucose	 is	 utilised.	 Anaerobic	 metabolism	
develops	in	the	hypoxic	environment	and	lactate	is	produced	as	a	by-product,	causing	the	dialysate	
lactate	concentrations	to	rapidly	rise.		Eventually	metabolism	fails	as	metabolites	are	consumed	and	
cell	 death	 takes	 place,	 lactate	 concentration	would	 plateau	 and	 then	 decline	 as	 the	 cells	 die	 and	
enzyme	activity	breaks	down	free	lactate	molecules.	Without	seeing	this	predicted	profile,	I	cannot	
conclusively	say	that	the	online	rsMD	assay	has	provided	the	baseline	ischaemic	profile	for	porcine	
kidneys	whilst	also	validating	 this	 technique	as	a	 tool	 for	assessing	 the	 ischaemic	 injury	 in	porcine	
kidneys.	
Due	to	logistical	reasons,	I	was	unable	to	transport	the	rsMD	analyser	to	the	animal	research	facility,	
to	 start	 the	 monitoring	 earlier.	 I	 attempted	 to	 find	 alternative	 locations,	 however	 this	 was	 very	
limited	and	still	would	have	resulted	in	significant	data	loss.	Other	than	having	the	rsMD	at	the	point	
of	 retrieval,	 it	was	 clear	 that	 further	modification	of	 the	methodology	 is	 required	 to	allow	 further	
understanding	of	the	metabolic	processes	that	take	place	in	this	crucial	period.	
	
	 	
	 186	
5.5 	SUB-STUDY	2	
5.5.1 Aim		
My	aim	 in	 this	 sub-study	was	 to	address	 the	 limitation	 that	 I	 identified	 in	 sub-study	1,	 in	order	 to	
identify	 the	 key	 metabolic	 processes	 that	 take	 place	 within	 the	 renal	 cortex	 in	 the	 initial	 warm	
ischaemia	period.	
5.5.2 Method	
In	 sub-study	2,	 as	previously	described,	 I	 changed	 the	method	of	 organ	procurement,	moving	 the	
retrieval	process	to	a	local	abattoir.	This	allowed	me	to	control	and	standardise	the	retrieval	process.	
With	 this	new	methodology	8	DCD	kidneys	were	 retrieved	 from	7	adult	 landrace	pigs	 (80-100	kg),	
terminated	 by	 stunning	 and	 exsanguination.	 Retrieval	 involved	 rapid	 laparotomy	 and	 en	 bloc	
dissection	of	both	kidneys.	Renal	arteries	were	identified,	cannulated	and	flushed	with	500ml	of	cold	
UW	solution	until	the	venous	effluent	was	clear.	Organs	were	then	stored	in	the	preservation	fluid	
and	transported	on	ice	to	the	laboratory.	Median	warm	ischaemia	time	was	15	minutes	(range:	11-
20	min).	
In	 the	 laboratory,	 the	 kidneys	 were	 removed	 from	 the	 polyethylene	 bag	 and	 taken	 off	 ice.	
Microdialysis	monitoring	of	the	kidneys	took	place	immediately,	as	the	temperature	rose	to	ambient	
room	temperature	(23oC).	Monitoring	took	place	throughout	this	second	period	of	warm	ischaemia.	
Monitoring	of	 lactate	took	place	every	60	seconds	and	continued	until	 the	amplitude	of	 the	peaks	
generated	 at	 the	 electrode	 dropped	 down	 to	 baseline.	 This	 indicated	 that	 lactate	 concentrations	
were	negligible	and	at	this	point	the	monitoring	was	discontinued.	The	length	of	monitoring	varied	
from	10	hours	to	48	hours,	which	represent	a	significant	variance.	
Having	 identified	 the	critical	 limitation	 in	 sub-study	1,	 I	designed	 the	new	study	protocol	with	 the	
aim	of	 lowering	metabolism	and	postponing	 the	onset	of	 anaerobic	metabolism	and	 ischaemia.	 It	
was	 these	 periods	 that	 were	 crucial	 to	 my	 investigations.	 This	 also	 partly	 replicated	 the	 clinical	
practice	of	transplantation,	by	having	an	initial	short	period	of	warm	ischaemia,	followed	by	a	longer	
period	of	cold	ischaemia	and	finally	a	period	of	warm	ischaemia.	On	overview	of	the	study	protocol	
is	illustrated	in	Figure	116.	
Kidney	 8	 and	 kidney	 9	 were	 retrieved	 from	 the	 same	 pig,	 which	 allowed	 us	 to	 monitor	 cortical	
lactate	 concentrations	 as	 per	 our	 experimental	 protocol	 in	 sub-study	 1.	 However,	 in	 subsequent	
retrievals,	 I	 only	monitored	 one	 kidney	 and	 this	 was	 standardised	 to	 the	 right	 kidney.	 The	 other	
kidney	 was	 used	 by	 another	 researcher.	 All	 retrievals	 were	 performed	 by	 myself	 using	 a	
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standardised	protocol.	This	allowed	me	to	insert	a	microdialysis	probe	in	to	the	cortex	and	another	
probe	into	the	medulla,	enabling	me	to	monitor	both	cortical	and	medullary	lactate	concentrations	
simultaneously.	 Microdialysis	 probes	 were	 implanted	 in	 the	 same	 fashion,	 with	 inlet	 and	 outlet	
tubing	connected	to	the	rsMD	analyser	and	syringe	pump	via	FEP	tubing.		
In	 kidney	 12,	 I	 tested	 a	 newly	 acquired	 temperature	 probe	 (Thermalert	 TH-5,	 Physitemp,	 Clifton,	
USA).	This	was	inserted	into	the	cortex	of	the	kidney	in	the	same	manner	as	the	microdialysis	probe	
and	initially	seemed	to	work	well.	However,	6	hours	 into	the	monitoring	the	probe	malfunctioned,	
despite	my	attempts	to	troubleshoot	the	probe	had	to	be	sent	back	to	the	U.S	for	repair.	I	was	not	
able	to	monitor	for	temperature	changes	in	the	rest	of	sub-study	2.	
	
	
Figure	116	–	Overview	of	experimental	protocol	–	sub-study	2	
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5.5.3 Results		
In	sub-study	2,	I	monitored	8	kidneys	from	7	large	landrace	pigs,	using	the	same	methodology.	Each	
individual	 experiment,	underwent	 calibration	 testing	before,	during	and	at	 the	end	of	monitoring.	
Calibration	 interval	was	extended	from	2hr	 (as	 in	sub-study	2)	 to	6hrs.	This	was	done	for	 logistical	
reasons	 as	 some	 of	 the	monitoring	 took	 place	 over	 night.	 In	 conjunction	with	 data	 presented	 by	
Corcoles	 et	 al	 (Use	 of	 online	 rapid	 sampling	 microdialysis	 electrochemical	 biosensor	 for	 bowel	
anastomosis	monitoring	 in	swine	model).	 I	was	confident	that	this	would	not	result	 in	error	 in	our	
results.	Calibration	data	and	liner	regression	is	shown	below	(Figure	117)	
	
	
	
	
Figure	117	–	Lactate	calibration	data	–	sub-study	2	–	kidney	8	+	9	
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Current	at	electrode	(μA) Sample	4 5.1 4.023 1.789 0.671 0.714 0.415 0.099
Mean	current	(μA) 6.01 3.90 1.99 1.00 0.60 0.37 0.21
Standard	deviation 0.85 0.33 0.43 0.51 0.17 0.25 0.15
	 189	
In	Figure	118	I	have	illustrated	a	summary	of	the	kidneys	monitored	in	this	sub-study.	Kidneys	8	+	9	
were	retrieved	from	the	same	pig,	and	therefore	only	cortical	monitoring	took	place.	All	subsequent	
kidney	 (10	 -15)	 were	monitored	 independently,	 allowing	 both	 cortical	 and	medullary	monitoring.	
Only	temperature	monitoring	took	place	in	kidney	12.	In	kidney	12	the	cortical	lactate	enzyme	bed	
failed	and	therefore	no	data	was	collected,	however	medullary	monitoring	took	place.		
	
Figure	118	–	Sub-study	2	–	Summary	of	kidneys	monitored	
This	sub-study	was	significantly	larger	and	more	complex,	resulting	in	14	metabolic	traces,	compared	
to	7	in	sub-study	1.	The	data	collected	in	sub-study	2	represented	a	total	of	approximately	440	hours	
of	monitoring,	with	over	50,000	data	points.	 I	 attempted	 to	 consolidate	 the	data	 from	 the	all	 the	
kidneys	into	a	trace	that	would	allow	direct	comparison	of	all	kidneys	in	this	group,	however	there	
was	such	variability	between	kidneys	that	much	definition	was	 lost	 in	many	cases.	Several	kidneys	
displayed	very	high	concentrations	of	 lactate,	 in	contrast	to	some	that	displayed	very	 low	levels	of	
concentration.	Placing	these	groups	together	resulted	in	loss	of	definition	in	the	lower	concentration	
groups	 as	 profiles	 appeared	 flattened.	 I	 attempted	 to	 group	 kidneys	 into	 cortical	monitoring	 and	
medullary	monitoring,	however	the	same	patterns	developed.	Neither	methods	allowed	appropriate	
characterisation	of	the	data	and	were	in	fact	unhelpful.	There	did	seem	to	be	significant	congruence	
when	 comparing	 the	 cortical	 and	medullary	 monitoring	 of	 each	 individual	 kidney,	 which	 allowed	
reasonable	 characterisation	 of	 the	 data,	 however	 very	 little	 inter-kidney	 congruence	 was	
demonstrated.	 	 I	 have	 illustrated	 the	paired	medullary	 and	 cortical	monitoring	 for	 each	 individual	
kidney,	with	the	exception	of	the	paired	kidneys	8	and	9.	
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5.5.3.1 Kidney	8	and	9	–	Cortical	and	medullary	monitoring	
Figure	 119	 demonstrates	 the	metabolic	 profiles	 for	 kidney	 8	 and	 kidney	 9,	 which	 were	 retrieved	
from	the	same	animal,	and	allows	direct	comparison	during	the	period	of	monitoring.	Examination	
of	kidney	8	demonstrates	that	the	initial	dialysate	lactate	concentration	is	stable	with	a	relatively	flat	
baseline	 fluctuating	 between	 0.35	 and	 0.45mM.	We	 can	 see	 that	 there	 is	 a	 slow	 increase	 in	 the	
lactate	concentration	as	the	temperature	slowly	increases,	followed	by	a	significant	increase	in	the	
dialysate	 lactate	 concentrations.	 It	 is	 likely	 that	 we	 get	 a	 surge	 in	 the	 lactate	 production	 as	 the	
temperature	 reaches	 a	 certain	 point	 that	 extends	 beyond	 the	 enzyme	 threshold	 for	 activity.	 As	
enzyme	activity	and	anaerobic	metabolism	ensues	 in	 the	absence	of	oxygen,	 the	 concentration	of	
cortical	 lactate	 increases.	 This	 rise	 in	 dialysate	 lactate	 concentration	 reaches	 a	 peak	 of	 1.5mM	at	
approximately	2,300	minutes	and	then	slowly	drops.	It	is	likely	at	this	point	that	the	cortex	loses	the	
ability	to	continue	producing	lactate.	This	rise	is	secondary	to	anaerobic	metabolism	initially	and	the	
cell	death	 subsequently.	At	 this	point,	 it	 is	 likely	 that	most	 cells	have	undergone	apoptosis	due	 to	
ischaemia.	 The	 areas	 where	 there	 is	 data	 loss	 reflect	 significant	 artefact	 that	 has	 been	manually	
removed.	 The	 artefact	 is	 likely	 to	 be	 secondary	 to	 inaccuracies	 and	 errors	 within	 the	 degrading	
enzyme	bed	due	 to	 the	 long	period	of	 time	 that	 this	 kidney	underwent	monitoring.	 It	 is	not	 clear	
why	 the	 expected	 rise	 in	 dialysate	 lactate	 concentration	 takes	 place	 so	 late	 in	 the	 monitoring,	
greater	than	24	hours	following	time	of	death.	It	would	be	expected	that	this	increase	takes	place	far	
sooner	and	that	at	24	hours	post	termination	all	cells	within	the	cortex	are	dead.	In	kidney	9	we	see	
initially	quite	unstable	levels	within	the	beginning	period	of	the	monitoring.	It	 is	 likely	that	this	is	a	
combination	of	 the	molecules	within	 the	extracellular	 fluid	reaching	equilibrium	with	the	dialysate	
fluid	and	possibly	changing	recovery	properties	of	the	probe	due	to	the	cold	extracellular	fluid	that	
bathes	the	probe.	However,	between	800-1300	mins,	we	see	a	flat	and	stable	trace	between	0.25-
0.33mM.	 At	 approximately	 1600	 minutes	 there	 is	 a	 large	 increase	 in	 the	 dialysate	 lactate	
concentrations	 to	a	maximum	of	0.9mM,	which	 is	 reached	at	 the	 same	 time	as	 that	of	 the	paired	
kidney	8.	Both	kidneys	show	similar	 flat,	 stable	baseline	 trends	within	 the	 first	24	hours.	Between	
1600	–	1700	mins,	both	kidneys	display	changes	suggesting	an	increase	in	lactate	concentration	with	
renal	 cortex.	 As	 previously	 described,	 this	 is	 an	 unexpected	 finding	 and	 with	 limited	 information	
should	be	taken	into	context	as	a	possible	aberration.	It	is	possible	this	is	secondary	to	degradation	
of	the	enzyme	beds,	changing	recovery	properties	of	the	probe	or	perhaps	further	release	of	lactate	
into	the	interstitial	fluid	by	direct	bacterial	action	on	the	dead	tissue.	
	
	
	 191	
	
Figure	119	–	Sub	study	2	–	Kidney	8	+	9	
The	dialysate	 lactate	concentration	 (mM)	 is	 shown	as	a	green	 trace	 for	kidney	9	 (right)	and	blue	 trace	 for	kidney	8	 (left)	during	 the	
period	of	monitoring	(mins).		
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5.5.3.2 Kidney	10	–	Cortical	and	medullary	monitoring	
Figure	120	demonstrates	 the	medullary	and	cortical	monitoring	 respectively	 for	kidney	10.	we	see	
that	 the	 retrieval,	 flushing	and	cold	 storage	process	has	been	 refined	and	 the	 time	of	 starting	 the	
monitoring	is	much	earlier.	The	starting	medullary	lactate	concentrations	are	close	to	zero	following	
a	short	period	of	time	for	equilibrium	to	be	reached.	The	medullary	lactate	concentration	increase	to	
a	 steady	 state	 between	 0.45-0.5mM.	 During	 the	 same	 period,	 we	 see	 that	 the	 cortical	 lactate	
concentration	 is	 virtually	 nil.	 It	 would	 appear	 that	 starting	 lactate	 concentration	 is	 higher	 in	 the	
medulla	 than	 the	 lactate,	 suggesting	 increased	 sensitivity	 to	 ischaemia	 within	 the	 medullary	
parenchyma.	 Unfortunately,	 technical	 failure	 with	 the	 HPLC	 pump	 resulted	 in	 lost	 data	 at	 a	 key	
point,	however	interpreting	the	data	before	and	after	the	event,	it	is	likely	that	lactate	concentration	
starts	 to	 increase	 during	 this	 point.	 The	 lactate	 concentration	 likely	 plateaus	 at	 this	 point	 in	 the	
monitoring	and	drops	down	to	zero.	The	decline	here	is	slower	than	previously	seen	in	kidneys	8	&	9.	
	
	
Figure	120	–	Sub	study	2	–	Kidney	10	
The	 dialysate	 lactate	 concentration	 (mM)	 is	 shown	 as	 a	 green	 trace	 for	 medulla	 and	 blue	 trace	 for	 cortex	 during	 the	 period	 of	
monitoring	(mins).		
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5.5.3.3 Kidney	11	–	Cortical	and	medullary	monitoring	
Figure	 121	 represent	 the	 traces	 for	 kidney	 11,	 demonstrating	 both	 cortical	 and	 medullary	
monitoring.		We	see	a	similar	pattern	with	higher	lactate	concentrations	within	the	medulla	than	the	
cortex.	The	cortex	display	a	steady	rise	in	lactate	as	anaerobic	metabolism	ensues,	however,	early	in	
the	monitoring,	the	lactate	production	within	the	medulla	accelerates	and	is	far	greater	than	that	of	
the	 lactate.	There	 is	a	small	period	of	data	 loss,	due	to	pump	failure,	at	around	the	24-hour	mark,	
which	likely	obscures	a	spike	in	cortical	and	medullary	lactate	concentrations.	This	was	also	seen	in	
kidney	8	and	9.	
	
	
Figure	121	–	Sub	study	2	–	Kidney	11	
The	 dialysate	 lactate	 concentration	 (mM)	 is	 shown	 as	 a	 green	 trace	 for	 medulla	 and	 blue	 trace	 for	 cortex	 during	 the	 period	 of	
monitoring	(mins).	 	
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5.5.3.4 Kidney	12	–	Medullary	monitoring	
Figure	 122	 demonstrates	 the	 medullary	 monitoring	 of	 kidney	 12,	 unfortunately	 the	 enzyme	 bed	
allocated	for	cortical	monitoring	failed	and	could	not	be	replaced	in	time.	The	medulla	monitoring	is	
also	coupled	with	a	temperature	probe	that	was	also	inserted	in	the	medulla.	We	can	see	that	as	the	
temperature	quickly	reaches	room	temperature	there	is	a	coupled	increase	in	anaerobic	metabolism	
with	an	increase	in	lactate	production	within	the	renal	medulla.	
	
Figure	122	–	Sub	study	2	–	Kidney	12.	The	dialysate	lactate	concentration	(mM)	is	shown	as	a	green	trace	for	medulla	and	blue	trace	for	
temperature	within	the	cortex	during	the	period	of	monitoring	(mins).	
5.5.3.5 Kidney	13	–	Cortical	and	medullary	monitoring	
The	monitoring	of	kidney	13	(Figure	123)	shows	some	similarities	to	kidney	11,	despite	being	from	
different	animals	and	monitored	on	different	occasions.	There	is	rapid	increase	in	lactate	production	
in	the	medulla,	coupled	with	a	slow	and	stable	rise	in	the	cortex.		
	
Figure	123	–	Sub	study	2	–	Kidney	13	–	The	dialysate	lactate	concentration	(mM)	is	shown	as	a	green	trace	for	medulla	and	blue	trace	
for	cortex	during	the	period	of	monitoring	(mins).	
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5.5.3.6 Kidney	14	–	Cortical	and	medullary	monitoring	
Figure	 124	 demonstrates	 the	monitoring	 for	 kidney	 14.	 The	 initial	 period	 of	monitoring	 is	 slightly	
different	as	 lactate	production	within	the	cortex	and	medulla	 is	approximately	equal,	however	the	
cortical	values	drop	suddenly,	faster	than	that	of	the	medulla.	
	
Figure	124	–	Sub	study	2	–	Kidney	14	
The	 dialysate	 lactate	 concentration	 (mM)	 is	 shown	 as	 a	 green	 trace	 for	 medulla	 and	 blue	 trace	 for	 cortex	 during	 the	 period	 of	
monitoring	(mins).	
5.5.3.7 Kidney	15	–	Cortical	and	medullary	monitoring	
Figure	125	demonstrates	the	medullary	monitoring	for	kidney	15.	We	see	very	low	levels	of	lactate	
production,	over	a	much	shorter	period	of	 time.	Much	of	 the	monitoring	period	demonstrated	no	
lactate	production;	 these	periods	have	been	removed	 from	the	trace	 to	allow	focus	on	the	period	
where	lactate	concentrations	were	identified.	As	well	as	identifying	very	small	concentrations,	there	
was	a	lot	of	‘noise’	evident	within	the	trace.	‘Noise’	is	characterised	by	spurious	fluctuations	in	the	
signal	 generated	 by	 the	 detector	 electrode.	 It	 can	 be	 caused	 by	 physical	 or	 chemical	 processes,	
instrumental	noise	or	environmental	noise.	I	have	attempted	to	clean	this	‘noise’	by	applying	a	10-
point	moving	average	across	both	races.	We	can	see	stable	but	very	low	levels	of	medullary	lactate;	
these	 concentrations	 are	 negligible.	We	 see	 a	 rise	 in	 the	 cortical	 lactate	 concentration	 at	 t	 =	 540	
mins,	 which	 represents	 a	 significant	 rise	 from	 baseline,	 however	 the	 absolute	 levels	 of	 cortical	
lactate	are	overall	low.	It	is	unlikely	that	these	traces	identify	any	ongoing	tissue	metabolism.	There	
is	such	variation	in	the	ischaemic	profile	 in	all	the	kidneys	monitored	in	sub-study	2.	Comparing	all	
the	kidneys	as	a	cohort	is	likely	unhelpful	and	distracting.	Examining	kidneys	11,	12,	13	and	14	there	
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are	numerous	interesting	findings.	Kidneys	within	this	sub-group	consistently	demonstrate	an	initial	
increase	in	both	cortical	and	medullary	lactate	concentration,	within	200	and	300	minutes	after	the	
time	of	death,	 this	 is	close	 to	 the	beginning	of	 the	monitoring.	 In	 these	cases,	 the	rsMD	 is	able	 to	
detect	 increasing	 lactate	 concentrations	 within	 10-15	 minutes	 of	 monitoring	 commencing.	
Examining	the	temperature	data	in	kidney	12,	the	initial	rise	in	the	lactate	concentration	correlates	
well	with	the	rapid	rise	 in	parenchymal	temperature.	 Increasing	temperature	causes	the	metabolic	
rate	 to	 increase	and	 the	onset	of	 aerobic	metabolism,	quickly	 followed	by	 the	onset	of	 anaerobic	
metabolism	with	 increasing	 lactate	concentrations.	 In	these	cases,	as	the	temperature	of	the	renal	
parenchyma	stabilises	with	the	ambient	temperature,	we	see	the	lactate	concentration	plateau	and	
then	fall	to	steady	baseline.	This	is	likely	the	same	finding	that	we	would	see	if	we	were	to	monitor	
kidneys	in	vivo	and	then	ligate	the	renal	artery,	thereby	causing	ischaemia.	Of	course,	this	would	be	
over	a	much	shorter	time	frame	and	changes	would	be	more	pronounced.	We	also	see	consistently	
that	 medulla	 monitoring	 exhibits	 greater	 lactate	 concentrations	 than	 cortical	 monitoring.	 This	 is	
unexpected,	as	it	would	indicate	a	greater	level	of	ischaemia	within	the	tissue.	
	
Figure	125	–	Sub	study	2	–	Kidney	15	–	The	dialysate	lactate	concentration	(mM)	is	shown	as	a	green	trace	for	medulla	and	blue	trace	
for	cortex	during	the	period	of	monitoring	(mins).	
Examining	 kidneys	 8,	 9,	 10	 and	 15,	 demonstrates	 very	 different	 profiles.	 The	 initial	 periods	 of	
monitoring	exhibit	flat	and	stable	profiles	with	very	low	lactate	concentrations.	We	do	typically	see	a	
rise	in	the	lactate	concentration,	however	this	is	very	late	in	the	monitoring	(>24hrs)	and	is	unlikely	
due	to	metabolic	changes.	It	is	highly	likely	that	the	tissue	is	dead,	and	possible	bacterial	breakdown	
and	putrification	in	the	warm	environment	causes	leakage	of	lactate	into	the	interstitium.	
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5.6 SUB-STUDY	3	
5.6.1 Aim	
In	 my	 sub-study	 2,	 I	 attempted	 to	 demonstrate	 a	 baseline	 ischaemic	 profile	 for	 porcine	 kidneys	
whilst	also	validating	this	technique	as	a	tool	for	assessing	the	ischaemic	injury	in	porcine	kidneys.	In	
4	out	of	the	8	kidneys	monitored,	I	was	able	to	show	strong	evidence	towards	this.	I	also	attempted	
to	reflect	clinical	practice,	by	utilising	the	concept	of	warm	and	cold	 ischaemia.	 In	sub-study	3,	my	
aim	was	 to	 further	advance	 the	clinical	 relevance	and	application	of	 this	 research,	and	 to	monitor	
the	kidneys	during	a	period	of	cold	storage.	
5.6.2 Method	
Kidneys	were	 retrieved	 in	 the	 same	manner	 as	 in	 sub-study	2,	 aiming	 to	 standardise	 the	 retrieval	
process.	Kidneys	were	retrieved	from	slaughtered	pigs	at	the	abattoir,	dissected	en	bloc,	cannulated,	
flushed	 and	 packed	 on	 ice.	 Kidneys	were	 transported	 back	 to	 the	 laboratory	 and	 the	 experiment	
setup.	 A	 plastic	 container	 was	 used	 to	 cradle	 the	 kidney	 in	 cold	 preservation	 fluid,	 which	 was	
surrounded	by	ice	within	a	Styrofoam	box.	The	set	up	was	similar	to	that	utilised	for	the	storage	and	
transport	of	organs	 for	 transplantation.	The	 temperature	of	 the	water	was	periodically	 tested	and	
ice	added	to	cool	if	needed.	In	the	first	experiment	within	sub-study	3,	I	retrieved	one	kidney	from	a	
single	 pig,	 which	 allowed	 me	 to	 monitor	 both	 cortex	 and	 medulla.	 Microdialysis	 probes	 were	
inserted,	ensuring	that	they	did	not	come	into	contact	with	the	solution,	and	a	temperature	probe	
was	 inserted	to	monitor	parenchymal	 temperature.	The	 temperature	probe	was	placed	within	 the	
cortex.	Monitoring	commenced	for	a	period	of	36	hours,	with	lactate	concentrations	sampled	every	
60	seconds.	After	36	hours,	 the	kidneys	were	removed	from	cold	storage	and	allowed	to	passively	
warm	to	ambient	room	temperature.	Figure	126	provides	an	overview	of	the	experimental	protocol	
for	sub-study	3.	
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Figure	126	–	Figure	10	–	Overview	of	experimental	protocol	–	sub-study	3	
	
Figure	127	–	Experimental	setup	of	sub-study	3	
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5.6.3 Results	
In	sub-study	3,	I	monitored	5	kidneys	that	were	retrieved	from	4	large	landrace	pigs.	Each	individual	
experiment,	underwent	calibration	testing	before,	during	and	at	the	end	of	monitoring.	Calibration	
interval	was	6hrs	for	all	cases,	which	also	involved	a	change	of	the	enzyme	beds.	Figure	128	below	
demonstrates	the	calibration	data	for	the	first	experiment.	
	
	
Figure	128	–	Lactate	calibration	data	–	sub-study	2	–	kidney	15	
Figure	129	demonstrates	a	summary	of	the	kidneys	monitored	within	sub-study	3.	Kidney	16	was	
monitored	as	a	single	kidney	and	therefore	allowed	me	to	monitor	both	cortex	and	medulla	
simultaneously.	Remaining	kidneys	(17-20)	were	monitored	as	pairs,	allowing	cortical	measurements	
of	lactate	only.	Temperature	monitoring	was	vital	for	this	study	and	was	therefore	included.
	
Figure	129	–	Sub-study	3	-	Summary	of	kidneys	monitored	
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Figure	 130	 displays	 the	 cortical	 and	medullary	 lactate	 concentrations,	 during	 the	 entire	 period	 of	
monitoring	for	nearly	36	hours.	The	temperature	monitoring	data	is	also	shown.	Both	medullary	and	
cortical	 lactate	 concentrations	 demonstrate	 negative	 concentrations,	 for	 the	 entire	 period	 of	
monitoring.	 This	 would	 suggest	 that	 there	 is	 no	 lactate	 produced	 in	 the	 renal	 parenchyma.	
Examining	the	raw	data	confirmed	negative	amplitude	peaks.	We	know	from	control	calibration	data	
that	a	negative	peak	equates	 to	a	concentration	of	zero,	as	 the	peak	allocation	algorithm	 in	Chart	
automatically	subtracts	the	value	of	the	baseline	from	the	amplitude.	By	all	accounts,	hypothermic	
storage	effectively	stops	metabolism,	preventing	anaerobic	metabolism	and	any	subsequent	lactate	
production.	All	subsequent	kidneys	monitored	within	this	sub-group	(kidneys	16-19)	demonstrated	
near	identical	patterns	of	metabolism,	exhibiting	amplitude	peaks	of	negative	value	throughout.	For	
these	kidneys,	the	raw	data	was	not	converted	to	concentration	values,	as	they	would	have	been	all	
negative,	which	equates	to	concentrations	of	zero.	
	
Figure	130	–	Sub	study	3	–	Kidney	16	
The	dialysate	lactate	concentration	(mM)	is	shown	as	a	green	trace	for	medulla,	blue	trace	for	cortex,	light	blue	trace	for	temperature	
during	the	period	of	monitoring	(mins).	
	 	
-5
-4
-3
-2
-1
0
1
2
3
4
5
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
200 400 600 800 1000 1200 1400 1600 1800 2000 2200
Te
m
pe
ra
tu
re
	(C
en
tig
ra
de
)
La
ct
at
e	
Co
nc
	(m
M
)
Time	(Mins)
Sub-study	3	- Kidney	16
Medullary	&	Cortical	 Monitoring	 whilst	 on	cold	storage
Medulla Cortex Temperature
	 201	
5.7 SUB-STUDY	4	
5.7.1 Aim	
My	objectives	in	sub-study	4	were	to	further	assess	feasibility	of	using	the	rsMD	to	monitor	changes	
in	lactate	concentration	within	the	renal	cortex	during	SCS	and	during	HMP	in	a	comparative	porcine	
model	whilst	also	comparing	the	effects	of	SCS	and	HMP	on	renal	cellular	metabolism	and	ischemia	
during	the	preservation	period.		
5.7.2 Method	
As	per	my	previous	sub-studies,	 I	used	an	experimental	porcine	DCD.	Kidneys	were	retrieved	from	
slaughtered	pigs	from	an	abattoir,	dissected	en	bloc,	cannulated,	flushed	and	packed	on	ice.	Special	
attention	was	made	to	ensure	adequate	length	of	the	renal	artery	(Figure	131)	for	cannulation	to	the	
HMP	 device.	 Kidneys	 were	 transported	 back	 laboratory	 and	 the	 experiments	 were	 setup.	 The	
standardised	warm	ischaemia	time	was	15	minutes,	with	‘knife	to	microdialysis’	time	approximately	
4	hours.	 This	 included	 significant	 transport	and	 set	up	 time.	Key	 information	was	documented	 for	
later	analysis,	 such	as	 the	mass	of	each	kidneys	 (following	preservation,	 all	 kidneys	were	weighed	
again),	 time	 of	 death,	 time	 of	 flushing,	 transport	 time	 and	 retrieval	 time.	 Upon	 arrival	 at	 the	
laboratory,	both	kidneys	from	the	same	animal	were	allocated	to	one	of	two	experimental	groups:	
Group	1	was	static	cold	storage	and	Group	2	was	hypothermic	machine	perfusion.		
5.7.2.1 Group	1	–	Static	Cold	Storage	
The	kidney	was	positioned	in	a	plastic	box,	partially	submerged	in	UW	solution	and	placed	on	ice.	A	
microdialysis	 probe	 was	 tunnelled	 into	 the	 lateral	 cortex	 of	 each	 kidney	 using	 the	 previously	
described	technique.	A	temperature	probe	was	also	inserted	into	the	cortex	of	the	kidney	to	enable	
simultaneous	 online	 monitoring	 of	 tissue	 temperature.	 Microdialysis	 and	 temperature	
measurements	were	commenced	immediately	and	continued	for	24	hours.		
5.7.2.2 Group	2	–	Hypothermic	Machine	Perfusion	
The	 contralateral	 kidney	 was	 placed	 on	 the	 RM3TM	 perfusion	 device	 (Waters	 Medical	 Systems,	
Rochester,	 USA).	 After	 carefully	 dissection	 of	 the	 renal	 vessels,	 ensuring	 adequate	 length	 on	 the	
renal	artery,	a	straight	renal	cannula	(Waters	Medical,	Rochester,	Minnesota)	was	inserted	into	the	
renal	artery.	Using	a	2/0	Vicryl	suture	(Ethicon,	UK),	the	cannula	was	secured	and	then	placed	into	
the	perfusion	circuit.	The	initial	perfusion	pressure	was	set	for	a	systolic	pressure	between	40	to	45	
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mmHg.	 As	 the	 renal	 vascular	 system	 dilated,	 the	 systolic	 pressure	 dropped	 and	 the	 perfusion	
pressure	was	adjusted	to	maintain	systolic	pressure.	
Prior	to	commencement	of	perfusion,	a	microdialysis	probe	was	tunnelled	into	the	lateral	cortex	of	
each	 kidney,	 as	 in	 Group	 1.	 Upon	 perfusion,	 the	 system	 delivered	 a	 pulsatile	 flow	 of	 cold	 UW	
solution	through	the	renal	artery	of	each	kidney	for	a	period	of	10	hours.	UW	solution	(Viaspan)	was	
used	as	the	HMP	perfusate	 in	these	experiments.	The	same	solution	was	chosen	for	both	SCS	and	
HMP	to	limit	the	effect	of	external	variables	on	our	data.		
Microdialysis	measurements	were	commenced	at	the	outset	of	perfusion	and	continued	throughout	
the	study	period.	 In	addition	to	providing	flow,	the	RM3TM	 is	able	to	provide	real	time	information	
concerning	organ	viability	during	preservation,	 including	perfusion	pressures	(systolic,	diastolic	and	
mean),	 temperature,	 flow	 rate	 and	 internal	 vascular	 resistance.	 The	display	 screen	on	 the	 control	
unit,	 shows	 the	 real-time	perfusion	data.	This	data	was	 recorded	and	analysed.	At	 set	 time	points	
during	 the	 protocol	 perfusion,	 volume	 was	 adjusted	 such	 that	 kidneys	 met	 the	 basic	 perfusion-
parameter-based	viability	criteria	employed	clinically	by	Talbot	et	al.	190	
Following	the	allocated	preservation	period,	each	kidney	was	allowed	to	warm	passively	for	a	period	
of	 2	 hours	whilst	microdialysis	measurements	were	 continued.	My	 aim	was	 to	 detect	 changes	 in	
lactate	 concentrations	 as	 parenchymal	 temperature	 increased	 and	 ischemic	 cellular	 injury	
accumulated.	I	would	be	able	to	identify	if	there	was	a	difference	between	preservations	groups	in	
response	 to	 this	 simulated	 warm	 ischaemia.	 Findings	 would	 be	 correlated	 with	 temperature	
measurements,	 that	 were	 recorded	 form	 the	 probe	 in-situ.	 Figure	 134	 displays	 the	 experimental	
protocol	for	sub-study	4.	
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Figure	131	-	Back-table	dissection	of	porcine	kidney.	Renal	artery	and	vein	are	demonstrated	
	
Figure	132	-	Hypothermic	machine	perfusion	
Each	kidney	from	one	animal	were	connected	to	a	perfusion	circuit	generated	by	individual	Waters	Medical	RM3®	perfusion	machines	
via	the	renal	arteries	as	illustrated.	Microdialysis	probes	can	be	seen	located	in	the	lateral	cortex	(left)	and	medulla	(right)	of	the	kidney	
Surgery & Anaesthesia 10/11  Nicholas Bullock 
Part C: BSc Project  Page | 30  
 
 
  
Figure 2 | Setup of organ preservation techniques. A: static cold storage: both kidneys 
from the same donor animal were placed in a plastic box, partially submerged in 
University of Wisconsin solution and surrounded by ice. Microdialysis probes can be seen 
located in the lateral cortex (above) and medulla (below) and a temperature probe in the 
cortex of the right kidney.  B and C: hypothermic machine perfusion: each kidney from 
one animal were connected to a perfusion circuit generated by individual Waters Medical 
RM3® perfusion machines via the renal arteries as illustrated in in C.  Microdialysis probes 
can be seen located in the lateral cortex (left) and medulla (right) of the kidney shown in 
C. NOTE: whilst medullary microdialysis probes can be seen in-situ, data recorded from 
these was not intended for inclusion in this study.  
A 
B 
 
C B	
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Figure	133	-	Typical	set	up	of	HMP.	Renal	artery	cannulated	and	kidney	perfused	
	
Figure	134	Figure	10	-	Overview	of	experimental	protocol	–	Sub-study	
Sub	study	3:	Overview	of	experimental	protocol
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5.7.3 Results	
I	 retrieved	 14	 kidneys	 from	 seven	 large	 landrace	 pigs	 (80-100kg).	 I	 utilised	 the	 same	 retrieval	
protocol,	 as	 in	 previous	 sub-studies	 (sub-study	 2	 &	 3).	 Each	 pig	 was	 stunned	 and	 terminated	 via	
exsanguination.	 I	 performed	 a	 rapid	 laparotomy	 and	 en	 bloc	 resection	 of	 both	 kidneys.	 I	 would	
perform	back	table	dissection,	 identifying	the	renal	arties.	These	would	be	cannulated	sequentially	
and	flushed	with	500ml	of	cold	UW	solution	until	the	venous	effluent	was	clear.	Despite	the	need	for	
rapid	onset	cold	flushing,	significant	care	was	needed	when	performing	sharp	dissection	on	the	renal	
artery.	It	was	imperative	that	the	arteries	were	long	enough,	to	allow	cannulation	in	the	HMP	circuit.	
Care	 had	 to	 be	 taken	 to	 not	 cause	 any	 tears	 or	 avulse	 small	 arterial	 branches,	 which	 would	
complicate	machine	 perfusion.	 Once	 the	 kidneys	were	 adequately	 flushed	with	 cold	 preservation	
fluid,	 I	 would	 carefully	 dissect	 the	 renal	 artery	 and	 vein,	 excising	 any	 insulating	 adipose	 tissue.	
Retrieval	time	and	hence	warm	ischaemia	times	were	standardised	to	approximately	15	mins.		
Unfortunately,	 excessive	 mechanical	 noise	 arising	 from	 a	 technical	 fault	 with	 the	 rsMD	 analyser	
rendered	data	from	four	experiments	uninterpretable,	leaving	a	total	of	four	and	six	kidneys	in	the	
SCS	and	HMP	groups	respectively.		
Figure	135	shows	a	summary	of	 the	kidneys	monitored	 in	sub-study	4	and	Figure	136	summarises	
procurement	and	organ	characteristic	data.	
There	were	no	significant	differences	between	the	pre-preservation	mass	or	warm	ischaemia	times	
of	kidneys	in	each	group.	Those	in	the	HMP	group	were	however	subject	to	significantly	higher	pre-
preservation	 cold	 ischaemia	 times,	 defined	 as	 the	 time	 between	 flushing	 and	 commencement	 of	
microdialysis	monitoring	(means	of	187±14	and	249±22	hours	for	SCS	and	HMP	groups	respectively,	
P	=	0.001).		
There	was	no	significant	difference	between	the	in-vitro	RR	of	the	system	for	the	monitoring	of	each	
group	(means	of	26.4%	±	5.8	and	22.3%	±	1.5	for	SCS	and	HMP	groups	respectively,	P	=	0.245).	Three	
experiments	were	conducted	to	compare	the	effect	of	temperature	on	RR	of	the	system.	In	each	the	
reduction	 from	ambient	 to	 hypothermic	 temperatures	 led	 to	 a	 decrease	 in	RR	 (mean	decrease	of	
14.9	±	6.7	percent),	although	this	failed	to	reach	significance	(P	=	0.066).		
Each	 kidney	underwent	 calibration	with	 known	concentrations	of	 lactate	 solution.	Calibration	was	
performed	pre-commencement	of	monitoring,	 every	2	hours	during	monitoring	and	at	 the	end.	A	
sample	 of	 the	 calibration	 data	 and	 accompanying	 trace	 is	 shown	 (Figure	 137)	 for	 the	 first	 kidney	
monitored	in	the	SCS	group.	
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Figure	135	-	Sub-study	4	-	Summary	of	kidneys	monitored	
	
Figure	136	-	Sub-study	4	-	SCS	vs	HMP	-	organ	characteristics	
Kidney	No. Pig	No.
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rsMD malfunction
SCS (N=4) HMP (N=6)
Mean  ± SD Mean  ± SD
Pre-preservation mass (g) 185.7  ± 11.1 189.1  ± 28.4 0.824
Post-preservation mass (g) - 228.5  ± 36.8 -
Total warm ischaemia time (mins) 15  ± 3 15  ± 3 1
Pre-preservation cold ischaemia time (mins) 187  ± 14 249  ± 22 0.001
Cortex tissue temperature (˚C) 4.41  ± 0.16 7.12  ± 0.61 ≤ 0.001
In-vitro relative recovery at room temperature (%) 26.4  ± 5.8 22.3  ± 1.5 0.245
P value
	 207	
	
	
Figure	137		Lactate	calibration	data	-	sub-study	4	-	kidney	1	SCS	
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5.7.4 Organ	preservation	
5.7.4.1 Static	Cold	Storage	
Figure	138	demonstrates	 cortical	 lactate	monitoring	 for	 the	 first	 kidney	within	 the	SCS	 sub-group.	
The	kidney	was	subjected	to	cold	storage	and	then	allowed	to	warm	passively	to	room	temperature.	
The	trace	represents	the	dialysate	lactate	concentrations	within	the	renal	cortex.	Following	a	short	
period	where	the	lactate	concentration	stabilises	and	equilibrium	is	reached,	the	subsequent	period	
of	monitoring	for	1400	minutes	is	very	stable	with	an	overall	flat	baseline	between	0.15-0.2mM.	We	
can	 see	 at	 1480	minutes,	 when	 the	 kidney	 is	 taken	 out	 of	 the	 ice	 bath	 and	 allowed	 to	 passively	
warm,	 the	 lactate	concentration	rapidly	 increases	 to	0.7mM.	Once	a	steady	state	 is	 reached	there	
are	 numerous	 events	where	 the	 lactate	 concentration	 oscillates	 around	 the	 baseline.	 This	maybe	
secondary	 to	 localised	 fluctuations	within	 the	metabolism	 of	 the	 renal	 cortex	 or	 due	 to	 changing	
recovery	properties	of	the	probe.	
Figure	 139	 below	 shows	 the	 final,	 warming	 period	 of	 monitoring.	 The	 grey	 trace	 represents	 the	
microdialysis	monitoring	of	the	renal	cortex	and	demonstrates	the	lactate	concentrations,	the	blue	
line	represents	the	output	from	the	temperature	probe	that	was	 inserted	 into	the	renal	cortex.	At	
the	end	of	 the	 cold	 ischaemia	period	 (T=1459),	when	 the	kidney	 is	 “out	of	 ice”,	we	 see	a	 smooth	
linear	 increase	 in	the	cortical	 temperature.	This	 is	 followed	by	a	 lag	of	approximately	6-7	minutes,	
whereby	 a	 very	 large	 and	 rapid	 surge	 in	 the	 cortical	 lactate	 concentration	 is	 evident.	 This	 likely	
represents	a	significant	increase	in	anaerobic	metabolism	following	cessation	of	hypothermia.	Once	
the	increase	reaches	its	peak,	within	10	minutes	there	is	a	slow	and	progressive	drop	in	the	cortical	
lactate	concentration.	This	is	likely	to	represent	a	combination	of	reduction	in	anaerobic	metabolism	
as	cells	die	with	a	washout	effect	of	the	microdialysis	sampling,	as	molecules	are	removed	from	the	
extracellular	 fluid	but	not	 replaced	by	the	dead	tissue	or	due	to	degradation	of	 lactate	by	enzyme	
action.		
Examination	of	the	data	of	the	other	kidneys	monitored	within	this	sub-group,	demonstrate	similar	
patterns,	 with	 reasonable	 levels	 of	 congruency.	 A	 discussion	 of	 the	 entire	 sub-group	 follows.	
Individual	 traces	 of	 the	 other	 kidneys	 monitored	 within	 this	 sub-group	 are	 presented	 within	 the	
appendix.	
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Figure	138	–	Sub	study	4	–	Kidney	1	SCS	
The	dialysate	lactate	concentration	(mM)	is	shown	as	a	grey	trace	during	the	period	of	monitoring	(mins).		
	
Figure	139	–	Sub	study	4	–	Kidney	1	SCS	
Warming	period.	The	dialysate	lactate	concentration	(mM)	is	shown	as	a	grey	trace	during	the	period	of	monitoring	(mins),	whilst	the	
temperature	is	demonstrated	by	the	blue	trace.	
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 100 200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600
Di
al
ys
at
e	
La
ct
at
e	
co
nc
en
tr
at
io
n	
in
	m
M
Time	mins
Sub-study	4	- Kidney	1	SCS
Cold	Storage	Group
Entire	period	of	monitoringCortical	 Lactate	Conc	 (mM)
0
5
10
15
20
25
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
1440 1460 1480 1500 1520 1540 1560 1580 1600
Te
m
p	
(C
en
t)
Di
al
ys
at
e	
La
ct
at
e	
co
nc
en
tr
at
io
n	
in
	m
M
Time	mins
Sub-study	4	- Kidney	1	SCS
Cold	Storage	Group
Warming	period	of	monitoring
Cortical	 Lactate	Conc	 (mM)
Cortical	 Temperature	 (Cent)
	 210	
5.7.4.2 Hypothermic	machine	perfusion	
The	 figure	 below	 displays	 the	 cortical	 monitoring	 of	 kidney	 1	 in	 the	 HMP	 group.	 The	 grey	 trace	
represents	cortical	lactate	concentration	(mM)	during	the	period	of	monitoring,	whilst	the	blue	trace	
demonstrates	 the	 cortical	 temperature.	 The	 initial	 lactate	 concentration	 is	 at	 0.1mM,	which	 is	 in	
keeping	with	other	kidneys	 that	underwent	a	 cold	 flushing	and	subsequent	hypothermic	protocol.	
The	 lactate	 concentration	 is	 stable	 for	10	hours	and	 is	maintained	between	0.1-0.14mM.	After	10	
hours,	it	appears	that	the	cortical	lactate	concentration	slowly	increases	to	0.2	over	a	2-hour	period,	
this	 corresponds	 with	 the	 moment	 that	 the	 kidney	 is	 removed	 from	 ice	 and	 allowed	 to	 warm	
passively.	 In	 the	 first	 15	minutes	 of	monitoring,	 the	 lactate	 concentration	 stabilises,	 however	 the	
fluctuations	around	the	narrowing	baseline	range,	that	we	saw	in	the	SCS	group	are	lost	in	the	HMP	
model.	This	lends	wait	to	the	theory	that	these	fluctuations	are	a	result	of	local	metabolic	changes	
rather	microdialysis	 sampling	 artefact.	 Figure	 203	 demonstrates	 the	 initial	 4	 hours	 of	monitoring,	
which	 further	 demonstrates	 the	 stable	 metabolic	 profile.	 The	 sudden	 increase	 in	 the	 cortical	
temperature	marks	the	time	when	the	kidney	was	removed	from	the	perfusion	circuit	and	allowed	
to	warm	 passively,	 partially	 simulating	 a	 clinical	 warm	 ischaemia	model.	 The	 process	 of	 warming	
causes	a	perceptible	rise	in	the	lactate	concentration	within	the	cortex,	however	it	is	not	as	rapid	or	
as	great	as	that	identified	in	the	SCS	group.	
Figure	141	demonstrates	the	machine	perfusion	parameters	for	Kidney	1HMP	that	were	generated	
by	 the	 RM3	 perfusion	 device,	 these	 were	 recorded	 during	 the	 period	 of	 monitoring	 and	
subsequently	 analysed.	We	 can	 see	 that	 the	 intravascular	 resistance	 is	 initially	 high,	 perhaps	 due	
microthrombosis	 that	 is	not	 initially	 removed	by	manual	 flushing	or	oedema	 formation	within	 the	
microvasculature.	As	HMP	is	commenced	we	see	a	rapid	drop	in	the	resistance,	with	a	subsequent	
increase	in	the	flow	rate	within	the	kidney.	The	perfusion	pressures	also	mirror	this	pattern	and	are	
all	in	keeping	with	a	viable	organ	that	would	potentially	be	used	in	clinical	transplantation.193		
Examination	of	the	data	of	the	other	kidneys	monitored	within	this	sub-group,	demonstrate	similar	
pattern,	 however	 with	 some	 differences.	 A	 discussion	 of	 the	 entire	 sub-group	 follows.	 Individual	
traces	of	the	other	kidneys	monitored	within	this	sub-group	are	presented	within	the	appendix.	
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Figure	140	–	Sub	study	4	–	Kidney	I	HMP	
Entire	period	of	monitoring.	The	dialysate	lactate	concentration	(mM)	is	shown	as	a	grey	trace	during	the	period	of	monitoring	(mins),	
whilst	the	temperature	is	demonstrated	by	the	blue	trace.	
	
	
Figure	141	–	Sub-study	4	–	Kidney	1	HMP	
Perfusion	Parameters:	 Systolic	and	diastolic	pressure,	mean	arterial	pressure,	 intra-vascular	 resistance,	 flow	arte	and	perfusion	 flow	
index.	 	
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5.7.5 Comparison	of	organ	preservation	modalities	–	SCS	+	HMP		
Both	models	of	organ	preservation	maintained	continuous	hypothermic	conditions	throughout	the	
study	period.	The	cortical	temperature	of	kidneys	preserved	using	SCS	was	significantly	 lower	than	
that	of	those	preserved	using	HMP	(means	of	4.41	±	0.16	and	7.12	±	0.61	̊C	respectively,	P	=	≤0.001).	
All	 kidneys	 in	 the	 HMP	 group	 demonstrated	 excellent	 perfusion	 characteristics	 (Figure	 142),	 such	
that	by	the	end	of	the	study	period	all	would	have	been	considered	acceptable	for	transplantation	
according	to	the	perfusion-parameter-based	viability	criteria	employed	clinically	by	Talbot	et	al.	193	
During	 perfusion,	 flow	 rate	 gradually	 increased	 whilst	 internal	 vascular	 resistance	 decreased	
(Appendix	3)	with	overall	mean	values	of	28.06	±	7.66	ml/min/100g	and	0.61	±	0.41	mmHg/ml/min	
respectively.	The	rsMD	system	was	able	to	reliably	detect	lactate	in	the	dialysate	recovered	from	the	
cortex	of	all	of	kidneys	 in	each	group.	 In	both	groups	 there	was	an	 initial	period	of	approximately	
four	hours	in	which	the	dialysate	lactate	concentrations	were	unstable,	as	shown	below	(Figure	143	
and	Figure	144)	In	the	case	of	kidneys	preserved	using	SCS,	the	dialysate	lactate	concentration	began	
high	and	gradually	decreased	until	a	steady	state	was	reached.	A	contrasting	trend	was	observed	in	
kidneys	 preserved	 by	 HMP,	 although	 some	 did	 exhibit	 an	 initially	 high	 dialysate	 lactate	
concentration.	It	is	plausible	this	could	be	artefact	caused	by	manual	manipulation	and	thus	cannot	
be	 reliably	 interpreted.	 Following	 approximately	 15	 minutes	 of	 perfusion,	 dialysate	 lactate	
concentration	appeared	to	reach	a	maximum	level	 in	all	kidneys,	after	which	it	gradually	 increased	
until	steady	state	was	achieved.		
The	cortical	lactate	concentrations	of	each	kidney	within	its	sub-group,	within	a	defined	period	(15	–	
30	mins)	 has	 been	 pooled	 together,	 allowing	 calculation	 of	 the	mean.	 Figure	 145	 shows	 that	 the	
initial	 dialysate	 lactate	 concentration	of	 kidneys	 preserved	using	 SCS	was	 significantly	 higher	 than	
that	of	kidneys	preserved	using	HMP	(medians	of	332.8	(255.0	-	388.0)	and	105.5μM	(66.9	-	180.2)	
respectively,	P	=	0.010).		
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Figure	142	-	Perfusion	parameters	of	kidneys	preserved	using	hypothermic	machine	perfusion.		
All	values	provided	as	a	mean	of	those	obtained	directly	from	the	machine	at	15	minutes	and	every	subsequent	hour	of	perfusion.		
	
	
Figure	143	–	Sub	Study	4	–	Static	Cold	Storage	–	Kidneys	1-	4	
Kidney
1	HMP 6.81 ±	 1.12 34.4 ±	 2.6 22.8 ±	 6 1.05 ±	 0.65 0.51 ±	 0.13
2	HMP 6.93 ±	 0.67 32.9 ±	 3.1 26.8 ±	 5 0.78 ±	 0.30 0.62 ±	 0.14
3	HMP 8.24 ±	 1.12 19.4 ±	 5.5 24.2 ±	 7 0.43 ±	 0.32 0.76 ±	 0.26
4	HMP 6.42 ±	 1.11 26.5 ±	 2.4 25.4 ±	 6 0.53 ±	 0.24 0.66 ±	 0.16
5	HMP 7.13 ±	 0.65 22.8 ±	 3.1 32.2 ±	 5 0.41 ±	 0.13 0.91 ±	 0.17
6	HMP 6.77 ±	 0.83 26.5 ±	 2.2 37.1 ±	 7 0.44 ±	 0.14 0.94 ±	 0.17
Overall 7.05 ±	 1.07 27.1 ±	 6.2 28.1 ±	 8 0.61 ±	 0.41 0.73 ±	 0.23
(Mean	±	SD) (Mean	±	SD) (Mean	±	SD) (Mean	±	SD) (Mean	±	SD)
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Figure	144	–	Sub	Study	4	–	Hypothermic	Machine	Perfusion	–	Kidneys	1-	6	
	
Figure	145	-	Comparison	of	average	dialysate	lactate	concentration	of	kidneys	preserved	using	static	cold	storage	
Initial	dialysate	lactate	concentration	values;	defined	as	the	mean	dialysate	lactate	concentration	between	the	first	15	and	30	minutes	
of	preservation.	
	
	
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 20 40 60 80 100 120 140 160 180 200 220 240
Di
al
ys
at
e	
La
ct
at
e	
co
nc
en
tr
at
io
n	
(m
M
)
Time	(mins)
Hypothermic	Machine	Perfusion	Kidneys	1-6
0	- 240	mins
Kidney	1 Kidney	2
Kidney	3 Kidney	4
Kidney	5 Kidney	6
Surgery & Anaesthesia 10/11  Nicholas Bullock 
Part C: BSc Project  Page | 34  
 
  
Figure 6 | Comparison of average dialysate lactate concentration of kidneys 
preserved using static cold storage and hypothermic machine perfusion. A: initial 
dialysate lactate concentration values; defined as the mean dialysate lactate 
concentration between the first 15 and 30 minutes of preservation. B: steady state 
dialysate lactate concentration values; defined as the mean lactate concentration 
between the fourth hour and the cessation of preservation. Group A represents those 
kidneys preserved using HMP with a high dialysate lactate concentration. Group B 
represents those kidneys preserved using HMP with a low dialysate lactate concentration 
† Mann-Whitney U-Test used to calculate significance value. NS: not significant.     
P = 0.010† 
NS† 
NS† NS† 
A 
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Figure	146	and	Figure	147	demonstrate	the	relationship	between	cortical	lactate	concentration	and	
time	for	the	entire	duration	of	SCS	and	HMP	respectively.	Examining	the	monitoring	of	SCS	kidneys,	
with	 the	 exception	 of	 one	 kidney,	 the	 dialysate	 lactate	 concentration	 reaches	 a	 steady	 state;	 the	
levels	remain	constant	for	the	remainder	of	the	preservation	period.		
This	 phenomenon	 is	 also	 observed	 in	 kidneys	 preserved	 using	 HMP.	 The	 dialysate	 lactate	
concentrations	 similarly	 maintain	 a	 steady	 state	 after	 the	 first	 four	 hours	 of	 preservation.	 In	 the	
period	 that	 steady	 state	 is	 achieved	 and	maintained,	 mean	 cortical	 lactate	 concentrations	 for	 all	
kidney	within	a	sub-group	can	be	calculated.	Steady	state	is	achieved	within	4	hours	and	continues	
during	the	preservation	period,	prior	to	the	commencement	of	warming.		
With	the	exception	of	the	two	kidneys	from	the	same	animal,	there	was	marked	variation	between	
the	 steady	 state	 lactate	 concentrations	 of	 kidneys	 in	 the	 SCS	 group.	 In	 contrast,	 the	 kidneys	
preserved	using	HMP	appeared	to	fall	into	two	distinct	populations,	as	shown	in	Figure	147.	In	three	
kidneys,	collectively	termed	group	A,	the	median	dialysate	lactate	concentration	was	similar	to	that	
seen	 in	 the	 SCS	 group	 (264.1	 (252.5-269.5)	 and	 238.3μM	 (137.2-291.3)	 respectively,	 P=1.00).	
However,	in	the	other	three	kidneys,	termed	group	B,	the	levels	were	considerably	lower	than	those	
seen	 in	 either	 the	 SCS	 group	 or	 group	 A	 (median	 120.6μM	 (112.6-121.9),	 although	 this	 failed	 to	
reach	 significance	 (P=0.400	 and	 0.100	 respectively).	 The	 relationship	 between	 the	 three	 groups	 is	
shown	in	Figure	148.	
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Figure	146	–	Sub	Study	4	–	Static	Cold	Storage	–	Kidneys	1-	4	SCS.	Cortical	lactate	concentrations	demonstrated	for	the	entire	period	of	monitoring.	
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Figure	147	–	Sub	Study	4	–	Hypothermic	Machine	Perfusion	–	Kidneys	1-	6	HMP.	Cortical	lactate	concentrations	demonstrated	for	the	entire	period	of	monitoring	
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
-25 25 75 125 175 225 275 325 375 425 475 525 575 625
Di
al
ys
at
e	
La
ct
at
e	
co
nc
en
tr
at
io
n	
(m
M
)
Time	(mins)
Sub-study	4	- Kidney	1	- 6	HMP
Hypothermic	Machine	Perfusion	
Entire	Period	of	monitoringKidney	1
Kidney	2
Kidney	3
Kidney	4
Kidney	5
Kidney	6
A	
B	
	Figure	148	Comparison	of	average	dialysate	lactate	concentration	of	kidneys	preserved	using	hypothermic	machine	perfusion.		
Steady	 state	 dialysate	 lactate	 concentration	 values;	 defined	 as	 the	mean	 lactate	 concentration	 between	 the	 fourth	 hour	 and	 the	 cessation	 of	
preservation.	 Group	 A	 represents	 those	 kidneys	 preserved	 using	 HMP	 with	 a	 high	 dialysate	 lactate	 concentration.	 Group	 B	 represents	 those	
kidneys	 preserved	 using	HMP	with	 a	 low	dialysate	 lactate	 concentration	 †	Mann-Whitney	U-Test	 used	 to	 calculate	 significance	 value.	NS:	 not	
significant.	
5.7.6 Quantifying	ischaemic	injury	
Figure	 149	 and	 Figure	 150	 demonstrates	 the	 cortical	 lactate	 concentration	 during	 the	 warming	 period.	
Whilst	 exact	 warming	 rates	 could	 not	 be	 standardised,	 the	 tissue	 warming	 profile	 were	 similar	 in	 both	
groups.	 In	 those	 kidneys	 preserved	 using	 SCS,	 warming	 lead	 to	 a	 rapid	 initial	 rise	 in	 dialysate	 lactate	
concentration	followed	by	a	similarly	rapid	decline	to	a	second	steady	state.	This	trend	was	not	seen	in	the	
HMP	group	 in	which	the	kidneys	exhibited	a	more	 linear	 increase	 in	dialysate	 lactate	concentration	during	
warming.	During	the	warming	period,	defined	as	 the	moment	the	kidney	 is	 removed	from	preservation	to	
the	end	of	monitoring,	cortical	lactate	concentrations	were	pooled	for	each	kidney	within	its	sub-group,	with	
calculation	of	mean	values.		
In	 all	 kidneys	 during	 this	 30-minute	 period,	 this	 change	 in	 cortical	 lactate	 concentration	 was	 positive,	
representing	 an	 increase	 in	 lactate	 concentration	 that	was	 highly	 significant	 (P≤0.001	 in	 all	 kidneys).	 The	
kidneys	preserved	using	SCS	displayed	a	consistent	increase	in	dialysate	lactate	concentration,	with	a	median	
value	of	61.1μM	(54.5-65.8).	 In	contrast,	 there	was	great	variation	between	 individual	kidneys	 in	the	HMP	
group.	 Those	 kidneys	 belonging	 to	 group	 A	 demonstrated	 a	 marked,	 yet	 varied,	 increase	 in	 lactate	
concentration	 over	 the	 warming	 period,	 with	 a	 median	 of	 272.9μM	 (150.2	 –	 283.7).	 Conversely,	 those	
belonging	to	group	B	exhibited	a	similar	increase	to	those	preserved	by	SCS,	with	a	median	value	of	61.1μM	
(54.5	–	65.8)	(Figure	151).	However,	all	differences	failed	to	reach	significance.		
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Figure 6 | Comparison of average dialysate lactate concentration of kidneys 
preserved using static cold storage and hypothermic machine perfusion. A: initial 
dialysate lactate concentration values; defined as the mean dialysate lactate 
concentration between the first 15 and 30 minutes of pre ervation. B: steady state 
dialysate lactate concentration values; defined as the mean lactate concentration 
between the fourth hour and the cessation of preservation. Group A represents those 
kidneys preserved using HMP with a high dialysate lactate concentration. Group B 
represents those kidneys preserved using HMP with a low dialysate lactate concentration 
† Mann-Whitney U-Test used to calculate significance value. NS: not significant.     
P = 0.010† 
NS† 
NS† NS† 
A 
B 
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Figure	149	–	Sub	Study	4	–	Static	Cold	Storage	–	Kidneys	1-	4	SCS.	Cortical	lactate	concentrations	demonstrated	for	the	warming	period.	
	
Figure	150	–	Sub	Study	4	–	Hypothermic	Machine	Perfusion	–	Kidneys	1-	6	HMP	
Cortical	lactate	concentrations	demonstrated	for	the	warming	period.	
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Figure	151	-	Comparison	of	the	change	in	dialysate	lactate	concentration	after	two	hours	of	warming	in	kidneys	preserved	using	static	cold	storage	
and	hypothermic	machine	perfusion.		
Concentration	 change	defined	as	 the	difference	between	 the	mean	dialysate	 lactate	 concentration	during	 the	30	minutes	prior	 to	 cessation	of	
preservation,	 and	 the	 mean	 dialysate	 lactate	 concentration	 during	 the	 final	 30	 minutes	 of	 the	 warming.	 Group	 A	 represents	 those	 kidneys	
preserved	using	HMP	with	a	high	dialysate	 lactate	concentration.	Group	B	 represents	 those	kidneys	preserved	using	HMP	with	a	 low	dialysate	
lactate	concentration.	†	Mann-Whitney	U-Test	used	to	calculate	significance	value.	NS:	not	significant	
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Figure 8 | Comparison of the change in dialysate lactate concentration after two 
hours of warming in kidneys preserved using static cold storage and hypothermic 
m chine perfusion. Co cent ation change defined as the difference between the mean 
dialysate lactate concentration during the 30 minutes prior to cessation of preservation, 
and the mean dialysate lactate concentration during the final 30 minutes of the warming. 
Group A represents those kidneys preserved using HMP with a high dialysate lactate 
concentration. Group B represents those kidneys preserved using HMP with a low 
dialysate lactate concentration. † Mann-Whitney U-Test used to calculate significance 
value. NS: not significant.     
NS† 
NS† NS† 
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5.8 DISCUSSION	
In	sub-study	1	my	aim	was	to	test	the	feasibility	of	using	the	rsMD	assay	to	detect	and	monitor	renal	cortical	
lactate	concentrations,	as	a	marker	of	ischaemic	injury.	I	wanted	to	develop	a	baseline	ischaemic	profile	of	a	
freshly	retrieved	kidney,	demonstrating	the	metabolic	processes	that	take	place	during	this	warm	ischaemia	
period.	With	 this	 goal	 in	mind,	 I	 developed	an	experimental	 porcine	DCD	model.	 I	 learnt	how	 to	perform	
rapid	 large	animal	organ	retrieval	and	over	the	course	of	4	sub-studies	(21	pigs),	 I	was	able	to	standardise	
and	 refine	 the	 process	 to	 reduce	 the	 retrieval	 time	 down	 to	 approximately	 15	 minutes.	 I	 designed	 and	
implemented	the	technique	of	implanting	microdialysis	catheters	into	the	renal	cortex,	allowing	continuous	
online	monitoring	of	lactate.	In	sub-study	1	I	monitored	7	kidneys.	Several	of	the	kidneys	were	paired	from	
the	 same	 pig	 (n=3),	 which	 prefers	methodological	 advantage	 for	 the	 researcher.	 These	 kidneys	will	 have	
identical	genetic	expressions;	assuming	there	is	no	unilateral	pathology	in	the	kidney,	we	can	expect	these	
kidneys	 to	behave	 similarly	 in	 response	 to	 ischaemia.	 The	 retrieval	 process	 and	warm	 ischaemia	 time	will	
also	 be	 identical.	 In	 confirmation	 of	 this,	 we	 identified	 a	 close	 correlation	 in	 the	 cortical	 lactate	
concentration	amongst	the	pairs.	These	kidneys	demonstrated	congruent	ischaemic	profiles.		
Consistent	with	all	 cases	was	 the	 initially	high	 lactate	concentrations,	which	dropped	 to	 steady-state	 level	
within	10-15	minutes.	This	likely	represents	development	of	equilibrium	between	the	molecules	across	the	
semi-permeable	 membrane	 in	 the	 microdialysis	 catheter.	 Following	 rapid	 drop	 in	 cortical	 lactate	
concentrations,	I	identified	in	all	kidneys	a	gradual	but	constant	fall	in	concentration.	The	mean	extracellular	
lactate	 concentration	 was	 212.2	 ±	 48.8mM	 at	 100	 min	 post	 termination.	 I	 successfully	 identified	 a	
subsequent	 fall	 in	 the	 lactate	 level	 to	 135.1	 ±	 47.4mM	at	 300	min.	 It	 is	 likely	 that	 following	 a	 90-minute	
warm	ischaemia	time,	there	are	no	viable	cells	within	the	parenchyma,	this	would	result	in	a	fall	in	lactate,	
and	cells	are	no	longer	able	to	undergo	anaerobic	metabolism.	The	high	lactate	concentration	secondary	to	
anaerobic	metabolism	in	the	hypoxic	conditions,	will	take	place	in	the	very	early	period	of	warm	ischaemia.	
This	drop	in	lactate	therefore	represents	the	tissues	inability	to	continue	to	undergo	metabolic	processes.	By	
examining	 the	 metabolic	 processes	 90	 minutes	 into	 the	 ischaemic	 injury,	 it	 is	 clear	 that	 much	 of	 the	
metabolic	and	biochemical	changes	secondary	 to	 ischaemia	are	 lost	with	 the	methodology	utilised	 in	sub-
study	1.		
Attempts	were	made	to	address	these	finding	in	sub-study	2.	By	flushing	the	kidney	with	cold	preservation	
fluid	 immediately	after	 retrieval,	 I	had	hoped	that	 the	metabolic	processes	would	slow	down	significantly,	
allowing	me	sufficient	time	to	transport	the	kidney	back	to	the	lab.	With	this	consideration,	sub-study	2	was	
designed	and	carried	out.	 In	 sub-study	2	eight	 kidneys	were	 retrieved,	most	of	which	were	 single	kidneys	
rather	than	pairs.	This	allowed	me	to	measure	cortical	and	medullary	lactate	concentration	simultaneously.	
Monitoring	of	 these	kidneys	demonstrated	 some	 interesting	 findings.	Overall	 there	was	much	variation	 in	
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the	 ischaemic	profile	of	 the	 kidneys,	however	4	of	 the	 kidneys	 showed	 some	congruency,	with	 increasing	
lactate	 concentration	within	 the	 same	period.	These	events	 took	place,	early	 in	 the	monitoring	 (200	mins	
after	 the	 time	of	death)	and	demonstrate	strong	evidence	of	 increasing	anaerobic	metabolism,	and	hence	
rising	lactate	concentration.	The	lactate	concentrations’	subsequent	plateau	is	followed	by	a	gradual	decline.	
This	would	indicate	the	point	where	the	rate	of	anaerobic	metabolism	starts	to	decline,	causing	the	levelling	
effect	 in	 lactate	 concentration,	 followed	 by	 further	 reduction	 in	 metabolism	 and	 increasing	 enzymatic	
lactate	 breakdown.	 These	 findings	 are	 mirrored	 within	 the	 medullary	 lactate	 profiles	 and	 are	 highly	
suggestive	 of	 the	 ischaemic	 profile	 that	 is	 expected,	 and	 further	 more	 demonstrate	 a	 strong	 positive	
validation	of	rsMD	as	a	tool	to	monitor	and	detect	the	ischaemic	profile	within	the	renal	parenchyma	during	
the	preservation	period.		
Sub-study	2	was	characterised	by	the	integration	of	clinical	practice	and	basic	science	methodology	through	
the	use	of	cold	preservation	fluid.	In	sub-study	3,	I	attempted	to	further	build	on	the	clinical	application	of	
this	work	 and	monitored	 5	 kidneys	 that	were	 retrieved	 and	 flushed	 using	 the	 standardised	 experimental	
protocol,	however	with	the	modification	that	monitoring	would	take	place	during	cold	preservations.		
In	sub-study	3	I	monitored	each	kidney	for	36	hours	and	maintained	cortical	temperature	at	approximately	
2oC.	 The	 cortical	 and	medullary	 concentrations	 were	 effectively	 zero	 throughout	 the	monitoring	 with	 no	
perceptible	rise	 in	 lactate	concentration	and	no	evidence	of	metabolism;	these	findings	are	unexpected.	 It	
was	anticipated	that	lactate	concentrations	would	be	low	but	nonetheless	present.	Malfunctions	within	the	
assay	may	 result	 in	 similar	 findings,	 however	 to	 have	 identical	 findings	 on	 all	 the	 cases,	 despite	multiple	
equipment	service	and	checks,	is	highly	unlikely.	Damage	or	faulty	microdialysis	similarly	would	cause	issues,	
however	 it	 is	unlikely	that	this	would	be	reproduced	with	all	 five	cases.	 It	 is	most	 likely	that	these	findings	
are	genuine	representations	of	the	metabolic	process,	or	 lack	thereof,	taking	place.	We	know	from	clinical	
practice	 that	 long	 periods	 of	 cold	 ischaemia	 causes	 delayed	 graft	 function,	 which	 is	 likely	 the	 result	 of	
cellular	injury	that	takes	place,	secondary	to	direct	injury	from	hypothermia	and	secondly	from	low	levels	of	
ongoing	 anaerobic	metabolism	 that	 continues	 to	 cause	 cellular	 dysfunction.	 This	would	 indicate	 that	 low	
levels	of	 lactate	concentration	should	be	evident.	The	second	potential	cause	of	these	findings,	 is	 that	the	
preservation	setup	was	 too	cold	 (2oC),	which	 resulted	 in	cell	damage	and	 injury.	Whilst	 it	was	outside	 the	
remit	of	the	protocol	for	this	sub-study,	introducing	a	period	of	warming	to	the	kidney	may	have	elucidated	
the	answer	as	 to	 the	cause	of	 this	dysfunction.	 If	after	warming	 the	kidney,	 there	was	a	 significant	 rise	 in	
lactate	concentration	this	would	indicate	resumption	of	anaerobic	metabolism	and	suggest	that	the	absence	
of	 lactate	 was	 caused	 by	 cessation	 of	 metabolism.	 If	 however,	 there	 was	 no	 clear	 rise	 in	 lactate	
concentration	 following	 a	 rise	 in	 cortical	 temperature,	 this	would	 suggest	 that	 the	 renal	 parenchyma	was	
unviable,	having	had	cold	ischaemia	related	injury.	This	was	however	subsequently	addressed	in	sub-study	4.	
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Sub-study	 4	 represents	 a	 novel	 attempt	 to	 directly	 compare	 the	 effect	 of	 static	 cold	 storage	 (SCS)	 and	
hypothermic	 machine	 perfusion	 (HMP)	 on	 cellular	 metabolic	 activity	 and	 ischaemic	 injury	 in	 real	 time	
utilising	an	online	rapid	sampling	microdialysis	analyser.		I	found	that	the	custom-built	rsMD	system	feasibly	
monitored	 lactate	 concentration	 in	 the	 cortex	 of	 kidneys	 during	 preservation	 by	 either	 SCS	 or	 HMP.	 The	
dialysate	 lactate	 concentration	profiles	 of	 kidneys	 preserved	using	 each	method	were	markedly	 different,	
particularly	 during	 the	 initial	 period	 and	 upon	 the	 prolonged	 ischaemic	 insult	 that	 takes	 place	 during	 the	
warming	period.	Based	on	my	 finding	 in	previous	experiments	presented	within	 this	 thesis,	 I	propose	 that	
this	change	in	lactate	concentration	was	produced	by	ischaemic	injury.	During	periods	of	hypoxia	and	hence	
ischaemia,	cells	undergo	anaerobic	metabolism	of	glucose	in	order	to	replenish	rapidly	depleting	ATP	stores.	
Instead	 of	 entering	 the	 tricarboxylic	 acid	 cycle,	 pyruvate	 generated	 in	 glycolysis	 is	 converted	 to	 lactate	
which,	 in	 the	 absence	of	 oxygen,	 accumulates	within	 cells	 and	 interstitium	where	 it	may	be	 sampled	 and	
quantified	using	an	appropriate	method,	such	as	the	custom	built	online	rsMD.		
A	number	of	 clinical	 trials	have	 shown	HMP	 to	provide	a	 reduced	 incidence	of	delayed	graft	 function	and	
improved	graft	survival	when	compared	with	SCS.194,195	However,	whilst	such	trials	appear	 to	show	clinical	
benefits	 of	 HMP,	 the	 cellular	 and	 molecular	 effects	 of	 HMP	 remain	 to	 be	 fully	 elucidated.	 Large	 animal	
studies	 suggest	 that	 perfusion	 reduces	 the	 cellular,	 biochemical	 and	metabolic	 processes	 characteristic	 of	
ischaemic	injury.	Jani	et	al	in	a	porcine	model	reported	that	24	hours	of	HMP	caused	a	significant	reduction	
in	 the	 number	 of	 apoptotic	 cells	 compared	with	 cold	 storage,	 and	 an	 increase	 in	 the	 expression	 of	 anti-
apoptotic	factors.260	This	would	suggest	that	preservation	using	HMP	is	more	protective	than	SCS	against	the	
deleterious	 ischaemic	events	occurring	during	preservation	and	potentially	warm	 ischaemia.	However,	 the	
evidence	 is	 limited	and	equivocal,	with	most	studies	 lacking	 the	ability	 to	demonstrate	 the	nature	of	 such	
protective	mechanism	in	real	time.		
In	sub-study	4	cortical	lactate	concentration	at	the	beginning	of	preservation	was	significantly	lower	in	those	
kidneys	preserved	by	HMP.	This	is	likely	the	result	of	perfusion	facilitating	rapid	internal	cooling	of	the	tissue	
and	flushing	accumulated	metabolic	waste	products	from	the	interstitium.	It	also	possible	that,	through	the	
delivery	 of	 oxygen,	 adenosine,	 glucose	 and	 other	metabolic	 precursors,	 the	 flow	 of	 preservation	 solution	
partially	 reverses	 the	 anaerobic	 switch	 occurring	 in	 ischaemia,	 thus	 enabling	 some	 cells	 to	 return	 to	 the	
more	 efficient	 aerobic	 metabolism	 of	 glucose	 and	 replenish	 ATP	 stores.	 Nevertheless,	 regardless	 of	 the	
underlying	 mechanism,	 this	 finding	 suggests	 that	 HMP	 is	 more	 effective	 than	 SCS	 at	 attenuating	 the	
ischaemic	 injury	 sustained	 and	 accumulated	 by	 the	 kidney	 during	 removal,	 warm	 ischaemia	 and	
transportation.	 This	 may	 therefore	 indicate	 that	 organs	 which	 would	 derive	 most	 benefit	 from	 HMP	 are	
those	 which	 have	 been	 pre-existing	 ischaemic	 injury	 secondary	 to	 prolonged	 warm	 ischaemia	 or	 cold	
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ischaemia.	 In	order	 to	 test	 this	hypothesis	 further,	 future	studies	could	 therefore	 include	an	experimental	
group	in	which	warm	ischaemia	time	has	been	prolonged.		
Following	the	initial	four	hours	of	preservation,	the	dialysate	lactate	concentration	of	each	kidney	reached	a	
steady	state	in	both	groups.	In	the	SCS	group,	the	steady	state	values	were	highly	variable	between	kidneys	
of	different	animals.	As	the	procurement	and	preservation	conditions	were	kept	consistent,	 it	 is	 likely	that	
this	 heterogeneity	 can	 be	 attributed	 to	 an	 unmeasured	 variable.	 However,	 it	 may	 also	 be	 the	 result	 of	
differences	in	cold	flushing,	as	some	kidneys	achieved	a	macroscopically	asanguinous	effluent	quicker	than	
others.	 However,	 this	 was	 not	 formally	 measured.	 It	 is	 possible	 in	 these	 kidneys,	 an	 efficient	 and	 even	
distribution	 of	 preservation	 solution	 may	 have	 led	 to	 greater	 protection	 from	 ischaemic	 injury,	 thus	
accounting	for	the	lower	steady	state	dialysate	lactate	concentrations.		
Interestingly,	 during	 the	 steady	 state	 period	 the	 kidneys	 preserved	 using	 HMP	 appeared	 to	 fall	 into	 two	
distinct	groups	(A	and	B).	The	existence	of	these	could	not	be	explained	by	differences	in	machine	perfusion	
or	experimental	parameters,	as	all	metrics	were	comparable	between	kidneys.	Unlike	in	the	SCS	group,	there	
appeared	to	be	some	inter-pair	variation	in	the	trends	seen	in	kidneys	from	the	same	pig.	In	one	case,	the	
right	kidney,	when	monitored,	produced	a	trace	that	was	similar	to	those	in	the	Group	A,	in	contrast	to	the	
left	 kidney,	which	 produced	 a	 trace	 similar	 to	 those	 in	 Group	 B.	 	 This	 therefore	 suggests	 that	 in	 kidneys	
preserved	using	HMP,	another	factor	may	render	some	kidneys	more	amenable	to	the	benefits	of	HMP	than	
others.	However,	in	order	to	confirm	that	this	observation	is	not	a	product	of	chance	or	confounding	factors	
further	testing	with	the	same	methodology	is	required.		
During	warming,	there	was	a	highly	significant	increase	in	the	dialysate	lactate	concentration	from	the	cortex	
of	all	kidneys.	Those	preserved	using	SCS	demonstrated	a	similar	trend,	characterised	by	a	large,	rapid	rise	in	
dialysate	lactate	concentration	followed	by	a	rapid	decline	to	a	new,	higher	SS.	In	contrast,	the	trend	seen	in	
kidneys	 preserved	 using	HMP	was	more	 regular,	with	 those	 belonging	 to	 group	A	 demonstrating	 a	much	
greater	 increase	 than	 those	 in	 group	B.	 This	 difference	 suggests	 that	 organs	 preserved	by	HMP	are	more	
resilient	 to	 changes	 in	 temperature	 and,	 as	 we	 are	 using	 lactate	 concentration	 as	 a	 surrogate	marker	 of	
ischaemic	injury,	may	therefore	also	provide	evidence	that	HMP	renders	kidneys	more	resilient	to	ischaemic	
insult.	However,	it	must	be	considered	that	the	observed	increase	in	dialysate	lactate	concentration	may	be	
partially	 attributable	 to	 temperature	 dependent	 increases	 in	 RR	 of	 the	 rsMD	 system.	 Although	 this	
confounding	effect	would	have	been	consistent	in	both	groups,	further	studies	are	required	to	elucidate	the	
relationship	 between	 temperature	 and	 RR	 to	 enable	 us	 to	more	 accurately	 quantify	 the	 effects	 of	 tissue	
ischaemia	 during	 warming.	 The	 finding	 that	 dialysate	 lactate	 concentration	 increases	 significantly	 as	
ischaemic	 injury	 accumulates	 during	 warming	 indicates	 that	 cortical	 lactate	 may	 have	 potential	 use	 as	 a	
biomarker	for	assessing	organ	viability	during	preservation.		
		
225	
Chapter	6	–	Conclusion	 	
		
226	
6 CHAPTER	6	–	CONCLUSION	
6.1 OVERVIEW	
In	my	 concluding	 chapter	 I	 present	 a	 summary	 of	 the	 findings	 from	my	 three	 studies,	 and	 attempt	 to	 tie	
together	all	 the	 themes	with	 respect	 to	 the	original	hypotheses.	 I	 critically	appraise	 the	 findings	and	 their	
interpretation,	whilst	 discussing	 the	 challenges	 faced	and	 the	 resulting	 limitations	of	 each	 study.	 I	 discuss	
potential	changes	to	the	study	methodology	in	light	of	the	limitations,	whilst	considering	future	studies	and	
potential	clinical	applications	as	a	result	of	future	work.	
Ischaemia	 is	 a	 common	 clinical	 entity	with	 a	 diverse	 array	 of	 pathologies	 and	 numerous	 presentations	 in	
various	 clinical	 systems.	 I	 have	 discussed	 in	 previous	 chapters,	 the	 effect	 of	 reducing	 the	 blood	 supply	 to	
organ	 systems	 and	 demonstrated	 the	 poor	 clinical	 outcome	 of	 organ	 transplantation,	 complex	 aortic	
aneurysm	surgery	and	G.I.	anastomotic	formation	in	the	presence	of	tissue	ischaemia.	Whilst	much	is	known	
of	the	complex	pathways	 involved	 in	cellular	 ischaemia,	 little	 is	understood	about	the	profound	effects	on	
clinical	disease	processes	at	a	biochemical	and	molecular	level.	As	physicians,	we	place	emphasis	on	treating	
disease	states	once	the	ischaemic	insult	has	taken	place.	This	reactionary	practice	even	exists	when	there	is	
an	 understanding	 that	 ischaemic	 processes	will	 undoubtedly	 take	 place,	 such	 as	 in	 organ	 transplantation,	
vascular	surgery	or	gastro-intestinal	surgery.	As	researchers	however,	we	must	act	to	prevent	or	ameliorate	
this	 injury	 and	 thereby	 reduce	 the	morbidity	 and	mortality	 associated	with	 these	 conditions.	With	 this	 in	
mind,	the	rsMD	analyser	was	built.	By	taking	the	concepts	of	microdialysis	and	augmenting	its	capability	and	
functionality,	 the	 rsMD	allows	 the	 researcher	 to	provide	a	highly	 selective,	 in	 vivo	biochemical	 analysis	 in	
real	time	of	any	target	tissue.	It	is	fully	automated,	custom	designed	and	capable	of	sampling	the	metabolic	
markers	 of	 ischaemia	 in	 high	 resolution.	 I	 have	previously	 described	how	 the	 rsMD	has	been	 validated	 in	
clinical	 models	 measuring	 the	 lactate	 in	 the	 cerebral	 cortex	 of	 patients	 with	 traumatic	 brain	 injuries,	 in	
clinical	models	of	bowel	ischaemia	in	patients	undergoing	colonic	resections	and	in	monitoring	ischaemia	in	
porcine	 gastro-intestinal	 anastomoses	 after	 artificial	 ligation	 of	mesenteric	 vessels.	Whilst	 these	 previous	
studies	 proved	 the	 suitability	 and	 efficacy	 of	 using	 the	 rsMD	 in	 experimental	 models	 with	 artificially	
established	bowel	ischaemia,	the	next	challenge	was	to	demonstrate	the	devices	sensitivity	and	specificity	in	
identifying	 tissue	 ischaemia	 in	 a	 human	 clinical	 model	 with	 pathologically	 derived	 ischaemia.	 It	 is	 this	
challenge	that	provides	the	context	and	one	of	the	primary	aims	of	this	PhD.		
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6.2 ETHICAL	CONSIDERATION	
Studies	 described	 in	 3	 and	Chapter	 4	 involved	human	 clinical	 intervention	 and	 as	 such,	 applications	were	
made	 to	 the	 St	Mary’s	 Research	 Ethics	 Committee.	 In	making	 this	 application,	 certain	 ethical	 issues	were	
addressed.	They	are	detailed	below.	
Minimise	risk	to	patient	–	there	were	several	instances	where	the	‘ideal’	methodology	could	not	be	attained,	
due	to	unacceptably	high	risk	to	the	patient.	As	an	example,	in	Chapter	3	I	discuss	that	it	would	have	been	
preferable	to	compare	microdialysis	findings	to	visualisation	with	flexible	sigmoidoscopy.	However,	I	felt	that	
it	was	inappropriate	to	unduly	subject	a	patient	to	that	level	if	risk	(albeit	low	risk)	
Informed	consent	–	this	was	performed	in	an	open	and	frank	discussion.	In	these	discussions,	potential	risks	
were	not	minimised	and	benefits	were	not	exaggerated.	Illustrations	were	used	to	facilitate	understanding	
and	discussion.	Patients	were	given	opportunities	to	ask	questions	and	the	right	to	refuse	consent.	No	undue	
pressure	was	placed	on	patients.	Several	patients	refused	consent,	which	was	accepted,	and	patients	were	
subsequently	 reassured	 that	 their	original	 surgical	 procedures	would	not	be	affected	 in	 any	way.	Patients	
were	given	copies	of	the	consent	form	and	an	in-depth	patients	information	leaflet	that	I	created.	
Both	studies	were	granted	ethical	approval	by	the	St	Mary’s	research	ethics	committee.		
In	our	final	study,	we	carried	out	research	on	animal	organs,	however	we	didn’t	require	an	animal	research	
licence	or	any	other	special	ethical	consideration	as	the	kidneys	were	removed	from	pigs	that	had	already	
been	terminated	following	other	clinical	research	(unrelated	to	my	work).		Terminations	were	approved	by	
the	animal	research	ethics	committee	of	the	Faculty	of	Medical	Sciences	of	St.	Mark’s	Hospital.	The	care	and	
handling	of	the	animals	were	in	accordance	with	the	Animals	(Scientific	Procedures)	Act	of	1986.	 
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6.3 IN-VIVO	DETECTION	OF	COLONIC	ISCHAEMIA	FOLLOWING	
ABDOMINAL	AORTIC	ANEURYSM	REPAIR	
6.3.1 Overview	of	results		
I	 have	 previously	 described	 the	 clinical	 entity	 of	 colonic	 ischaemia	 following	 AAA	 surgery,	 its	 associated	
morbidity,	high	incidence	of	mortality	and	the	difficulty	in	establishing	the	diagnosis.	There	is	clear	role	for	a	
real	time,	targeted	monitoring	device	to	assist	the	surgeon	in	the	post-operative	period	to	allow	for	the	early	
diagnosis,	 in	 a	 safe	 and	 effective	 manner.	 I	 hypothesised	 that	 microdialysis	 incorporated	 in	 to	 an	 rsMD	
analyser	could	be	effectively	utilised	 for	 this	purpose.	My	aim	was	 to	assess	 this	 feasibility	by	utilising	 the	
rsMD	analyser	to	monitor	and	detect	for	colonic	ischaemia	for	patients	that	had	undergone	AAA	repairs.		
In	my	 first	 study,	 I	enrolled	10	patients	undergoing	elective	AAA	repair,	 implanting	microdialysis	catheters	
into	the	mesentery	of	the	sigmoid	colon	and	monitored	each	patient	for	the	metabolic	markers	of	ischaemia.	
I	 successfully	monitored	all	10	patients,	measuring	 in	 real	 time	and	 in	high	resolution,	 lactate	and	glucose	
concentrations	within	the	colon.	Analysing	all	the	data	allowed	me	to	build	metabolic	profiles	of	the	target	
tissue	during	the	post-operative	period.	In	doing	so,	a	number	of	interesting	findings	were	identified.	None	
of	 the	 patients	 that	 were	monitored	 developed	 clinically	 evident	 bowel	 ischaemia,	 which	 was	 confirmed	
with	stable	metabolic	profiles	in	all	cases,	this	was	evidenced	by	the	relatively	constant	L/G	ratio	throughout.	
These	findings	build	on	the	work	of	Deeba	et	al	and	Corcoles	et	al,	further	demonstrating	that	L/G	ratio	is	a	
reliable	measurement	of	in-vivo	colonic	ischaemia	and	a	can	be	employed	as	a	key	parameter	in	comparative	
clinical	studies.56,250	
All	 the	 patients	 studied	 exhibited	 episodic,	 spontaneously	 resolving	 transient	 ischaemic	 events.	 These	
ischaemic	periods	where	categorised	by	an	increase	in	the	tissue	lactate	concentration	and	a	simultaneous	
and	parallel	drop	in	the	glucose	tissue	concentration.	This	is	the	hallmark	of	ischaemia,	with	a	reduction	in	
glucose	 delivery	 and	 subsequent	 lactic	 acidosis	 formation.	 These	 events	 were	 followed	 by	 spontaneous	
normalisation	 of	 glucose	 and	 lactate	 concentration	 indicating	 a	 possible	 element	 of	 auto-regulation	 of	
glucose	delivery,	metabolism	and	perfusion.	These	events	have	never	been	described	in	the	bowel	and	are	
therefore	 unprecedented,	 however	 they	 have	been	described	 in	 clinical	 studies	 examining	 hypoxic	 insults	
following	traumatic	brain	injury	using	the	same	rsMD.24	
I	 performed	 regression	 analysis	 to	 investigate	 any	 possible	 correlation	 between	 the	 blood	 and	 tissue	
dialysate	 concentrations.	 This	was	 carried	out	 individually	 and	with	pooled	data,	 identifying	no	 significant	
relationship	between	blood	and	tissue	lactate	concentrations.	
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In	examining	the	relationship	between	blood	glucose	and	dialysate	glucose,	a	number	of	patients	displayed	
minor	 correlations.	 This	 was	 likely	 due	 to	 outliers,	 which	 were	 then	 removed	 resulting	 in	 negligible	
correlations.	 The	 absence	 of	 a	 positive	 linear	 relationship	 between	 systemic	 and	 local	 concentrations,	
confirms	 that	 systemic	 concentrations	 have	 no	 effect	 on	 local	 concentrations.	 Therefore,	 lactate	
concentrations	 determined	 by	 the	 rsMD	 assay	 genuinely	 and	 solely	 reflect	 tissue	 concentrations.	 It	 also	
confirms	 that	 any	 change	 in	 the	 concentration	 in	 lactate	within	 the	 tissue,	 is	 a	 result	 of	 local	 changes	 in	
metabolism,	rather	than	systemic	concentrations	secondarily	influencing	concentrations.	
Whilst	none	of	our	patients	developed	 fulminant	bowel	 ischaemia,	 they	did	develop	evidence	of	 transient	
bowel	ischaemia	and	therefore	we	can	conclude	that	the	measurement	of	blood	glucose	and	blood	lactate	is	
a	poor	indicator	of	localised	subclinical	tissue	ischaemia.	
Our	 results	 have	 also	 demonstrated	 that	 the	 in	 vivo	microdialysis	monitoring	 protocol	 utilising	 the	 rsMD	
analyser	 successfully	 exhibited	 a	 metabolic	 profile	 of	 colonic	 tissue.	 The	 traces	 clearly	 demonstrated	
ischaemic	 profiles	 that	 correlate	 with	 typical	 findings	 following	 AAA	 repair.	We	 see	 lower	 tissue	 glucose	
concentrations,	as	glucose	delivery	declines	secondary	to	preferential	arterial	shunting	of	blood	along	with	
pathological	 disruption	 of	 vascular	 blood	 supply.	 We	 see	 tissue	 glucose	 concentration	 stabilising	 over	 a	
period	of	time	in	keeping	with	normalisation	of	homeostatic,	cardiovascular	and	metabolic	mechanisms.	We	
see	 high	 lactate	 concentrations	 following	 aortic	 cross-clamping,	 where	 hypoperfusion	 results	 in	 lactic	
acidosis.	This	persists	for	a	short	period	of	time,	in	keeping	with	the	relative	reduction	in	glucose	and	oxygen	
delivery	 in	 the	 immediate	 post-operative	 period.	 We	 see	 lactate	 levels	 drop	 to	 baseline,	 as	 cellular	
metabolism	shifts	from	anaerobic	to	aerobic	processes.	
6.3.2 Critical	analysis	and	limitations	
One	of	the	major	limitations	of	this	study	was	the	fact	that	none	of	the	patients	developed	clinically	evident	
ischaemic	bowel.	Whilst	this	 is	of	course	in	the	patients’	best	 interest,	without	the	opportunity	to	monitor	
and	 detect	 this	 clinical	 entity	 in	 real	 time	 with	 our	 rsMD	 assay,	 it	 is	 difficult	 to	 conclusively	 prove	 our	
hypothesis.	In	previous	studies,	Deeba	et	al	and	Corcoles	et	al	had	shown	frank	ischaemia	in	the	bowel	after	
mesenteric	vessels	were	 ligated.75,250	However	 this	was	artificially	 induced	and	one	of	 the	primary	aims	of	
this	study	was	to	characterise	bowel	ischaemia	in	a	genuine	clinical	pathological	setting	and	to	correlate	our	
findings	with	the	clinical	progress	of	the	patient.	To	confidently	prove	our	hypothesis,	that	the	rsMD	analyser	
can	be	used	in	the	early	detection	of	bowel	ischaemia	following	AAA	repair,	we	need	to	be	able	to	monitor,	
identify	and	detect	bowel	 ischaemia	and	correlate	these	findings	with	the	clinical	picture.	Whilst	 it	 is	 likely	
that	the	analyser	did	demonstrate	evidence	of	ischaemia,	we	know	from	the	work	carried	out	by	Deeba	et	al	
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using	the	same	assay,	that	lactate	concentrations	increased	to	16	fold	in	the	presence	of	frank	ischaemia.75	
The	lactate	changes	that	we	identified	were	between	2-3-fold	increase	from	baseline.	These	clearly	do	not	
represent	 gross	 ischaemic	 changes,	 which	 were	 ratified	 with	 clinical	 observation,	 however,	 they	 may	
represent	transient	ischaemic	changes.	We	have	previously	discussed	the	findings	that	are	highly	suggestive	
of	temporal	self-limiting	ischaemic	events,	displaying	the	typical	lactate	and	glucose	changes	that	we	would	
expect	to	see	in	a	relatively	anoxic	environment.	However,	in	the	absence	of	a	control	microdialysis	catheter	
in	a	portion	of	the	colon	that	is	not	typically	affected	by	ischaemia,	we	cannot	conclusively	prove	that	these	
events	 are	 indeed	 pathologically	 ischaemic	 as	 opposed	 to	 regularly	 occurring	 normal	 cyclical	 metabolic	
changes.	 The	 previous	work	 done	 by	 Boutelle	et	 al	 and	 Parkin	et	 al,	where	 similar	 changes	were	 seen	 in	
patients	known	to	suffer	 from	hypoxic	 injuries	 following	trauma,	would	suggest	however	that	the	changes	
we	 identified,	were	 in	 fact	 transient	 ischaemic	changes.25,255	Translating	 those	 findings	 to	my	work,	allows	
me	to	develop	a	better	understanding	of	the	metabolic	processes	taking	place	within	the	colon.	This	can	be	
further	 extrapolated	 to	 allow	 consideration	 of	 how	 frank	 ischaemic	may	 appear	 on	 a	 typical	 rsMD	 trace.	
However,	 without	 having	 a	 patient	 that	 has	 developed	 full	 transmural	 infarction,	 we	 are	 unable	 to	
demonstrate	the	levels	of	ischaemia	that	are	expected	and	self-limiting	between	those	that	are	more	serious	
and	suggest	impending	irreversible	ischaemia.	In	between	these	two	periods,	is	where	the	potential	window	
for	surgical	intervention	takes	place,	to	minimise	any	associated	morbidity	and	mortality.		
In	further	studies,	I	would	expand	the	number	of	patients	enrolled	into	the	study,	until	objective	evidence	of	
significant	clinically	evident	bowel	ischaemia	is	evident.	I	would	also	consider	placing	a	control	microdialysis	
catheter	into	a	portion	of	the	colon	that	will	unlikely	experience	ischaemia,	such	as	the	ascending	colon.	This	
will	allow	me	to	confirm	the	presence	of	isolated	bowel	ischaemia.		
It	would	have	been	beneficial	 to	 the	 study	 to	have	 an	objective	 comparative	 tool	 to	 assess	 clinical	 bowel	
ischaemia,	 perhaps	 in	 the	 form	 of	 flexible	 sigmoidoscopy	 or	 a	 contrast	 CT	 angiogram.	 This	 would	 have	
allowed	 direct	 comparison	 between	 our	metabolic	 ischaemic	 profiles	 and	 presence	 of	 ischaemic	mucosa,	
thrombus	 within	 the	 mesenteric	 vessels	 or	 lack	 of	 enhancement	 of	 the	 colonic	 wall.	 However,	 this	 was	
unfeasible	as	it	would	require	en	extra	procedure	or	an	increased	risk	of	potentially	harmful	radiation.	The	
vascular	surgery	undertaken	by	these	patients	was	complex	with	a	high	risk	of	complication,	and	therefore	
any	other	risk	or	potential	morbidity	would	not	have	been	in	the	patients’	best	interest.	
I	 initially	envisaged	this	experimental	protocol	 taking	place	 in	patients	undergoing	open	AAA	repairs,	 from	
which	I	could	then	compare	data	to	patients	undergoing	endovascular	repair	to	determine	if	there	was	any	
disparity.	However,	the	vascular	unit	where	the	experiments	and	surgery	took	place	was	a	tertiary	referral	
unit	 that	 undertook	 mainly	 complex	 hybrid	 procedures,	 where	 patients	 undergo	 a	 combination	 of	
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endovascular	aneurysm	repair	with	open	visceral	revascularisation.	This	is	unlikely	to	have	had	any	affect	on	
the	overall	results,	if	anything,	it	is	likely	to	increase	the	risk	of	ischaemic	bowel	and	allows	us	to	validate	the	
model	in	patients	undergoing	endovascular	repairs.	
The	microdialysis	catheter	was	always	inserted	at	the	end	of	the	procedure,	followed	by	the	abdomen	and	
skin	incision	being	closed.	The	patient	would	then	be	transferred	directly	to	the	ITU,	where	the	nursing	staff	
would	 set	 up	 the	 I.V	 lines	 and	 cardiac	monitoring	 devices.	 At	 this	 point,	 I	 would	 attach	 the	microdialysis	
catheter	to	the	rsMD	and	start	monitoring.	The	entire	period	between	implanting	the	catheter	and	starting	
monitoring	took	approximately	2-3	hours.	Ideally,	I	would	have	liked	to	start	monitoring	at	the	start	of	the	
procedure,	allowing	me	to	assess	the	metabolic	profiles	of	the	tissue	during	the	procedure,	the	effect	of	the	
aortic	 cross-clamping	 and	 the	 effect	 of	 the	 visceral	 revascularisation.	 However,	 this	 would	 have	 further	
lengthened	 the	 procedure	 time	 and	 would	 have	 taken	 place	 at	 a	 potentially	 critical	 time	 during	 the	
operation.	The	other	possibility	would	have	been	to	 implant	the	catheter	at	the	end	of	the	procedure	and	
start	monitoring	 immediately,	 thereby	 capturing	 all	 the	 data	 that	would	 indicate	 ischaemia.	 This	was	 not	
feasible	 as	 it	would	have	 required	 transporting	 the	 rsMD	around	 the	hospital	 and	due	 to	 its	 size	 and	 the	
fragility	 of	 the	 various	 components,	 this	 was	 deemed	 not	 appropriate.	 The	 rsMD	 would	 need	 further	
miniaturisation	and	simplification	in	order	for	this	to	take	place.	
Unfortunately,	for	several	reasons,	significant	portions	of	the	data	were	lost	during	the	monitoring	of	many	
of	the	patients.	The	microdialysis	catheter	was	fragile	and	only	attached	to	the	skin	via	small	sutures.	It	was	
easy	for	the	catheter	to	be	pulled	out	accidentally,	which	took	place	on	a	number	of	occasions.	The	catheter	
was	only	loosely	sutured	in	place,	as	it	was	felt	that	in	the	event	of	traction	on	the	tubing,	it	was	better	that	
the	 catheter	 be	 completely	 pulled	 free,	 rather	 than	 snapping	 with	 a	 portion	 being	 retained	 inside	 the	
abdomen.	Another	limitation	to	our	study	was	the	complexity	of	the	rsMD	assay,	comprising	of	a	number	of	
different	 components,	 which	 were	 prone	 to	 failure	 or	 malfunction.	 This	 required	 constant	 vigilance	 and	
would	however	still	result	in	lost	data.	More	work	is	required	with	the	rsMD	assay	to	simplify	and	stabilise	
the	device	to	prevent	malfunction	and	valuable	data	loss.	
I	have	previously	described	how	over	a	period	of	monitoring	the	enzyme	reactors,	their	function	is	degraded.	
Impurities	 from	 the	 buffering	 solution	 and	 the	 sampled	 extracellular	 fluid	 accumulate	 on	 the	 bio-
membranes,	 diminishing	 enzyme	 activity	 resulting	 in	 a	 loss	 of	 sensitivity.	 The	 enzyme	 membranes	 are	
therefore	changed	on	a	regular	basis	to	reduce	the	impact	of	this	limitation.	Corcoles	et	al,	when	using	the	
rsMD	to	monitor	for	bowel	ischaemia	in	GI	anastomoses,	demonstrated	a	52	and	61%	drop	in	sensitivity	for	
lactate	and	glucose	respectively,	after	8	hours	of	monitoring.250	I	have	previously	described	the	methods	that	
I	used	for	calibration	to	minimise	error	in	the	calculations,	however	despite	this	a	small	amount	of	error	is	
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undoubtedly	 introduced	 into	 the	 results.	 If	 I	 was	 to	 continue	 data	 collection,	 I	 would	 likely	 modify	 my	
experimental	 protocol,	 shortening	 the	 period	 of	monitoring	 and	 change	 the	 enzyme	membranes	 every	 2	
hours	to	further	reduce	error	introduction.	
One	of	 the	challenges	that	 I	 faced	was	the	 lack	of	 individual	control	 that	 I	had	over	certain	aspects	of	 the	
methodology,	being	reliant	on	various	other	factors	that	were	out	of	my	control	that	could	potentially	have	
an	 impact	on	my	results.	For	example,	 I	was	dependent	on	ITU	bed	availability	for	the	surgical	cases	to	go	
ahead	and	 reliant	on	 theatres	nursing	 staff	 to	assist	me	 in	preparation	 for	 the	 catheter	 implantation.	 The	
monitoring	of	each	patient	with	the	rsMD	was	contingent	on	the	operating	surgeon	allowing	to	implant	the	
catheter	and	the	ITU	nurses	not	to	accidentally	dismantle	the	catheter	attachments.			
The	identification	of	 ischaemic	bowel	in	the	clinical	setting,	once	transmural	 infarction	and	perforation	has	
developed,	 is	 relatively	 straightforward	 with	 numerous	modalities	 available	 to	 help	 in	 the	 diagnosis.	 The	
clinical	 signs	 and	 symptoms	 of	 irreversible	 infarction	 are	 relatively	 easy	 to	 elicit	 and	 arguably	 too	 late	 in	
doing	so,	however	to	be	able	to	clinically	detect	the	early,	subtle	signs	that	a	patient	may	potentially	develop	
worsening	ischaemia,	is	challenging	and	is	something	that	has	eluded	previous	investigators.	Our	study	has	
shown	that	the	rsMD	assay	is	sensitive	and	selective	enough	to	be	able	to	detect	and	monitor	for	sub-clinical	
ischaemia.	 These	 findings	 are	 novel	 and	 have	 never	 been	 described.	 This	 data	 alongside	 further	 studies,	
could	 confirm	 and	 validate	 the	 use	 of	 the	 rsMD	 analyser	 to	 potentially	 warn	 surgeons	 prior	 to	 the	
development	of	fatal	complications.	
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6.4 ONLINE	RAPID	SAMPLING	MICRODIALYSIS	FOR	THE	IN-VIVO	
DETECTION	OF	BOWEL	ANASTOMOTIC	LEAKS	
6.4.1 Overview	of	results		
I	have	previously	discussed	in	the	introduction	to	this	thesis,	and	continued	in	Chapter	4,	the	relevance	and	
necessity	of	this	study.		I	have	described	the	potentially	high	mortality	that	is	associated	with	major	elective	
or	emergency	GI	surgery.	 I	have	described	the	many	potential	post-operative	complications,	which	are	the	
source	of	significant	morbidity	in	patients	undergoing	GI	surgery.	I	have	described	the	lack	of	sensitive	and	
accurate	diagnostic	modalities	alongside	the	vague	and	indistinct	clinical	markers	that	result	in	the	diagnosis	
of	post-operative	complications,	such	anastomotic	leaks,	very	challenging.	The	focus	of	my	research	and	this	
study	is	to	develop	a	tool	that	will	allow	diagnosis	in	the	early	stage	of	such	complications.	With	this	in	mind,	
I	 hypothesised	 that	 online	 rsMD	 could	 be	 effectively	 and	 safely	 utilised	 in	 the	 monitoring	 of	 patients	
undergoing	major	GI	 surgery,	 for	 the	early	detection	of	post-operative	 complications	 such	as	anastomotic	
leaks.	Before	embarking	on	a	large,	lengthy	and	costly	clinical	in-vivo	study,	my	aim	was	to	perform	an	initial	
feasibility	study,	to	determine	if	sampling	intra-abdominal	lactate	could	correlate	with	the	early	prediction	of	
complications.	 My	 secondary	 aim	 was	 to	 design,	 test	 and	 validate	 an	 ex-vivo	 microdialysis	 protocol	 for	
sampling	 peritoneal	 fluid.	 If	 successful,	 this	 could	 be	 directly	 translated	 into	 the	 measurement	 of	 other	
clinically	important	biomarkers	in	comparative	studies.	
In	my	second	study,	I	recruited	19	patients	after	approaching	a	total	of	33	patients.	All	patients	underwent	
major	 elective	 or	 emergency	 GI	 surgery,	 underwent	 GI	 anastomoses	 intra-abdominal	 drain	 insertion.	 I	
sampled	peritoneal	 fluid	 from	the	drains	at	6	hourly	 intervals	and	analysed	each	sample	multiple	 times	to	
reduce	error.	 In	 total,	 I	 analysed	717	samples	 from	patients	 recruited	 into	 this	 study.	Of	 the	patients	 that	
were	enrolled,	9	patients	went	on	to	develop	complications	and	only	one	of	which	was	an	anastomotic	leak,	
therefore	I	proceeded	to	analyse	all	patients	in	two	distinct	groups:	complications	and	no	complications.	By	
calculating	the	median	change	in	 lactate	concentration	for	a	given	time	in	each	cohort,	 I	was	able	to	show	
that	 the	non-complication	 group	had	 a	 peritoneal	 lactate	 profile	 that	 started	high,	 but	 slowly	 declined	 to	
baseline.	However,	the	complication	cohort	had	high	lactate	concentrations,	which	continued	to	increase	for	
at	 least	48	hours,	before	a	 fall	 in	 concentration	was	 seen.	By	 recording	patients	CRP	and	WCC	during	 the	
period	of	monitoring,	I	was	able	to	compare	the	change	in	peritoneal	lactate	concentration	against	a	rise	in	
the	 inflammatory	markers	 in	 the	 complication	 group.	Both	CRP	and	peritoneal	 lactate	 exhibit	 equally	 fast	
rises	in	the	complication	cohort,	whilst	WCC	exhibited	a	significant	delay.	
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One	patient	developed	an	anastomotic	leak,	which	was	clinically	diagnosed	at	day	10,	however	a	significant	
change	 in	the	peritoneal	 lactate	profile,	demonstrated	by	a	 large	rise	 in	 lactate	concentration	was	seen	at	
day	 3.	 The	 observed	 lactate	 rise	 occurred	 7	 days	 prior	 to	 the	 diagnosis.	 This	 single	 case	 does	 potentially	
suggest	the	strong	predictive	ability	of	peritoneal	lactate	sampling.	
6.4.2 Critical	analysis	and	limitations	
The	results	of	this	simple	feasibility	study	are	thought	provoking	and	novel,	and	validate	the	need	for	further	
investigation.	However,	 this	 study	has	 several	 significant	 limitations.	My	original	 hypothesis	was	 aimed	at	
developing	 a	 tool	 that	 would	 allow	 for	 the	 early	 detection	 of	 anastomotic	 leaks,	 this	 was	 and	 still	 is	my	
primary	focus.	However,	 it	became	clear	after	recruiting	and	monitoring	the	proposed	number	of	patients,	
that	we	only	had	one	patient	with	a	confirmed	anastomotic	leak,	this	clearly	would	not	be	enough	data	to	
satisfy	the	original	objectives	or	even	come	close	to	proving	the	hypothesis.	Clearly	the	next	step	would	be	
to	 recruit	 more	 patients	 using	 a	 similar	 ex-vivo	 protocol,	 with	 the	 aim	 of	 identifying	 more	 patients	 that	
develop	anastomotic	 leaks.	With	a	 larger	data	set	and	multiple	peritoneal	 lactate	profiles	that	correlate	to	
clinically	 confirmed	 leaks,	 I	would	be	 able	 to	draw	more	meaningful	 conclusions.	Having	only	one	patient	
with	an	anastomotic	 leak,	 I	decided	to	also	examine	for	correlations	with	all	post-operative	complications.	
This	 is	 an	 umbrella	 term	 for	 a	 wide-ranging	 and	 disparate	 group	 of	 conditions,	 many	 of	 which	 have	
completely	 differing	 aetiologies	 and	 mechanisms.	 Whilst	 at	 first	 glance	 it	 may	 seem	 that	 opening	 the	
measurable	outcomes	to	many	different	conditions	in	such	a	small	cohort	is	questionable,	there	is	some	key	
basic	science	that	would	potentially	legitimise	this	a	protocol.	Most	post-operative	complications	are	a	result	
of	 tissue	 ischaemia,	 tissue	 injury	or	 tissue	 inflammation,	all	of	which	 sequester	 lactate	 into	 the	peritoneal	
fluid.	 This	 can	 be	 sampled	 and	 correlated	 with	 clinical	 outcome.	 	 However,	 with	 our	 small	 sample	 size,	
grouping	 divergent	 variables	 together	 prevented	 any	 further	 sub-group	 analysis.	 With	 a	 larger	 cohort,	
procedure	 or	 a	 region-specific	 grouping	 would	 provide	 more	 useful	 clinical	 data.	 This	 study’s	 approach	
therefore	 precludes	 any	 conclusions	 regarding	 the	 specificity	 of	 rising	 lactate	 concentrations	 in	 the	broad	
complication	group.	
Notably	 the	 sample	 size	 of	 this	 study	 (n=19)	 is	 small.	 This	 is	most	 likely	 the	 reason	 for	 the	 low	R2	 values	
acquired	for	the	linear	regression	modelling	of	the	peritoneal	lactate	concentration	trends.	It	could	also	have	
influenced	the	 lack	of	significant	difference	 in	peritoneal	dialysate	 lactate	during	the	1st	post-operative	24	
hours.	However,	this	was	an	exploratory	study,	and	whilst	strong	conclusion	clearly	cannot	be	drawn	from	
this	 study,	 there	 are	 many	 interesting	 findings	 that	 serve	 as	 an	 initial	 step	 for	 further	 larger	 scale	
investigation.		
		
235	
There	was	a	high	incidence	of	complications	among	the	study	participants	(>40%),	which	lends	question	to	
the	selection	criteria,	with	possible	inadvertent	selection	bias	resulting	from	several	factors.	Intra-abdominal	
drains	 are	 typically	 placed	 during	 open,	 dirty	 or	 major	 surgeries	 that	 are	 more	 prone	 to	 complications.	
Candidates	 for	 such	 surgical	 procedures	 may	 also	 have	 more	 inherent	 risk	 factors	 such	 as	 previous	
radiotherapy	and	adhesions.	Therefore,	 the	requirement	of	peritoneal	drains	 for	participation	 in	the	study	
may	 have	 unintentionally	 resulted	 in	 selection	 bias	 for	 patients	 with	 higher	 risks	 of	 post-operative	
complications.	 Also,	 the	 study	 was	 conducted	 in	 the	 specialist	 department	 of	 a	 tertiary	 referral	 hospital.	
Therefore,	the	sampled	population	may	also	have	higher	risks	of	complications.	
Finally,	 there	 were	 many	 opportunities	 for	 sample	 dilution,	 as	 drain	 bags	 were	 not	 emptied	 after	 every	
collection.	 It	was	difficult	 to	do	 this	as	peritoneal	 fluid	may	be	 required	 for	other	 investigations	as	part	of	
patient’s	management.	It	was	noticed	that	drain	bags	were	usually	emptied	by	the	nursing	staff	at	the	start	
of	a	new	shift	(6-7	hours	apart).	Collection	times	were	therefore	rescheduled	around	these	periods	to	allow	
fresh	sample	collection.	Nevertheless,	occurrence	of	sample	dilution	may	have	influenced	the	magnitude	of	
peritoneal	lactate	concentration	change	observed.	
Peritoneal	 drain	 sampling	 generally	 holds	 promise	 for	 early	 complication	 detection.	 However,	 there	 are	
potential	obstacles	to	routine	diagnostic	monitoring	of	peritoneal	lactate.	Firstly,	peritoneal	lactate	content	
is	 location	dependent.	 This	 is	 a	 shared	problem	with	 in-vivo	microdialysis	 catheter	 placement.	During	 the	
study,	patients	with	more	than	one	drain	in	situ	had	different	lactate	output	from	each	drain.	However,	the	
changes	in	lactate	concentration	over	time	were	similar.	Drains	placed	at	the	site	of	anastomosis	had	higher	
lactate	 output	 compared	 to	 those	 placed	 generally	 within	 the	 peritoneal	 cavity.	 Development	 and	
incorporation	of	a	drain	 fixation	device	may	help	 limit	 the	mobility	of	 the	drain.	However,	peritoneal	 fluid	
also	 moves	 with	 changes	 in	 patient	 position	 and	 posture.	 The	 significance	 of	 such	 mobility	 needs	 to	 be	
ascertained	 in	 further	studies.	 In	addition,	variations	 in	volume	of	drain	output	could	 influence	the	 lactate	
measurement.	This	may	therefore	need	to	be	taken	into	account	when	comparing	samples.	
The	 study	 successfully	 identified	 the	 trends	and	predictive	ability	of	peritoneal	 lactate	 in	 complicated	and	
uneventful	post-operative	courses.	Large	scale	trials	are	hereby	required	to	confirm	the	study’s	findings	and	
evaluate	identified	gaps	in	knowledge.	Such	larger	studies	will	benefit	from	the	involvement	of	nursing	staff	
in	 the	 research	 protocol.	 Experience	 from	 this	 study	 suggests	 that	 this	 is	 the	 best	way	 to	 ensure	 regular	
sampling	and	prevent	sample	dilution.	 In	addition,	the	ex-vivo	microdialysis	protocol,	developed	as	part	of	
this	 study,	 holds	 promise	 for	 future	 monitoring	 of	 peritoneal	 lactate.	 While	 its	 feasibility	 has	 been	
demonstrated,	 more	 research	 and	 development	 is	 required	 before	 clinical	 application.	 One	 such	
requirement	 is	miniaturisation	of	 the	analyser	 system.	Potential	development	approach	could	also	 involve	
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the	development	of	microdialysis	compatible	drain	bags.	Overall,	the	present	study	suggests	that	peritoneal	
lactate	is	worth	investigating	further	as	a	potential	predictive	tool	for	post-operative	complications.	
6.4.3 Future	work	and	potential	clinical	applications	–	bowel	ischaemia	&	
anastomotic	leaks	
I	 have	 grouped	 these	 two	 clinical	 entities	 together	 as	 I	 feel	 that	 any	 related	 future	 clinical	 research	 or	
application	would	build	on	these	areas	of	research	collectively.	In	terms	of	the	bowel	ischaemia	work,	clearly	
more	 cases	 need	 to	 be	 monitored	 to	 identify	 patients	 that	 develop	 ischaemic	 bowel.	 There	 would	 be	
benefits	 in	 translating	 this	 research	 to	 incorporate	 patients	 undergoing	 endovascular	 procedures.	 The	
majority	of	patients	that	undergo	AAA	repair	do	so	via	an	endovascular	route.	However,	challenges	remain	
in	 terms	 of	 obtaining	 access	 to	 the	 bowel	 or	 peritoneal	 cavity.	 Consideration	 should	 be	 given	 to	 develop	
microdialysis	catheters	that	can	be	placed	enterically.	These	can	be	placed	at	the	bed	side,	with	minimal	risk	
and	can	be	easily	pulled	out	after	use.	Despite	 this,	 fixation	challenges	persist,	as	well	methods	 to	 reduce	
artefact	from	transit	of	enteric	contents.	
In	 the	anastomotic	 leak	work,	 the	 feasibility	 study	 should	be	 continued,	 incorporating	more	patents,	with	
the	aim	of	identifying	patients	that	develop	anastomotic	leaks.	Once	the	concept	is	validated,	clinical	in-vivo	
studies	can	be	performed	whereby	microdialysis	catheters	are	placed	next	 lower	GI	anastomoses.	Patients	
undergoing	anterior	resections	can	be	recruited,	and	findings	correlated	with	gastrograffin	enemas	at	day	7.	
As	before,	enteric	placement	should	be	explored,	and	the	concepts	of	biodegradable	microdialysis	sensors	
and	drain	bags	that	can	sample	and	analyse	for	biomarkers	automatically	should	be	considered.		
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6.5 ALLOGRAFT	VIABILITY	ASSESSMENT	DURING	THE	
PRESERVATION	PERIOD	UTILISING	ONLINE	RAPID	SAMPLING	
MICRODIALYSIS	
6.5.1 Overview	of	results	
Over	 the	 last	 century,	 advances	 in	 surgical	 technique	 and	 immunobiology	 have	 resulted	 in	 the	 successful	
clinical	 application	 of	 organ	 transplantation,	 to	 such	 an	 extent	 where	 kidney	 transplantation	 is	 now	
considered	the	standard	treatment	option	for	renal	failure.		
However,	there	exists	a	significant	shortfall	in	the	number	of	patient	waiting	for	a	lifesaving	transplant	and	
the	number	of	suitable	organs.	With	ever	increasing	demand	to	expand	the	donor	pool,	clear	strategies	are	
needed	 to	 accurately	 assess	 viability	 and	 potentially	 modify	 the	 parenchymal	 environment.	 This	 will	
ultimately	allow	the	surgeon	to	stratify	potential	outcomes	and	improve	graft	survival.	Within	this	context,	I	
hypothesised	that	online	rsMD	could	be	applied	to	assess	organ	viability	in	the	preservation	period,	with	real	
time,	online	automatic	measurement	of	the	lactate	concentration,	as	marker	of	 ischaemic	 injury.	 In	partial	
fulfilment	 of	 this	 significant	 undertaking,	 my	 objectives	 to	 firstly	 assess	 the	 use	 of	 cortical	 lactate	
concentration	 as	 a	 biomarker	 for	 ischaemic	 injury.	 This	 would	 allow	 me	 to	 determine	 the	 suitability	 of	
employing	rsMD	in	the	viability	assessment	of	kidney	allografts	during	preservation.	Secondly	to	assess	the	
feasibility	of	using	 rsMD	 to	monitor	 changes	 in	 lactate	 concentration	within	 the	 renal	 cortex	and	medulla	
during	SCS	and	HMP	in	a	porcine	model	and	thirdly	to	compare	the	effects	of	SCS	and	HMP	on	metabolism	
and	ischemia	during	the	preservation	period.	
All	four	sub-studies	presented	within	Chapter	5,	use	an	experimental	porcine	DCD	renal	model	with	an	ex-
vivo	protocol	for	renal	cortical	 lactate	monitoring	that	was	designed	and	developed	de	novo.	No	work	had	
previously	been	carried	out	by	the	team	or	the	department	in	this	specific	field,	and	as	such,	much	research	
and	planning	was	required	before	the	implementation	stage.		
In	sub-study	1,	 I	 tested	the	 feasibility	of	using	 the	rsMD	assay	 to	detect	and	monitor	 renal	cortical	 lactate	
concentrations,	as	a	marker	for	 ischaemic	 injury.	 I	demonstrated	the	metabolic	processes	taking	place	 in	a	
freshly	retrieved	porcine	kidney,	by	 immediately	 implanting	a	microdialysis	probe	 into	the	renal	cortex.	As	
the	 ischaemia	 developed,	 the	 rsMD	 detected	 and	 monitored	 cortical	 lactate	 concentrations,	 partially	
providing	me	with	a	baseline	ischaemic	profile	of	renal	cortical	tissue.	However,	further	examination	of	the	
results	indicated	that	there	was	key	information	lost	during	the	transportation	time.	Without	this	key	data,	I	
could	 not	 conclusively	 prove	 that	 the	 online	 rsMD	 assay	 had	 provided	 the	 baseline	 ischaemic	 profile	 and	
therefore	 validating	 this	 technique	 as	 a	 tool	 for	 assessing	 the	 ischaemic	 injury	 in	 porcine	 kidneys.	
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Considering	this	 limitation,	 the	experimental	methodology	was	modified	 in	sub-study	2	by	cannulating	the	
renal	artery	at	the	time	of	retrieval	and	flushing	with	cold	preservation	fluid.	Monitoring	these	kidneys	with	
the	 experimental	 protocol	 demonstrated	 interesting	 findings.	 Whilst	 there	 was	 some	 variation	 in	 the	
ischaemic	profile	between	kidneys,	there	was	a	cohort	of	kidneys	that	displayed	similar	profiles	and	would	
be	considered	typical	of	ischaemic	tissue.	Traces	of	cortical	lactate	in	ischaemic	kidneys	appeared	similar	to	
that	demonstrated	by	Deeba	et	al	and	Corcoles	et	al	in	their	studies	utilising	the	same	rsMD	analyser.250,261		
Having	objective	evidence	that	the	rsMD	analyser	and	the	experimental	protocol	could	be	validated	in	their	
ability	to	monitor	and	detect	the	renal	ischaemic	profile,	further	attempts	to	clinically	integrate	this	research	
were	 undertaken.	 Using	 the	 same	 retrieval	 protocol,	 kidneys	were	monitored	whilst	 kept	 in	 hypothermic	
conditions.	Sub-study	3	was	designed	to	assess	the	metabolic	processes	that	take	place	during	typical	static	
cold	storage	in	clinical	practice.	Kidney	were	kept	on	ice	and	monitored	for	36	hours.	The	results	consistently	
demonstrate	that	no	lactate	was	produced	in	the	renal	parenchyma	during	the	period	of	monitoring.	These	
results	are	unexpected	and	likely	a	result	of	the	methodological	design	of	the	experiment.	These	limitations	
were	addressed	in	sub-study	4.	
In	 sub-study	 4	we	 assessed	 the	 feasibility	 of	 using	 the	 rsMD	 to	monitor	 cortical	 lactate	 concentration	 in	
kidneys	 preserved	 by	 both	 SCS	 and	 HMP.	We	 also	 sought	 to	 compare	 the	 effects	 of	 each	 technique	 on	
ischaemic	 injury	 and	 further	 assess	 the	 potential	 use	 of	 rsMD	 in	 the	 viability	 assessment	 of	 organs	 for	
transplantation.	 
The	 results	 demonstrated	 that	 during	 the	 initial	 preservation	 period	 cortical	 lactate	 concentration	 was	
significantly	lower	in	kidneys	preserved	using	HMP.	Levels	in	both	groups	reached	a	steady	state	after	four	
hours,	 with	 no	 significant	 difference	 between	 average	 steady	 state	 concentrations.	 Warming	 led	 to	 a	
significant	increase	in	cortical	lactate	concentration	in	all	kidneys.		
When	considering	all	the	cumulative	findings	from	the	four	sub-studies,	it	clear	that	rsMD	can	effectively	be	
used	for	assessment	of	cortical	 lactate	concentration	during	organ	preservation	and	may	have	a	promising	
future	 role	 in	 graft	 viability	 assessment.	 HMP	 appears	 superior	 to	 SCS	 at	 attenuating	 injury	 accumulated	
during	warm	 ischaemia,	 potentially	making	 this	 a	 favourable	option	 for	preservation	of	high-risk	marginal	
organs.	
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6.5.2 Critical	analysis	and	limitations	
The	results	of	these	novel	studies	are	interesting,	important	and	necessitate	further	investigation.	However,	
these	 studies	were	not	without	 their	 challenges,	and	 thus	a	 thorough	 reflection	of	 the	 limitations	of	each	
study	is	needed.	This	allows	insight	in	to	the	validity	of	any	conclusions	drawn	and	guides	future	work.	
One	of	the	major	limitations	in	sub-study	1,	as	previously	described,	was	the	lack	of	data	within	the	first	90	
minutes	 after	 time	 of	 death.	 It	 is	 likely	 that	 vital	 metabolic	 data	 is	 missed	 in	 this	 period,	 whilst	 the	
subsequent	lactate	concentration	detected	from	the	analyser	are	relevant,	it	is	most	likely	that	the	tissue	is	
non-viable	as	this	stage.	The	steady	decline	 in	 lactate	concentration	 is	 likely	as	a	result	of	reducing	 lactate	
concentrations	 within	 the	 tissue.	 The	 lactate	 that	 built	 up	 within	 the	 tissue	 during	 the	 early	 ischaemic	
period,	 is	 now	 degraded	 by	 enzyme	 activity.	 It	 could	 also	 be	 argued	 that	 the	 sampling	 effect	 of	 the	
microdialysis	tissue	also	results	in	a	steady	and	uniform	decline	in	lactate	concentration	as	molecule	diffuse	
across	 the	 semi-permeable	 membrane.	 However,	 we	 see	 in	 one	 particular	 case	 where	 the	 microdialysis	
catheter	 fell	 out	 of	 the	 kidney,	 and	 after	 the	 catheter	 is	 replaced,	 the	 new	measurements	 of	 lactate	 are	
lower	 than	 previous	 reading.	 This	 registered	 drop	 in	 concentration	 can	 only	 be	 due	 to	 tissue	 processes,	
rather	 than	 the	action	of	microdialysis.	Another	 finding	was	 the	 impact	of	movement	on	 readings.	 In	 sub-
study	1,	 the	 first	display	two	marked	artefact	 readings	related	to	movement	of	 the	kidney.	This	should	be	
considered	when	examining	results	where	the	tissue	in	mobile,	such	as	the	colon	in	Chapter	3.		
One	of	the	limitations	of	the	rsMD	device	is	that	only	two	fluid	inputs	can	be	analysed	simultaneously.	This	is	
suitable	If	only	examining	one	kidney,	allowing	the	researcher	to	implant	two	microdialysis	catheters,	in	our	
case	 this	was	medulla	 and	 cortex.	However,	 if	 comparing	 two	 kidneys	 simultaneously	 (e.g.,	 to	 assess	 two	
different	preservation	devices	such	as	in	sub-study	4),	then	only	one	catheter	can	be	placed	in	each	kidney.	
In	 our	 case,	we	 decided	 to	 preference	 cortex	 over	medulla.	 As	 previously	 described,	 there	 is	 evidence	 to	
suggest	that	the	cortex	is	more	prone	to	ischaemia	than	the	medulla.		It	was	my	assumption	that	the	cortex	
would	 then	 develop	 the	 greatest	 ischaemic	 injury,	 however	 results	 from	 sub-study	 2,	 show	 greater	
concentration	 of	 lactate	 in	 the	 medulla	 than	 the	 cortex.	 This	 is	 not	 necessarily	 congruent	 with	 previous	
assumptions.	 Further	 in-vivo	 studies,	 perhaps	 examining	 kidneys	 due	 to	 be	 removed	 for	 pathological	
reasons,	would	elucidate	clearer	results.		
Sub-study	 2	 is	 limited	 by	 the	 fact	 that	 the	 temperature	 probe	 malfunctioned.	 This	 resulted	 in	 no	
temperature	 levels	 in	 these	 cases.	 In	 this	 experiment	 the	 effect	 of	 re-warming	 on	 tissue	 lactate	
concentrations	 was	 investigated,	 therefore	 correlation	 with	 temperature	 data	 is	 vital.	 For	 subsequent	
studies,	 the	 temperature	 probe	 functioned	 without	 issue.	 The	 data	 from	 this	 is	 useful	 when	 drawing	
conclusions	from	the	data	set.		
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In	sub-study	3,	lactate	concentrations	were	imperceptible	in	all	kidneys	for	the	entire	period	of	monitoring.	
It	 is	 plausible,	 but	 highly	 unlikely	 that	 this	 finding	 was	 secondary	 to	 a	 batch	 of	 faulty	 probes	 or	 serial	
malfunctions	with	the	rsMD.	In	all	likelihood,	these	zero	concentrations	reflect	actual	tissue	concentrations.	
The	question	as	to	why	to	concentration	is	zero	is	difficult	to	answer.	As	discussed	previously,	it	is	expected	
that	 there	 should	 be	 trace	 levels	 of	 lactate;	 even	 in	 hypothermia	 low	 levels	 of	 metabolism	 take	 place.	
Another	possibility	is	that	the	temperature	is	too	low,	causing	hypothermic	injury	to	the	kidney,	resulting	is	
significant	cell	death.	Modifying	the	methodology,	by	allowing	warming	would	tell	us	if	the	cells	are	viable.	
Another	 likely	 theory	 is	 that	 the	 low	 temperatures	 (2oC),	 reduces	 the	 diffusion	 rate	 across	 the	 semi-
permeable	membrane.	Further	calibration	and	recovery	tests	need	to	be	performed	to	see	if	this	is	the	case.	
This	is	potentially	amenable,	as	the	flow	rate	can	be	reduced	to	allow	greater	recovery.	
Each	 experimental	 group	 in	 sub-study	 4	 contained	 only	 a	 small	 number	 of	 kidneys,	 as	 undertaking	 these	
experiments	was	costly	and	laborious.	Undertaking	one	experiment	and	analysis	required	almost	2	weeks	of	
continuous	work.	However,	this	meant	that	the	study	was	powered	only	to	detect	large	differences	between	
dialysate	lactate	concentrations	in	the	two	groups.	Additionally,	significant	differences	existed	between	the	
groups	 with	 respect	 to	 unmonitored	 cold	 ischaemia	 time	 and	 cortex	 tissue	 temperature.	 As	 the	 cold	
ischaemia	 time	 is	highly	variable	 in	clinical	practice,	 the	 relatively	small	differences	seen	here	are	 likely	 to	
have	had	negligible	effect	on	the	observed	results.		
In	 contrast	 the	 higher	 tissue	 temperature	 of	 those	 organs	 preserved	 by	 HMP	 may	 have	 profound	
implications	for	our	findings	as	increasing	temperature	leads	to	a	reduction	in	the	RR	of	the	rsMD	system.	It	
is	 surprising	 that	 the	 average	 SS	 dialysate	 lactate	 concentration	 of	 the	 two	 groups	 were	 similar.	 This	
potentially	means	 that	 if	 the	 HMP	 system	were	 adapted	 to	maintain	 tissue	 temperatures	 comparable	 to	
those	of	SCS,	we	may	see	a	further	reduction	in	dialysate	lactate	concentration,	and	thus	ischaemic	injury,	in	
HMP	preserved	kidneys.	This	requires	further	assessment.	
It	is	also	well	known	that	findings	in	animal	models	of	human	diseases	do	not	always	translate	to	the	clinical	
setting.	 Despite	 porcine	 kidneys	 being	 the	 gold	 standard	 preclinical	 tool	 in	 transplantation	 research,	 the	
mechanism	of	death	and	organ	 retrieval	 in	our	model	 is	 significantly	different	 to	 that	occurring	 in	 clinical	
practice.	It	 is	therefore	plausible	that	the	psychological	and	physiological	stress	experienced	by	the	animal,	
as	well	as	differences	 in	operative	technique,	may	also	 limit	the	direct	extrapolation	of	our	findings	to	the	
clinical	setting.	 
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6.5.3 Future	work	and	clinical	applications	
These	studies	validate	the	rsMD’s	capabilities	to	detect	and	monitor	the	ischaemic	profiles	of	kidneys	during	
the	preservation	period,	however	more	 investigation	 is	 required	before	 the	 tool	 can	be	used	 for	accurate	
organ	viability	assessment.	 Initially,	as	 the	sub-studies	are	underpowered,	 it	would	be	beneficial	 to	 repeat	
the	studies	with	more	kidneys.	The	methodology,	however,	would	need	further	modification,	including:	the	
consistent	use	of	temperature	measurement,	monitoring	of	medulla	and	lactate	concentrations,	the	use	of	
protocol	 biopsies	 to	 correlate	 histological	 findings	with	 dialysate	 concentrations,	 consistent	 use	 of	 paired	
kidneys	and	locating	the	rsMD	closer	to	the	site	of	the	retrieval.	
The	 baseline	 ischaemic	 profiles,	which	 are	 key	 to	 the	 providing	 a	 control	 for	 future	 viability	 assessments,	
would	need	to	be	repeated	in	human	clinical	model.	Patients	undergoing	nephrectomies	for	renal	pathology,	
such	as	renal	carcinomas,	could	have	microdialysis	catheters	 implanted	into	the	renal	parenchyma	prior	to	
the	vessels	being	ligated.	The	technique	could	potentially	be	modified	to	allow	a	laparoscopic	approach.		
Future	work	should	also	focus	on	utilising	the	current	validated	methodology	to	assess	other	biomarkers	of	
anaerobic	metabolism,	 such	ATP,	pyruvate	or	citrate	 in	an	ex-vivo	hypothermic	or	normothermic	machine	
perfusion	model.	The	 research	could	go	one	 step	 further	by	demonstrating	 the	complex	metabolic	profile	
that	may	occur	in	a	porcine	auto-transplant	model.	This	would	allow	us	to	monitor	every	phase	of	a	kidney	
transplant,	allowing	potential	translation	to	a	human	clinical	model.	
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7.4 APPENDIX	IV	
7.4.1 Sample	Data	
7.4.1.1 In-vivo	detection	of	Colonic	Ischaemia	following	Abdominal	Aortic	
Aneurysm	repair		
		
Table	35	-	Sample	data	set	from	a	patient	who	underwent	microdialysis	monitoring	of	the	colon	following	AAA	repair.			
Each	data	point,	taken	at	60	second	intervals,	represents	the	peak	amplitude	measured	at	the	electrode	and	a	corresponding	glucose	or	lactate	
dialysate	concentration.	The	furthest	column	on	the	right	illustrates	the	L/G	ratio	at	that	particular	point.	
	
7.4.1.2 Online	rapid	sampling	microdialysis	for	the	in-vivo	detection	of	bowel	
anastomotic	leakage	
			
Table	36	–	Sample	data	set	for	several	patients	that	underwent	drain	sampling	following	gastrointestinal	surgery	
The	peritoneal	lactate	concentrations	(mM)	are	shown	for	each	patient	at	6	hourly	intervals.	
	
Peak%Amplitude%(µA) Dialysate%Conc%(mM) Peak%Amplitude%(µA) Dialysate%Conc%(mM)
0 1.807 4.495024876 2.337 3.031521598 0.67441709
1 1.759 4.375621891 1.885 2.445193929 0.558822035
2 1.452 3.611940299 1.939 2.515241925 0.696368632
3 1.322 3.288557214 1.636 2.122194837 0.645327023
4 1.312 3.263681592 1.746 2.264885199 0.693966349
5 1.401 3.485074627 1.967 2.551563108 0.732140164
6 1.425 3.544776119 2.116 2.744843689 0.774334851
7 1.504 3.741293532 2.211 2.868076274 0.766600174
8 1.632 4.059701493 2.467 3.200155662 0.788273637
9 1.674 4.164179104 2.405 3.119730185 0.749182518
10 1.614 4.014925373 2.393 3.104163964 0.77315608
11 1.719 4.276119403 2.414 3.131404851 0.732300611
12 1.794 4.462686567 2.352 3.050979375 0.683664275
13 1.755 4.365671642 2.268 2.942015826 0.673897642
14 1.642 4.084577114 2.075 2.6916591 0.658981095
15 1.532 3.810945274 2.039 2.644960436 0.694043143
16 1.55 3.855721393 2.176 2.822674796 0.732074366
17 1.532 3.810945274 2.343 3.039304709 0.797519904
18 1.401 3.485074627 2.407 3.122324556 0.895913256
19 1.525 3.793532338 2.386 3.095083668 0.815884351
20 1.731 4.305970149 2.541 3.29614736 0.765483096
Glucose
Time+min
Lactate
L/G+ratio
Post%operative,drain,sampling
Patient,# 0,Hour 6,Hours 12,Hours 24,Hours 30,Hours 36,Hours
1 4.107 3.806 3.618 7..531 2.136
2 6.44 5.563 10.235 8.695 9.564 7.111
3 2.371 4.079 3.555 2.746 2.644
4 4.158 5.219 6.187 5.778 8.971 8.827
5 8.908 8.393 3.877 2.889 4.234
6 3.115 4.258 2.093 6.416
Peritoneal,Drain,Lactate,Conc,(mM)
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Figure	152	-	Batch	2-8	Lactate	calibration	with	linear	regression	
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7.4.1.3 Allograft	viability	assessment	during	the	preservation	period	utilising	
online	rapid	sampling	microdialysis		
		
Table	 37	 –	 Sample	 data	 set	 from	 an	 experimental	 setup,	 where	 the	 cortex	 of	 a	 freshly	 retrieved	 kidney	 undergoing	 hypothermic	 machine	
perfusion	is	continuously	sampled	for	lactate.		
Each	data	point	demonstrates	the	dialysate	lactate	concentration	(mM)	and	the	cortical	temperature	(oC)	at	1-minute	intervals.					 	
Time Temp&oC
Dialysate&Lactate&
Conc&(µM)
0 6.20 136.10
1 6.20 108.48
2 6.20 127.85
3 6.20 126.80
4 6.20 124.35
5 6.20 122.38
6 6.20 119.26
7 6.20 119.57
8 6.20 119.11
9 6.20 120.90
10 6.20 121.81
11 6.20 121.55
12 6.20 119.48
13 6.20 120.62
14 6.20 122.65
15 6.20 128.00
16 6.20 130.32
17 6.20 129.86
18 6.20 131.32
19 6.20 130.68
20 6.20 133.46
Cortical&Microdialysis&Monitoring
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7.5 APPENDIX	V	
7.5.1 Patients	consent	forms	
7.5.1.1 In-vivo	detection	of	Colonic	Ischaemia	following	Abdominal	Aortic	
Aneurysm	repair		
Study	Number:	
Patient	identification	number:	
Consent	Form	
Title	of	Project:	
Use	of	Microdialysis	in	the	post	operative	monitoring	of	bowel	after	Abdominal	Aortic	Aneurysm	Repair.	
	
Name	of	Researcher:	
Mr.	Samir	Damji	
Clinical	Research	Fellow	
Department	of	Biosurgery	&	Surgical	Technology,	Imperial	College	
10th	Floor	QEQM	Building	
St.	Mary’s	Hospital	
London,	W2	1NY		
Email:	s.damji@imperial.ac.uk	
Telephone:	07713632515	
Fax:	02078866950	
	
Please	tick	box	
 
o I	confirm	that	I	have	read	and	understand	the	information	sheet	dated	............................	 for	the	
above	study	and	have	had	the	opportunity	to	ask	questions.	
	
o I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time,	
without	giving	any	reason,	without	my	medical	care	or	legal	rights	being	affected.	
	
o I	understand	that	sections	of	any	of	my	medical	notes	may	be	looked	at	by	responsible	
individuals	from	Imperial	College	or	from	regulatory	authorities	where	it	is	relevant	to	my	taking	
part	in	research.		I	give	permission	for	these	individuals	to	have	access	to	my	records.	
o I	agree	to	take	part	in	the	above	study.	    
 
 
  
Name of Patient                                   Signature      Date 
 
 
  
Researcher                                          Signature      Date   
 
(COPIES: 1 for patient, 1 for researcher, and 1 to be kept with hospital notes) 
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7.5.1.2 Online	rapid	sampling	microdialysis	for	the	in-vivo	detection	of	bowel	
anastomotic	leakage 
	
Study	Number:	
Patient	identification	number:	
Consent	Form	
Title	of	Project:	
Online	rapid	sampling	microdialysis	for	the	in-vivo	detection	of	anastomotic	leakage	
	
Name	of	Researcher:	
Mr.	Samir	Damji	
Clinical	Research	Fellow	
Department	of	Biosurgery	&	Surgical	Technology,	Imperial	College	
10th	Floor	QEQM	Building	
St.	Mary’s	Hospital	
London,	W2	1NY		
Email:	s.damji@imperial.ac.uk	
Telephone:	07713632515	
Fax:	02078866950	
	
Please	tick	box	
 
o I	confirm	that	I	have	read	and	understand	the	information	sheet	dated	............................	 for	the	
above	study	and	have	had	the	opportunity	to	ask	questions.	
	
o I	understand	that	my	participation	is	voluntary	and	that	I	am	free	to	withdraw	at	any	time,	
without	giving	any	reason,	without	my	medical	care	or	legal	rights	being	affected.	
	
o I	understand	that	sections	of	any	of	my	medical	notes	may	be	looked	at	by	responsible	
individuals	from	Imperial	College	or	from	regulatory	authorities	where	it	is	relevant	to	my	taking	
part	in	research.		I	give	permission	for	these	individuals	to	have	access	to	my	records.	
o I	agree	to	take	part	in	the	above	study.	    
 
 
  
Name of Patient                                   Signature      Date 
 
 
 
  
Researcher                                          Signature      Date   
 
(COPIES: 1 for patient, 1 for researcher, and 1 to be kept with hospital notes)		 	
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7.6 APPENDIX	VI	
7.6.1 Patient	information	sheets	
7.6.1.1 In-vivo	detection	of	Colonic	Ischaemia	following	Abdominal	Aortic	
Aneurysm	repair		
Monitoring	Bowel	Health	Using	Microdialysis	
Patient	information	sheet	and	Consent	Form	
	
You	are	being	invited	to	take	part	in	a	research	study.		Before	you	decide,	it	is	important	for	you	to	understand	why	the	research	is	being	done	
and	what	it	will	involve.		Please	take	time	to	read	the	following	information	carefully	and	discuss	it	with	others	if	you	wish.		Ask	us	if	there	is	
anything	that	is	not	clear	or	if	you	would	like	more	information.		Take	time	to	decide	whether	or	not	you	wish	to	take	part.	
	
1. What	is	the	purpose	of	this	study?	
This	 study	aims	 to	 look	at	 the	 changes	 that	occur	 to	human	bowel	 after	 it	 has	had	 its	blood	 supply	 removed.	We	will	 be	 studying	 the	
segment	of	bowel	that	is	already	being	removed	as	part	of	your	planned	operation.	The	measurement	we	take	will	have	no	effect	on	the	
treatment	and	postoperative	care	you	receive.	
	
2. Why	have	I	been	chosen?	
You	have	been	chosen	for	this	study	because	you	are	undergoing	bowel	resection	surgery.	We	are	interested	in	the	changes	that	occur	to	
the	human	bowel	and	maybe	can	understand	better	why	complications	occur	after	surgery	and	can	help	other	patients	in	the	future.	
	
3. Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	whether	or	not	to	take	part.		If	you	do	decide	to	take	part	you	will	be	given	this	information	sheet	to	keep	and	be	
asked	to	sign	a	consent	form.	If	you	decide	to	take	part	you	are	still	free	to	withdraw	at	any	time	and	without	giving	a	reason	before	the	
operation.		A	decision	to	withdraw	at	any	time,	or	a	decision	not	to	take	part,	will	not	affect	the	standard	of	care	you	will	receive.	
	
4. What	will	happen	to	me	if	I	take	part?	
You	will	have	the	same	operation,	and	care	before	during	and	after	surgery	that	you	would	have	had	if	you	were	not	enrolled	in	this	study.	
We	will	be	making	some	measurements	on	bowel	that	 is	already	going	to	be	removed	as	part	of	your	planned	operation.	This	will	 take	
place	during	your	operation	but	will	not	affect	the	surgery	you	have.	The	study	involves	the	use	of	an	already	existing	technology	(that	has	
been	used	before	on	human	liver,	kidney,	brain,	and	muscle)	to	study	the	effect	of	interrupted	blood	supply	on	human	intestine.	We	will	
be	using	a	micro-catheter	in	the	intestinal	wall	of	the	segment	of	intestine	that	is	to	be	removed.	This	micro-catheter	is	of	miniature	size	
measuring	 no	 more	 than	 0.24	 mm	 in	 diameter	 and	 2cm	 in	 length	 and	 basically	 picks	 up	 the	 biochemical	 changes	 that	 occur	 in	 that	
segment	of	bowel.	It	will	enable	us	to	record	data	from	that	segment	when	it	is	subjected	to	interrupted	blood	supply.	The	only	difference	
your	taking	part	in	our	research	will	make	to	the	length	of	a	normal	operation	is	that	it	will	take	5	to	10	minutes	longer;		this	is	the	time	
needed	to	secure	the	micro	catheter	in	the	section	of	the	bowel	that	is	to	be	removed.	
Under	 no	 circumstance	will	 the	healthy	 bowel	 (that	 is	 not	 to	 be	 removed)	 be	 subject	 to	 any	 study	or	 handling	 other	 than	 the	 regular	
handling	that	happens	with	any	other	bowel	surgery.	
	
5. What	do	I	have	to	do?	
If	you	agree	to	take	part	in	this	study,	there	will	be	no	difference	in	the	treatment	you	receive	or	the	time	you	spend	in	hospital	after	your	
operation.	
	
6. What	are	the	possible	disadvantages	and	risks	of	taking	part?		
We	do	not	 foresee	 any	disadvantages	or	 risks	 of	 taking	part	 in	 this	 study	 since	 it	 does	not	 tackle	 but	 the	 segment	of	 intestine	 that	 is	
destined	for	resection	anyways.			
	
7.		 What	are	the	possible	benefits	of	taking	part?	
		
251	
Taking	part	in	this	study	does	not	affect	your	treatment	in	any	way.	If	you	agree	to	take	part	you	will	be	helping	us	understand	the	changes	
that	take	place	in	human	bowel	when	its	blood	supply	is	removed.	The	measurements	that	we	make	may	be	of	help	in	understanding	how	
bowel	heals	and	consequently	help	other	patients.	
	
7. What	happens	when	the	research	study	stops?	
When	the	research	study	ends,	we	will	look	at	the	results	and	try	to	use	these	to	understand	how	human	bowel	heals.	If	you	would	like	
any	information	on	our	progress	or	the	findings	of	this	study,	we	would	be	more	than	happy	for	you	to	get	in	touch	with	us	to	discuss	this.	
	
8. What	if	something	goes	wrong?	
Any	problem	with	the	devices	we	use	to	make	the	measurements	on	bowel	will	not	affect	you.	The	surgery	will	be	carried	out	as	planned	
by	the	experienced	surgical	team	members.		
	
9. Will	my	taking	part	in	this	study	be	kept	confidential?	
All	information	which	is	collected	about	you	during	the	course	of	the	research	will	be	kept	strictly	confidential	and	kept	in	a	secure	place.	
	
10. What	will	happen	to	the	results	of	the	research	study?	
The	results	of	the	research	will	be	analyzed	and	published	in	scientific	journals.	We	will	happily	provide	you	with	a	copy	of	the	results.	
	
11. Who	is	organizing	and	funding	the	research?	
This	is	being	undertaken	by	Imperial	College	London.	
Who	has	reviewed	the	study?	
The	study	has	been	reviewed	and	approved	by	the	research	ethics	committee	at	St.	Mary’s	Hospital.	
Contact	for	Further	Information	
You	may	 keep	 a	 copy	 of	 this	 information	 sheet	with	 you	 for	 further	 reference.	 If	 you	 have	 any	 questions	 feel	 free	 to	 ask	 the	 person	
consenting	you	for	the	study.	In	case	of	further	questions,	please	contact:	
	
Mr.	Samir	Damji	
Clinical	Research	Fellow	
Department	of	Biosurgery	&	Surgical	Technology,	Imperial	College	
10th	Floor	QEQM	Building	
St.	Mary’s	Hospital	
London,	W2	1NY	
	
Email:	s.damji@imperial.ac.uk	
Telephone:	07713632515	
Fax:	02078866950	
	
You	will	be	given	a	copy	of	the	information	sheet	and	a	signed	consent	form	to	keep.	
7.6.1.2 Online	rapid	sampling	microdialysis	for	the	in-vivo	detection	of	bowel	
anastomotic	leakage		
Online	Rapid	Sampling	Microdialysis	For	The	In-Vivo	Detection	Of	Anastomotic	Leakage	
Patient	information	sheet	and	Consent	Form	
You	are	being	invited	to	take	part	in	a	research	study.		Before	you	decide,	it	is	important	for	you	to	understand	why	the	research	is	being	done	
and	what	it	will	involve.		Please	take	time	to	read	the	following	information	carefully	and	discuss	it	with	others	if	you	wish.		Ask	us	if	there	is	
anything	that	is	not	clear	or	if	you	would	like	more	information.		Take	time	to	decide	whether	or	not	you	wish	to	take	part	
1. What	is	the	purpose	of	this	study?	
This	study	aims	to	 look	at	the	changes	that	occur	to	human	bowel	while	 it	 is	healing.	We	will	be	studying	the	segment	of	bowel	that	 is	
already	being	joined	as	part	of	your	planned	operation.	The	measurement	we	take	will	have	no	effect	on	the	treatment	and	postoperative	
care	you	receive.	
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2. Why	have	I	been	chosen?	
You	have	been	chosen	for	this	study	because	you	are	undergoing	bowel	joining	surgery.	We	are	interested	in	the	changes	that	occur	to	the	
human	bowel	and	maybe	can	understand	better	why	complications	occur	after	surgery	and	can	help	other	patients	in	the	future.	
	
3. Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	whether	or	not	to	take	part.		If	you	do	decide	to	take	part	you	will	be	given	this	information	sheet	to	keep	and	be	
asked	to	sign	a	consent	form.	If	you	decide	to	take	part	you	are	still	free	to	withdraw	at	any	time	and	without	giving	a	reason	before	the	
operation.		A	decision	to	withdraw	at	any	time,	or	a	decision	not	to	take	part,	will	not	affect	the	standard	of	care	you	will	receive.	
	
4. What	will	happen	to	me	if	I	take	part?	
You	will	have	 the	 same	operation,	and	care	before,	during	and	after	 surgery	 that	you	would	have	had	 if	 you	were	not	enrolled	 in	 this	
study.	 After	 your	 operation	 small	 amounts	 of	 fluid	will	 be	 removed	 from	drain	 bags	 that	will	 already	 be	 present.	 These	 drains	will	 be	
placed	by	your	surgeon,	and	are	routine	for	the	type	of	operation	that	you	are	having.		
	
5. What	do	I	have	to	do?	
If	you	agree	to	take	part	in	this	study,	there	will	be	no	difference	in	the	treatment	you	receive	or	the	time	you	spend	in	hospital	after	your	
operation.	
	
6. What	are	the	possible	disadvantages	and	risks	of	taking	part?		
There	is	absolutely	no	risk	to	your	self.	Removing	fluid	from	the	bag	is	completely	painless	and	should	cause	little	inconvenience	to	you	
	
7. What	are	the	possible	benefits	of	taking	part?	
Taking	part	in	this	study	does	not	affect	your	treatment	in	any	way.	If	you	agree	to	take	part	you	will	be	helping	us	understand	the	changes	
that	take	place	in	human	bowel	when	it	 is	 in	the	process	of	healing.	The	measurements	that	we	make	may	be	of	help	in	understanding	
how	bowel	heals	and	consequently	help	other	patients.	
	
8. What	happens	when	the	research	study	stops?	
When	the	research	study	ends,	we	will	look	at	the	results	and	try	to	use	these	to	understand	how	human	bowel	heals.	If	you	would	like	
any	information	on	our	progress	or	the	findings	of	this	study,	we	would	be	more	than	happy	for	you	to	get	in	touch	with	us	to	discuss	this.	
	
9. What	if	something	goes	wrong?	
The	surgery	will	be	carried	out	as	planned	by	the	experienced	surgical	team	members.	If	any	unforeseen	risks	is	encountered	the	study	will	
be	abandoned	directly.	
	
10. Will	my	taking	part	in	this	study	be	kept	confidential?	
All	information	which	is	collected	about	you	during	the	course	of	the	research	will	be	kept	strictly	confidential	and	kept	in	a	secure	place.	
	
11. What	will	happen	to	the	results	of	the	research	study?	
The	results	of	the	research	will	be	analyzed	and	published	in	scientific	journals.	We	will	happily	provide	you	with	a	copy	of	the	results.	
	
12. Who	is	organizing	and	funding	the	research?	
This	is	being	undertaken	by	Imperial	College	London.	
	
13. Who	has	reviewed	the	study?	
The	study	has	been	reviewed	and	approved	by	the	research	ethics	committee	at	St.	Mary’s	Hospital.	
	
Mr	Samir	Damji	
Clinical	Research	Fellow	
Department	of	Biosurgery	&	Surgical	Technology,	Imperial	College	
St.	Mary’s	Hospital	
Email:		s.damji@imperial.ac.uk	
You	will	be	given	a	copy	of	the	information	sheet	and	a	signed	consent	form	to	keep.	
	 	
		
253	
7.7 APPENDIX	VII	
7.7.1 Ethical	Approval	
7.7.1.1 In-vivo	detection	of	Colonic	Ischaemia	following	Abdominal	Aortic	
Aneurysm	repair		
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7.7.1.2 Online	rapid	sampling	microdialysis	for	the	in-vivo	detection	of	bowel	
anastomotic	leakage 
St	Mary's	REC	
Research	Ethics	Committees	
Room	4W/12,	4th	Floor	West	
Charing	Cross	Hospital	
Fulham	Palace	Road	
London	
W6	8RF		
Tel:	020	331	17251	
Fax:	020	331	17280	
05	March	2010	
Professor	Ara	Darzi	
Professor	of	Surgery	and	Head	of	Department	
10th	Floor	QEQM	Building	
St.	Mary's	Hospital	
London	
W2	1NY	
Dear	Professor	Darzi	
Study	title:	 The	Use	of	Microdialysis	for	Intra-	and	Post-Operative	
Biochemical	Monitoring	of	Human	Bowel	
REC	reference:	 06/Q0403/21	
	
This	study	was	given	a	favourable	ethical	opinion	by	the	Committee	on	03	March	2006.	
		
It	is	a	condition	of	approval	by	the	Research	Ethics	Committee	that	the	Chief	Investigator	should	submit	a	progress	report	for	the	
study	12	months	after	the	date	on	which	the	favourable	opinion	was	given,	and	then	annually	thereafter.			
		
Guidance	on	progress	reports	and	a	copy	of	the	standard	NRES	progress	report	form	is	available	from	the	National	Research	Ethics	
Service	website.	
		
The	NRES	website	also	provides	guidance	on	declaring	the	end	of	the	study.	
06/Q0403/21:																																																					Please	quote	this	number	on	all	correspondence	
		
Yours	sincerely	
  
Mrs	Rosalind	Cooke	
Committee	Co-ordinator	
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7.8 APPENDIX	VIII	
7.8.1 Online	rapid	sampling	microdialysis	for	the	in-vivo	detection	of	
bowel	anastomotic	leakage	
	
Table	38	–	Classification	of	surgical	complications:	a	new	proposal	with	evaluation	in	a	cohort	of	6336	patients	and	results	of	a	survey138	
7.8.2 Allograft	viability	assessment	during	the	preservation	period	
utilising	online	rapid	sampling	microdialysis	
	
Table	39	–	The	Maastricht	classification	of	Donation	after	Circulatory	Death	
	
Appendix	
	
	
	
The	Clavien-Dindo	Classification	of	Surgical	Complications	{Dindo, 2004 #2} 
Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of 
a survey 
 
	
	
Grades	 Definition	
1	
Deviation	from	normal	post-op	course	without	the	need	for	pharmacological,	surgical,	endoscopic	or	
radiological	interventions	
- Antiemetics,	antipyretics,	analgesics,	diuretics,	electrolytes	and	physiotherapy	are	not	
considered	as	intervention	in	Grade	1	
2	
Requiring	pharmacological	treatment	
- Other	than	listed	above	
- Includes	blood	products	and	TPN	
3	
Requiring	surgical,	endoscopic	or	radiological	intervention	
- 3a	–	Intervention	NOT	under	general	anesthesia	
- 3b	–	Intervention	under	general	anesthesia		
4	
Life-threatening	complication	requiring	ITU	management	
- 4a	–	Single	organ	dysfunction	
- 4b	–	multi	organ	dysfunction	
5	 Death	
	
	
	
Catgeory	 	 Circumstances	 Type	
1A	 Dead	in	the	out-of-
hospital	setting		
	
Unwitnessed	cardiocirculatory	death	
outside	the	hospital	
Uncontrolled		
	
1B	 	 Witnesed	Cardiocirculatory	death	
outside	the	hospital	and	rapid	
resuscitation	attempt.	
Uncontrolled	
	2A	 Unsuccessful	
resuscitation	
Unexpected	cardiocirculatory	death	in	
the	ICU.	
	
Uncontrolled	
2B	 	 Witnessed	unexpected	
cardiocirculatory	death	in	the	hospital	
with	rapid	resuscitation	
Uncontrolled	
3A	 Awaiting	cardiac	
arrest	
Expected	cardiocirculatory	death	in	the	
ICU		
Controlled	
3B	 	 Expected	cardiocirculatory	death	in	
theatre	(withdrawal	phase	>30	min).	
Controlled	
3C	 	 Expected	cardiocirculatory	death	in	
theatre	(withdrawal	phase	<30	min).		
Controlled	
4A	 Cardiac	arrest	
while	brain-dead	
Unexpected	cardiocirculatory	arrest	in	
a	brain-dead	donor	(in	the	ICU)	
Uncontrolled	
4B	 	 Expected	cardiocirculatory	arrest	in	a	
brain-dead	donor		
Controlled	
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7.8.2.1 Sub	study	4	
	
Figure	153	–	Sub	study	4	–	Static	Cold	Storage	–	Kidney	1	
	
Figure	154	–	Sub	study	4	–	Static	Cold	Storage	–	Kidney	2	
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Figure	155	–	Sub	study	4	–	Static	Cold	Storage	–	Kidney	3	
	
Figure	156	–	Sub	study	4	–	Static	Cold	Storage	–	Kidney	4	
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Figure	157	–	Sub	study	4	–	Hypothermic	Machine	Perfusion	–	Kidney	1		
	
Figure	158	–	Sub	study	4	–	Hypothermic	Machine	Perfusion	–	Kidney	2	
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Figure	159	–	Sub	study	4	–	Hypothermic	Machine	Perfusion	–	Kidney	3	
	
Figure	160	–	Sub	study	4	–	Hypothermic	Machine	Perfusion	–	Kidney	4	
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Figure	161	–	Sub	study	4	–	Hypothermic	Machine	Perfusion	–	Kidney	5	
	
	
Figure	162	–	Sub	study	4	–	Hypothermic	Machine	Perfusion	–	Kidney	6	
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